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Welcome to the 35th EPS in Dublin
Dear friends, partners and fellow colleagues
On behalf of the organising committee, it is our pleasure to invite you to join in the 35th European Peptide Symposium,
35EPS, on 26-31 August 2018 at the Dublin City University, Dublin, Ireland. Ireland has been known as the land of Saints
and Scholars. The capital city of Dublin lies at the mouth of the river Liffey embracing the Irish Sea. There is evidence of a
community living in Dublin since the fifth century. It is a city rich in historical and cultural attractions including the unique
Book of Kells, the famous Guinness brewery, the neighbouring hills of Tara and the monastic village of Glendalough.
The European Peptide Society is a non-profit association established for the public benefit to promote in the advancement
of education and scientific study of the chemistry, biochemistry, biology and pharmacology of peptides in Europe and in
neighbouring countries. In co-operation with John Wiley & Sons, the EPS publishes the Journal of Peptide Science and the
EPS Newsletter. The EPS supports the organisation of the European Peptide Symposium, sponsors local and specialised
meetings and workshops, and supports and promotes young scientists with travel grants and dedicated seminars.
The European Peptide Symposium is a well-established biennial peptide conference that has grown substantially. It has
been well attended by Nobel Laureates, world-class scientists, leading scientific investigators, world-renowned commercial
partners, publishers and leading companies in the area of peptide research and its applications. This symposium includes
sessions covering every aspect of the research, education and innovation related to the peptide science.
The 35EPS will take place at the Helix, a purpose built conference venue associated with the Dublin City University. The
Helix is located approximately 5 km north of Dublin city centre short distance away from the Dublin International Airport.
The scientific sessions, poster sessions and exhibition will take place in the Helix and its adjacent rooms. Dublin City
University has excellent on-site accommodation, restaurants and cafes which will cater for symposium delegates.
The 35EPS symposium will start on 26th of August with award and prize giving lectures and a welcome reception. In
addition to plenary and invited speaker presentations, there will be poster presentations and a mini symposium for young
scientists for covering every aspect of peptide science. The symposium gala dinner will take place on the 30th of August at
the Crowne Plaza Hotel and the excursions are planned on Friday for sampling the history and culture of Dublin and its
surroundings towns.
The executive council, the scientific advisory board, and the program committee hope to make the 35EPS symposium
an exciting and memorable scientific event. You will also have the opportunity to visit the hospitable and attractive city
of Dublin with many cultural attractions. It is our pleasure to welcome you to Dublin, and we hope that you enjoy the
symposium and your visit.
35 EPS Organising Committee
Chandralal Hewage, University College Dublin (Chairman)
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Dear colleagues and friends in the worldwide peptide community
The 35th edition of the European Peptide Society symposium, 35EPS, is well on the move! We are happy that this
symposium signals the expansion of our society’s sphere of influence into a so far unvisited EPS member nation. With
a rich cultural heritage, a forward-looking society and, more to the point, a dynamic biotech sector, Ireland is an ideal
location for talking shop on peptides in the 21st century. In continuation of the highly successful 34EPS in Leipzig, to be
followed by equally enticing calls in Barcelona (2020) and Florence (2022), this upcoming 35EPS promises to be a unique
opportunity to learn about the ever-growing impact of peptide research in a multitude of scientific areas, to share your own
results and interests, and to build productive professional ties with like-minded scientists on a worldwide scale. Assisted by
capable scientific and program committees, Prof. Chandralal Hewage, the symposium chair, is planning not only a first-rate
scientific event but has also arranged for top-notch conference facilities, including affordable accommodation, and for an
attractive social program.
On behalf of the European Peptide Society, I look forward to greeting you personally in Dublin, August 26-31, 2018!
With best personal regards,
David Andreu
President, European Peptide Society
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General Information
Registration desk and conference office
The registration desk and conference office are located in the Helix and will be open Sunday the 19th August and
remain open until the end of the symposium. The registration desk opening hours are as follows:
Sunday 26th 14:15 - 19:00
Monday 27th 08:00 - 18:30
Tuesday 28th 08:00 - 16:00
Wednesday 29th 08:00 - 16:00
Thursday 30th 08:00 - 16:00
Locations of sessions
The poster sessions will be held in the Helix. Odd numbered posters will be presented on Monday and Tuesday,
and even numbered posters will be presented on Tuesday and Wednesday.
Name Badges & Regulations
Name badges are required when in the Helix, for all of the symposium sessions, including the poster session
and hospitality suites, and all other symposium functions and related activities. No smoking is permitted on the
DCU campus grounds. Mobile phones must be turned off or silenced during the symposium. No photography or
recording is permitted in any session, including the poster session.
Speakers
Stewards will be available to assist speakers in transferring their presentations to provided computers or setting
up personal computers. Speakers are kindly asked to be present in the lecture hall 30 minutes before the session
starts.
Speaker Rooms
The speaker ready room will be available for speakers only; the room is located on the ground floor of the Helix,
close to the main auditorium. Please note computers are not provided in these rooms.
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Poster Presentations
Categories
Amino acids and peptide synthesis P1 - P46
Protein synthesis and semi-synthesis P47 - P57
Peptide-based materials and catalysis P58 - P74
Nanotechnology, imaging and analytical techniques P75 - P86
Macromolecular assemblies P87 - P89
Glycopeptides and lipopeptides P90 - P95
Peptide mimetics P96 - P112
Structural and conformational studies P113 - P140
Biochemistry and biology P141 - P147
Biologically active peptides P148 - P186
Peptides in chemical biology and therapeutics P187 - P225
Prodrugs, conjugates, targeting and update P226 - P248
Peptides in proteomics and bioinformatics P249 - P250
Set-up and removal
Authors are kindly asked to have their posters put up before 14:00 on Monday the 27th of August, and leave
them on display for the duration of the symposium.
Poster areas are separated according to category and all boards will be labelled with the individual abstract code
which can be found in this book in the list of abstracts.
Posters should be removed before 17:30 on Thursday the 30th or 10:00 on Friday the 31st of August; any
unclaimed posters will be discarded.
Sessions
There are three poster sessions, from Monday the 27th of August to Wednesday the 29th of August each day
between 14:15 and 15:45. Authors are kindly asked to be present at their posters on the day they have been
allocated. Poster session allocations are as follows:
Odd Numbers: Monday and Tuesday
Even Numbers: Tuesday and Wednesday
Lunch, Tea/Coffee, and Water
Tea/Coffee will be provided in the Helix conference centre.
Lunches will be held in the DCU Restaurant.
Welcome mixer, farewell reception and conference banquet
The welcome reception will be held in the Helix on Sunday, August 26th at 19:00 and we invite you to join us
for some refreshments.
The closing reception will be held by BACHEM in the Helix on Thursday, August 30th at 18:00.
The conference banquet will be held at the Crowne Plaza Dublin Airport Hotel, Santry, Dublin 9 on Thursday at
20:00. This is a ticketed dinner. Coach transport is arranged for travel to the venue.
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Public transportation
DCU accommodation is located on campus; however several bus routes serve the university.
A bus stop located near the Helix is serviced by bus number 44, which departs approximately every hour.
A bus stop located on the Ballymun Road, near the university, is serviced by bus numbers 4, 9, 11 and 13.
A single ticket from DCU to St Stephen’s Green (central location) costs C2.15 (Leap Card) or C2.85 (cash,
coins only, no change given). Visitor Leap Cards are available for purchase at Dublin Airport.
Additional information, including real time passenger information for the above routes, can be found at
www.dublinbus.ie
Internet
There is a free WiFi service available throughout the Helix. The username for DCU Guest WiFi is ’wifiguest’.
No password is required.
Conference Tours
The following tours will be available for symposium participants:
National Stud and Japanese Gardens Tour
Dublin City and Guinness Storehouse Tour
Coastal Scenic Tour with Malahide Castle and Gardens Tour
Dublin Tour with Trinity College & Book of Kells
For further information contact the registration desk.
Next EPS Symposia
The 36 EPS will be held in Barcelona, Spain on August 30 - September 4, 2020. The 37 EPS will be held in
Florence, Italy in 2022.
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Awards
Miklós Bodanszky Award
The Miklós Bodanszky Award is presented in commemoration of his outstanding contributions to peptide science.
The award is given to the scientist who made significant contributions to peptide-based drug research in the
period of ten years after having obtained the PhD degree. The Award is presented during the EPS Symposium
and is sponsored by BCN PEPTIDES. The 2018 award will be announced at the 35th EPS opening ceremony.
Awardee: Norman Metanis; The Hebrew University of Jerusalem, Israel
Leonidas Zervas Award
The Leonidas Zervas Award is presented in commemoration of his outstanding contributions to peptide science.
The award is given to the scientist who has made the most outstanding contributions to the chemistry, biochemistry
and/or biology of peptides in the five years preceding the date of selection, and is sponsored by the donation of
Dr. Rao Makineni. The 2018 award will be announced at the 35th EPS opening ceremony.
Awardee: Christian Hackenberger; FMP Berlin, Germany
Josef Rudinger Memorial Award
The Josef Rudinger Memorial Lecture Award is presented “in commemoration of Josef Rudinger’s role in the
foundation of the European Peptide Symposia and of diverse contributions he made to peptide chemistry”. The
Award is presented during the EPS Symposium and is sponsored by PolyPeptide Group. The 2018 award will be
announced at the 35th EPS opening ceremony.
Awardee: James P. Tam; Nanyang Technological University, Singapore
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ESCOM Science Foundation (ESF) Dr. Bert L. Schram Symposium and Awards
On behalf of the ESCOM Science Foundation (ESF), 35EPS is pleased to announce the Dr. Bert L. Schram
Young Investigators’ Mini Symposium (YIMS) for speakers under 35 years of age. Additionally, there will be
oral presentation and poster presentation awards and a networking mixer.
The Dr. Bert L. Schram Oral Presentation Awards
There will be two oral presentation awards, C750 for the winner and of C500 for the runner-up. They will also
receive a signed certificate in the joint names of EPS and ESF. Awards will be presented by ESF representatives
at the symposium banquet.
The Dr. Bert L. Schram Poster Presentation Awards
There will be six poster presentation awards. The top two winners will receive each a cash amount of C500 and
the next four winners a cash amount of C250 each. They will also receive a signed certificate in the joint names
of EPS and ESF. Awards will be presented by ESF representatives at the symposium banquet.
The Dr. Bert L. Schram Networking Mixer
The Networking Mixer is a buffet lunch bringing together EPS young scientists and international senior scientists
from academia and corporate research. This is an exclusive event and the attendees will gain invaluable insights
on current research trends, and orientation on career planning and professional opportunities. Attendees will
have ample opportunity to network and meet and greet EPS officers and ESF representatives.
S17
G
e
n
In
fo
Sp
o
n
so
rs
Sponsors, Exhibitors and Supporters
Silver Sponsors
CEM
BACHEM
SCIENCE FOUNDATION IRELAND
Bronze Sponsors
Merck
CBL Peptide Technology and Manufacturing
Fáilte Ireland
Award and other Sponsors
BCN PEPTIDES
EPS - Dr. Rao Makineni
PolyPeptide Group
ESCOM Science Foundation - Dr. Bert L. Schram
WILEY
Supporters
ChemPep
MDPI - molecules
ORPEGEN
Exhibitors
aapptec
Advanced ChemTech / peptides&elephants
Almac Group
BCN PEPTIDES SA
Belyntic GmbH – HPLC-free Peptide Purification
Biametrics
Biopeptek Pharmaceuticals
Biotage AB, from Sweden
C.A.T. GmbH & Co KG
Chinese Peptide Company
CSBio Co.
GL BIOCHEM (SHANGHAI) LTD
Gyros Protein Technologies
HECHENG
INTAVIS
Iris Biotech GmbH
Luxembourg Bio Technologies
ONTORES
PeptART Bioscience GmbH
Peptides International / Peptide Institute
PolyPeptide Group – The Ultimate Peptide Partner
Polypure
Purolite Life Sciences
Rapp Polymere GmbH
Senn Chemicals AG
Sunresin New Materials Co., Ltd
Teledyne ISCO
YMC Europe GmbH – The Selectivity Company
ZEOCHEM AG
Zhejiang Peptites Biotech Co., Ltd
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Ground Floor Exhibitors
CEM
BACHEM
CBL Peptide Technology and Manufacturing
BCN PEPTIDES SA
PolyPeptide Group – The ultimate Peptide Partner
Merck
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First Floor Exhibitors
Rapp Polymere GmbH
Chinese Peptide Company
Luxembourg Bio Technologies
Polypure
Almac Group
Advanced ChemTech / peptides&elephants
CSBio Co.
PeptART Bioscience GmbH
C.A.T. GmbH & Co KG
Biametrics
Peptides International/Peptide Institute
Biopeptek Pharmaceuticals
Senn Chemicals AG
Biotage AB, from Sweden
ONTORES
Iris Biotech GmbH
Gyros Protein Technologies
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Second Floor Exhibitors
GL BIOCHEM (SHANGHAI) LTD
aapptec
ZEOCHEM AG
HECHENG
YMC Europe GmbH – The Selectivity Company
Belyntic GmbH – HPLC-free Peptide Purification
Sunresin New Materials Co., Ltd
Purolite Life Sciences
Teledyne ISCO
EPS - WILEY - 36EPS (EPS2020) - 37EPS (EPS2022)
INTAVIS
Zhejiang Peptites Biotech Co., Ltd
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Supporters & Media Partners
Science Foundation Ireland
Fáilte Ireland
WILEY
European Peptide Society (EPS)
MDPI - Molecules
ESCOM Science Foundation (ESF)
ORPEGEN
ChemPep
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August 26 Sunday PM
14.00-17.00 REGISTRATION
OPENING CEREMONY
AWARDS
Miklós Bodanszky Award
AL1 - Norman Metanis, The Hebrew University of Jerusalem, Israel
Lessons from Selenium Chemistry to Study Protein Science
Leonidas Zervas Award
AL2 - Christian Hackenberger, FMP Berlin, Germany
The power of chemoselectivity: Functional peptide- and protein-conjugates for extra- 
and intracellular targeting
Josef Rudinger Memorial Award
AL3 - James P Tam, Nanyang Technological University, Singapore
Advances in Site-specific and Linkage-specific Ligation
16.30-19.00
Pr
o
g
ra
m
m
e
August 27 Monday AM
Chairs: David Andreu
08.30-09.10 IL1 - David R Spring
Adventures in Drugging Undruggable Targets
Chairs: Tia Keyes, Glenn King
Biologically Active Peptides 1
09.10-09.25 OP1 - Nermina Malanovic
Lipid domain formation induced by antimicrobial peptides OP-145 and SAAP-
148 results in efficient killing of Escherichia coli
09.25-09.40 OP2 - Steven Ballet
Engineering Hybrid Peptidomimetics for Improved Pain Treatments
09.40-09.55 OP3 - Norelle Daly
An engineered cyclic peptide alleviates symptoms of inflammation in a murine 
model of inflammatory bowel disease
09.55-10.10 OP4 - Sarah Jones
Penetrating the Impenetrable: Progress towards a Non-hormonal Male 
Contraceptive
10.10-10.25 OP5 - Marta De Zotti
Peptide-Based Biopesticides
Chair: Marc Devocelle
11.00-11.30 IL2 - Finbarr O’Harte
The design and assessment of the therapeutic potential of apelin-13 peptide 
mimetics for alleviating metabolic dysfunction in diabetes and obesity
Chairs: Ekaterina Kolesanova, David Spring
Glycopeptides, Lipopeptides and Macromolecular Assemblies
11.30-11.45 OP6 - Andy Wilson
Development and Exploitation of Photo-Crosslinking Methodology to Study 
Protein-Protein Interactions
11.45-12.00 OP7 - Claudia Bello
Toward homogeneous glycoproteins via auxiliary-assisted sequential 
glycosylation and ligation of peptides
12.00-12.15 OP8 - Oliver Zerbe
Peptide-Guided Assembly of Armadillo Repeat Protein Fragments
12.15-12.30 OP9 - Veronica Dodero
Are gluten-related disorders a new protein aggregation disease?
12.30-12.45 OP10 - Eoin Scanlan
Chemical Synthesis of Glycopeptides and Glycoproteins Using Acyl-thiol-ene 
Mediated ‘Click’ Ligation
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August 27 Monday PM
Chairs: Jane Aldrich, David Craik
Young Investigator Mini Symposium
16.15-16.30 MS1 - Jakob Gaar
Generation and characterisation of novel antibodies from selectively Advanced 
Glycation Endproduct (AGE) modified Collagen Model Peptides (CMPs)
16.30-16.45 MS2 - Lea Albert 
Light-controlled inhibition of MLL1 methyltransferase by azo-containing 
peptides: towards optoepigenetic leukemia regulation
16.45-17.00 MS3 - Chun Yuen Chow
Development of NaV-Selective Agonists with Potential for Treatment of Dravet 
Syndrome Epilepsy
17.00-17.15 MS4 - Varsha Thombare
Exploiting thioamide reactivity in peptide synthesis
17.15-17.30 MS5 - Karlijn Hollanders
Zn-catalyzed tert-butyl nicotinate-directed amide cleavage for applications in 
peptide synthesis and peptidomimetic design
17.30-17.45 MS6 - Daria Roshchupkina 
Synthesis of peptides glycated at Lys residues
17.45-18.00 MS7 - Tyler Lalonde
Targeting Ghrelin Receptor Homodimer: Bivalent Ligands with Exceptional 
Binding Affinity and Potency
18.00-18.15 MS8 - Elise Naudin
De novo designed proteins catalyzing amide bond forming reactions
18.15-18.30 MS9 - Sabine Schuster
Synthesis and biochemical evaluation of GnRH-III-drug conjugates
18.30-18.45 MS10 - Esben Matzen Bech
Directing PYY3-36 internalization through half-life extenders
18.45-19.00 MS11 - Clara Pérez-Peinado
Mechanisms of bacterial membrane permeabilization of snake venom-derived 
peptides crotalicidin (Ctn) and Ctn[15-34]
Pr
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August 28 Tuesday AM
Chair: Paula Gomes
08.30-09.10 IL3 - Marion de Jong
Theranostic radiopeptides
Chairs: Zbigniew Szewczuk, John Wade
Amino Acids, Proteins and Synthesis 1
09.10-09.25 OP11 - Chuanliu Wu
Multicyclic peptides constrained through noncanonical disulfide bonds and 
thioether crosslinks
09.25-09.40 OP12 - Tsubasa Inokuma
Novel methodology for the synthesis of α-indolyl-glycine containing peptide via 
direct asymmetric Friedel–Crafts reaction to peptidyl imine
09.40-09.55 OP13 - Muhammad Jbara
Palladium Prompted On-Demand Cysteine Chemistry for the Synthesis of 
Challenging Proteins
09.55-10.10 OP14 - William Lubell
Synthesis and Biomedical Applications of Substituted Amino-Lactam and 
Amino-Imididazolone Constraints
10.10-10.25 OP15 - Kirtikumar B Jadhav
Recombinant synthesis and purification of hTFF2 protein in S. Cerevisiae
Chair: Anna Maria Papini
11.00-11.30 IL4 - Meritxell Teixidó
Gate2Brain Shuttle Peptides, From Discovery to Applications
Chairs: Marion de Jong, Finbarr O'Harte
Biologically Active Peptides 2
11.30-11.45 OP16 - Evelien Wynendaele
Do Quorum Sensing Peptides Play a Role in Psychiatric Disorders?
11.45-12.00 OP17 - Hidehito Mukai
Mitocryptides: First Demonstration of Pathophysiological Involvements in 
Inflammatory Diseases
12.00-12.15 OP18 - Thibaut Thery
Antifungal activity and immunomodulation of a de novo synthetic peptide
12.15-12.30 OP19 - Shai Rahimipour
Targeting Amyloidogenic Proteins with Self-assembled Cyclic D,L-alpha-
Peptides
12.30-12.45 OP20 - Marina Rautenbach
Tyrocidines and Gramicidin S: Glorified cyclodecapeptide detergents or precise 
chemical scalpels
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August 28 Tuesday PM
Chairs: Florine Cavelier, Fintan Kelleher
Amino Acids, Proteins and Synthesis 2
16.15-16.30 OP21 - Robert Zitterbart
Enabling Parallel Peptide Purification by a Novel Traceless Purification Linker
16.30-16.45 OP22 - Christian Becker
Effects of non-enzymatic posttranslational modifications on protein function
16.45-17.00 OP23 - Yoshio Hayashi
A New Aspect of Npys-based Solid Phase Disulfide Peptide Synthesis
17.00-17.15 OP24 - Vincent Aucagne
N-2-hydroxybenzyl-cysteine peptide crypto-thioesters for native chemical 
ligation
17.15-17.30 OP25 - Sira Defaus
Expanding the potential and multivalency of the B2T synthetic peptide vaccine 
against foot-and-mouth disease virus
17.30-17.45 OP26 - Gerbrand van der Heden van Noort
A general method towards ADPr ribosylated peptides and proteins
Chairs: Meritxell Teixidó, John Howl
Prodrugs, Conjugates, Targeting and Uptake
17.45-18.00 OP27 - Ming-Hsin Li
A Novel Evans Blue Organic Compound-appended PSMA-617 Peptide as SPECT 
Molecule Imaging Agent for Human Prostate LNCaP Animal Model
18.00-18.15 OP28 - Gilles Subra
Sol-gel and peptides: an attractive route to unprecedented biomaterials
18.15-18.30 OP29 - Ikuhiko Nakase
Arginine-rich cell-penetrating peptide-modified exosomes for 
macropinocytosis induction and effective cellular uptake
18.30-18.45 OP30 - Adina Borbély
Novel Cryptophycin-based Conjugates for Tumor Targeting
18.45-19.00 OP31 - Conan Wang
A Journey Alongside Cyclosporin on the Road to Peptide Oral Bioavailability
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August 29 Wednesday AM
Chair: Paul Alewood
08.30-09.10 IL5 - Knud Jensen
Selective N-terminal acylation of peptides and proteins with an optimized His-
sequence
Chairs: Tamara Paypanova, William Lubell
Peptide Mimetics
09.10-09.25 OP32 - Jung-Mo Ahn
Structure-Based Design of Alpha-Helix Mimetics to Target and Disrupt Estrogen 
Receptor-Coregulator Interactions in Breast Cancer
09.25-09.40 OP33 - Jean-Alain Fehrentz
Ghrelin receptor ligands: from the bench to the drug on the market
09.40-09.55 OP34 - Stefan Roesner
Macrocyclization of Small Peptides Enabled by Oxetane Incorporation
09.55-10.10 OP35 - Carles Mas Moruno
The use of RGD peptidomimetics on biomaterials: new advances via selective 
integrin-subtype targeting
10.10-10.25 OP36 - Steven L Cobb
Stabilising Peptoid Helices Using Non-Chiral Fluoro-Alkyl Monomers
Chair: Norbert Sewald
11.00-11.30 IL6 - Beate Koksch
Fluorine in Peptide and Protein Engineering
Chairs: Ernest Giralt, Dick FitzGerald
Proteomics, Bioinformatics, Structural and Conformational Studies
11.30-11.45 OP37 - Jose Martins
Concerted biophysical and biological evaluation of Pseudomonas lipopeptides 
as a premise to unlock their application potential
11.45-12.00 OP38 - Andrew Jamieson
Rationally Designed Peptidomimetics
12.00-12.15 OP39 - Daniela Marasco
Amyloidogenicity of  regions of Nucleophosmin 1: a direct link between protein 
misfolding and Acute Myeloid Leukemia
12.15-12.30 OP40 - Quentin Kaas
Inhibition of nicotinic acetylcholine receptor subtypes by the ribbon isomers of 
α-conotoxins.
12.30-12.45 OP41 - Zbigniew Szewczuk
Quaternary Ammonium Isobaric Labeling for a Relative and Absolute 
Quantification of Peptides
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August 28 Wednesday PM
Chairs: Maria Luisa Mangoni, Wilfred van der Donk
Peptides in Chemical Biology and Therapeutics 1
16.15-16.30 OP42 - Andrew White
Development of serine protease inhibitors using the 1,2,3-triazole motif as a 
disulfide mimetic in the cyclic peptide sunflower trypsin inhibitor-1
16.30-16.45 OP43 - Dorien Van Lysebetten
Peptide-Bile acid Cyclisation as a Tool for the Development of a Universal 
Vaccine Against Influenza A
16.45-17.00 OP44 - Piotr A Mroz
Stereochemically modified glucagon with improved biophysical parameters
17.00-17.15 OP45 - Benjamin Liet
Design, synthesis and study of multimeric peptidic conjugates for a new 
approach of anti-tumoral immunotherapy
17.15-17.30 OP46 - Nir Qvit
Engineered protein-protein interaction regulators for therapeutic applications
17.30-17.45 OP47 - Victor J Hruby
Utilizing Combinations of New Approaches to Peptide and Peptidomimetic 
Design for G-Protein Coupled Receptors
Chairs: Nuno Santos, Kund Jensen
Nanotechnology, Imaging and Analytical Techniques
17.45-18.00 OP48 - Friedrich Bialas
Immobilising integral membrane proteins on silica
18.00-18.15 OP49 - Konstantin Kuhne
Cathepsin B-Activatable Cell-Penetrating Peptides for Imaging Cancer-related 
Cathepsin B
18.15-18.30 OP50 - Neil O'Brien-Simpson
Designing antibiotic peptide polymer adjuvants for multidrug resistant bacteria
18.30-18.45 OP51 - Dorian J Mikolajczak
Tuning the Catalytic Activity and Substrate Specificity of Peptide-Nanoparticle 
Conjugates
18.45-19.00 OP52 - Ramon Subiros-Funosas
Lighting up programmed cell death in real-time: apoTRACKER as an in vivo 
compatible apoptosis diagnostic tool
Pr
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August 30 Thursday AM
Chair: Luis Morodor
08.30-09.10 IL7 - Dek Woolfson
Peptide design and assembly: from the test tube to inside cells
Chairs: Alethea Tabor, Gábor Mező
Peptides in Chemical Biology and Therapeutics 2
09.10-09.25 OP53 - Anne Conibear
Synthetic integrin-binding immune stimulators target cancer cells and prevent 
tumor formation.
09.25-09.40 OP54 - Ana Salomé Veiga
Activity of the viral-derived peptide pepR against Staphylococcus aureus 
biofilms and insights into the mechanism of action
09.40-09.55 OP55 - Timothy Reichart
Development of Mirror-Image Monobodies for Targeted Cancer Therapies
09.55-10.10 OP56 - Paul Alewood
Subtle modifications to oxytocin produce ligands that retain potency and 
improved selectivity across species
10.10-10.25 OP57 - Roland Hellinger
Cyclotides as novel inhibitors of the human prolyl oligopeptidase
Chair: Norbert Sewald
11.00-11.30 IL8 - Wilfred van der Donk
Posttranslational Modifications during Cyclic Peptide Biosynthesis
Chairs: Rosario Gonzalez-Muñiz, Christian Gruber
Peptides in Chemical Biology and Therapeutics 3
11.30-11.45 OP58 - Youhei Sohma
Near-infrared photoactivatable oxygenation catalyst of amyloid peptide
11.45-12.00 OP59 - Minying Cai
Development of the MC1R Selective Ligands for the Melanoma Prevention
12.00-12.15 OP60 - Sónia Henriques
Is the mirror image a true reflection? Lipid chirality in the activity of the 
prototypic cyclotide kalata B1
12.15-12.30 OP61 - Jane Aldrich
Substitution of Aromatic Residues in the Macrocyclic Opioid Peptide [D-Trp]CJ-
15,208 Alters the Opioid Activity Profile in vivo
12.30-12.45 OP62 - Maayan Gal
Developing novel bi-specific peptide as an immunosuppressant using directed-
evolution optimization
Pr
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August 30 Thursday PM
Chair: Maurice Manning
14.15-14.45 Glenn F King
From pain to pain-killers: using spider-venom peptides to help us understand 
and treat chronic pain
Chairs: Beate Koksch, Ale Närvänen
Peptides in Chemical Biology and Therapeutics 4
14.45-15.00 Christina Schroeder
The use of peptide-membrane interactions in the design of selective and 
potent sodium channel inhibitors
15.00-15.15 Lydia Behring
Dipeptide-derived Alkynes as Novel Irreversible Inhibitors of Cathepsin B
15.15-15.30 Tamis Darbre
Potent Antimicrobial Peptide Dendrimers against Multi-Drug Resistant 
Pseudomonas aeruginosa and Acinobacter baumanii
15.30-15.45 Garry Laverty
Modifying short phenylalanine-phenylalanine peptide sequences to create 
multifunctional nanomaterials with biomaterial and drug delivery applications
Chairs: Norman Metanis, Steven Ballet
Amino Acids, Proteins and Synthesis 3
16.15-16.30 Abhishek Iyer
Reviving Old Protecting Group Chemistry for Site-Selective Peptide-Protein 
Conjugation
16.30-16.45 Hironobu Hojo
Use of selenoester for the efficient synthesis of protein
16.45-17.00 Hannes Ludewig
Eukaryotic macrocyclases enhance biocatalytic production of cyclic peptides
17.00-17.15 Juergen Machielse
Cost Effective peptide Purification via ZEOsphere DRP Mixed-Mode 
Chromatography
17.15-18.00 CLOSING CEREMONY
18.00-20.00 BACHEM RECEPTION
20.00-22.00 CONFERENCE BANQUET
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AL1/A228
Lessons from Selenium Chemistry to Study Protein Science
Norman Metanis
HUJI, Israel
Selenium occurs rarely in natural proteins, but is becoming a commonly used element in unnatural contexts to aid in the study of protein structure and
function. In its natural context, selenium’s role remains uncovered in half of the 25 human selenoproteins. With the aid of chemical protein synthesis, a
full characterization of many of these proteins looms close on the horizon. In unnatural contexts, selenium serves as a traceless handle in native chemical
ligations and as a folding chaperone. New amino acids containing selenium allow previously unfavorable protein syntheses to occur with good yield.
These lessons also allow us to study protein chemistry without the use of selenium. We will discuss selenium’s contributions to protein chemistry thus
far, as well as its potential in future applications.
AL2/A235
The power of chemoselectivity: Functional peptide- and protein-conjugates for extra- and intracellular targeting
Christian Hackenberger
FMP and HU Berlin, Germany
Our lab aims to identify new bioorthogonal reactions for the synthesis and modification of functional peptides and proteins. We apply these highly
selective organic reactions1 to study functional consequences of naturally occurring posttranslational protein modifications (PTMs), in particular phos-
phorylated Lys- and Cystein-peptides,2 as well as to generate novel peptide- and protein-conjugates for pharmaceutical and medicinal applications. In
this presentation l will focus on the chemical modification of functional proteins as well as their cellular delivery. Thereby, we employ cyclic cell
penetrating peptides (cCPPs) to transport a functional full length protein to the cytosol of living cells as recently demonstrated by the direct delivery of
GFP-conjugates.3 For protein modification we use a combined approach of intein expression as well as recently developed bioorthogonal reactions and
enzymatic ligations, for instance the so-called Tub-tag labeling.4 This concept is finally applied to generate new antibody-drug conjugates, multivalent
protein-scaffolds as well as cell-permeable nanobodies, i.e. small antigen binding proteins that remain active within the reductive milieu inside living
cells, to interfere with intracellular targets.5
References 1. D. Schumacher, C.P.R. Hackenberger, Curr. Opin. Chem. Biol. 2014, 22, 62-69. 2. a) J. Bertran-Vicente, R.A. Serwa, M. Schümann,
P. Schmieder, E. Krause, C.P.R. Hackenberger, J. Am Chem. Soc. 2014, 136(39), 13622-13628; b) J. Bertran-Vicente, M. Penkert, O. Nieto, M.
Schümann, P. Schmieder, E. Krause, C.P.R. Hackenberger, Nature Comm. 2016, 7,12703. 3. N. Nischan, H.D. Herce, F. Natale, N. Bohlke, N. Budisa,
M.C. Cardoso, C.P.R. Hackenberger, Angew. Chem. Int. Ed. 2015, 54(6), 1950-1953. 4. a) D. Schumacher, J. Helma, F.A. Mann, G. Pichler, F. Natale,
E. Krause, M.C. Cardoso, C.P.R. Hackenberger, H. Leonhardt, Angew. Chem. Int. Ed. 2015, 54(46), 13787-13791, b) D. Schumacher, O. Lemke,
J. Helma, L. Gerszonowicz, V. Waller, T. Stoschek, P.M. Durkin, N. Budisa, H. Leonhardt, B.G. Keller, C.P.R. Hackenberger, Chem. Sci. 2017, 8,
3471-3478 5. H. Herce, D. Schumacher, F.A. Mann, A. Ludwig, A. Schneider, M. Filies, S. Reinke, C. Cardoso, C.P.R. Hackenberger, Nature Chem.
2017, 9, 762-771.
AL3/A247
Advances in Site-specific and Linkage-specific Ligation
James Tam
School of Biological Sciences, Synzymes and Natural Products Center, Nanyang Technological University, Singapore
Over the past 25 years, major advances are ligation chemistries to form peptide or non-peptide bonds between molecules. These advances are enabled
by the development of novel chemical ligation methods and expansion of genetic condons as well as the discovery of inteins and peptide ligases. Of
particular interest to our laboratory are methods to bond specifically between peptides, peptide-to-protein, and protein-to-protein, without protecting
groups, activating agents and under aqueous conditions. Here, I will present our work in ligation chemistry to enable site-specific bonding of chemicals,
polymers, peptides and proteins to form new compounds under physiological conditions. In particular, I will discuss our work on the Asx-specific
peptide ligases such as the Butelases which act as peptide stapler or superglue for labeling proteins and live cells as well as precision biomanufacturing
industrial enzymes and therapeutics.
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IL1
Adventures in Drugging Undruggable Targets
David Spring
University of Cambridge, United Kingdom
The pharmaceutical industry is an enormously successful business sector.
However, the current challenges facing the industry are unprecedented. A
high attrition rate of clinical candidates (ca. 93-96%) is prevalent through-
out the industry. My talk aims to highlight some of the underlying factors
of this. Namely, (1) the relative lack of structural diversity and (2) the rela-
tive lack of targets exploited in drug discovery. The talk will include recent
research within my laboratory aimed at addressing these issues, especially
our work on conformationally constrained peptides.
IL2
The design and assessment of the therapeutic potential
of apelin-13 peptide mimetics for alleviating metabolic
dysfunction in diabetes and obesity
Finbarr O’Harte
Ulster University, United Kingdom
Peptides involved in cross-talk between tissues could hold multiple benefi-
cial metabolic effects which in turn could be harnessed for drug develop-
ment. With the success of glucagon-like peptide-1 (GLP-1) mimetics for
treating Type 2 diabetes over the past two decades, interest in the potential
of peptide therapeutics for managing metabolic disorders has increased.
Peptides have the ability to target specific receptors in multiple tissues and
improve various metabolic functions. This work will focus on stable pep-
tide mimetics of the adipokine apelin-13, which we have shown has im-
portant anti-diabetic and anti-obesity actions. Preproapelin processing in
adipose tissue leads to the production of multiple molecular isoforms de-
rived from the C-terminal region of the 58 amino acid precursor, including
apelin-36, -17, -13 and pGlu-apelin-13. Apelin-13 remains the smallest
bioactive form of the peptide which binds to the cognate APJ receptor.
Apelin is already well recognised for its benefits in cardiovascular physiol-
ogy. Here we have produced multiple stable mimetics of apelin-13 which
show very promising metabolic benefits in various mouse models of obe-
sity and diabetes. The work of designing, testing their efficacy in vitro
using cell models, assessing their stability in mouse plasma and their acute
and chronic metabolic actions in vivo will be covered here. Selected sta-
ble apelin-13 analogues were tested in comparative studies against estab-
lished GLP-1 mimetics such as exendin-4 and liraglutide, in high fat fed
diet induced obese diabetic mice, as well as diabetic db/db mice. Chronic
treatment with acylated apelin-13 analogues show similar or enhanced ther-
apeutic benefit compared with incretin mimetics in diabetic mice. In con-
clusion, these analogues show promising anti-diabetic and anti-obesity ac-
tions which could be further exploited to target these common metabolic
diseases.
IL3
Theranostic radiopeptides
Marion De Jong
Erasmus MC Rotterdam, Netherlands
One of the research programs of the department of Radiology at the Eras-
mus MC in Rotterdam focuses on peptide receptor-targeted imaging (PRI),
applying positron emission tomography (PET) and single photon emission
computed tomography (SPECT), and peptide receptor-targeted radionu-
clide therapy (PRRT) of receptor-positive cancers with radiolabelled pep-
tides. Selective receptor-targeting radiopeptides have emerged as a very
important class of radiopharmaceuticals for molecular imaging and ther-
apy of tumours that overexpress peptide receptors on the cell membrane.
After such peptides labeled with gamma-emitting radionuclides bind to
their receptors, they allow visualization of receptor-expressing tumors non-
invasively. Peptides labeled with beta- or alpha-particle emitters can erad-
icate receptor-expressing tumors. In the clinic we imaged thousands pa-
tients using radiolabelled somatostatin analogues, whereas over 2000 treat-
ments were given. Our efforts now concentrate on widening the thera-
peutic window by combination therapies, increasing the tumour radiation
dose, and/or decreasing the dose to the normal, healthy, organs. Finally we
aim at curing these now incurable metastasized cancers. We also design
and evaluate analogues of other peptides, including bombesin, CCK, and
neurotensin analogues, that bind to their receptors in a variety of different
tumours, to expand the panel of tumours to be imaged and treated.
IL4
Gate2Brain Shuttle Peptides, From Discovery to
Applications.
Meritxell Teixidó
IRB Barcelona, Spain
Gate2Brain shuttle peptides represent salvage for new or previously re-
jected CNS drug candidates by providing a way to cross the blood-brain
barrier (BBB).
Gate2Brain technology consist on a toolbox of peptides able to cross the
BBB and carry compounds covalently attached (including small molecules,
peptides, proteins, antibodies, plasmids, siRNA or mRNA loaded nanopar-
ticles, etc. . . ) that cannot cross this barrier unaided. They have proofed
to carry these cargoes in vitro and in vivo. These peptide shuttles use the
existing transport mechanisms at the BBB without affecting the normal
functioning of these mechanisms and preserving brain homeostasis.
By improving the delivery of therapeutic candidate to the CNS, we will
ensure immediate impact in many CNS diseases patients. In addition, in
a broader perspective, Gate2Brain technology may help to repurpose ex-
isting therapies previously rejected because of difficulty to reach the brain,
accelerating the translation towards clinical development. Gate2Brain will
also result in the application of lower concentrations of therapeutic agent,
thereby significantly lowering systemic side effects and reducing the cost
of the treatment.
Gate2Brain peptides combine protease resistance, capacity to carry a wide
range of cargoes thanks to their versatility, low production costs, and low
immunogenic risk. They provide a non-invasive, non-antigenic, permeable,
stable, soluble and receptor-specific way to transport drugs across the BBB
and into the CNS.
References:
1 B. Oller-Salvia et al. Chem. Soc. Rev. (2016), 45, 4690-4707. 2. M.
Sánchez-Navarro et al. Curr. Opin. Chem. Biol. (2017), 38, 134-140. 3.
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M. Sánchez-Navarro et al. Acc. Chem. Res. (2017), 50, 1847-1854. 4.
R. Prades et al. Angew. Chem. Int. Ed. (2015), 54, 3967-3972. 4. B.
Oller-Salvia et al. Angew. Chem. Int. Ed. (2016), 55, 572-575.
IL5
Selective N-terminal acylation of peptides and proteins
with an optimized His-sequence
Knud J. Jensen
University of Copenhagen, Denmark
Site-selective modification of proteins is highly desirable for the controlled
introduction of bioorthogonal handles, small probes like biotin, or larger
moieties such as PEG. Due to their general applicability, chemical meth-
ods targeting the N-terminus are highly attractive. We set out to develop
a new, flexible and mild method for selective N-terminal acylation of pro-
teins. The starting point was a side-reaction found to occur during protein
expression, where an N-terminal His-tag reacts with gluconolactone. First,
we optimized the N-terminal end to promote its selective acylation. We dis-
covered that Gly-His3-6 promoted near-quantitative N-terminal acylation.
Next, we fine-tuned the acylating agents, with 4-methoxyphenyl esters pro-
viding excellent selectivity. Finally, the method was successfully applied
to three model proteins. Maltose-binding protein, a small ubiquitin-like
modifier, and enhanced green-fluorescent protein were selectively modi-
fied with azido and biotin moieties. We believe that this novel and highly
selective method could find general application for the chemical modifica-
tion of expressed proteins.
IL6
Fluorine in Peptide and Protein Engineering
Beate Koksch
Freie Universität Berlin, Institute for Chemistry and Biochemistry,
Germany
In a league of its own, fluorine has the potential to enable us to engineer
biopolymers with highly desirable properties. However, the particular chal-
lenge in using it as a tool lies in our ability to juggle the interplay between
the specific properties of the fluorinated building block and its responsive-
ness to the environment it is exposed to. Fluorine has been shown to impart
often favorable but seldom predictable properties to peptides and proteins,
a phenomenon that is caused by the nature of the fluorine atom and prop-
erties of the C-F bond. Up until about two decades ago, the outcomes of
fluorine modification of peptides and proteins were largely left to chance.
Driven by the motivation to extend the application of the unique properties
of the element fluorine from medicinal and agro chemistry to peptide and
protein engineering we have established multiple peptide and protein mod-
els with different properties for the purpose of studying the consequences
of fluorine substitution in the context of a protein environment. In gen-
eral, the consequences of incorporating the C-F bond into a biopolymer
can be attributed to two distinct yet related phenomena: 1) the fluorine
substituent can directly engage in intermolecular interactions with its en-
vironment and/or 2) the other functional groups present in the molecule
can be influenced by the electron withdrawing nature of this element (in-
tramolecular) and in turn interact differently with their immediate environ-
ment (intermolecular). Also, we could show that not only the nature of the
side chain but also its immediate environment determine the outcome of
this substitution. We have especially been fascinated to observe that the
difference of as subtle as one fluorine atom in the side chain of an amino
acid can dramatically influence the key properties of peptides and proteins
such as hydrophobicity, polarity and secondary structure propensity. These
properties are crucial factors in peptide and protein engineering as they di-
rect properties as important as proteolytic stability and folding, and thus
affect protein function. One of our current projects studies the way in
which not just biomolecules in the laboratory, but whole living organisms
accommodate fluorine and this talk will introduce our first results of this
endeavor.
IL7
Peptide design and assembly: from the test tube to
inside cells
Dek Woolfson
Schools of Chemistry and Biochemistry & Bristol BioDesign Institute,
University of Bristol, United Kingdom
Protein design—that is, the construction of entirely new protein sequences
that fold into prescribed structures—has come of age. It is now possible
to design proteins de novo using simple rules of thumb or computational
design methods. The designs can be made rapidly via peptide synthesis
or the expression of synthetic genes; and the resulting proteins can usually
be characterised all the way through to high-resolution X-ray crystal struc-
tures. Contemporary questions in the protein-design field include: What
do with these new-found skills? What protein structures and functions do
we target? How far can we move past the confines of natural protein struc-
tures and functions? And, how can we take protein design from an exercise
largely done in silico and in vitro into a truly synthetic biology and take it
in vivo?
This talk will address these questions with reference to simple through to
complex and functional peptide designs and assemblies that we have ex-
plored over the past 5 – 10 years. These use a straightforward protein
structure, called the α-helical coiled coil, which are bundles of 2 or more
α helices found in many protein-protein interactions. Coiled coils provide
an excellent basis for building proteins from the bottom up.
The vast majority of coiled-coil designs have been based on simple rules of
thumb learnt from natural proteins or derived empirically through experi-
ment.1 These rules relate sequence to structure to guide the specification of
coiled-coil oligomerization state, strand orientation, partner selection, and,
to some extent, stability. This has been extremely informative and pro-
ductive, and design and engineering is probably more advanced for coiled
coils than for any other protein structure.2 However, to move past the low-
hanging fruit of coiled-coil design, and into the so-called dark matter of
protein structures, we will all have to learn new tricks. To address this we
have begun to tackle coiled-coil design parametrically using computational
methods.3 We have developed easy-to-use computational modelling tools4
and a more-sophisticated suite of programs called ISAMBARD5 that allow
the rapid generation and optimisation of protein designs in silico.
References De novo protein design: how do we expand into the universe
of possible protein structures? Curr Opin Struct Biol 33, 16-26 (2015)
Engineered synthetic scaffolds for organizing proteins within the bacterial
cytoplasm. Nature Chem Biol 14, 142-147 (2018)
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IL8
Posttranslational Modifications during Cyclic Peptide
Biosynthesis
Wilfred van der Donk
Department of Chemistry and Howard Hughes Medical Institute,
University of Illinois at Urbana-Champaign, United States
The genome sequencing efforts of the first decade of the 21st century
have revealed that ribosomally synthesized and post-translationally mod-
ified peptides (RiPPs) constitute a very large class of peptide natural prod-
ucts. These molecules are produced in all three domains of life, their
biosynthetic genes are ubiquitous in the currently sequenced genomes,
and their structural diversity is vast. Lanthionine-containing peptides
(lanthipeptides) are examples of this growing class and many members
are highly effective antimicrobial agents that display nanomolar mini-
mal inhibitory concentrations (MICs) against pathogenic bacteria (lantibi-
otics). These peptides are post-translationally modified to install multiple
thioether crosslinks. During their biosynthesis, a single enzyme typically
breaks 8-16 chemical bonds and forms 6-10 new bonds with high control
over regio- and chemoselectivity. This presentation will discuss investiga-
tions of the mechanisms of these remarkable catalysts as well as their use
for the generation of non-natural cyclic peptide libraries.
IL9
From pain to pain-killers: using spider-venom peptides
to help us understand and treat chronic pain
Glenn King
The University of Queensland, Australia
Most venoms have evolved to facilitate defense against predators, either
as the sole purpose of the venom (e.g., bees and caterpillars) or as a func-
tion that is secondary to its role in predation (e.g., centipedes, cone snails,
snakes, and spiders). In most cases, the primary method of predator de-
terrence is the injection of venom peptides that cause immediate, intense
pain. We are taking advantage of the ability of venoms to robustly activate
nociceptive pathways in mammalian neurons to interrogate novel pain sig-
naling mechanisms and identify new analgesic drug targets. Moreover,
since the venoms of arthropod predators such as spiders are dominated by
disulfide-rich peptides that target a wide variety of ion channels, we are
screening these natural combinatorial libraries to identify peptides that tar-
get newly identified ion channel drug targets.
We used this approach to show, for the first time, that the voltage-gated
sodium channel Nav1.1 is involved in transduction of mechanical pain,
such as the abdominal pain that occurs in inflammatory bowel syndrome
(IBS). This was made possible by isolation of a spider-venom peptide
(Hm1a) that selectively inhibits inactivation of Nav1.1, and to a lesser
extent Nav1.3, without affecting any of the other seven human sodium
channel subtypes [1]. We show that Hm1a inhibits channel inactivation by
impeding movement of the domain IV voltage sensor, which is linked to
the channel inactivation gate. By screening a large panel of spider venoms
we isolated several disulfide-rich peptides that selectively inhibit activa-
tion of Nav1.1 and the well known analgesic target Nav1.7. We have used
these peptides to show that dual targeting of these channels is an effective
strategy for abrogating gut pain in a mouse model of IBS.
[1] Osteen JD, Herzig V, Gilchrist J, Emrick JJ, Zhang C, Wang X, Castro
J, Garcia-Caraballo S, Grundy L, Rychkov GY, Dekan Z, Undheim EAB,
Alewood PF, Brierley SM, Basbaum AI, Bosmans F, King GF & Julius
D (2016) Selective spider toxins reveal a role for the Nav1.1 channel in
mechanical pain. Nature 534, 494–499.
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OP1
Lipid domain formation induced by antimicrobial
peptides OP-145 and SAAP-148 results in efficient
killing of Escherichia coli
Nermina Malanovic1, Ayse Ön1, Jan Wouter Drijfhout2,
Karl Lohner1
1University of Graz, Institute of Molecular Biosciences, Biophysics
Division, Graz, Austria
2Leiden University Medical Center, Leiden, Netherlands
OP-1451 and SAAP-1482, two amphipathic antimicrobial peptides devel-
oped from the human cathelicidin LL-37, kill Gram-positive bacteria such
as Staphylococcus aureus by permeabilizing the cytoplasmic membrane
interacting preferentially with their major lipid constituent, the negatively
charged phosphatidylglycerol. Both peptides also kill Gram-negative bac-
teria at similar concentrations. Here, we show that the killing of Es-
cherichia coli does not fully correlate with membrane permeabilization
of live bacteria, although both peptides neutralize the surface charge of
Escherichia coli as shown by Zeta potential measurements. Whereas
both peptides fully permeabilize membranes composed of phosphatidyl-
glycerol, they exhibit limited permeabilization of membranes composed
of either lipids extracted from Escherichia coli or mixtures of synthetic
phosphatidylglycerol/phosphatidylethanolamine/cardiolipin, which mimic
the inner membrane of Gram-negative bacteria. Nevertheless, differential
scanning calorimetry studies clearly indicate lipid domain formation and
a disordering of the lipid chain packing. Formation of lipid domains is
also observed in staining experiments on live Escherichia coli using the
fluidity sensitive dye Nile Red. Interestingly, the concentration-dependent
domain formation is in accordance to the killing rate of Escherichia coli.
[1] Malanovic et al, Biochim Biophys Acta. 2015.; [2] de Breij et al, Sci
Transl Med. 2018
OP2
Engineering Hybrid Peptidomimetics for Improved
Pain Treatments
Steven Ballet
Research Group of Organic Chemistry, Departments of Chemistry and
Bioengineering Sciences, Vrije Universiteit Brussel, Belgium
To address the different types of pain, different classes of medications,
mainly non-steroidal anti-inflammatory drugs and narcotics (opioids), are
used. The alleviation or treatment of moderate to severe pain states, in par-
ticular, commonly invokes the use of opioids. Unfortunately, their chronic
administration induces various undesirable side effects. One strategy to
overcome these major side effects and to prolong the antinociceptive effi-
ciency of the applied drugs involves the creation of multifunctional com-
pounds which contain hybridized structures. Combination of opioid ago-
nist and antagonist pharmacophores in a single chemical entity has been
considered and extensively investigated, but opioids have also been com-
bined with non-opioid bioactive neurotransmitters and peptide hormones
that are involved in pain perception (e.g. substance P, neurotensin, etc.).[1]
Such novel chimeras (also called designed multiple ligands or DMLs), may
interact independently with their respective receptors and potentially re-
sult in more effective antinociceptive properties. The designed multiple
ligands presented in this work include peptide-based opioid-non-opioid
dimer analogs, such as for example opioid-neurokinin 1 receptor,[2,3]
opioid-nociceptin [4] and opioid-neuropeptide FF DMLs.[5] Some of the
prepared ligands demonstrated to be dually effective in both acute and neu-
ropathic pain models. Gratifyingly, compounds with reduced analgesic
(cross-)tolerance (with morphine), physical dependence, and respiratory
depression were unraveled. The synthesis and in vitro and in vivo phar-
macological evaluation will be discussed. Additionally, another type of
hybridization will be presented: a fusion between opioid pharmacophores
and hydrogel-forming hexapeptide sequences. While the above opioid
pharmacophores induce analgesic effects up to 8 hours post injection, fu-
sion with self-assembling hexapeptide sequences allowed formation of in-
jectable hydrogels, which slowly degrade subcutaneously after injection.
This innovative controlled-drug delivery method gave antinociceptive ef-
fects of 72-96h.[6] The generic nature of this methodology indicates that
this system could be broadly applicable to other biologically active pep-
tides as well.
[1] Kleczkowska, P. et al. Curr. Pharm Des. 2013, 19, 7435-7450. [2]
Guillemyn, K. et al. Eur. J. Med. Chem. 2015, 92, 64-77. [3] Betti, C. et
al. ACS Med. Chem. Lett. 2015, 6, 1209-1214. [4] Guillemyn, K. et al. J.
Med. Chem. 2016, 59, 3777-3792. [5] Ballet, S. et al. Pain, in press. [6]
Martin, C. et al. unpublished data.
OP3
An engineered cyclic peptide alleviates symptoms of
inflammation in a murine model of inflammatory
bowel disease
Claudia Cobos Caceres, Paramjit Bansal, Severine Navarro,
David Wilson, Laurianne Don, Paul Giacomin, Alex
Loukas, Norelle Daly
James Cook University, Australia
Inflammatory bowel diseases (IBDs) are a set of complex and debilitat-
ing diseases, for which there is no satisfactory treatment. Recent studies
have shown that small peptides show promise for reducing inflammation
in models of IBD. However, these small peptides are likely to be unsta-
ble and rapidly cleared from the circulation, and therefore, if not modi-
fied for better stability, represent non-viable drug leads. We hypothesized
that improving the stability of these peptides by grafting them into a sta-
ble cyclic peptide scaffold may enhance their therapeutic potential. Using
this approach, we have designed a novel cyclic peptide, which comprises
a small bioactive peptide from the annexin A1 protein grafted into a sun-
flower trypsin inhibitor cyclic scaffold. We used native chemical ligation
to synthesize the grafted cyclic peptide. This engineered cyclic peptide
maintained the overall fold of the naturally occurring cyclic peptide, was
more effective at reducing inflammation in a mouse model of acute colitis
than the bioactive peptide alone, and showed enhanced stability in human
serum. Our findings suggest that the use of cyclic peptides as structural
backbones offers a promising approach for the treatment of IBD and po-
tentially other chronic inflammatory conditions.
OP4
Penetrating the Impenetrable: Progress towards a
Non-hormonal Male Contraceptive
Sarah Jones, John Howl
University of Wolverhampton, United Kingdom
The intracellular delivery of bioactive agents and subsequent therapeu-
tic manipulation of sperm physiology poses a significant challenge. The
sperm plasma membrane presents a static physical barrier and mechanisms
such as endocytosis, which facilitate the movement of macromolecules
into the majority of eukaryotic cells, are severely restricted in mature sper-
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matozoa. This limitation is further compounded by the fact that at the
time mammalian sperm are released into the seminiferous tubules, the pro-
cesses of transcription and translation have largely been silenced thus limit-
ing therapeutic targets to protein-protein interactions and post-translational
modifications. We have previously established that cell penetrating pep-
tides (CPPs) rapidly and efficiently enter bovine and human spermatozoa
whilst being compatible with sperm physiology. Moreover, a range of
structurally diverse CPPs demonstrate a propensity to accumulate in dif-
ferent sperm compartments, thus propounding their utility for the deliv-
ery of bioactive cargoes to specific intracellular loci [1,2]. The develop-
ment and application of bioportides, bioactive cell permeable peptides that
mainly act by a dominant-negative mode of action, is a unique approach
to the regulation of sperm physiology. Identified by QSAR prediction
algorithms designed to recognize CPPs within entire proteins or sites of
protein-protein interactions, bioportides possess the dual features of cellu-
lar penetration and biological activity and are therefore distinct from the
more commonly used inert vectors such as tat and penetratin [3]. As an ini-
tial proof of concept we utilized bioportide technology to modulate Ca2+
signalling in human spermatozoa, which governs fundamental processes
such as hyperactivation, capacitation and the acrosome reaction. Synthe-
sis and evaluation of STIM371-392, a candidate bioportide corresponding
to the cationic region the STIM1-Orai1-activating domain of STIM1, an
endoplasmic reticulum calcium sensor and regulator of [Ca2+]i, sustained
progesterone-induced [Ca2+]i transients in human spermatozoa[2]. Our
recent endeavours have focused on bioportides that control male fertility.
Sperm motility, a prognostic parameter of human fertilization capacity, is
regulated by the activity of a male gamete-specific isoform of phosphopro-
tein phosphatase 1 (PPP1), phosphoprotein phosphatase 1 catalytic subunit
gamma 2 (PP1gamma2) during epididymal transit. Bioportides designed
to target the PP1gamma2 interactome, discretely and rapidly inhibit hu-
man sperm motility and have proven unmatched potential for validation
as a non-hormonal male contraceptive [4]. In conjunction with Margarida
Fardilha at the University of Aviero, our strategy has been to selectively
target post-testicular events with these peptide therapeutics and in doing
so, avoid the many side effects associated with hormonal-based male con-
traception. Our current objective is to further develop these bioportides
towards clinical utility as a potential contraceptive option.
1. Jones S, et al. Hum. Reprod. 2013, 25, 1874-1889. 2. Morris J, et
al. Mol. Hum. Reprod. 2015, 21, 563-570 3. Howl J, Jones S. Expert
Rev. Mol. Med. 2015, 17, e1 doi.org/10.1017/erm.2014.24 4. UK Patent
Application No.1711620.3 filed 19th July 2017.
OP5
Peptide-Based Biopesticides
Marta De Zotti, Luca Sella, Fernando Formaggio,
Francesco Favaron
University of Padova, Italy
In this presentation we describe the great potential of peptides as biopes-
ticides. Currently Europe is greatly encouraging research in sustainable
pest-management. Finding eco-friendly, effective alternatives to synthetic
pesticides is of paramount importance, especially against the so-called pri-
ority pests of fruits and vegetables. For some of these pests, such as botry-
tis cinerea and peronospora viticola, no effective bio-alternatives to small
organic molecules are available so far. Fungi belonging to the genus Tri-
choderma are distributed worldwide and have been used successfully in
field trials against many crop pathogens. They produce peptaibols, a pe-
culiar family of peptides, as part of their defense system against other
microorganisms. Such secondary metabolites are known for their plant-
protection properties: they (i) possess antimicrobial activity, (ii) act as stim-
ulants of plant defences and growth (iii) elicit plant production of volatiles
to attract natural enemies of herbivorous insects. By means of a versatile
SPPS strategy, we produced several analogs of such naturally occurring
peptides. With such compounds, we can circumvent both the health haz-
ards and the unreliable effectiveness in open field connected with the use
of antagonistic microorganisms as biological control agents, while keep-
ing the biomolecules responsible for their beneficial effects. Our peptides
have been tested (alone or in combination) both in vitro and in vivo against
a variety of priority pests, such as the fungi Botrytis cinerea and Penicil-
lum italicum, and the bacterium Pectobacterium carotovorum. We identi-
fied several peptaibol analogs with a broad-spectrum activity as biopesti-
cides, able to completely inhibit the growth of B. cinerea and many other
pathogens for over a week at low micromolar concentrations.
OP6
Development and Exploitation of Photo-Crosslinking
Methodology to Study Protein-Protein Interactions
Andrew Wilson
University of Leeds, United Kingdom
A key problem in life-sciences research is to understand protein-protein
interactions (PPI) with molecular and temporal resolution – this would
allow the identification of the transient intermediates that play key roles
in the function of biomacromolecular machines, signalling, translocation
and folding to illuminate our understanding of disease development e.g.
aberrant intracellular cell signalling in cancer and aggregation in amy-
loid disease. In this presentation we will describe our latest develop-
ments in the area of photo-activated peptide/protein labelling and cross-
linking chemistry. In the first section we will discuss the development of a
suite of diazirine-based cross-linking reagents; these reagents could trans-
form structural proteomics methodology. Diazirines are ideal cross-linking
groups because upon excitation with UV light, they generate highly reac-
tive carbenes capable of indiscriminate insertion into proximal bonds.[1]
We are interested in applying these reagents to study β -sheet mediated
PPIs specifically assembly of peptides into amyloid fibrils[2] and will il-
lustrate how, in combination with state-of the art mass-spectrometry, cross-
linking encodes non-covalent structure in cross-linked peptides.[3] In the
second part of the presentation, focusing on the helix mediated NOXA-
B/MCL-1 PPI[4] we will describe efforts to develop peptides conjugated
to ruthenium (II) (tris)chelates as reagents that can perform photo-activated
traceless protein-labelling reactions[5] – a necessary first step in being able
to label proteins in live cells without abrogating their normal function
References [1] G. W. Preston, A. J. Wilson, Chem. Soc. Rev. 2013, 42,
3289. [2] P.-N. Cheng, J. D. Pham, J. S. Nowick, J. Am. Chem. Soc.
2013, 135, 5477. [3] G. W. Preston, S. E. Radford, A. E. Ashcroft, A. J.
Wilson, ACS Chem. Biol. 2014, 9, 761; G. W. Preston, S. E. Radford, A.
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E. Ashcroft, A. J. Wilson, Anal. Chem. 2012, 84, 6790. [4] J. A. Miles,
D. J. Yeo, P. Rowell, S. Rodriguez-Marin, C. M. Pask, S. L. Warriner, T.
A. Edwards, A. J. Wilson, Chem. Sci. 2016, 7, 3694. [5] Y. Takaoka, A.
Ojida, I. Hamachi, Angew. Chem. Int. Ed. 2013, 52, 4088; S. Sato, H.
Nakamura, Angew. Chem. Int. Ed. 2013, 52, 8681.
OP7
Toward homogeneous glycoproteins via
auxiliary-assisted sequential glycosylation and ligation
of peptides
Claudia Bello1, Anna Maria Papini2, Christian F.W.
Becker3
1University of Florence, Department of Chemistry “Ugo Schiff”,
Interdepartmental Laboratory of Peptide & Protein Chemistry & Biology,
Italy and University of Vienna, Faculty of Chemistry, Institute of
Biological Chemistry , Austria
2University of Florence, Department of Chemistry “Ugo Schiff”,
Interdepartmental Laboratory of Peptide & Protein Chemistry & Biology,
Italy
3University of Vienna, Faculty of Chemistry, Institute of Biological
Chemistry, Austria
Having access to homogeneous proteins carrying complex posttransla-
tional modifications (PTMs) is essential for studying the role of the PTMs
in protein function and misfunction.
We established a strategy for the synthesis of peptides carrying multiple
and complex PTMs, focusing at first on the preparation of homogenously
glycosylated peptides. The tumor marker MUC1, a protein abundantly
O-glycosylated in his extracellular domain, was chosen as synthesis target.
Chemically synthesized mucin peptides are conjugated to a photocleavable
ligation auxiliary [1], obtained via multistep synthesis, that supports native
chemical ligation (NCL) and carries a PEG polymer. This facilitates effec-
tive enzymatic glycosylation and recovery of the resulting glycopeptides
without the need for chromatographic steps [2]. It also gives access to
glycosylated peptide α-thioesters that are otherwise inaccessible [3]. The
conjugates are linked to each other via auxiliary-mediated NCL and the
ligation products are recovered as unprotected glycopeptides after UV irra-
diation.
Currently a library of mucin polypeptides with multiple glycosylations is
assembled that will be used in proteomic studies to provide new insights
into the role of glycosylation in mucin functions and cancer progression.
At the same time we are expanding the approach to sequential ligation
[4] in combination with sequential glycosylation, to gain access to larger,
more complex homogenous glycoproteins.
These developments also require extension of this method towards liga-
tion at sites different from glycine and to other PTMs, in order to broaden
it toward the synthesis of any kind of homogeneously posttranslationally
modified protein.
[1] Bello, C.; Wang, S.; Meng, L.; Moremen, K. W. and Becker, C. F. W.
Angew. Chem. Int. Ed. 2015, 54, 7711–7715. [2] Bello, C.; Farbiarz, K.;
Moeller, J.F.; Becker, C.F.W.; Schwientek T. Chem. Sci. 2014, 5, 1634-
1641. [3] Bello, C.; Kikul, F.; Becker, C.F.W. J. Pept. Sci., 2015, 21 (3),
201-207. [4] Bello, C. and Becker, C. F. W. Bioorg. Med. Chem., 2017,
25 (18), 5016-5021.
OP8
Peptide-Guided Assembly of Armadillo Repeat
Protein Fragments
Oliver Zerbe
University of Zurich, Switzerland
We have recently discovered that it is possible to reconstitute a designed Ar-
madillo repeat protein (ArmRP) from complementary fragments [1]. The
two fragments, when mixed, will form a complex with nanomolar affinity.
The structure of the complex is almost identical to the structure of the entire
(single-chain) protein. ArmRP can be split at several places, within repeats
as well as between repeats. The affinity of the fragments varies between
nanomolar and micromolar Kd’s, depending on the exact location of the
split site. We have further shown that an ArmRP binder for a peptide can
be split into two fragments, and that the reconstituted complex again rec-
ognizes the peptide. Moreover, it is possible to split the ArmRP such that
the two fragments only interact in the presence of a peptide ligand (condi-
tional assembly). We have then created a small library consisting of one
(unlabeled) N-terminal plus a number of amino-acid selectively isotope-
labeled C-terminal fragments. We could demonstrate using heteronuclear
NMR that addition of a peptide shifts the equilibrium of formed complexes
such that the complex that represents the best binder for that peptide is sig-
nificantly enriched [2], even when the differences in binding affinities of
the corresponding proteins complexes are small. I present spectroscopic
(NMR) and other biophysical data to characterize the underlying proteins
and protein complexes. We feel we have discovered a novel interesting
property of ArmRP, in that they can be reconstituted from a large number
of different complementary fragments, and that interesting biochemical ap-
plications may emerge from these systems. We feel that the methodology
has distinct advantages when maturing new peptide binders over existing
methods in that the split system has superior discriminatory power when
compared to the usual single-chain approaches.
References: 1) R. Watson, M. Christen, C. Ewald, F. Bumback, C. Re-
ichen, M. Mihajlovic, E. Schmidt, P. Güntert, A. Plückthun, A. Caflisch,
O. Zerbe (2014): Spontaneous Self-Assembly of Engineered Armadillo
Repeat Protein Fragments into a Folded Structure, Structure, 22, 985-995.
2) E. Michel, A. Plückthun, O. Zerbe (2018): Peptide-Guided Assembly
of Repeat Protein Fragments, Angew. Chem. Int. Ed., 57, 4576-4579.
OP9
Are gluten-related disorders a new protein aggregation
disease?
Veronica Dodero
Universität Bielefeld, Germany
Gliadin, an immunogenic protein present in wheat, is not fully degraded by
humans and after the normal gastric and pancreatic digestion, the immun-
odominant 33-mer gliadin peptide remains unprocessed. This 33 amino
acid fragment is directed involved in celiac disease and probably in other
immune pathologies associated to gliadin, with high prevalence such as
non-celiac gluten sensitivity (7%). Although, the immunological response
observed in the chronic phase of the celiac disease is well characterized;
the cause and the initiation of the inflammatory events are still obscure (1).
From the molecular point of view, the 33-mer behaves as an amphiphile
forming nano-aggregates. The morphology of the nano-aggregates depend
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strongly on concentration, and the secondary structure ranges from ran-
dom, and PPII to parallel beta structure (2, 3). Recently, we reported that
only large structures of 33-mer (>200 nm) induce an innate immune re-
sponse in macrophages which is mediated by Toll-like receptor (TLR) 4
activation in humans. (4) Our investigations showed that if the 33-mer
peptide aggregates, can trigger a specific innate immune response. Herein,
I will present new insights into 33-mer oligomerization and its behavior in
the cellular context by super-resolution optical microscopy. Our findings
open a new understanding of the early stages of the disease and connect
these disorder in the context of protein aggregation disease.
References (1) L. M. Lammers, M G. Herrera, V. I. Dodero, Translational
Chemistry meets gluten-related disorders, ChemistryOpen 7 (2018) 217.
(2) M. G. Herrera, F. Zamarreño, M. Costabel, H. Ritacco, A. Hütten,
N. Sewald, V. I. Dodero, Circular Dichroism and Electron Microscopy
Studies in vitro of 33-mer Gliadin Peptide revealed Secondary Structure
Transition and Supramolecular Organization, Biopolymers 101 (2014) 96.
(3) M. G. Herrera, L. A. Benedini, C. Lonez, P. L. Schilardi, T. Hell-
weg, J.-M. Ruysschaert, V. I. Dodero, Self-assembly of 33-mer gliadin
peptide oligomers, Soft Matter 11 (2015) 8648. (4) M. G. Herrera, M.
Pizzuto. C. Lonez, K. Rott, A. Hütten, N. Sewald, J-M Ruysschaert, V. I.
Dodero, Large Supramolecular Structures of 33-mer Gliadin Peptide Ac-
tivate Toll-like Receptors in Macrophages, Nanomedicine: NBM (2018),
doi:10.1016/j.nano.2018.04.014.
OP10
Chemical Synthesis of Glycopeptides and
Glycoproteins Using Acyl-thiol-ene Mediated ‘Click’
Ligation
Eoin Scanlan, Lauren McSweeney, Rita Petracca
Trinity College Dublin, Ireland
Thiol-ene ligation has emerged as a highly efficient ‘click’ process with di-
verse applications in peptide synthesis and chemical biology. The high
yield, mild reaction conditions and complete regioselectivity have en-
abled site specific elaboration of peptides and proteins with a range of
biomolecules including carbohydrates. The methodology is fast and is
compatible with oxygen, buffers and an aqueous environment. We have
developed a novel thiol-ene mediated ligation strategy involving thio-acyl
radicals (Acyl-Thiol-ene) for the rapid chemical synthesis of N-linked gly-
copeptides and glycoproteins. Using an sequential, one-pot, ligation/acyl-
transfer/desulfurisation approach we have prepared a range of glycopep-
tides and glycoproteins with native linkages. The Acyl-Thiol-ene ligation
is suitable for both peptide ligation and late stage N-glycosylation, render-
ing it an extremely useful methodology for glycoprotein synthesis. This
approach represents a highly efficient strategy for accessing homogeneous
peptides and proteins suitable for biological evaluation.
OP11
Multicyclic peptides constrained through noncanonical
disulfide bonds and thioether crosslinks
Chuanliu Wu
Xiamen University, China
Multicyclic peptides, lying between larger biologics and small molecules
in size and presumably combining the advantages of both, have been a trea-
sured chemical space for drug development. Among the diverse peptide
scaffolds constrained through covalent crosslinks, disulfide-rich peptides
are most extensively explored. However, the synthesis and reengineering
of these disulfide-constrained peptides are challenging, owing to the com-
plexity of the oxidative folding process involving a number of diverse iso-
meric structures. In my group, we developed orthogonal disulfide pairing
technologies to direct the oxidative folding of peptides into specific iso-
mers, which involve synergistic manipulations of CXC motifs and cysteine
analogs such as penicillamine.[1,2] By taking advantage of our orthogo-
nal disulfide pairing technologies, a great diversity of multicyclic peptides
with different disulfide patterns or connectivities have been designed and
synthesized.[3,4,5] More importantly, these multicyclic scaffolds are ex-
tremely tolerant to sequence manipulations and disulfide isomerizations,
thus are of particular interest for further designing or screening peptides
with new structures and functions. Considering that disulfide-rich pep-
tides might be not stable in biologically reducing environments, we also
developed novel crosslink strategies to design and synthesize multicyclic
peptides constrained with stable thioether bonds.[6,7] Benefiting from the
recent development of these crosslink strategies, many new multicyclic
scaffolds and bioactive peptides were de novo designed and synthesized
in our lab. This lecture will describe the latest progress on the design and
synthesis of multicyclic peptides constrained through disulfide or thioether
crosslinks in our group.
1. Y. Zheng, L. Zhai, Y. Zhao, C. Wu*, Orthogonal Cysteine-Penicillamine
Disulfide Pairing for Directing the Oxidative Folding of Peptides, J. Am.
Chem. Soc., 2015, 137, 15094. 2. C. Wu, J-C. Leroux,* M.A. Gauthier*,
Twin Disulfides for Orthogonal Disulfide Pairing and the Directed Fold-
ing of Multicyclic Peptides, Nature Chem., 2012, 4, 1044. 3. Y. Zheng,
Z. Li, J. Ren, W. Liu, Y. Wu, Y. Zhao, C. Wu*, Artificial Disulfide-Rich
Peptide Scaffolds with Precisely Defined Disulfide Patterns and a Mini-
mized Number of Isomers, Chem. Sci., 2017, 8, 2547. 4. Y. Zheng, X.
Meng, Y. Wu, Y. Zhao, C. Wu*, De Novo Design of Constrained and
Sequence-Independent Peptide Scaffolds with Topologically-Formidable
Disulfide Connectivities, Chem. Sci., 2018, 9, 569. 5. M. Zha, P. Lin, H.
Yao, Y. Zhao, C. Wu*, A Phage Display-Based Strategy for the De Novo
Creation of Disulfide-Constrained and Isomer-Free Bicyclic Peptide Affin-
ity Reagents, Chem. Commun., 2018, 54, 4029. 6. W. Liu, Y. Zheng,
X. Kong, C. Heinis, Y. Zhao, C. Wu*, Precisely Regulated and Efficient
Locking of Linear Peptides into Stable Multicyclic Topologies through a
One-Pot Reaction, Angew. Chem. Int. Ed., 2017, 56, 4458. 7. J. Wang,
M. Zha, Q. Fei, W. Liu, Y. Zhao, C. Wu*, Peptide Macrocycles Developed
from Precisely-Regulated Multiple Cyclization of Unprotected Peptides,
Chem. Eur. J., 2017, 23, 15150.
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OP12
Novel methodology for the synthesis of
α-indolyl-glycine containing peptide via direct
asymmetric Friedel–Crafts reaction to peptidyl imine
Tsubasa Inokuma, Kodai Nishida, Akira Shigenaga,
Ken-Ichi Yamada, Akira Otaka
Tokushima University, Japan
Peptides containing unnatural amino acids have received considerable at-
tention as novel drug candidates because they often exhibit better biologi-
cal activity and/or proteolytic stability than those of the peptides consisting
of proteinogenic amino acids. The conventional strategy for the prepara-
tion of unnatural amino acid-containing peptides relied on (1) asymmetric
construction of unnatural amino acids and (2) installation of those parts
into peptide synthesis. As a method for the synthesis of unnatural amino
acids, 1,2-addition to α-imino esters is a powerful tool because it can
access diverse derivatives by changing only the nucleophiles. However,
multi-step reactions are required for the preparation of protected amino
acids suitable for peptide synthesis, which has hampered the diversity-
oriented synthesis of peptides bearing unnatural amino acids. To solve
this problem, we envisioned a novel strategy which employs an asymmet-
ric construction of unnatural amino acid units by asymmetric 1,2-addition
in a growing peptide chain. If an α-imino amide moiety could be installed
onto the N-terminus of an elongating peptide, asymmetric 1,2-addition of
the nucleophiles into the imino moiety would yield a peptide possessing
an unnatural amino acid in its N-terminus. In this protocol, change of nu-
cleophiles allows for the easy access to a diverse range of unnatural amino
acid-containing peptides. We planned to incorporate a hydrophobic anchor
that makes the peptidic substrate soluble in less-polar solvents because
peptidic compounds are basically insoluble in less-polar organic solvents,
such as toluene, chloroform, and dichloromethane, which are often most
suitable for asymmetric catalytic reactions. As an unnatural unit of the tar-
get peptide, we chose α-indolyl glycine, which can be used as an analogue
for proteinogenic aromatic amino acids. The first step is peptide elonga-
tion on the amine moiety of a hydrophobic anchor using liquid-phase pep-
tide synthesis. Next, condensation of N-protected glycine on the growing
peptide chain followed by oxidation of the N-terminal residue to the corre-
sponding imine provides the site at which a wide range of unnatural amino
acid residues can be incorporated. Next, asymmetric 1,2-addition of indole
on the resulting imine is performed. Subsequent removal of the protect-
ing group of N-terminus followed by the usual manipulations for peptide
elongation, cleavage of hydrophobic anchor, and global deprotection by
acidic treatment afford the desired peptides bearing α-indolyl glycine. In
this presentation, we will discuss (1) optimization of the reaction condi-
tion of the asymmetric Friedel–Crafts reaction, (2) substrate scope of the
Friedel–Ctafts reaction, (3) model study for deprotection and peptide elon-
gation of α-indolyl glycine which is constructed by our reaction system,
and (4) application to the synthesis of the α-indolyl glycine-containing
peptide.
OP13
Palladium Prompted On-Demand Cysteine Chemistry
for the Synthesis of Challenging Proteins
Muhammad Jbara1, Shay Laps1, Michael Morgan2, Guy
Kamnesky1, Guy Mann1, Cynthia Wolberger2, Ashraf Brik1
1Technion, Israel
2Johns Hopkins University, United States
Thiazolidine (Thz) and Acetamidomethyl (Acm) protecting groups (PGs)
are widely utilized in peptide and protein synthesis, however, the reaction
time and the harsh conditions of their removal limit their utilities. Devel-
oping optimal removal conditions for theses PGs remains a challenge. We
recently reported that palladium complexes can remove multiple Cys PGs
within minutes in a fully aqueous medium,[2,3] which also could be cou-
pled in-situ with native chemical ligation conditions to provide excellent
yields of the desired products.[4,5,6] Although these new conditions have
resulted in important advances in chemical protein synthesis, the utility of
these approaches is limited by the lack of chemoselectivity of the palla-
dium complexes when applying more than one PG in the synthesis. Here,
we demonstrate unprecedented palladium chemoselectivity in a fully aque-
ous medium for on-demand orthogonal deprotection of Thz and Acm pro-
tections. We also show for the first time the efficient removal of Cys t-butyl
PG using palladium in a fully aqueous medium and demonstrate its stabil-
ity under the removal conditions of the Thz and Acm protections. The new
chemistries reported here were applied for one-pot and site-specific modifi-
cation of peptides containing multiple Cys residues, as well as for the total
chemical synthesis of the CSP-1 protein, which contains 13 Cys residues.
We also show the first total chemical synthesis of an activity-based probe of
ubiquitinated histone H2A at Lys119 for the preparation of ubiquitinated
nucleosome core particle probes. This probe exhibited reactivity with the
with Calypso/ASX heterodimer deubiquitinase to form a stable covalent
nucleosome-enzyme complex.
[1] S. Bondalapati, M. Jbara, A. Brik, Nat. Chem. 2016, 8, 407–418. [2]
M. Jbara, S. k. Maity, A. Brik. Angew. Chem. Int. Ed. 2017, 56, 2–14. [3]
S. K. Maity, M. Jbara, G. Mann, G. kamnesky, A. Brik, Nature Protocols,
2017, 12, 2293-2322. [4] M. Jbara, S. K. Maity, M. Seenaiah, A. Brik, J.
Am. Chem. Soc. 2016, 138, 5069–5075. [5] S. K. Maity, M. Jbara, S.
Laps, A. Brik, Angew. Chem. Int. Ed. 2016, 55, 8108–8112. [6] M. Jbara,
S. Laps, S. K. Maity, A. Brik. Chem. Eur.J. 2016, 22, 14851–14855.
OP14
Synthesis and Biomedical Applications of Substituted
Amino-Lactam and Amino-Imididazolone Constraints
William Lubell1, Azade Geranurimi1, Julien Poupart1,
Colin Cheng2, Xin Hou2, Christiane Quiniou2, Sylvain
Chemtob2
1Department of Chemistry, Université de Montréal, Canada
2Department of Pediatrics, Université de Montréal, Canada
Employing structural constraints to identify active peptide geometry and
enhance therapeutic potential, our laboratory has pursued the synthe-
sis of alpha-amino-gamma-lactam (Agl) and N-aminoimidazalone (Nai)
residues [1]. The Agl and Nai residues can favor peptide backbone beta-
turn geometry, as first shown for the former by Freidinger and Veber [2].
Extending their utility to study both side chain and backbone geometry,
methods have been explored to add substituents respectively at the beta-
and 5-positions of Agl and Nai residues [3]. Our presentation will describe
the synthetic methods as well as application of these heterocycles to study
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the conformation of peptide allosteric modulators of the interleukin-1 re-
ceptor for the treatment of preterm labour and related complications, such
as retinopathy of prematurity [4,5].
[1] St-Cyr, D.J.; García-Ramos, Y.; Doan, N.-D.; Lubell, W.D. “Amino-
lactam, N-Aminoimidazolone, and N-Aminoimdazolidinone Peptide Mim-
ics” in Peptidomimetics I, Series: Topics in Heterocyclic Chemistry, W.
Lubell (Ed.) Vol. 48, 2017, 125-175. [2] Freidinger, R. M.; Veber, D.
F.; Perlow, D. S.; Saperstein, R., Science 1980, 210, 656-658. [3] St-Cyr,
D. J.; Jamieson, A. G.; Lubell, W. D. Org. Lett. 2010, 12, 1652-1655
[4] Jamieson, A. G.; Boutard, N.; Beauregard, K.; Bodas, M. S.; Ong,
H.; Quiniou, C.; Chemtob, S.; Lubell, W. D. J. Am. Chem. Soc. 2009,
131, 7917-7927. [5] Rivera, J.-C.; Sitaras, N.; Noueihed, B.; Hamel, D.;
Madaan, A.; Zhou, T.; Honoré, J.-C.; Quiniou, C.; Joyal, J.-S.; Hardy, P.;
Sennlaub, F.; Lubell, W.; Chemtob, S. Arteriosclerosis, Thrombosis, and
Vascular Biology 2013, 33, 1881-1891.
OP15
Recombinant synthesis and purification of hTFF2
protein in S. Cerevisiae
Kirtikumar B. Jadhav, Gerhard Niederacher, Markus
Muttenthaler
Institute for Biological Chemistry, Austria
Human trefoil factor family protein 2 (hTFF2) belongs to a family of pep-
tides containing one or more characteristic trefoil domains —a distinctive
three-leaved structure formed and stabilized by three disulfide bonds.[1]
hTFF2 contains 106 amino acid residues and two trefoil domains formed
by 6 disulfide bonds and these domains are interconnected with a 7th disul-
fide bond.[1b] Because of these disulfide bonds, they are stable secretory
proteins expressed in gastrointestinal mucosa. Their physiological func-
tions are not defined,[3] but they may protect the mucosa from insults,
stabilize the mucus layer and affect healing of the epithelium.[2,4] Their
size and cysteine-rich character are the main reason why these peptides
have never been successfully synthesized. Only very limited amounts of
hTFF2 can be prepared from human tissue extraction. Here, we describe a
yeast expression system designed for the production of sufficient amounts
of hTFF2 for physiological and biochemical studies. To obtain natively
folded hTFF2 protein, we chose to express it in S. cerervisiae. We designed
the hTFF2 gene encoding a fusion protein consisting of a hybrid leader se-
quence and the hTFF2 sequence. Recombinant plasmids were constructed.
The leader sequence served to direct the fusion protein into the secretory
pathway of cell and to expose it to the Kex 2 processing enzyme system.
We optimized conditions for protein expression. The secreted hTFF2 was
found in a glycosylated and an non-glycosylated form.[5] The two forms
of hTFF2 were purified from the yeast fermentation broth by a combina-
tion of ultrafiltration, ion-exchange chromatography & preparative HPLC.
The hTFF2 and glycosylated hTFF2 were analyzed by HR-MS.[5] Subse-
quently, we have synthesized N15 enriched analogue of hTFF2 protein and
currently, we are analyzing its three dimensional structure by NMR. More-
over, this recombinant hTFF2 would serve to identify its receptor by using
LRC-TRICEPs method and elucidate its role in intestinal wound healing.
References: 1. a) Kjellev S. Cell. Mol. Life Sci. 2009; 66, 1350-1369; b)
Thima, L., May F. E. B. Cell. Mol. Life Sci. 2005, 62, 2956. 2. a) Aa-
mann L, Vestergaard EM, Groenbaek H. World J. Gastroenterol. 2014; 20,
3223-3230; b) Taupin D, Podolsky DK. Nat. Rev. Mol. Cell Biol. 2003; 4,
721. 3. a) Lefebvre O., Chenard M. P., Masson R., Linares J., Dierich A.,
Lemeur M. et al. Science 1996, 274, 259.; b) Farrell J. J., Taupin D., Koh
T. J., Chen D., Zhao C. M., Podolsky D. K. et al. J. Clin. Invest. 2002, 109,
193. 4. a) Dignass A., Lynch-Devaney K., Kindon H., Thim L., Podolsky
D. K. J. Clin. Invest. 1994, 94, 376.; b) Kindon H., Pothoulakis C., Thim
L., Lynch-Devaney G., Podolsky D. K. Gastroenterology 1995, 109, 516.
5. Jadhav K. B., Niederacher, G., Muttenthaler, M.; in preparation.
OP16
Do Quorum Sensing Peptides Play a Role in
Psychiatric Disorders?
Evelien Wynendaele, Yorick Janssens, Nathan Debunne,
Kurt Audenaert, Bart De Spiegeleer
Ghent University, Belgium
The human microbiota is known to influence health. However, a changing
human (gut) microbiota has also been linked to several diseases, including
several psychiatric manifestations and neuro-developmental/-degenerative
diseases like increased anxiety, depression, autism spectrum disorders, al-
terations in social behavior, and memory loss disorders. The mechanisms
by which the gut microbiota influence these health conditions are how-
ever not yet fully understood. Currently, evidence indicates that these
pathologies can be influenced by different bacterial metabolites, such as
short chain fatty acids (SCFAs). In vitro studies from our group have now
shown that quorum sensing peptides, i.e. bacterial metabolites which are
constitutively produced and used by bacteria as inter-bacterial communi-
cation molecules, are also able to functionally modify neuronal brain cells
[1]. Initial kinetic studies further indicated that these peptides are able to
permeate the intestinal wall (in vitro), as well as the blood-brain barrier (in
vivo) [2,3]. One of these quorum sensing peptides is PapRIV, a heptapep-
tide originating from Bacillus species and demonstrating pro-inflammatory
effects on BV-2 microglia cells: significantly increased levels of IL-6 and
TNF-alpha, together with an increased expression of NFkB both demon-
strate a clear effect of PapRIV on these cells, which are crucial in physi-
ological brain function. These results thus indicate a possible causal rela-
tionship between microbially produced quorum sensing peptides and men-
tal disorders, which need to be confirmed by on-going in vivo mice studies.
References [1] Janssens Y, Wynendaele E, Verbeke F, Debunne N, Gevaert
B, Audenaert K, Van De Wiele C, De Spiegeleer B. (2018). Screening
of quorum sensing peptides for biological effects in neuronal cells. Pep-
tides 101: 150-156. [2] De Spiegeleer B, Verbeke F, D’Hondt M, Hendrix
A, Van De Wiele C, Burvenich C, Peremans K, De Wever O, Bracke M,
Wynendaele E. (2015). The quorum sensing peptides PhrG, CSP and EDF
promote angiogenesis and invasion of breast cancer cells in vitro. Plos One,
DOI: 10.1371/journal.pone.0119471. [3] Wynendaele E, Verbeke F, Stal-
mans S, Gevaert B, Janssens Y, Van De Wiele C, Peremans K, Burvenich
C, De Spiegeleer B. (2015) Quorum sensing peptides selectively penetrate
the blood-brain barrier. PLos One, DOI: 10.1371/journal.pone.0142071.
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OP17
Mitocryptides: First Demonstration of
Pathophysiological Involvements in Inflammatory
Diseases
Tatsuya Hattori, Hiroki Morikawa, Yoshito Takamuro,
Takayuki Marutani, Takenori Yamada, Yoshiaki Kiso,
Hidehito Mukai
Laboratory of Peptide Science, Graduate School of Bio-Science,
Nagahama Institute of Bio-Science and Technology, Japan
Mitocryptides are a novel family of endogenous bioactive peptides that
induce neutrophilic migration and activation. Namely we have purified
and identified novel neutrophil-activating cryptides, mitocryptide-1 and
mitocryptide-2, which were derived from mitochondrial cytochrome c ox-
idase subunit VIII, and cytochrome b, respectively, from healthy porcine
hearts [1-3]. We also identified more than 40 neutrophil-activating cryp-
tides derived from various mitochondrial proteins in silico, and found that
many of mitochondrial transit signal sequences that nuclear-encoded mi-
tochondrial proteins have efficiently activate neutrophils after the cleav-
age of mitochondrial transit signal sequences from their parent proteins
by mitochondrial processing peptidases. Recently, mitochondrial damage-
associated molecular patterns (mtDAMPs) are intensively studied as proin-
flammatory factors for non-infective inflammatory diseases. It has been
proposed that damaged cells possibly release endogenous mtDAMPs that
stimulate innate immune responses associating excessive neutrophilic func-
tions [4, 5]. However, it is obscure what molecules are responsible for
those functions. Mitocryptides are promising candidates for those un-
known activating factors in mtDAMPs since they are derived from mito-
chondrial proteins and efficiently activate neutrophils at nano-molar con-
centrations. In this presentation, we firstly demonstrate that mitocryptides
involve the onset of non-infective inflammatory diseases including hepatic
injury as “mtDAMPs factors”. We also discuss about various physiological
regulations by mitocryptides.
[1] Ueki, N.; Someya, K.; Matsuo, Y.; Wakamatsu, K.; Mukai, H. (2007)
Biopolymers (Pep. Sci.), 88, 190–198. [2] Mukai, H.; Hokari, Y.; Seki, T.;
Takao, T.; Kubota, M.; Matsuo, Y.; Tsukagoshi, H.; Kato, M.; Kimura, H.;
Shimonishi, Y.; Kiso, Y.; Nishi, Y.; Wakamatsu, K.; Munekata, E. (2008)
J. Biol. Chem., 283, 30596-30605. [3] Mukai, H.; Seki, T.; Nakano, H.;
Hokari, Y.; Takao, T.; Kawanami, M.; Tsukagoshi, H.; Kimura, H.; Kiso,
Y.; Shimonishi, Y.; Nishi, Y.; Munekata, E. (2009) J. Immunol., 182, 5072-
5080. [4] Zhang, Q.; Raoof, M.; Chen, Y.; Sumi, Y.; Sursal, T.; Junger,
W.; Brohi, K.; Itagaki, K.; Hauser, C. J. (2010) Nature, 464, 104-107. [5]
Marutani, T.; Hattori, T.; Tsutsumi, K.; Koike, Y.; Harada, A.; Noguchi,
K.; Kiso, Y.; Mukai, H. (2016) Biopolymers (Pep. Sci.), 105, 580–587.
OP18
Antifungal activity and immunomodulation of a de
novo synthetic peptide
Thibaut Thery, Laila Shwaiki, Nora M. O’Brien, Yvonne C.
O’Callaghan, Elke K.A. Arendt
University College Cork, Ireland
The reduction of ingredients and food waste due to fungal contamination
is one of the global major challenges, from both a health and an eco-
nomic point of view. The research of novel solutions to fight microbial
food contaminants rests upon two pillars, which are the development of
resistant strains and consumer’s demand for less chemical preservatives,
which suffer from bad reputation. Natural antimicrobial peptides possess
the qualities to overcome these issues but their tedious purification is a
major drawback to their use. De novo design of novel antifungal com-
pounds is a major progress that the identification of parameters involved
in the antimicrobial activity has allowed. We designed a 14-residue pep-
tide named KK14, with the sequence KKFFRAWWAPRFLK-NH2. This
peptide inhibited conidial germination and fungal growth of food contam-
inants within the range 6.25-50 µg/ml and 50-100 µg/ml, respectively.
The study of three analogues of the peptide highlighted the role of some
residues in the structural conformation of the peptide and its antifungal
activity. The substitution of a Pro residue with Arg increased the helical
content of the peptide, its antifungal activity but also its cytotoxicity. De-
spite a more prominent side chain, the insertion of unnatural bulky residue
β -diphenylalanine did not improve the antifungal activity or the stability
of KK14. A full d-enantiomerization appeared as the best modification
to increase the antifungal potency. The four peptides showed similar be-
haviour towards salt increase, heat treatment and pH decrease. Interest-
ingly, only the d-enantiomer remains the most active at high pH and after
proteolytic digestion. The four peptides did not present haemolytic activity
up to 200 µg/ml but different behaviours of cytotoxicity and immunomod-
ulation. These differences could be crucial for potential application as
pharmaceutical or food preservative. So far, in contrast to natural extracts,
the use of these synthetics peptides remains a concept due the cost of syn-
thesis and the difficulties to get authorizations. However, as observed for
the antibacterial peptide nisin, the decrease of the price and the easy of
upscaling make conceivable their use in food products.
OP19
Targeting Amyloidogenic Proteins with
Self-assembled Cyclic D,L-alpha-Peptides
Shai Rahimipour
Bar-Ilan University, Israel
Protein misfolding and aggregation is the fundamental cause of more
than 20 amyloidogenic diseases affecting either the central nervous sys-
tem or a variety of peripheral tissues. Although peptides and proteins of
various sequences can self-assemble into toxic amyloid structures, they
share common three-dimensional features that may promote their cross-
reaction. Given the significant structural and biochemical similarities be-
tween amyloids and the architecture of self-assembled cyclic D,L-alpha-
peptides, we screened an unbiased library of six-residue cyclic D,L-alpha-
peptides and optimized the activity of a lead peptide to discover cyclic
D,L-alpha-peptide (CP-2) that interacts strongly with Alzheimer’s disease
associated Abeta and inhibits its aggregation and toxicity. Further stud-
ies including Thioflavin T assays, electron microscopy, circular dichroism
spectroscopy and NMR, collectively suggested that CP-2 could also ef-
fectively cross-interact with Parkinson’s disease associated alpha-syn and
tau-derived PHF6 peptide, prevent their aggregation, and remodel their
fibrils to non-toxic amorphous species, through an ’off pathway’ mecha-
nism. NMR studies show that CP-2 interacts with the N-terminal and the
non-Abeta component region of alpha-syn, which are responsible for its
membrane interactions and self-assembly, and so changes its conformation.
Dot-blot and cell survival assays suggest that CP-2 reduces the amount of
toxic alpha-syn oligomers and protects PC-12 and SH-SY5Y cells from
alpha-syn-induced toxicity. Moreover, CP-2 permeates cells through en-
dosomes/lysosomes, co-localizes with intracellular alpha-syn and reduces
its accumulation and toxicity in neuronal cells overexpressing α-syn. CP-
2 also prevents alpha-syn- and PHF6-dirved membrane damage as shown
by liposome dye release experiments. Our studies suggest that targeting
the common structural conformation of amyloids may be a promising ap-
proach for developing new therapeutics for amyloidogenic diseases.
References: [1] Wilik, S., Richman, M., Chemerovski, M., Wärmländer,
S., Wahlström, A., Gräslund, A., Rahimipour, S. J. Am. Chem. Soc.
135, 3474 (2013). [2] Chemerovski, M., Belostozky, A., Richman M.,
Rahimipour, S. Tetrahedron 70, 7639 (2014). [3] Chemerovski-Glikman,
M., Rozentur-Shkop, E., Grupi, G., Richman, R., Getler, G., Cohen,
H.Y., Wallin, C., Wärmländer, S., Haas, E., Gräslund, A., Chill, J.H.,
Rahimipour, S. Chemistry –Eur. J. 22, 14236 (2016). [4] Belostozky, A.,
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Richman, M., Lisniansky, E., Tovchygrechko, A., Chill, J.H., Rahimipour,
S. Chem. Commun. 54, 5980 (2018).
OP20
Tyrocidines and Gramicidin S: Glorified
cyclodecapeptide detergents or precise chemical
scalpels
Marina Rautenbach1, Micaela Wenzel2
1Stellenbosch University, South Africa
2Free University, Netherlands
The dogma that cationic antimicrobial peptides primarily target mem-
branes rich in anionic phospholipids still prevails nearly 30 years after the
frog peptide magainin was discovered. Pore formation via barrel-stave
and toroidal models, and membrane damage via detergent action or via the
carpet model are still is used to explain the physiological phenomena of
membrane disfunction. As the models were generated using only model
membranes, the question must be asked how an AMP truly works in under
in vivo conditions where membranes consists of multiple types of phos-
pholipids, functional regions such as rafts containing specific membrane
proteins, specific areas of high fluidity associated with certain peripheral
proteins, as well as highly organized positive and negative curvature strain
areas within the membrane architecture to maintain the cell shape. We
investigated the mode of action of homologous cyclic β -sheet decapep-
tides from the tyrocidine group and gramicidin S by (1) model membranes
utilizing biophysical techniques and (2) a bacterial cytological profiling ap-
proach using Bacillus subtilis as in vivo target. The model membrane stud-
ies revealed that the tyrocidine exposure led to very fast leakage kinetics
by forming defined long-life ion-conducting pores without inducing lipid
distortion. Gramicidin S also lead to leakage, but at a much slower rate
without the formation of defined pores. Gramicidin S and the tyrocidines
all led to changes in phase transition temperature of model membranes. In
vivo the tyrocidines induced lipid phase separation, as well reducing mem-
brane fluidity. This resulted in delocalization of a broad range of peripheral
and integral membrane proteins. Gramicidin S had a much subtler effect
and only caused mild lipid de-mixing with minor effects on membrane flu-
idity and permeability, despite that gramicidin S share 50 % sequence iden-
tity with tyrocidines. Gramicidin S also delocalized peripheral membrane
proteins, particularly those involved in cell division and cell envelope syn-
thesis. We observed that the tyrocidines directly or indirectly also caused
DNA damage and interfered with DNA-binding proteins, while gramicidin
S did not affect integral membrane proteins or DNA. The tyrocidines and
gramicidin S are highly lytic and membrane active molecules at high con-
centrations. However, we have shown at concentrations where the cell
remains intact these peptides still have a major effect on the membrane
architecture and in particular on membrane proteins that are crucial for
cell growth and survival. Our in vivo profiling study highlighted the mul-
tifaceted antibacterial mechanisms of these small antimicrobial peptides.
The fact that the peptides do not have localized affect on the cell membrane,
but that they globally disrupt the membrane architecture and membrane
proteins could explain why resistance to them is virtually non-existent.
OP21
Enabling Parallel Peptide Purification by a Novel
Traceless Purification Linker
Oliver Reimann1, Dominik Sarma1, Gavin Noble2, Oliver
Seitz3, Robert Zitterbart1
1Belyntic GmbH, Germany
2Bachm (UK) Ltd., United Kingdom
3Bioorganic Synthesis, Department of Chemistry, Humboldt-Universität
zu Berlin, Germany
Solid-phase peptide synthesis (SPPS) is a powerful and flexible tool pro-
viding facile access to peptides required in drug research, development and
production. However, purification of peptides via preparative HPLC is a
bottleneck, especially regarding higher throughput missions. Furthermore,
purification by preparative HPLC is a formidable challenge when difficult
peptides have low solubility, a tendency to aggregate or when truncations
co-elute with the full-length peptide. Herein, we report the facilitated pu-
rification by covalent catch (of crude peptides) and reduction-triggered re-
lease (of pure peptides) that allows purification of standard and difficult
peptides in parallel formats. Our method is based on a new purification
linker (PL) that is coupled to the N-terminal end of the peptide in the last
step of solid-phase synthesis. The PL contains an alkoxyamine group con-
nected to the peptide via a reductively cleavable azido unit. Owing to
capping, truncations do not carry the PL. Thereby, only the full-length pep-
tide obtained after solid-phase synthesis is immobilized onto an aldehyde-
modified agarose resin by means of oxime ligation. This bio-orthogonal re-
action is complete in less than one hour. Immobilization can be performed
directly from the cleavage cocktail, avoiding laborious ether precipitation
prior to purification and enabling the purification of strongly hydrophobic
peptide. If precipitation is desired, denaturing agents such 7 M urea, TFA
or organic solvents can be used to facilitate solubilization of aggregation-
prone peptides. After immobilization, the truncated, acetylated peptide se-
quences are removed by simple washing. The PL is designed to allow liber-
ation of the native peptide by a reduction-triggered 1,6-elimination, which
yields the desired native peptide in pure form without occurrence of side
reactions. By using catch & release based purification with the new PL, the
peptide can be efficiently isolated from complex mixtures and especially
potentially co-eluting truncations. The feasibility of the method has been
tested with many peptides, including very hydrophobic amyloid ß (1-20),
rationally designed peptides with co-eluting truncations and base-sensitive
sequences. Peptides were purified in parallel set-ups using vacuum mani-
folds to prove practicability. The tolerance of our catch & release process
to TFA or denaturing agents and the ability to liberate peptides of a high
purity by reductive cleavage renders the method universal, paving the way
for a true alternative to HPLC.
OP22
Effects of non-enzymatic posttranslational
modifications on protein function
Christian F.W. Becker
University of Vienna, Austria
At least 50% of all human proteins are predicted to experience one or more
posttranslational modification (PTM) during their life cycle [1]. These
PTMs can result from enzymatic or non-enzymatic reactions and enzy-
matic PTMs are well-known for being involved in regulating many cel-
lular events such as gene expression, intracellular and extracellular signal
transduction, protein-protein as well as cell-cell interactions [2, 3]. Non-
enzymatic posttranslational modifications (nPTMs) are increasingly recog-
nized to affect such events as well, with a special emphasis on age-related,
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metabolic and neurodegenerative diseases [4].
Here two examples that involve different semisynthesis routes to access
site-specific, non-enzymatic enzymatic PTMs within the N-, C- and mid-
dle domains of proteins with 205 to 441 amino acids will be discussed.
One example is the small heat shock protein Hsp27 that has been shown
to carry argpyrimidine modifications in certain cancers and for which we
can demonstrate that a single argpyrimidine modification significantly in-
fluences Hsp27 function [5]. The second example deals with the incorpora-
tion of a carboxymethylated lysine residue within the microtubule binding
region of Tau4, a non-enzymatic PTM that significantly influences tubulin
polymerization.
References [1] Khoury, G.A. et al. Sci Rep 2011, 1, 139. [2] Walsh, C.T. et
al. Angew Chem Int Ed 2005, 44, 7342. [3] Deribe, Y.L. et al. Nat Struct
Mol Biol 2010, 17, 6662. [4] Jaisson, S. et al. Clin Chem 2010, 56, 1401.
[5] Matveenko, M. et al Angew Chem Int Ed 2016, 55, 11397 –11402
OP23
A New Aspect of Npys-based Solid Phase Disulfide
Peptide Synthesis
Akihiro Taguchi, Kyohei Muguruma, Kiyotaka Kobayashi,
Yan Cui, Cédric Rentier, Kentaro Takayama, Atsuhiko
Taniguchi, Yoshio Hayashi
Tokyo University of Pharmacy and Life Sciences, Japan
3-Nitro-2-pyridinesulfenyl (Npys) is a unique functional group for protect-
ing a thiol (SH) group [1]. The “-Cys(Npys)-” readily reacts with an un-
protected SH group to form a disulfide bond [2]. Many applications using
this chemistry have already been reported to particularly be effective for
the regioselective disulfide bond formation in peptide synthesis [3]. In the
presentation, we would like to discuss the new aspect of Npys-based pep-
tide chemistry with an emphasis on our very recent studies. Using a newly
synthesized “Npys chloride resin”, we developed a “solid-phase-assisted
disulfide ligation method” to prepare a disulfide peptide from two kinds
of peptide fragments with cysteine residues [4]. Application of this new
Npys solid-phase strategy realizes a unique and innovative “disulfide-led
synthetic methodology” for disulfide-containing cyclic peptides. Oxytocin
and Endothelin with one and two disulfide bonds, respectively, were effi-
ciently synthesized as a fundamental model of this method for more com-
plex cyclic peptides. This strategy also realizes the solid-phase synthesis of
tandemly arranged multi-disulfide-peptides for example disulfide-bridged
oligo RGD peptide, and moreover provides an efficient method for chem-
ical conjugation between hydrophilic and hydrophobic components with
solubility problem, particularly useful for peptide-drug conjugation [5,6].
As another new aspect of Npys chemistry, we will discuss a new solid- or
no-solid-supported Npys reagent (Npys-sulfenate, Npys-OR) [7,8]. This
reagent enhances intra-molecular disulfide bond formation between two
cysteine residues for the effective synthesis of cyclic-disulfide peptides.
The use of this moderate oxidizing agent successfully affords synthetic
hANP and α-conotoxin without oligomer formation under mildly acidic
conditions (but not basic conditions) even applying a relatively higher pep-
tide concentration.
References [1] Matsueda R., et al., Int. J. Pept. Protein Res. 1980, 16,
392-401. [2] Bernatowicz M., et al., Int. J. Pept. Protein Res. 1986, 28,
107-112. [3] Rentier C., et al., J. Pept. Sci. 2017, 23, 496-504 [4] Taguchi
A., et al., Org. Biomol. Chem. 2015, 13, 3186-3189. [5] Muguruma K.,
et al., Bioconjugate Chem. 2016, 27, 1606-1613. [6] Muguruma K., et al.,
Angew. Chem. Int. Ed. 2018, 57, 2170-2173. [7] Taguchi A. et al., Chem.
Eur. J. 2017, 23, 8262-8267. [8] Cui Y. et al., J. Pept. Sci. 2018, 24, e3070.
Current address of Cédric Rentier : Biotage Japan Ltd, 1-14-4 Kameido,
Koto, Tokyo 136-0071 Japan
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N-2-hydroxybenzyl-cysteine peptide crypto-thioesters
for native chemical ligation
Mehdi Amoura1, Daad Sarraf2, Lionel Nauton3, Victor
Terrier1, Dominique Lelièvre1, Arnaud Gautier3, Denis
Servent2, Pascal Kessler2, Agnès Delmas1,
Vincent Aucagne1
1Centre de Biophysique Moléculaire, CNRS UPR 4301, Orléans, France
2Service d’Ingénierie Moléculaire des Protéines, Institut des Sciences du
Vivant Frédéric Joliot, CEA Saclay, France
3Institut de Chimie de Clermont-Ferrand, UMR 6296 CNRS-Université
Clermont Auvergne, Clermont-Ferrand, France
Recent advances in Fmoc-based solid phase synthesis of peptide α-
thioesters for the convergent synthesis of proteins via native chemical lig-
ation (NCL) significantly contributed to push up the boundaries of the
field. In particular, promising beta-mercapto amide-based thioesterifica-
tion devices have emerged. If most systems require an acid catalysis, a
few of them can undergo an N → S acyl shift under NCL conditions
(neutral pH): peptide bearing such devices are called crypto-thioesters.1
We recently reported an N-(2-hydroxy-4-nitrobenzyl)cysteine-based de-
vice (N-Hnb-Cys),2-5 which allows routine automated synthesis of crypto-
thioesters from inexpensive building blocks. Conveniently, no post-SPPS
steps are required, and these thioester surrogates are perfectly stable to
handling, storage and purification. This strategy is thus easily and readily
usable by non-specialists. We illustrated the potential of this methodol-
ogy for the synthesis of long,2,3,5 cyclic4 and N-terminal Cys-containing3
disulfide-rich peptides. To assess the scope and limitations of the method,
we undertook systematic kinetic studies that showed that NCL reactions
using N-Hnb-Cys-based crypto-thioesters are only 4-to-5 fold slower than
those using a benchmark preformed alkyl thioester. These relatively fast ki-
netics are thought to arise from a bio-inspired design, aimed at mimicking
intein-like intramolecular catalysis with a well-positioned phenol group.2
In order to rationally design further optimized second-generation devices,
we aimed at finely understand the molecular basis underlying the fast rear-
rangement. These efforts gratifyingly led to a promising second generation
device with a 2 fold increase of the NCL kinetics.
[1] T. Kawakami, S. Aimoto, Chem. Lett., 2007, 36, 76–77; (b) S. Tsuda,
A. Shigenaga, K. Bando, A. Otaka, Org. Lett., 2009, 11, 823–826; (c) N.
Ollivier, J. Dheur, R. Mhidia, A. Blanpain, O. Melnyk, Org. Lett., 2010,
12, 5238–5241; (d) W. Hou, X. Zhang, F. Li, C.-F. Liu, Org. Lett., 2011,
13, 386–389; (e) F. Burlina, G. Papageorgiou, C. Morris, P. D. White, J. Of-
fer, Chem. Sci., 2014, 5, 766–770; (f) Y. Asahina, K. Nabeshima, H. Hojo,
Tetrahedron Lett., 2015, 56, 1370–1373; (g) S. Tsuda, M. Mochizuki, K.
Sakamoto, M. Denda, H. Nishio, A. Otaka, T. Yoshiya, Org. Lett., 2016,
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18, 5940–5943; (h) M. Eto, N. Naruse, K. Morimoto, K. Yamaoka, K.
Sato, K. Tsuji, T. Inokuma, A. Shigenaga, A. Otaka, Org. Lett., 2016, 18,
4416–4419. [2] V. P. Terrier, H. Adihou, M. Arnould, A. F. Delmas, V.
Aucagne, Chem. Sci., 2016, 7, 339–345. [3] D. Lelièvre, V. P. Terrier, A.
F. Delmas, V. Aucagne, Org. Lett., 2016, 18, 920–923. [4] V. P. Terrier, A.
F. Delmas, V. Aucagne, Org. Biomol. Chem. 2017, 15, 316–319. [5] G.
Martinez et al. Mol. Hum. Rep., 2017, 23,116–131.
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Expanding the potential and multivalency of the B2T
synthetic peptide vaccine against foot-and-mouth
disease virus
Sira Defaus1, Mar Forner1, Laura Höh2, Francisco
Sobrino3, Esther Blanco4, David Andreu1
1Universitat Pompeu Fabra, Spain
2Universität Leipzig, Germany
3Severo Ochoa Center for Molecular Biology, Spain
4Centro de Investigación en Sanidad Animal, Spain
Foot-and-mouth disease virus (FMDV) causes a highly transmissible in-
fection of pigs and other animals, recognized as the animal disease with
the direst economic effects worldwide. High incidence rates in large ar-
eas of Eurasia, Africa or Latin America stress the need for effective ways
to control FMD, among which safe, marker vaccines (i.e., allowing to tell
infected from vaccinated animals) are viewed as the most sensible option,
with peptide-based vaccines receiving growing attention in this regard. In
2016 we reported the full protection of swine against FMD by vaccina-
tion with B2T, a platform displaying two and one copies, respectively, of
FMDV B- and T-cell peptide epitopes in a branched fashion. To the known
advantages of peptide vaccines (safety, marker nature, fine-tuning to vari-
ous strains, easy shipping and storing), B2T adds highly efficient synthesis
by thiol-ene conjugation of prepurified modules, confering it fast adapt-
ability in emergency responses to new outbreaks. We are now exploring
the potential of the B2T design to provide enhanced performance in terms
of, e.g., lower dosage, longer-lasting protection and/or multivalency. To
this end, strategies such as tandem display of >1 T-cell epitope, or back-to-
back fusion of homologous or heterologous B2T units by chemoselective
reactions (e.g., CuAAC) are being studied. Results from trial vaccinations
of Swiss mice and swine will be discussed.
OP26
A general method towards ADPr ribosylated peptides
and proteins
Gerbrand van der Heden van Noort
Leiden University Medical Centre, Netherlands
Ubiquitination of target proteins is a post-translational modification in-
volved in almost all aspects of eukaryotic biology including the regulation
of immune responses, cell proliferation and cell survival. The attachment
of the 76 amino acid long protein Ubiquitin (Ub) to a nucleophilic function-
ality in the amino acid side chain of proteins alters the fate of the modified
protein. The distinct signals that are brought about by this modification
are mostly invoked by poly ubiquitination. Ub has the ability to form poly-
mers by connecting one of eight amines of the first Ub molecule and the
C-terminal carboxylic acid of a second Ub molecule etc. This will lead to
eight differently linked homotypic poly Ub chains. All of these linkages
have been detected in cells and their abundance changes during specific
cellular events, indicative of their various functions. Extensive investiga-
tions of Ub led to the discovery of proteins able to assemble, recognize and
break down Ub chain types specifically. In general Ub is activated and lig-
ated to its target protein by a cascade of E1-, E2-, and E3-enzymes. This
process is reversed by a large group of proteases called deubiquitinating
enzymes (DUBs) that break down the ubiquitin modification, liberating
the substrate protein and recycling Ub. The basis of the Ub system thus
is fairly simple, but complexity comes from the large amounts of possible
combinations of E2/E3 enzymes that dictate substrate specificity and for-
mation of the appropriate poly Ub linkage type. We thought we understood
the system, but do we actually? Recently it has been discovered that Ub
can be regulated on a totally new level via modification with adenosine di-
phosphate ribose (ADPr), a modification that is found to play crucial roles
in bacterial infection and DNA damage response pathways. Enzymes re-
sponsible for this are able to activate the hosts’ Ub pool and catalyze the
ubiquitination of substrates proteins independent of the regular E1–E2-E3
ubiquitination machinery and without the use of energy source ATP. Syn-
thesis of ADPr-peptides is tricky business due to the incompatibility of the
nucleotide and pyrophosphate regions in the ADPr part with strong acidic
conditions commonly used in peptide chemistry. Reversely the alkaline
conditions commonly used in nucleotide chemistry are incompatible with
peptide integrity. To circumvent such issues a general strategy to produce
ADPr-peptides or more specific ADPribosyl-ubiquitin conjugates based on
a copper catalyzed click reaction between an alkyne carrying ADPribosyl
building block and a site selective azide mutant peptide or protein to gener-
ate a triazole linked ADPr-protein analogue was developed. This method
gives easy access to the first example of ADPribosylated peptides and pro-
teins. Such post-translationaly modified proteins retain their biologic ac-
tivity and can be applied in the studies of this highly irregular pathogenic
pathway.
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A Novel Evans Blue Organic Compound-appended
PSMA-617 Peptide as SPECT Molecule Imaging
Agent for Human Prostate LNCaP Animal Model
Ming-Hsin Li, Sheng-Nan Lo, Shih-Min Wang, Ming-Wei
Chen, Shih-Ying Lee, Chun-Fang Feng, Shih-Wei Lo,
Su-Jung Chen, Chih-Hsien Chang
Institute of Nuclear Energy Research, Taiwan
The PSMA-617 is a high binding affinity ligand for prostate-specific
membrane antigen (PSMA) which is strongly expressed in prostate can-
cer and up-regulated in poorly differentiated, metastatic and hormone-
refractory carcinoma compared with health tissue. To conjugate with
albumin is a new method for improving the pharmacokinetic profile of
peptides. We used a new R&D strategy that changed the linking site
of tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid in PSMA-617 and
modified with truncated Evans blue which was a good human serum al-
bumin binder. The modified PSMA-617 was abbreviated to DOTA-EB-
PSMA-617. The DOTA-EB-PSMA-617 were prepared by linking a trun-
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cated Evans blue to the lysine attaching the DOTA chelator to the α-
amine, attaching a maleimide to the ε-amine, and finally, attaching thio-
lated PSMA-617 peptide to the maleimide. To determine radiolabeling
parameters, the DOTA-EB-PSMA-617 (peptide amount 10-25µg) was la-
beled with 6mCi indium-111 chloride (from INER, Institute of Nuclear
Energy Research in Taiwan) in sodium acetate (NaOAc) with pH 6.0 at
95°C for different incubation time (5 to 20mins). The radiochemical pu-
rity (RCP) of In-111-DOTA-EB-PSMA-617 was qualified by radio-TLC
with citric acid/ sodium citrate buffer. The solvent front was free indium-
111 and the origin spot was In-111-DOTA-EB-PSMA-617. Then we used
prostate carcinoma cells LNCaP (PSMA +) and PC-3 (PSMA-) to deter-
mine the in vitro bio-activity of radiolabeled products by cell binding as-
say. And we used LNCaP tumor bearing mice to determine the in vivo
bio-distribution of In-111-DOTA-EB-PSMA-617 via nanoSPECT/CT. The
radiochemical purity of In-111-DOTA-EB-PSMA-617 was greater than
95%. In cell binding assay, the peptide concentration of In-111-DOTA-
EB-PSMA-617 was 2.5nM to 250nM and incubated for 45mins at 37°C.
With the amount of treated peptide increase, there had been strong and
higher radio-counts in LNCaP cells than PC-3 cells analyzed by γ-counter.
And we found that radio-activity accumulated in the LNCaP tumor site at
48 hours post-injection of 18.5MBq In-111-DOTA-EB-PSMA-617. There
has longer circulating time of In-111-DOTA-EB-PSMA-617 compared
with In-111-PSMA-617 on literature. In conclusion, we altered the phar-
macokinetic/pharmacodynamic (PK/PD) profile of PSMA-617 success-
fully by conjugating PSMA-617 with EB. And PSMA-617 modified with
EB motif has potential to be a theranostics agent to change the therapeutic
cycle of PSMA-617 in shorter time.
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Sol-gel and peptides: an attractive route to
unprecedented biomaterials
Gilles Subra1, Laurine Valot1, Manon Maurel1, Titouan
Montheil1, Cécile Echalier1, Muriel Amblard1, Danièle
Noël2, Marie Maumus2, Tao Jia3, Jean-Luc Coll3, Ahmad
Mehdi4, Jean Martinez1
1Institute of Biomolecules Max Mousseron, France
2Institute of Regenerative Medicine and Biotherapies, France
3Institute of Advanced Biotechnologies, France
4Institute Charles Gerhardt, France
Affording biological properties to a material is one of the challenges the
chemists have to tackle, to improve the efficiency of existing devices and
also to propose new biomaterials. Most of synthetic approaches to obtain
functional materials rely on non-covalent coatings or post-grafting realized
by multistep ligation chemistry.
In this context, we envisioned a bottom-up strategy to introduce bioactive
peptides in polymers or materials. The approach relies on the synthesis of
hybrid blocks displaying one or several hydroxysilane groups. The con-
densation of such moieties proceeds chemoselectively, at room tempera-
ture and is compatible with the handling of biomolecules. Interestingly,
any type of peptides but also biopolymers and dyes can be silylated and
thus can participate to the covalent formation of the material.
Grafting of wound-healing or antibacterial peptides on glass, silicone
catheter[1] and dressings[2], silica and titanium[3] surfaces was performed
but direct synthesis of hybrid materials can be also operated[4]. Comb-like
and silicone linear polymers were prepared.[5,6]
We recently focus our attention on 3D printing of cell-containing hydrogels
using collagen-inspired hybrid peptides[7–9], and multi-ligands nanopar-
ticules for cancer imaging.[10,11]
[1] C. Pinese, et al. Adv. Healthc. Mater. 2016, 5, 3067–3073. [2] C.
Pinese, et al., Mater. Today Chem. 2017, 4, 73–83. [3] N. Masurier, et al.,
J. Mater. Chem. B 2018, DOI 10.1039/C8TB00051D. [4] S. Jebors, et al.J.
Mater. Chem. B 2013, 1, 6510–6515. [5] S. Jebors, Jet al., Angew. Chem.
Int. Ed. 2015, 54, 3778–3782. [6] S. Jebors, et al. J. Pept. Sci. 2015,
21, 243–247. [7] C. Echalier, et al. Chem. Mater. 2016, 28, 1261–1265.
[8] C. Echalier, et al., RSC Adv 2017, 7, 12231–12235. [9] C. Echalier,
et al., Mater. Today n.d., DOI 10.1016/j.mattod.2017.02.001. [10] T. Jia,
et al. Biomaterials 2017, DOI 10.1016/j.biomaterials.2017.10.042. [11] J.
Ciccione, et al., Chem. Mater. 2016, 28, 885–889
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Arginine-rich cell-penetrating peptide-modified
exosomes for macropinocytosis induction and effective
cellular uptake
Kosuke Noguchi1, Ayako Aoki1, Nahoko Bailey
Kobayashi2, Tomoka Takatani-Nakase3, Tetsuhiko
Yoshida2, Ikuo Fujii1, Shiroh Futaki4, Ikuhiko Nakase1
1Graduate School of Science, Osaka Prefecture University, Japan
2Institute for Advanced Sciences, Toagosei Co., Ltd., Japan
3School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women’s
University, Japan
4Kyoto University, Japan
Exosomes (extracellular vesicles, EVs) are small secretory vesicles (30
200 nm in diameter) released from various cell types and contain bioac-
tive molecules [1]. Exosomes are highly expected to be next-generation
biological tools for delivering therapeutic molecules because of their phar-
maceutical advantages, including controlled immunogenicity, utilization
of cell-to-cell communication pathway, modification and encapsulation of
therapeutic molecules. In this presentation, we will discuss novel tech-
niques to enhance cellular exosome uptake by chemical modification of
arginine-rich cell-penetrating peptides (CPPs) [2] that can actively induce
macropinocytosis [3, 4]. We recently found that macropinocytosis (ac-
companied by actin reorganization, ruffling of the plasma membrane, and
engulfment of large volumes of extracellular fluid) induced by cancer-
receptor activation (e.g. EGFR) and oncogenic K-Ras expression is an
important cellular uptake route of exosomes [5]. Therefore, we modified
exosomes to actively induce macropinocytosis by utilizing oligoarginines,
which are CPPs and induce macropinocytosis via the proteoglycan on
plasma membranes [3, 4]. Oligoarginine (Rn; n = 4–16)-modified exo-
somes were prepared by cross-linking the peptides and exosomes using a
N-ε-maleimidocaproyl-oxysulfosuccinimide ester linker. When we exam-
ined the effects of the peptide modification on cellular exosome uptake,
the number of arginine residues in the peptide sequence was found to sig-
nificantly affect cellular uptake via macropinocytosis induction. In addi-
tion, we artificially encapsulated the ribosome-inactivating protein, saporin
(SAP), in exosomes (SAP-exosomes) modified with oligoarginines. Modi-
fication of hexadeca-arginine (R16) peptide on the SAP-exosomes resulted
in effectively attained anti-cancer activity, suggesting efficient cytosolic re-
lease of the SAP [4]. Our findings may contribute to the development
of intracellular exosome-based delivery systems with advanced exosomal
functionality.
References [1] Katsuda, T. et al. Proteomics 14, 412-425 (2014) [2] Futaki,
S., Nakase, I. Acc. Chem. Res. 50, 2449–2456 (2017) [3] Nakase, I. et al.
Sci. Rep. 6, 34937 (2016) [4] Nakase, I. et al. Sci. Rep. 7, 1991 (2017)
[5] Nakase, I. et al. Sci. Rep. 5, 10300 (2015)
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Novel Cryptophycin-based Conjugates for Tumor
Targeting
Adina Borbély1, Eduard Figueras1, Ana Martins2, Paola
Gallinari2, Simone Esposito3, Giulio Auciello3, Daniela
Modena4, Marcel Frese1, Christian Steinkühler5, Norbert
Sewald1
1Bielefeld University, Organic and Bioorganic Chemistry, Bielefeld,
Germany
2Exiris S.r.l., Rome, Italy
3IRBM Science Park SpA, Pomezia, Italy
4Italfarmaco SpA, Cinisello Balsamo, Italy
5Exiris S.r.l., Rome and Italfarmaco SpA, Cinisello Balsamo, Italy
The lack of tumor preference in traditional chemotherapeutics causes se-
vere side effects. Indeed, some promising highly cytotoxic agents (e.g.
cryptophycins) can not be currently used due to the narrow therapeutic
window. For this reason, targeted therapy has recently come to the fore-
front in pharmacotherapy for cancer treatment pursuing the “magic bullet”
early vision of Paul Ehrlich [1]. Cryptophycins are very potent antimitotic
agents that interrupt cell division by inhibiting the assembly of tubulin into
microtubules. Their activity is from 100- to 1000- fold greater than other
agents such as paclitaxel or Vinca alkaloids. This activity is not impaired
by multidrug resistance mechanisms, making cryptophycins very promis-
ing agents for targeted therapy [2]. These interesting properties attracted
the attention of different companies that developed novel cryptophycin
analogues containing an addressable functional group for the formation
of antibody-drug conjugates. However, they faced a major problem con-
cerning the stability of the macrocycle that halted the clinical development
[3, 4]. Among many, cryptophycin-55 glycinate, a synthetic analogue con-
taining a suitable functional group for conjugation is of particular interest.
It is known to display high cytotoxicity and the stability of the macrocy-
cle is greatly enhanced, according to our findings. These characteristics
provide solid evidence to use it as payload in a directed therapy approach.
The construction of small-molecule drug conjugates using the above men-
tioned payload with the homing device octreotide, an octapeptide targeting
the somatostatin receptors, will be reported. The stability of the conjugates
was highly depending on the linker used and one showed good stability in
mouse and human plasma. The cytotoxic effects of the novel conjugates
were evaluated on a diverse panel of tumor cell lines revealing high ac-
tivity of these compounds. In order to prove the selective delivery of the
conjugate to tumor, a fluorescently labeled analogue was prepared for in-
ternalization and uptake studies, which showed selectivity for somatostatin
receptors, as it was envisioned.
[1] M. Srinivasarao, et al. Chem. Rev. 2017, 117, 12133–12164. [2] C.
Weiss, et al. J. Pept. Sci. 2017, 23, 514–531. [3] V. A. Verma, et al. Bioor-
ganic Med. Chem. Lett. 2015, 25, 864–868. [4] D. Su, et al. Bioconjug.
Chem. 2018, 29, 1155–1167.
This project has received funding from the European Union’s Horizon
2020 research and innovation program under the Marie Sklodowska-Curie
grant agreement No 642004.
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A Journey Alongside Cyclosporin on the Road to
Peptide Oral Bioavailability
Conan Wang, David Craik
The University of Queensland, Australia
The path of translation from peptide lead to drug is too often blocked by
the challenge of poor oral bioavailability. What is it about cyclosporin
then that allows it to defy the odds to achieve high membrane permeabil-
ity? And, can we use these ’secrets’ in peptide design? To address these
questions, let me take you on a journey that investigates its structural fea-
tures - i.e., its hydrogen bonding network, lipophilicity, and flexibility -
and their effects on cell and membrane permeability of peptides. Let me
begin with our initial work probing the hydrogen bond network of peptides
using NMR temperature coefficients to select amides for N-methylation,
resulting in designed peptides with high in vitro permeability, including
one with an oral bioavailability of 30% in a rat model. Let me then walk
you through subsequent work on the permeability of a library of 62 cyclic
hexapeptides, establishing the importance of lipophilicity and solubility.
Beyond these structural features is one that is perhaps less well understood -
flexibility - because of the difficulty in studying it using conventional chem-
ical means. We have used extended molecular dynamics simulations to ob-
serve and manipulate the conformational behavior of cyclosporin (as well
as other cyclic peptides) in explicit water, chloroform, water/chloroform
mixture, cyclohexane, and in the presence of a POPC lipid bilayer. The
simulations were validated against NMR experiments, measuring confor-
mational exchange, nuclear spin relaxation, and structures in matched so-
lutions, such as DPC micelles, to mimic the lipid environment. We have
found that conformational dynamics is a key determinant of the membrane
permeability of cyclic peptides, and affects all stages of passage across
membranes. Not only does dynamics enable cyclic peptides to transition
into conformations that have physicochemical properties that favor mem-
brane insertion but also enable them to wiggle their way through the dy-
namic polymer-like network of the membrane core. At the end of this talk,
I will show how the structural features discussed so far are in fact inter-
related using a model of permeation. By understanding the features that
limit or enable the permeability of peptides, the hope is to venture towards
a future of oral peptide therapeutics.
Wang CK, et al. (2014) Rational design and synthesis of an orally bioavail-
able peptide guided by NMR amide temperature coefficients. Proc Natl
Acad Sci USA 111:17504-17509. Wang CK, et al. (2015) Exploring exper-
imental and computational markers of cyclic peptides: Charting islands of
permeability. Eur J Med Chem 97:202-213. Wang CK, et al. (2016) Cyclic
peptide oral bioavailability: Lessons from the past. Biopolymers 106:901-
909. Wang CK, et al. (2018) Conformational Flexibility is a Determinant
of Permeability for Cyclosporin. J Phys Chem B 122:2261-2276.
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Structure-Based Design of Alpha-Helix Mimetics to
Target and Disrupt Estrogen Receptor-Coregulator
Interactions in Breast Cancer
Jung-Mo Ahn
The University of Texas at Dallas, United States
Protein-protein interactions (PPIs) are fundamental biochemical processes
that regulate numerous cellular pathways, and often found to be mediated
by key secondary structures like alpha-helices. Whereas short peptides
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derived from proteins have been used to inhibit such PPIs, peptides in gen-
eral may suffer from drawbacks that severely compromise their effective
in vivo use, such as rapid degradation, poor bioavailability, and low cell
permeability. Thus, small molecules that mimic functions of helical pep-
tides would be of great interest in targeting and disrupting PPIs that take
place inside cells. We have designed oligo-benzamides as rigid templates
to emulate protein helical surfaces. A tris-benazmide scaffold can place
3 functional groups to match the side chains found at the i, i+4, and i+7
positions in a helix. And, it can accommodate two additional functional
groups at its N- and C-termini to render higher target interaction, selectiv-
ity, and improved physicochemical properties. In addition, tris-benzamides
are easy to be assembled by following high-yielding and iterative steps in
solution- and solid-phase. As estrogen receptor (ER) recognizes a heli-
cal and consensus LXXLL motif to recruit its coregulators, we have de-
signed and synthesized a series of tris-benzamides based structural design.
A leading compound TK11 disrupts both ER dimerization and interaction
with several coregulators, and effectively blocks ER-mediated oncogenic
signaling. It showed potent growth inhibition on therapy-sensitive and -
resistant breast cancer cells, in both preclinical mouse xenograft models
and patient-derived tumor explant models. It is orally bioavailable with
no identifiable toxicity, showing a new mechanism of action to treat breast
cancer.
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Ghrelin receptor ligands: from the bench to the drug
on the market
Jean-Alain Fehrentz1, Vincent Guerlavais2, Céline
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Jean Martinez1
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2Aileron Therapeutics, Cambridge, MA, United States
Ghrelin receptor or GHS-R1a for Growth Hormone Secretagogue Recep-
tor type 1a is a G protein-coupled receptor (GPCR) that mediates ghrelin-
induced growth hormone (GH) secretion, food intake, and reward-seeking
behaviors. Because of its possible implication in several physiological dis-
orders such as obesity and drugs/alcohol addictions, GHS-R1a represents
a major target for the development of therapeutic small molecules. We
previously described a potent Growth Hormone Secretagogue (GHS), the
pseudopeptide compound JMV 1843. This compound is a selective agonist
of GHS-R1a able to mimick ghrelin and to act by oral route in man. Acting
as a GHS, it is able to elicit a large secretion of GH which can be dosed
in the blood. It has completed its clinical phases and was approved by the
FDA for GH deficiency diagnosis in aldults. This compound will be com-
mercialized by Æterna-Zentaris in 2018 under the trademark of Macrilen®.
It is also in clinical phase II for the treatment of cachexia. The implication
of GHS-R1a in food intake focused the attention on ghrelin receptor antag-
onists for the treatment of obesity. However for an efficient anti-obesity
activity, a GHS-R1a antagonist should counteract the orexigenic effect of
ghrelin but not the GH secretagogue effect, since GH deficiency is fre-
quently associated with increased adiposity. Starting from JMV 1843, we
achieved to design and prepare a series of novel small molecules, based on
the 1,2,4-triazole scaffold, able to antagonize ghrelin-induced GHS-R1a
signaling. This peptidomimetic series have been investigated on one hand
for their ability to compete for ghrelin binding and to activate or to in-
hibit calcium uptake in cells transiently expressing GHS-R1a and on the
other hand for their effects on food intake and GH secretion in animal mod-
els. Our results showed that several non-peptide compounds characterized
in vitro as antagonist or partial agonist of GHS- R1a inhibited food in-
take without altering GH secretion in vivo. We found that the dissociated
effect of these ligands on food intake and GH secretion was correlated
with their functional selectivity toward signaling pathways of GHS-R1a,
making these ligands “biased”. Thus this study supports the feasibility
of a specific pharmacological modulation of the ghrelin effect on appetite.
The preclinical results obtained with some of our best compounds (such
the JMV 2959) will be presented. Finally, as GHS-R1a displays a very
high constitutive activity (more than 50% of its maximal activity) it is
thought that inverse agonists could potentially decrease food intake and
body weight. Starting from JMV 2959, we recently developed a series of
inverse agonists based on our 1,2,4-triazole scaffold. In vitro results of
these compounds will also be presented.
OP34
Macrocyclization of Small Peptides Enabled by
Oxetane Incorporation
Stefan Roesner
The University of Warwick, United Kingdom
Compared to their linear counterparts, cyclic peptides benefit from en-
hanced cell permeability, increased target affinity, and higher resistance to
proteolytic degradation. Moreover, they are capable of acting as inhibitors
against some of the most challenging targets, including protein-protein in-
teractions. One major obstacle to the discovery and development of new
cyclic peptide drugs relates to the difficulties associated with their synthe-
sis. The head-to-tail cyclization of short peptides containing seven or less
amino acids is especially challenging. Common problems encountered dur-
ing cyclization are C-terminal epimerization, cyclooligomerization and the
appearance of side products arising from polymerization. Consequently,
there is a pressing need to discover new macrocyclization strategies that
can provide easy access to a variety of small cyclic peptide scaffolds.
A new type of turn-inducing element for peptide macrocyclization in which
one of the backbone C=O bonds is replaced with an oxetane ring is re-
ported. The cyclization precursors are conveniently made in solution or
by solid-phase peptide synthesis. The subsequent macrocyclizations are
demonstrated to be general, enabling a variety of difficult ring closures in-
cluding those producing head-to-tail and side-chain to side-chain linkages.
The method tolerates variation in the size of the macrocyclic ring and the
location of the turn-inducing 3-amino-oxetane element with respect to the
amide bond being formed. Additional data reveal that oxetane modified
cyclic peptides are excellent bioisosteres of conventional cyclic peptides
and as such this new method offers considerable potential in drug discov-
ery programs.
OP35
The use of RGD peptidomimetics on biomaterials:
new advances via selective integrin-subtype targeting
Roberta Farioli1, José M. Manero1, Horst Kessler2,
Carles Mas-Moruno1
1Universitat Politècnica de Catalunya, Spain
2Technical University of Munich, Germany
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Engineering biomaterials with integrin-binding activity is a very powerful
approach to promote cell adhesion, modulate cell behavior, and induce spe-
cific biological responses at the surface level. However, most strategies in
this field have focused on using RGD-containing peptides or proteins with
relatively low integrin-binding potential and receptor selectivity.
In this work, I will present the recent development of highly active and
selective αvβ3- or α5β1-binding peptidomimetics derived from the RGD
peptide sequence (Figure 1), and their use to modify material surfaces and
generate cell instructive and bioactive biomaterials (1).
In detail, I will focus on 3 recent examples: i) the capacity of pep-
tidomimetic ligands to promote osteoblast adhesion, proliferation and min-
eralization on implant materials (2); ii) their potential to support stem cell
adhesion and osteo-differentiation on highly nanostructured surfaces (3);
and finally iii) their capability to instruct stem cell response in an integrin-
selective manner in vitro and enhance bone formation in vivo (4).
References: (1) Mas-Moruno, C. et al., Angew. Chem. Int. Ed 2016, 55,
7048-7067. (2) Fraioli, R. et al. Colloids Surf. B Biointerfaces 2015, 128,
191-200. (3) Fraioli, R. et al. Sci. Rep. 2017 7, 16363. (4) Unpublished
results
OP36
Stabilising Peptoid Helices Using Non-Chiral
Fluoro-Alkyl Monomers
Steven Cobb
Durham University, United Kingdom
Peptoids are a class of synthetic foldamers that are being developed as po-
tential therapeutics, biomaterials, and organocatalysts. In particular, pep-
toids represent an attractive platform for pharmaceutical applications, as
they are highly resistant to protease degradation. However, given their ter-
tiary amide backbone, peptoids lack the capacity to form hydrogen bonds
so their secondary structures are dominated by relatively weak interac-
tions. Considerable efforts have been made to try and understand the re-
lationships between a peptoid primary sequence and its folded structure.
Cis/trans isomerization of the tertiary amide bond is the major cause of
conformational heterogeneity in peptoid oligomers. Despite this, Zuck-
ermann and Barron have demonstrated that α-chiral aromatic monomers,
like NSpe can stabilize the cis configuration of the peptoid amide bond
largely through steric effects. Gorske and Blackwell, found that the syn-
ergistic application of steric and non-covalent n→pi* interactions (NCIs)
in aromatic systems could also be used to design stable cis-amide peptoid
monomers (e.g. Ns1npe). However, it is not possible to use NCIs to sta-
bilize the cis-amide conformation of alkyl peptoid monomers and this has
meant that the design of stable peptoid helices remains dominated by the
use of chiral aromatic residues. Recently, Faure and Taillefumier exploited
steric effects in the design of a non-chiral tBu alkyl monomer, which has
a clear cis-amide preference (NtBu). While NtBu offers one route to con-
trol peptoid structure that avoids the use of aromatic building blocks the
design of non-chiral but stable cis-amide alkyl monomers is an area that
is still highly underdeveloped. We sought to explore the application of
fluorine as a tool to modulate the conformational preferences of alkyl pep-
toid monomers. Through NMR and X-ray analysis we demonstrate that
simple non-chiral fluoro-alkyl monomers can be used to influence the key
Kcis/trans equilibria of a peptoid amide bond in model systems and induce
a remarkable degree of cis-amide preference. The cis-isomer preference
displayed is highly unprecedented given the fact that neither chirality nor
charge is being used to control the peptoid amide conformation. Our data
supports that inductive effects imparted by the fluorine atom(s) and not
fluorine gauche effects underpin the cis-isomer stabilization observed. We
have also used the novel fluoro-alkyl monomers to prepare a series of pep-
toid oligomers that exhibit stable helical structures despite only having
one chiral aromatic residue. The application of fluorine in the design of
alkyl monomers offers a new approach to control amide bond isomerism
in peptoid sequences, overcoming the current need for high levels of chi-
ral side chains. Given the lack of alternatives available the fluoro-alkyl
monomers developed offer exciting new tools to design structurally stable
peptoid systems with applications in a range of areas including medicine
and biomaterials.
OP37
Concerted biophysical and biological evaluation of
Pseudomonas lipopeptides as a premise to unlock their
application potential
José Martins, Yentl Verleysen, Benjamin Kovacs, Vic De
Roo, Christophe Ampe, Annemieke Madder, Marleen Van
Troys, Niels Geudens
Ghent University, Belgium
Cyclic lipodepsipeptides (CLPs) are secondary metabolites with a broad ar-
ray of biological functions, mostly produced by Bacillus and Pseudomonas.
First recognized for their antimicrobial action, their involvement as natu-
ral agents in plant protection has led to their application in the context
of plant biocontrol and crop protection. More recently, scattered litera-
ture reports have indicated their anticancer activity as well. Given their
appearance as promising tools for biomedical and agricultural research
or applications, studies that aim to elucidate their mechanism of action,
and structure-activity relationship studies in particular, should be high
on the agenda. However, the study of these compounds quite often fol-
lows an approach where following their initial isolation and MS charac-
terization, a short-cut is taken to directly assess their biological activity,
thereby altogether bypassing their chemical and biophysical characteriza-
tion. Even then, with more than 100 CLPs from Pseudomonas (Ps-CLPs)
currently reported, a detailed investigation of biological activity reports
for 51 Ps-CLPs indicates that, beyond some generalisations, little tan-
gible information with respect to structure-activity relationships may be
extracted from these, given the diversity of assays and assay conditions
used. As a result, we have advocated that a concerted research action
should be undertaken if the full potential of the different classes of CLPs
is to be realized.[ https://www.future-science.com/doi/abs/10.4155/fmc-
2017-0315 ] We propose the results of our first steps towards this goal.
Despite the large diversity in amino acid sequence we show that a novel
and simplified nomenclature scheme can be introduced to organize the
large diversity of CLPs from Pseudomonas. Using subsequent sequence
alignment, we show that all currently known Ps-CLPs can be assigned to
up to 15 different groups, each containing multiple members with varying
degrees of homology. Next, using the solution structure determination by
NMR of representative structures from 6 different groups (bananamides,
viscosin, orfamides, amphisins, xantholysins and one newly uncovered
group) and 2 available from literature (tolaasin and syringomycin) we pro-
pose that all Ps-CLPs adopt one of three folds: a stapled helix fold, a
golf-club fold and a tennis-ball seam fold. All these are characterized by
an amphipathic character that lies at the core of the variety of biological
activities. Newly isolated Ps-CLPs can now easily be classified according
to group and fold family provided their sequence is determined. Also, the
added level of organization – 3 fold families rather than 15 Ps-CLPs groups,
provides critical guidance in selecting Ps-CLPs for further biophysical and
biological evaluation. By screening a selection of 8 Ps-CLPs belonging to
the stapled-helix fold or the golf-club fold against a variety of cancer cell
lines, the importance of the fold is illustrated while simultaneously, a link
between trends in activity and overall amphipathicity appears to emerge.
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OP38
Rationally Designed Peptidomimetics
Andrew Jamieson
University of Glasgow, United Kingdom
Peptides are well known to act as potent and selective ligands for a vari-
ety of bimolecular targets. Although there are a many peptide drugs in
clinical use, their potential has been limited by unfavorable physicochem-
ical properties including limited plasma stability and a lack of cell perme-
ability. Peptidomimetics are molecules that can be rationally designed to
overcome many of the issues associated with peptides and provide tool
molecules for chemical biology and lead compounds for drug discovery.
In this presentation I will discuss the Jamieson Group’s efforts in the de-
velopment of new chemical technologies including girder peptides and a
disulfide bond mimetic. The application of these new conformational con-
straints to conotoxins will also be discussed.
OP39
Amyloidogenicity of regions of Nucleophosmin 1: a
direct link between protein misfolding and Acute
Myeloid Leukemia
Daniela Marasco, Ettore Novellino, Giancarlo Morelli, Sara
La Manna
University of Naples Federico II, Italy
Nucleophosmin (NPM1) is a multidomain protein involved in a variety of
biological processes and identified as the most frequently mutated gene
in Acute Myeloid Leukemia (AML). Its C-terminal domain (CTD) is en-
dowed with a three helix bundle tertiary structure: H1 (243-259), H2 (264-
277) and H3 (280-294) helices fold through a compact transition state and
unfold keeping a residual secondary structure at the interface between H2
and H3 helices (Grummitt, et al. 2008). Our studies outline that the neigh-
bouring regions H2 (Di Natale, al. 2015) (Russo, et al. 2017) and H3 in
AML mutated variants (Scognamiglio, et al. 2016) form amyloid-like as-
semblies endowed with fibrillar morphology and b-sheet structure proved
to be toxic in cell viability assays. These regions are able to interact with
membranes with different mechanisms and the presence of cholesterol re-
vealed of crucial importance. Noticeably, wt CTD and Cterm mutA (the
most common AML mutation) directly bind to membrane models in vitro
albeit with different mechanisms (De Santis, et al. 2018). A short stretch
(nine residues) deriving from the aromatic core of the helical bundle So-
lution and fiber state experiments related on demonstrated able to self-
aggregate and that helical intermediates have a clear prompting role in the
aggregation process: derived nanostructures revealed flat with twisted pro-
files at higher concentrations and typical cross-β structures (La Manna S,
submitted). These investigations led to speculate that the destabilization of
the a-helical bundle by AML-associated mutations predispose it to the for-
mation of toxic aggregates causing the exposure of the H2 and H3 regions.
More recently we found that all AML mutations, from A to F, without both
or one Trp of the NoLS (nucleolar localization signal) induce amyloid-like
aggregation and cytotoxicity. These findings are crucial to unveil the AML
molecular mechanisms and leukemogenic potentials of AML mutations.
OP40
Inhibition of nicotinic acetylcholine receptor subtypes
by the ribbon isomers of α-conotoxins.
Quentin Kaas1, Xiaosa Wu1, Han-Shen Tae2, Yen-Hua
Huang1, David J Adams2, David Craik1
1The University of Queensland, Australia
2llawarra Health and Medical Research Institute, The University of
Wollongong, Australia
α-Conotoxins are a large family of toxins extracted from the venom of
carnivorous marine cone snails and inhibiting with exquisite selectivity
some subtypes of nicotinic acetylcholine receptors (nAChRs), which are
involved in cognition, memory and learning as well as related neuronal
diseases. α-Conotoxins display two disulfide bond cross-links, which can
form three distinct connectivities: ribbon, bead and globular, with the latter
displayed by wild-type toxins. We have previously discovered that the non-
native ribbon isomer of α-conotoxin AuIB inhibits a specific stoichiometry
of the α3β4 nAChR subtype and with greater potency than the wild-type
toxin, providing a high-precision molecular probe for neuroscience stud-
ies. We here present a complete structure-activity relationship study of
ribbon AuIB, and we determined the binding mode of the toxin on the
α3β4 nAChR using a combination of peptide synthesis, molecular dynam-
ics simulations, nuclear magnetic resonance spectroscopy and electrophys-
iology experiments. We compare the binding mode of the well-studied α-
conotoxin globular isomers with that of the ribbon isoforms, highlighting
differences that could be exploited to design probes of nAChR subtypes
that have been hitherto difficult to target selectively. We also identified po-
sitions of the ribbon scaffold that could influence its folding, dynamics and
therefore activity. This study lays the groundwork for utilising the ribbon
connectivity of α-conotoxins as an alternative to the globular isoform to
design selective nAChR inhibitors.
OP41
Quaternary Ammonium Isobaric Labeling for a
Relative and Absolute Quantification of Peptides
Mateusz Waliczek, Bartosz Setner, Monika Kijewska,
Remigiusz Ba˛chor, Dorota Ga˛szczyk, Piotr Stefanowicz,
Zbigniew Szewczuk
Faculty of Chemistry, Wrocław University, Poland
Isobaric tags for relative and absolute quantitation (iTRAQ) is a labeling
method used in quantitative analysis of peptides by tandem mass spec-
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trometry to determine the amount of peptides in complex mixtures in a
single experiment. Although the isobaric labeling quantification has be-
come a widely used method in proteomics studies, the currently available
isobaric tags are very expensive and do not offer significant improvement
of sensitivity of detection during MS experiment. Tagging of peptides with
quaternary ammonium (QA) salts has been widely used to increase sensi-
tivity of detection by ESI-MS[1]. Previously we have proposed linear[2]
and bicyclic[3] QA as ionization enhancers for analysis of peptides at the
attomole level [4]. Herein we design two new classes of quaternary am-
monium isobaric tags for relative and absolute quantitation (QA-iTRAQ
2-plex). The first procedure is based on the combination of 18O exchange
catalysed by trypsin followed by chemical modification of primary amines
groups with isotopically labeled pyrylium salt[5] which allows isobaric
labeling of tryptic digests. Each isobaric labeled peptide contains zero
or four 13C atoms in the mass reporter group, which results in a unique
reporter mass during tandem MS/MS for sample identification and rela-
tive quantitation. The second procedure is based on application of N-(4-
iodobenzylpiperidinylcarbonyl)-β -alanine tag, with two deuterium atoms
incorporated into the benzyl (stabile reporter group) or β -alanine (balance
group) residues.[6] We tested the QA-iTRAQ 2-plex reagents on various
peptides as well as protein tryptic digests and podocyte cells. Obtained
results suggest usefulness of the isobaric ionization tags for relative and
absolute quantification of trace amounts of peptides. This work was sup-
ported by a grant No. UMO-2016/23/B/ST4/01036 from the NSC, Poland.
References: 1. Stefanowicz, P., Kluczyk, A., Szewczuk, Z., Amino Acids,
Pept. Proteins, 2016, 40, 36. 2. Cydzik, M., Rudowska, M., Stefanowicz,
P., Szewczuk, Z., J. Am. Soc. Mass Spectrom., 2011, 22, 2103. 3. Setner,
B., Rudowska, M., Klem, E., Cebrat, M., Szewczuk, Z., J. Mass Spectrom.,
2014, 49, 995. 5. Ba˛chor, R., Mielczarek, P., Rudowska, M., Silberring,
J., Szewczuk, Z., Int. J. Mass Spectrom., 2014, 362, 32. 5. Waliczek, M.,
Kijewska, M., Rudowska, M., Setner, B., Stefanowicz, P., Szewczuk, Z.,
2016, Sci. Rep. 6, 37720. 6. Setner, B., Stefanowicz, P., Szewczuk, Z., J.
Mass Spectrom., 2018, 53, 115-123.
OP42
Development of serine protease inhibitors using the
1,2,3-triazole motif as a disulfide mimetic in the cyclic
peptide sunflower trypsin inhibitor-1
Andrew White, Simon Deveer, Joakim Swedberg, Thomas
Durek, David Craik
The University of Queensland, Australia
Disulfide-rich peptides are a diverse class of highly constrained molecules
that have potential in drug design due to their ability to be adapted towards
a broad range of therapeutic targets. Despite having high proteolytic stabil-
ity, one potential therapeutic limitation of these peptides is the redox insta-
bility of the disulfide bond, with reduction or shuffling often rendering the
peptide unstable or inactive. Applications of redox stable disulfide bond
mimetics have demonstrated that 1,5- and 1,4-disubstituted 1,2,3-triazole
motifs can be used to successfully replace disulfide bonds as a conforma-
tional restraint in certain applications [1-2]. In this project, our aim was
to further explore the utility of the triazole bridge as a disulfide mimetic
in highly constained backbone cyclized (N-C) Sunflower Trypsin Inibitor-
1 (SFTI-1) and engineered variants. Using solution phase triazole bridge
synthesis, we successfully synthesized a series of triazole bridged variants,
with the best SFTI-1 based analogue exhibiting highly potent trypsin inhi-
bition (Ki: 76 pM). Capitalizing on this success, we further implemented
the use of the 1,5-disubstituted 1,2,3-triazole to target other serine pro-
teases using engineered SFTI-1 based inhibitors which will be discussed
in this presentation.
1. Empting M, Avrutina O, Meusinger R, Fabritz S, Reinwarth M, Biesal-
ski M, Voigt S, Buntkowsky G, Kolmar H. “Triazole bridge”: Disulfide-
bond replacement by ruthenium-catalyzed formation of 1,5-disubstituted
1,2,3-triazoles. Angewandte Chemie International Edition. 2011;50:5207-
5211 2. Gori A, Wang CA, Harvey PJ, Rosengren KJ, Bhola RF, Gelmi
ML, Longhi R, Christie MJ, Lewis RJ, Alewood PF, Brust A. Stabilization
of the cysteine-rich conotoxin MrIA by using a 1,2,3-triazole as a disul-
fide bond mimetic. Angewandte Chemie International Edition. 2015, 54,
1361-4.
OP43
Peptide-Bile acid Cyclisation as a Tool for the
Development of a Universal Vaccine Against Influenza
A
Dorien Van Lysebetten1, Bert Schepens2, Xavier Saelens2,
Annemieke Madder1
1Ghent University, Belgium
2Ghent University, VIB, Belgium
Peptide cyclisation is considered to enhance the therapeutic properties of
peptide drugs because it allows to modulate for example the conforma-
tional flexibility, susceptibility to proteases, potency and selectivity of such
drugs. In this work, cyclisation is achieved by grafting the peptide se-
quence onto a bile acid scaffold, more specifically deoxycholic acid. Apart
from being rigid, the scaffold is also very cheap and has amphipathic prop-
erties which equips the molecules with a hydrophobic side [1]. In this way,
the scaffold can constrain the peptide as well as help to increase cellular up-
take[2], bioavailability[2], albumin binding, protease stability[3], etc. This
bile acid cyclisation can be used for a variety of targets. Here, we present
a conjugate peptide antigen designed to generate broadly protective anti-
bodies against Influenza A. We chose to graft a peptide corresponding to
the extracellular part of matrix protein 2 (M2e) onto the scaffold because
M2e is conserved across different influenza A virus subtypes and can thus
act as a universal antigen for influenza A[4]. The M2e peptide adopts
a U-shape when bound to a M2e-specific and protective monoclonal an-
tibody (mAb 65)[5,6]. Therefore, we hypothesized that constraining this
peptide can promote the induction of mAb 65-like antibodies. The grafting
reaction involves an easy one-step synthesis delivering two regioisomers,
which can be separated and purified with optimised HPLC conditions. In-
terestingly, the cyclic peptide-bile acid conjugates are recognized by M2e-
specific monoclonal antibodies and polyclonal serum in an ELISA assay.
In addition, the immunogenicity of the constrained M2e peptide that best
competed with the linear M2e peptide for mAb 65 binding was evaluated
in vivo. Immunisation of laboratory mice with the cyclic M2e peptide in-
duced serum antibodies that were specific for M2e, and for M2 expressed
by mammalian cells. We conclude that constraining a peptide antigen on a
bile-acid scaffold is an efficient method to design a universal influenza A
vaccine candidate.
[1] A. Enhsen, W. Kramer, G. Wess, Drug Discov. Today 1998, 3, 409–418.
[2] W. Kramer, G. Wess, et al., J. Biol. Chem. 1994, 269, 10621–10627.
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[3] C. a Bodé, T. Bechet, E. Prodhomme, K. Gheysen, P. Gregoir, J. C. Mar-
tins, C. P. Muller, A. Madder, Org. Biomol. Chem. 2009, 7, 3391–3399.
[4] A. Kolpe, B. Schepens, W. Fiers, X. Saelens, Expert Rev. Vaccines
2017, 16, 123–136. [5] K. J. Cho, B. Schepens, et al., J Virol 2015, 89,
3700–3711. [6] S. Van den Hoecke, K. Ehrhardt, et al., J. Virol. 2017, 91,
e02500-16.
OP44
Stereochemically modified glucagon with improved
biophysical parameters
Piotr Mroz1, Diego Perez-Tilve2, John Mayer3, Richard
Dimarchi1
1Indiana University Bloomington, United States
2University of Cincinnati, United States
3Novo Nordisk Research Center Indianapolis, United States
Glucagon serve seminal role in maintaining physiological homeostasis of
the sugar metabolism buffering against insulin induced hypoglycemia. De-
spite its importance as the lifesaving therapeutics and missing element
in artificial pancreas, development of the glucagon has been hindered by
the peptide’s poor solubility, high aggregation propensities and chemical
instability. Over the years number of approaches has been deployed to
overcome biophysical issues -predominately modification in amino acid
sequence to adjust isoelectric point. On the other hand, introduction of the
D-amino acids into the native sequence of the pharmaceutically relevant
peptide has been popular mean to enhance peptides proteolytic resistance
and increase circulation. In our minimalistic approaches to peptide opti-
mization we demonstrated that single point steroinversions lead to dramat-
ically increased solubility in physiological buffer with preservation of full
in vitro and in vivo bioactivity. Furthermore, D-amino acid insertions are
associated with significant decrease in glucagon’s fibrillation.
OP45
Design, synthesis and study of multimeric peptidic
conjugates for a new approach of anti-tumoral
immunotherapy
Benjamin Liet, Eugénie Laigre, Claire Tiertant, Didier
Boturyn, Nathalie Berthet, Olivier Renaudet
Département de Chimie Moléculaire, France
Despite significant progress in cancer therapy, current treatments are still
controversial due to intolerable side effects. Targeted immunotherapy has
emerged as an ideal alternative to improve treatment modalities but very
limited approaches are available today and major issues remain to be ad-
dressed. Our objective is to design bi-modular systems called “Antibody-
Recruiting Molecules” (ARM) with the objective of redirect endogen an-
tibodies already present in the bloodstream against cancer cells, without
preimmunization [1]. The first module (ABM for “Antibody Binding Mod-
ule”), is composed of multivalent carbohydrate antigens for endogenous
antibodies [2]. The second module (TBM for “Tumoral Binding Module”)
is composed of selective ligands for markers expressed by diverse cancer
cell lines [3]. Several ARMs have been synthesized with variable size,
geometry and valency by using peptide scaffolds and chemoselective lig-
ations [4]. These molecular architectures have been tested in vitro with
several cancer cell lines by Fluorescence Activated Cell Sorting (FACS).
Here we report the synthesis and biological evaluation of the best com-
pounds obtained so far.
[1] McEnaney, P. J.; Parker, C. G.; Zhang, A. X.; Spiegel, D. A. ACS
Chem. Biol. 2012, 7 (7), 1139. [2] Chen, W.; Gu, L.; Zhang, W.; Motari,
E.; Cai, L.; Styslinger, T. J.; Wang, P. G. ACS Chem. Biol. 2011, 6 (2),
185. [3] Garanger, E.; Boturyn, D.; Coll, J.-L.; Favrot, M.-C.; Dumy, P.
Org. Biomol. Chem. 2006, 4 (10), 1958. [4] Boturyn, D.; Defrancq, E.;
Dolphin, G. T.; Garcia, J.; Labbe, P.; Renaudet, O.; Dumy, P. J. Pept. Sci.
2008, 14 (2), 224.
OP46
Engineered protein-protein interaction regulators for
therapeutic applications
Nir Qvit
Bar-Ilan University, Israel
Protein-protein interactions (PPIs) are intimately involved in almost all bi-
ological processes, including inter- and intracellular signal transduction,
gene expression, cell proliferation and apoptosis. Therefore, they are im-
portant phenomena in basic research and promising targets for treating hu-
man disease. Nevertheless, targeting PPIs is challenging, as PPI interfaces
are large, flat, and are usually endowed with a significant degree of con-
formational flexibility. Peptides are ideal candidates for targeting PPIs as
they have demonstrated high conformational flexibility, increased selectiv-
ity, and are generally inexpensive. Moreover, peptide limitations, such as
poor stability and inefficient crossing of cell membranes, can be overcome
using peptidomimetics (modified peptides). Here we combine two tech-
niques for the development of peptidomemetics. The first is an approach
for the identification of the two critical PPI interfaces. We developed novel
algorithms to detect specific PPI interfaces between a vital protein and only
one of its many partners, using rational design, based on unique interac-
tion sites. A second technique is an already established approach used for
the development of peptidomimetics that retain the functional groups of
the substrate side chain residues essential for their bioactivity. We thus
convert active sequences into peptidomimetics while retaining their con-
formational flexibility. Together, these techniques allow the development
of selective inhibitors of specific binding sites that are metabolically stable
and highly active. One example of inhibition of specific PPIs is the selec-
tive inhibition of the phosphorylation of pyruvate dehydrogenase kinase
(PDK) by protein kinase C (δPKC), which demonstrated its correlation
with cellular processes following cardiac ischemia. Since δPKC phospho-
rylates many substrates, the extent to which this specific phosphorylation
is critical for cardiac damage could not be previously explored. We devel-
oped an inhibitor of the δPKC/PDK PPI,ψPDK, which selectively inhibits
PDK phosphorylation. In animal models of heart attack, ψPDK reduced
infarct size by 70% and tripled ATP levels. ψPDK was found to be highly
active (EC50 5 nM) and specific, and did not affect the phosphorylation of
other δPKC substrates even at 1 µM. A second example of specific PPI
inhibition involves proteins that regulate mitochondrial fission, dynamin-
related protein 1 (Drp1) and mitochondrial outer membrane protein, Fis1.
Excessive mitochondrial fission results in oxidative stress and contributes
to the pathology of neurodegenerative diseases. We developed a selec-
tive inhibitor of the Drp1/Fis1 PPI, p110. The selective inhibition reduced
ROS production, improved mitochondrial membrane potential and reduced
apoptosis. Our overall findings demonstrated that P110 prevents mitochon-
drial fragmentation and cell death under pathological conditions. Inhibi-
tion of δPKC/PDK and Drp1/Fis1 PPIs are both examples of specific and
selective inhibition by rationally designed peptidomimetics. These novel,
highly selective PPI inhibitors may be used as lead compounds for ther-
apeutic applications. Furthermore, similar approaches can be applied for
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the development of various other specific PPI regulators.
OP47
Utilizing Combinations of New Approaches to Peptide
and Peptidomimetic Design for G-Protein Coupled
Receptors
Victor J. Hruby
Department of Chemistry and Biochemistry, University of Arizona,
Tucson, Arizona 85721, United States
The renewed interest in peptides and peptidomimetics in drug development
presents a welcome challenge for enhanced design of desired properties
including selectivity, bioavailability, stability, etc. This requires enhanced
integration of computational, design, synthetic and topographical consider-
ations. G-Protein Coupled Receptors (GPCRs) are particularly challenging
because they are the current targets of over one third of drugs. However,
their inherent flexibility and instability and the fact that of their native lig-
ands also are often flexible has made it very difficult to obtain x-ray crystal
structures of the native proteins binding to their native ligands. To over-
come these difficulties we have made increasing use of a combination of
conformational and topographical constraint of the native hormones and
neurotransmitters coupled with enhanced computational approaches for ho-
mology modeling of the receptors, and for docking of novel ligands. This
is used in conjunction with state of the art receptor ligand design for selec-
tivity to specific GPCR subtypes (both agonists and antagonists), for lig-
and bioavailability, and for enhanced penetration of the blood brain barrier.
We will illustrate this approach by examples of the design of melanocortin
1 receptors (MC1R) selective ligands that converted the non-selective na-
tive hormone gamma-melanocyte stimulating hormone to a highly selec-
tive peptide ligand, using only eukaryotic L-amino acids. We also have
designed MC3R and MC4R selective ligands with enhanced bioavailabil-
ity and blood-brain barrier penetration that are conformational and topo-
graphically constrained, both agonists and antagonists. Supported in part
by the U.S. Public Health Service, National Institutes of Health and by
Tech Launch Arizona
OP48
Immobilising integral membrane proteins on silica
Friedrich Bialas, Christian F.W. Becker
University of Vienna, Austria
The 19 amino acid R5 peptide is a repetition sequence from the diatom
Cylindrotheca fusiformis sil1p protein. Even in the absence of post-
translational modifications, it can be used as a silica precipitation tag for
small molecules and proteins.[1] The silica structures can be obtained at
ambient pressure and room temperature within minutes. Silica nanoparti-
cles are non-toxic and have tunable bio-degradability.[2] Silica materials
can be used for drug delivery into cells and improving enzymatic activity
of immobilised proteins.[3] The aim of this project is to develop a sys-
tem to incorporate functional membrane proteins into silica nanoparticles.
To this end, nanodiscs, which use a truncated version of the human apo
A1 protein to create nanometer-sized lipid bilayers in solution,[4] were
combined with the R5 peptide. The new construct was shown by TEM
to enable nanodisc formation and silica precipitation and will be used to
embed functional membrane proteins and immobilise them in lipid-silica
particles.
Acknowledgements We gratefully acknowledge financial support through
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In our understanding of the many drivers of malignant progression and
cancer metastasis, proteases are increasingly drawn into the spotlight as
crucial modulators in cancer angiogenesis, invasion, and metastasis [1].
Elevated activities of multiple members of the cathepsin family have been
shown to correlate with increased metastasis and high therapy resistance
[2, 3]. Especially high expression levels of extracellular cathepsin B (CTB)
indicate poor prognosis in neoplastic diseases, making CTB an interesting
target for activity-based molecular imaging in cancer diagnostics as well
as in cancer therapy monitoring for personalised therapies. It is our aim to
develop such an imaging probe for CTB by combination of a polyarginine-
based, activatable cell-penetrating peptide (ACPP), as first described by
R. Tsien, and an optimised endopeptidase substrate for CTB [4]. Sub-
strate optimisation proofed to be challenging as two entirely opposite fac-
tors needed to be balanced – high stability against serum proteases to pre-
vent premature cleavage of the activation sequence, while retaining effi-
cient and specific endoproteolytic cleavability by CTB. We have gener-
ated a CTB-endoprotease substrate by C-terminally elongating the CTB-
carboxydipeptidase substrate Abz-GIVR*AK(Dnp)-OH (Abz - aminoben-
zoyl, Dnp – dinitrophenyl, * – cleavage site), described by Cotrin et al. in
2004, to the octapeptide Abz-GIVR*AK(Dnp)GX-CONH2, which could
be used as activation site in the final ACPP [5]. Introduction of any amino
acid other than glycine at the P4’ position resulted in hysteretic kinetics for
the CTB-catalysed hydrolysis of the octapeptides, which might indicate the
displacement of the occluding loop from the active site upon interaction
with the substrates. Using LC-ESI-MS-based analysis of serum-incubated
substrates, the positions P1 and P3’ where determined to be primary de-
terminants of serum stability. After suppression of the P3’ instability by
Nα-methylation and optimisation within the positions P1-P3, we were able
to increase serum half-life from < 5 min to > 1440 min under concomitant
improvement of kinetic substrate efficiency towards CTB. Currently, the
substrate is optimised towards CTB-specificity within the cathepsin pro-
tease family. Additionally, cell uptake studies of a fluorescently labelled
ACPP using the optimised CTB-endoprotease substrate sequence are on-
going. Using this fluorescent probe, we plan to study cell uptake, in vivo
stability and initial biodistribution. Furthermore, ACPPs conjugated to
radiometal-chelating entities are currently prepared, which will allow for
PET imaging in vivo.
Literature [1] Yang et al., Cancer Growth Metastasis 2009, 2, 13-27 [2]
Aggarwal and Sloane, Proteomics Clin. Appl. 2014, 8(5-6), 427-437 [3]
Löser and Pietzsch, Front. Chem. 2015, 3, article 37 [4] Jiang et al., PNAS,
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The continuing rise in antibiotic and multi-drug resistant bacterial infec-
tions is a major global medical health issue, which is not being met by
traditional antibiotic research. Here, we show that a new class of antimicro-
bial agents, termed ‘Structurally Nanoengineered Antimicrobial Polypep-
tide Particles’ (SNAPPs), synthesized using ring-opening polymerization
(ROP) of α-amino acid N-carboxyanhydrides (NCAs) to produce star-
shaped polypeptide nanoparticles exhibit antibiotic-adjuvant properties re-
sulting in colistin-multi-drug resistant (CMDR) bacteria becoming sensi-
tive to antibiotics once more. Synergistic interactions were demonstrated
between a model SNAPP and ampicillin, imipenem, doxycycline, gentam-
icin, or silver ions. We show that different peptide architectures alter the
activity of the SNAPPs. We also show that the effective antibiotic dose
could be decreased by 3.7 to 16 fold from the original lethal dose while
retaining synergistic interactions with SNAPPs against CMDR bacteria.
Further, we demonstrate that the combination treatment approach using
SNAPPs is able to attenuate toxicity. Interestingly, our studies show that
SNAPPs sensitise bacteria to antibiotics that were previously ineffective.
Overall, this study demonstrates the potential of synergistic combinations
of SNAPPs with conventional antibiotics where the SNAPP not only has
antimicrobial activity in its own right but also acts as an adjuvant for the
conventional antibiotic to treat CMDR bacterial infections
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Tuning the Catalytic Activity and Substrate Specificity
of Peptide-Nanoparticle Conjugates
Dorian Mikolajczak, Jonas Scholz, Beate Koksch
Freie Universität Berlin, Germany
The rational design and synthesis of complex systems that mimic the out-
standing substrate specificity and catalytic properties of enzymes, is still a
challenging task. The self-assembly of cysteine-containing peptides onto
the surface of gold nanoparticle (Pep-Au-NP) emerged as a promising strat-
egy towards the development of artificial enzymes. The high local peptide
concentration leads to dense functional monolayers that create novel, co-
operative features and catalytic properties, different from the monomeric
peptide in solution.1,2 In this context we studied the effect the location of
the catalytic unit within the peptide-monolayers relative to the nanoparticle
surface has on the esterolytic activity and substrate specificity of three Pep-
Au-NP, that only differ in the position of the catalytic unit (surface prox-
imal, intermediate, surface distal). Rates of ester hydrolysis were found
to correlate with the hydrophobicity of the substrate and the position of
the catalytic unit. Highly hydrophobic ester substrates are cleaved more
efficiently surface proximal, whereas less hydrophobic substrates showed
higher rates of hydrolysis in the intermediate region of the monolayer. Ad-
ditionally, positive cooperativity in substrate binding was observed and
presents another striking property of natural enzymes achievable in the
here described artificial systems. The results point to the importance the
position of the catalytic center has on the catalytic activity and substrate
specificity of peptide-nanoparticle conjugates.
(1) Mikolajczak, D. J.; Heier, J. L.; Schade, B.; Koksch, B. Biomacro-
molecules 2017, 18 (11), 3557–3562. (2) Pengo, P.; Polizzi, S.; Pasquato,
L.; Scrimin, P. J. Am. Chem. Soc. 2005, 127 (6), 1616–1617.
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1The University of Edinburgh, United Kingdom
2Instituto Biofisika, Universidad del País Vasco, Spain
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Programmed cell death (apoptosis) is an essential biological process that
stands out as a potential key biomarker of development and progression
of several diseases. Therefore, there is the need for sensitive and broadly
applicable methods for detection of apoptotic cells as diagnostic tools for
unraveling the mechanisms accounting for disease pathogenesis. The cur-
rent gold standard in optical imaging of apoptosis are fluorescent versions
of Annexin V, a protein that binds with high affinity to phosphatidylser-
ine (PS), a membrane phospholipid which is translocated to the external
side of the plasma membrane in the early stages of the apoptotic process,
including apoptotic bodies [1]. However, Annexin requires high concen-
trations of Ca2+, which can translate into functional damages. Herein we
introduce a novel peptide-based fluorogenic probe (apoTRACKER), which
represents a Ca2+-free imaging platform for selective staining and detec-
tion of cells undergoing programmed death.
Our vision was that amphipatic peptides could display affinity for
negatively-charged phospholipids exposed in apoptotic cells, while retain-
ing selectivity over viable ones. The presence of the environmentally sen-
sitive Trp-BODIPY amino acid allows for fluorogenic imaging of the inter-
action between peptide and their cellular target in the green GFP channel
[2]. We designed a panel of peptides to study the hydrophylic and aro-
matic sequence requirements that define the optimal binding to PS. From
a chemical point of view, the sensitivity of the BODIPY chromophore to-
wards acid needs to be taken into account when planning the synthetic
strategy [3]. Therefore, mild acid-labile CTC resin and hydrogen sensitive
side-chain protecting groups were employed. Peptides were cyclized using
COMU to ensure desirable proteolytic stability in vivo. Fully cyclic, un-
protected peptides were obtained after hydrogenolysis using Pd-catalysis
in mild conditions.
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apoTRACKER emerged as the most promising analogue of the evalua-
tion against apoptotic neutrophils in vitro. We have successfully used
apoTRACKER to image apoptosis in real-time in a wide variety of cell
lines and demonstrate selective binding to apoptotic. Using a combination
of optical and biophysical methods we have verified that apoTRACKER
binds with strong affinity to PS. Finally, we have effectively used apo-
TRACKER to image apoptosis in vivo in a murine model of inflammation.
apoTRACKER stands out as the next gold standard in the field of apopto-
sis imaging, avoiding the need for high Ca2+ media, and allowing in vivo
labelling of cells undergoing apoptosis.
[1] Mendive-Tapia, L., et al., Preparation of a Trp-BODIPY fluorogenic
amino acid to label peptides for enhanced live-cell fluorescence imaging.
Nat. Protocols, 2017. 12(8),1588-1619. [2] Mendive-Tapia, L., et al.,
Spacer-free BODIPY fluorogens in antimicrobial peptides for direct imag-
ing of fungal infection in human tissue. Nat. Commun., 2016. 7, 10940.
[3] Subiros-Funosas, R., et al., A Trp-BODIPY cyclic peptide for fluo-
rescence labelling of apoptotic bodies. Chem. Commun., 2017. 53(5),
945-948.
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High-affinity monoclonal antibodies are seen as promising cancer thera-
peutics, leading to the development of antibody derivatives as well as other
protein-based scaffolds that couple selective targeting of cancer cells with
the stimulation of an adaptive immune response.(1) Peptides can also bind
with high affinity to cancer cells and are intermediate in size between an-
tibodies and small molecules.(2) Furthermore, chemical peptide synthesis
and chemoselective ligations can be used to generate a variety of cancer-
targeting molecules with different numbers and combinations of binding
moieties in a modular and homogeneous fashion. In several recent studies,
we have designed and synthesized a suite of synthetic ‘immune system
engagers’ (ISErs) that mimic the functions of antibodies by binding specif-
ically to cancer cells and stimulating an immune response.(3) To explore
avidity and valency effects, we constructed ISErs bearing different num-
bers and combinations of two ‘binder’ peptides that target integrin α3 and
ephrin A2 receptors linked via monodisperse PEG-based polymers to an
‘effector’ peptide that binds to formyl peptide receptors and stimulates an
immune response.(4) ISErs are able to activate human neutrophils after tar-
geted binding to cancer cells and injection of the integrin α3-targeting ISEr
led to immune cell infiltration and prevented tumor formation in guinea pig
and mouse models. The anti-tumor activity and synthetic accessibility of
ISErs demonstrate that these novel compounds could be applied to a wide
variety of cancer cell targets as well as towards other diseases with such
specific markers.
References 1. Sliwkowski, M. X., and Mellman, I. (2013) Antibody thera-
peutics in cancer, Science 341, 1192-1198. 2. Conibear, A. C., Schmid, A.,
Kamalov, M., Becker, C. F. W., and Bello, C. (2017) Recent Advances in
Peptide-Based Approaches for Cancer Treatment, Curr Med Chem 25,doi:
10.2174/0929867325666171123204851. 3. Brehs, M., Potgens, A. J. G.,
Steitz, J., Thewes, K., Schwarz, J., Conibear, A. C., Bartneck, M., Tacke,
F., and Becker, C. F. W. (2017) Synthetic integrin-binding immune stimu-
lators target cancer cells and prevent tumor formation, Sci. Rep. 7, 17592.
4. Conibear, A. C., Potgens, A. J. G., Thewes, K., Altdorf, C., Hilzen-
deger, C., and Becker, C. F. W. (2018) Synthetic Cancer-Targeting Innate
Immune Stimulators Give Insights into Avidity Effects, ChemBioChem 19,
459-469.
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Bacterial infections are a major human health problem given not only the
increasing incidence of drug-resistant bacteria, but also the ability of bacte-
ria to form biofilms. Biofilm-related infections are particularly difficult to
treat due to their reduced susceptibility to conventional antibiotics. Thus,
it is urgent to develop new and effective antimicrobial agents against bac-
terial biofilms. Antimicrobial peptides (AMPs) have been considered po-
tential alternatives for this purpose. However, the development of new
peptide sequences and the study of their mechanism of action against
biofilms is important to expand the potential use of peptides as antibiofilm
agents. We investigated the activity of pepR, a multifunctional peptide de-
rived from the Dengue virus capsid protein, against Staphylococcus aureus
biofilms, with a focus on the peptide’s mechanism of action at the molec-
ular level. We show that pepR is able to both prevent the formation and
act on preformed S. aureus biofilms. Mechanistic studies using flow cy-
tometry and confocal fluorescence microscopy show that pepR targets the
bacterial membrane. Prevention of biofilm formation results from the fast
bactericidal membrane permeabilization of bacteria in the planktonic form.
More important, the peptide is able to diffuse through a preformed biofilm
and rapidly kill biofilm-embedded bacteria through the same mechanism.
Overall, our work demonstrates the potential of pepR as a lead towards the
development of novel membrane-active antibiofilm peptides.
OP55
Development of Mirror-Image Monobodies for
Targeted Cancer Therapies
Timothy Reichart, Tim Kükenshöner, Oliver Hantschel
Ecole Polytechnique Fédérale de Lausanne, Switzerland
Monoclonal antibody therapies for targeted cancer treatment are a tremen-
dous clinical success. CD20 alone is the target of six different monoclonal
antibodies (mAbs) approved for clinical use, across a variety of therapeu-
tic indications including chronic lymphocytic leukemia, Non-Hodgkin’s
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lymphoma, rheumatoid arthritis, and multiple sclerosis. These and other
mAbs targeting CD20 are under investigation for yet more indications.
However, these mAbs possess significant downsides in common with other
mAb therapies, including serious potential side effects and the possibility
of severe immune responses. One strategy to ameliorate these disadvan-
tages is to use mirror-image protein therapies. Since mirror-image pro-
teins use unnatural D-amino acids, these proteins are resistant to proteases
and are non-immunogenic. However, since proteins consisting entirely of
D-amino acids (and achiral glycine) cannot be produced in biological sys-
tems, mirror image proteins cannot be directly used in protein libraries in
order to select synthetic binding proteins. Instead, development of mirror-
image protein therapies requires chemical synthesis of the mirror-image
protein target, a selection step to identify or produce a protein therapeutic
effective against the D target, then chemical synthesis of the D-protein ther-
apeutic effective against the natural target. Our protein scaffold of choice
is the monobody, an attractive class of molecules that retain the essential
features of antibodies while ameliorating their disadvantages. Specifically,
monobodies are based on the fibronectin type 3 domain with a highly sta-
ble beta-sandwich core structure with three randomizable surface loops
and one randomizable beta-strand presents a large surface for potential
protein-protein interactions. Crucially, at 100 amino acids in length they
are obtainable by chemical synthesis. We report here the development,
characterization, and testing of a mirror-image monobody targeting the
membrane protein CD20, including the synthesis of the mirror image of
the target, the selection of a monobody that binds the target using both
phage and yeast display technologies, the total chemical synthesis of both
enantiomers of the selected monobody, and in vitro characterization of the
binding of the synthetic mirror-image monobody.
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Subtle modifications to oxytocin produce ligands that
retain potency and improved selectivity across species
Paul Alewood
The University of Queensland, Australia
Poor oral availability and susceptibility to reduction and protease degra-
dation is a major hurdle in peptide drug development for peripheral or
central nervous system candidates. In contrast, druggable receptors in the
gut present an attractive niche for peptide therapeutics. Here we demon-
strate, in a mouse model of chronic abdominal pain, that oxytocin receptors
are significantly upregulated in nociceptors innervating the colon. Corre-
spondingly, we have developed novel chemoselective strategies to engi-
neer non-reducible stable oxytocin analogues that are equipotent to native
oxytocin. Moreover, we identified a selective and more stable oxytocin re-
ceptor (OTR) agonist by subtly modifying the pharmacophore framework
of human oxytocin andvasopressin. [Se-Se]-oxytocin-OH displayed sim-
ilar potency to oxytocin but improved selectivity for OTR, an effect that
was retained in mice.. Nuclear magnetic resonance structural analysis of
native oxytocin and the seleno-oxytocin derivatives reveals that oxytocin
has a pre-organized turn structure in solution, in marked contrast to earlier
X-ray crystallography studies. These seleno-oxytocin analogues potently
inhibit colonic nociceptors both in vitro and in vivo in mice with chronic
visceral hypersensitivity. Our findings have important implications for the
clinical use of oxytocin analogues and disulfide-rich peptides in general.
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Cyclotides as novel inhibitors of the human prolyl
oligopeptidase
Roland Hellinger, Christian W. Gruber
Medical University of Vienna, Austria
Cyclotides are plant-derived mini-proteins. Their characteristic circular
cystine-knot motif confers them structural stability. Cyclotides have been
discovered in the plant families of Cucurbitaceae, Fabaceae, Solanaceae,
Poaceae, Rubiaceae and Violaceae and recently their distribution in the
Psychotria tribe (Rubiaceae) was further refined [1]. They are expressed
as natural peptide libraries essentially with a high molecular diversity and
hence these peptides are an interesting starting point for screening toward
molecular proteins. In general, native cystine-knot peptides are potent and
selective inhibitors of some serine-type proteases. Here we present the
discovery of the first cyclotide as a specific inhibitor of the human prolyl
oligopeptidase (POP) using a bioassay-guided fractionation approach com-
bined with target-based pharmacology. Plant extracts of four species of the
Psychotria and one Viola species were characterized for inhibition of hu-
man POP in-vitro at concentrations of 100 to 400 µg/ml. The most promis-
ing Psychotria solitudinum extract submitted to a pharmacology guided
isolation resulted in the novel cyclotide psysol 2 (IC50 25 µM) as the most
abundant compound in this plant peptide library. The molecular structure
and amino acid sequence of psysol 2 was characterized by manual de-novo
sequencing using tandem mass spectrometry. The specificity for POP in-
hibition was determined by comparison of the inhibitory activity towards
other serine-proteases, namely trypsin and chymotrypsin, which both ap-
peared unaffected by psysol 2 up to 100 µM. Preliminary structure activity
studies suggested that proline residues might by important for the observed
POP inhibition since kalata B1, a cyclotide with high sequence homology
to psysol 2, also inhibited POP activity with an IC50 of 5.6 µM [2]. The
enzyme POP is well known for its role in memory and learning processes,
and it is currently being considered as a promising therapeutic target for
cognitive deficits and neurodegenerative diseases, such as schizophrenia
and Parkinson’s disease. In the context of discovery and development of
future POP inhibitors for therapeutic applications, cyclotides may be suit-
able starting points considering that small molecule POP inhibitors fail to
provide enough selectivity for the enzyme class of post prolyl cleaving
endopeptidases.
Acknowledgements We would like to thank Johannes Koehbach and
Richard Clark (The University of Queensland), as well as Albert Puigpinós
Teresa Tarragó and Ernest Giralt (Institute for Research in Biomedicine
Barcelona) for contributing to this research. This work has been supported
by the Austrian Science Fund – FWF (P24743-B21).
References [1] Koehbach J., et al. Biopolymers. 2013. 100(5): 438−452.
[2] Hellinger R., et al. J Nat Prod. 2015. 78(5): 1073-1082.
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Aggregation of peptide/protein is intimately related to a number of human
diseases [1]. More than twenty have been identified to aggregate into fib-
rils containing extensive beta-sheet structures, and species generated in
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the aggregation processes (i.e., oligomers, protofibrils, and fibrils) con-
tribute to disease development. Amyloid-beta (designated Abeta), related
to Alzheimer disease (AD), is the representative example. Artificial chemi-
cal transformation of toxic, aberrant Abeta to less toxic forms at the disease
site might be a new candidate for AD treatment. Thus, covalent installa-
tion of hydrophilic oxygen atoms to Abeta using aerobic oxygen and visi-
ble light as oxygen atom and energy sources, respectively, in the presence
of a catalyst (i.e., catalytic photooxygenation) was used. Selective, cell-
compatible photooxygenation of Abeta by a flavin catalyst attached to an
Abeta-binding peptide markedly decreased aggregation potency and neuro-
toxicity of Abeta [2]. Moreover, we designed photooxygenation catalysts
that can be turned on only when binding with the higher-order structures
of amyloid aggregates [3]. This on/off switchable activity of the catalyst
that senses amyloid structure enabled highly Abeta-selective oxygenation
in the presence of other bioactive peptides and living cells. In this con-
text, we recently succeeded to develop new switchable oxygenation cat-
alysts that can be activated by a near-infrared light [4], and demonstrate
the applicability of the catalyst to the disease mouse. Thus, the photooxy-
genation in living AD model mice significantly decreased the Abeta level.
Therefore, chemical transformation of Abeta by use of photooxygenation
catalyst would be a novel strategy for AD prevention and treatment.
References 1) F. C. Chiti, M. Dobson, Annu. Rev. Biochem. 2006, 75, 333.
2) A. Taniguchi, D. Sasaki, A. Shiohara, T. Iwatsubo, T. Tomita, Y. Sohma,
M. Kanai, Angew. Chem. Int. Ed. 2014, 53, 1382. 3) A. Taniguchi, Y.
Shimizu, K. Oisaki, Y. Sohma, M. Kanai, Nature Chem. 2016, 8, 974. 4)
J. Ni, A. Taniguchi, S. Ozawa, Y. Hori, Y. Kuninobu, T. Saito, T. C. Saido,
T. Tomita, Y. Sohma, M. Kanai, Chem 2018, 4, 807.
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Development of the MC1R Selective Ligands for the
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Minying Cai, Yang Zhou, Saghar Mowlazadeh Haghighi,
Victor Hruby
University of Arizona, United States
Seeking effective treatments of melanoma is very hot in current era of
science and technology. However, prevention of melanoma has been ne-
glected. Here, we propose developing selective hMC1R selective ligands
for the melanoma prevention agents. We have been very successful in de-
veloping selective hMC1R ligands. Lately we first successfully developed
only natural amino acid made peptide, [Leu3, Leu7, Phe8]-γ-MSH-NH2,
which is a potent selective hMC1R agonist; and many other hMC1R selec-
tive agonists which are more druggable and bioavailable. In vivo studies
demonstrated these peptides can cause immediately pigmentation. The
natural skin color can be resumed less than 20 hours. The high selectivity
of the [Leu3, Leu7, Phe8]-γ-MSH-NH2 for the hMC1R and shorter half-
life provides a safer and reduced side-effect agent for the prevention of
melanoma skin cancer. This research will be more applicable and benefit
for most of people for skin cancer prevention.
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Benfield, Conan Wang, David Craik
The University of Queensland, Australia
Cyclotides, a family of cyclic disulfide-rich peptides from plants, possess
an outstanding structure, intrinsic biological properties (e.g. insecticidal,
anticancer, anti-HIV), cell penetrating properties and potential as a scaf-
fold for drug design and intracellular delivery. In previous studies, we have
shown that some cyclotides have an unusual ability to specifically recog-
nise phosphatidylethanolamine (PE)-phospholipids in cell membranes.
This lipid selectively is intimately related with the highly conserved three-
dimensional structure, biological activities and cell-penetrating properties
of cyclotides. It is normally assumed that membrane-active peptides and
their mirror images have identical activity, but in previous studies, we have
shown that the mirror form of the prototypic cyclotide kalata B1, D-kalata
B1, although active in all the activities tested, is less potent than the native
kalata B1. The lower activity of the D-kalata B1 correlated with a lower
affinity for PE-containing lipid bilayers. In the current study, we were
specifically interested in investigating whether the chiral environment cre-
ated by biological membranes can discriminate between kalata B1 enan-
tiomers and would explain the lower potency of D-kalata B1. We have
synthesised unnatural enantiomers of two phospholipids (referred here as
D-phospholipids) and compared the L- and D-kalata B1 enantiomers in
their ability to bind model membranes composed with either L- or D-
phospholipids. Using kalata B1 analogues, cell-based assays, NMR spec-
troscopy, fluorescence spectroscopy and surface plasmon resonance we
showed that kalata B1 recognises PE-headgroups in a chiral-independent
manner, but inserts into lipid bilayers via a mechanism dependent on mem-
brane chirality. This study shows that, contrary to the generally assumed,
chiral environment of lipid bilayers can modulate the activity of peptides
and proteins.
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The macrocyclic peptide [D-Trp]CJ-15,208 (cyclo[Phe-D-Pro-Phe-D-
Trp]) exhibits kappa opioid receptor (KOR) antagonist activity in vivo in
the mouse 55 oC warm-water tail withdrawal assay, but the alanine scan
analogs of this peptide also unexpectedly exhibited robust antinociceptive
(agonist) activity in this assay (Aldrich et al., Br. J. Pharmacol. 2014,
171, 3212–3222). As part of our exploration of the structure-activity rela-
tionships (SAR) of this peptide, additional substitutions were made for the
phenylalanine residues, including both aliphatic residues and substituted
aromatic residues. Most of the analogs examined to date retained KOR an-
tagonist activity in the antinociceptive assay after intracerebroventricular
(i.c.v.) administration, although the potency varied substantially depending
upon the substitution. One analog evaluated exhibited robust KOR antago-
nist activity after oral administration (10 mg/kg). The agonist (antinocicep-
tive) activity, however, varied substantially depending on the substitution,
with some analogs exhibiting full agonist activity (EC50 = 20-35 nmol
i.c.v.). Selected peptides were also shown to prevent stress-induced rein-
statement of morphine seeking behavior in a conditioned place preference
assay. These results advance our understanding of the SAR of these novel
opioid peptides and support further exploration of these peptides for the
treatment of drug abuse. This research supported by grants PR141230 and
PR141230P1 from the U.S. Army and grant R01 DA018332 from the Na-
tional Institute on Drug Abuse.
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Developing novel bi-specific peptide as an
immunosuppressant using directed-evolution
optimization
Nesly Dotan, Vera Gayder, Itai Bloch, Maayan Gal
Migal Research Center, Israel
The serine/threonine phosphatase calcineurin targets the nuclear factors of
activated T cells (NFATs) and leads to the activation of cytokine genes.
Calcium influx activates calcineurin to dephosphorylate multiple serine
residues within the 400 residue NFAT homology region; this triggers NFAT
nuclear translocation. The binding of the two proteins relies on the inter-
action between two sites in calcineurin, harboring the conserved motifs
PxIxIT and LxVP, located at the N- and C-terminal to the phosphoryla-
tion sites in NFAT’s homology region. NFAT’s PxIxIT motif binds cal-
cineurin’s catalytic domain at a location that is a distance from the catalytic
site of calcineurin. The LxVP motif binds at the interface of calcineurin’s
regulatory and catalytic domains; however, it can also bind to the same
site on the catalytic domain as the PxIxIT, but with a lower affinity. Ow-
ing to the role of calcineurin-NFAT in T-cell activation, calcineurin is the
target for immune suppression drugs such as cyclosporine and tacrolimus,
thus obscuring the latter catalytic site. However, the vast range of cellu-
lar processes regulated by the calcineurin-NFAT interaction has aroused
great interest in the discovery of protein-protein interaction inhibitors that
will interfere with the calcineurin-NFAT complex formation while keep-
ing calcineurin’s catalytic site free. Recently, we developed a new Enzyme
Linked Immuno Sorbent Assay (ELISA) that is based on the interaction
of the heterodimer calcineurin, i.e., catalytic and regulatory domain, with
a NFAT homology region that includes the phosphorylation sites flanked
by PxIxIT and LxVP binding motifs. This experimental scheme provides
valuable data regarding the interaction of the two binding motifs of NFAT
with calcineurin. Based on this setup, we are currently developing an op-
timized di-peptide constructs by linking peptides derived from the PxIxIT
and LxVP motifs. Furthermore, directed-evolution is being used for the op-
timization of this chimeric peptide and for the creation of a novel protein-
protein interaction inhibitor that can act as a new immunosuppressant.
OP63
The Use of Peptide-Membrane Interactions in the
Design of Selective and Potent Sodium Channel
Inhibitors
Christina Schroeder1, Akello Agwa1, Alexander Mueller1,
Chun Yuen Chow1, Steve Peigneur2, Nicole Lawrence1,
Evelyne Deplazes3, Alan Mark4, David Craik1, Jan Tytgat2,
Glenn King1, Irina Vetter1, Sónia Troeira Henriques1
1Institute for Molecular Bioscience, Australia
2Katholic Univeristy of Leuven, Belgium
3Curtin University, Australia
4The University of Queensland, Australia
Peptide toxins isolated from spiders are potent inhibitors of human voltage-
gated sodium channels (NaV). Some of these peptides are selective against
subtypes NaV1.7, reported to be involved in nociception, and may thus
have potential as pain therapeutic leads. Peptide toxins can inhibit NaV
activity by blocking the pore domain (i.e, pore blockers) or by binding
to the membrane-embedded voltage sensor domain of the sodium chan-
nel (i.e. gating-modifier toxins). It is now well established that some
gating-modifier toxins also interact with lipid membranes surrounding
the voltage-sensor domains. However, it is less well-known to what ex-
tent these peptide-lipid interactions are relevant for the inhibitory activity
and/or sodium channel selectivity. Using a range of biophysical techniques,
we have examined the importance of membrane binding on the inhibitory
activity of a subset of peptides, showing a direct correlation between mem-
brane binding affinity and NaV selectivity, highlighting the importance of
considering potential membrane-binding events when designing sodium
channel voltage-gating modifier inhibitors. Using this information, we
have designed modified gating-modifier toxins with improved potency and
off-target selectivity for the therapeutically relevant sodium channel sub-
type NaV1.7.
OP64
Dipeptide-derived Alkynes as Novel Irreversible
Inhibitors of Cathepsin B
Lydia Behring1, Christian Trapp2, Robert Wodtke1,
Konstantin Kuhne1, Birgit Belter1, Jörg Steinbach1, Jens
Pietzsch1, Reik Löser1
1Helmholtz-Zentrum Dresden-Rossendorf, Germany
2Hochschule Zittau/Görlitz, Germany
Until recently, alkynes were considered to be bioinert. Thus, they are
popular reaction partners in bioorthogonal click reactions in vitro and in
vivo. Despite the virtual chemical inertness of the alkyne moiety, two
research groups observed the irreversible inhibition of a cysteine pro-
tease by an alkyne-functionalised substrate derivative: both EKKEBUS
et al. and SOMMER et al. independently described the unexpected
inactivation of de-ubiquitinating enzymes by ubiquitin or ubiquitin-like
modifiers bearing propargylamine in place of C-terminal glycine [1, 2].
We intended to harness that finding for the design of inhibitor-based
probes for the imaging of tumour-associated cysteine proteases. Cys-
teine cathepsins play an important role in tumour progression. In partic-
ular cathepsin B is involved in a variety of tumour progression-related
processes and elevated extracellular levels are linked to increased malig-
nancy and poor prognosis [3]. Therefore, this enzyme represents a promis-
ing target for the therapy and imaging of tumours. GREENSPAN et
al. reported a potent and highly selective dipeptidyl nitrile-based cathep-
sin B inhibitor (N-[2-[(3-Carboxyphenyl)methoxy]-1(S)-cyanoethyl]-3-
methyl-Nα-(2,4-difluorobenzoyl)-L-phenylalaninamide) [4]. Based on
that lead compound, cathepsin B-targeting dipeptide alkynes were de-
signed by isoelectronic replacement of the nitrile nitrogen atom by a me-
thine group and consecutive variation of the 2,4-difluorobenzoyl and (3-
carboxybenzyl)oxymethyl residue. Formation of the C-C triple bond by
reaction of the corresponding open-chain serine-derived aldehyde with the
Bestmann-Ohira reagent was accompanied by partial enantiomerisation.
Therefore, the synthesis was performed via Garner’s aldehyde, which ac-
counted for a high stereochemical purity of the final compounds. The in-
hibitory potential was investigated against cathepsin B, S, L and K. The
most potent compound exhibited irreversible inhibition of cathepsin B with
an inactivation constant (kinact/KI) of 771 1/(M*s). Values for cathepsins
L and S were significantly lower; no irreversible inhibition was observed
for cathepsin K. In addition, inhibition of cathepsin B activity in human
glioblastoma cell lysates and living cells has been demonstrated. Based on
these promising results, dipeptidyl alkynes have the potential to become a
valuable tool for imaging due to the expected low activity towards other
cysteine proteases. In further studies, selected inhibitors for cathepsin B
will be labelled with suitable radionuclides to obtain an inhibitor-based
probe directed towards cathepsin B.
[1] Ekkebus et al., J. Am. Chem. Soc., 2013, 135, 2867-2870. [2] Sommer
et al., Bioorg. Med. Chem., 2013, 21, 2511-2517. [3] Löser and Pietzsch,
Front. Chem., 2015, 3:37. [4] Greenspan et al., J. Med. Chem., 2001, 44,
4524-4534.
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Potent Antimicrobial Peptide Dendrimers against
Multi-Drug Resistant Pseudomonas aeruginosa and
Acinobacter baumanii
Tamis Darbre
Deparment of Chemistry and Biochemistry, University of Bern,
Switzerland
Multi-drug resistant bacteria represent a public health threat that needs
urgent handling. In particular, resistant Gram-negative bacteria are diffi-
cult to treat and the arsenal of antibiotics still effective is dwelling. Pep-
tide based antimicrobials offer an attractive opportunity to control these
pathogens [1].
While natural peptide antimicrobials are normally linear or cyclic se-
quences we have explored branched and bridged bicyclic topologies for
antimicrobial activity. Branched peptide dendrimers with high activity
against multi-resistant clinical isolates of P. aeruginosa and Acinetobacter
baumanii were designed and further optimized by screening a third gen-
eration peptide dendrimer library. The third generation dendrimer G3KL
incorporating natural lysine and leucine residues in the branches and as
branching point (37 amino acid residues) gave a MIC (minimal inhibitory
concentration) value of 2 6= g/mL against P. aeruginosa and good activity
against a large panel of multi-resistant strains [2,3]. We have now dis-
covered second generation peptide dendrimers (17 amino acid residues)
incorporating a C10 lipid chain with high potency against the multidrug
resistant strains. The lipophilic alkyl chain is essential for interaction with
the lipopolysaccharide in the bacterial cell wall. Mechanistic studies indi-
cate that the lipid chain may fold onto the peptide dendrimer branches in
water and unfold in contact with the bacterial membrane to expose the hy-
drophobic lipid chain leading to membrane disruption and rapid cell death.
[4] The antimicrobial peptide dendrimers showed low toxicity to red blood
cells and, in contrast to linear peptides, stability and high activity in human
serum. The combination of topology, peptide sequence and a lipid chain
represents a new design to discover antimicrobials to fight multi-resistant
bacterial pathogens.
References: 1. Hancock, R. E. W., Sahl, H.-G. Nat. Biotechnol. 2006, 24,
1551- 1557; 2. Stach M., Siriwardena, T. N., Köhler, T., van Delden, C.
, Darbre, T., Reymond, J.-L. Angew. Chem. Int. Ed. 2014, 53, 12827-
12831; 3. J Pires, J., Siriwardena, T. N., Stach, M., Tinguely, R. Kasra-
ian,S., Luzzaro,F., Leib,S. L., Darbre, T., Reymond,J.-L., Endimiani, A.
Antimicrob. Agents Chemother., 2015, 59, 7915-7918. 4. Siriwardena, T.
N.; Stach, M., Darbre, T.; Reymond, J.-L. et al. J. Am. Chem. Soc., 2018,
140, 423–432.
OP66
Modifying short phenylalanine-phenylalanine peptide
sequences to create multifunctional nanomaterials with
biomaterial and drug delivery applications
Garry Laverty
Queen’s University Belfast, Ireland
Background: The threat of antimicrobial resistance to society is com-
pounded by a relative lack of new clinically effective licensed therapies
reaching patients over the past three decades. Phenylalanine-phenylalanine
(FF) peptides have attracted increased interest due to their ability to self-
assemble into nanotubes or nanofibrous hydrogel structures that can be
utilised as drug delivery and biomaterial platforms. The chemical versatil-
ity of the peptide motif enables antimicrobial and anti-inflammatory activ-
ity to be built into a peptide capable of self-assembling into a nanomaterial
structure.
Methods: The antimicrobial activity of FF peptide nanotubes and FF (in-
cluding naphthalene, Fmoc and naproxen) hydrogelators were investigated
against planktonic and biofilm forms of microorganisms implicated in
hospital-acquired infections (Staphylococcus aureus, Staphylococcus epi-
dermidis, Escherichia coli, Pseudomonas aeruginosa and Candida albi-
cans) using viable counting methods. Scanning electron microscopy was
used to visualise the nanomaterial’s effect on biofilms. Cell cytotoxicity
was evaluated using LIVE/DEAD, MTS and LDH assays against a variety
of relevant cell lines (e.g. NCTC 929).
Results: Both peptide nanotube and hydrogel platforms demonstrated po-
tent activity against planktonic forms of hospital superbugs. NH2-FF-
COOH nanotubes demonstrated potent activity against planktonic and
biofilm forms of Gram-positive bacteria, possessing minimal cell tox-
icity. 5mg/mL peptide nanotubes demonstrated 6.25 log10 reduction
in colony forming units per ml (CFU/ml) against planktonic S. aureus
and a 5.4 log10 reduction in CFU/ml against S. aureus biofilm. SEM
images showed bacterial membrane damage had occurred and this was
supported by a bacterial membrane permeability (NPN) assay.An ul-
trashort cationic hydrogelator (naphthalene-2-ly)-acetyl-diphenylalanine-
dilysine-OH (NapFFKK-OH) possessed broad-spectrum antimicrobial ef-
ficacy including ability to eradicate surface attached biofilms form as-
sociated with increased tolerance to standardly employed antimicrobials.
Naproxen attached FFKK-OH (NpxFFKK-OH) possessed additional anti-
inflammatory activity (COX inhibition) which may be of benefit to chronic
wounds.
Conclusions: Peptide nanomaterials demonstrate significant promise as fu-
ture drug delivery and biomaterial platforms. This is the first study to
prove the activity of FF peptide nanotubes against microbial biofilms, a
major healthcare and industrial problem. The architecture of these peptide
nanostructures mean antibiotics could be potentially encapsulated within
the hollow hydrophilic pores of FF nanotubes or within their hydropho-
bic phenylalanine walls to provide synergistic antibiofilm action leading to
improved therapy and at lower antibiotic concentrations. Multifunctional
ultrashort peptide hydrogels also demonstrate potential as wound healing
products or biomaterial coatings. Peptide hydrogel dressings may resolve
issues in the case of chronic wounds which fail to heal (e.g. diabetic ul-
cers).
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Reviving Old Protecting Group Chemistry for
Site-Selective Peptide-Protein Conjugation
Smita B. Gunnoo1, Abhishek Iyer1, Willem Vannecke1,
Klaas W. Decoene1, Tim Hebbrecht1, Jan Gettemans1,
Mathias Laga2, Stefan Loverix2, Ignace Lasters2,
Annemieke Madder1
1Ghent University, Belgium
2Complix NV, Belgium
Given the increasing importance of biopharmaceuticals in the modern drug
scene, methodologies to conjugate proteins to property-enhancing entities
including peptides are highly sought after. Use of a thiol functionality in
a protein via a cysteine residue provides an orthogonal attachment point
for conjugation of these entities.[1] Cysteine’s relatively low abundance
in proteins coupled with the fact that it can be uniquely nucleophilic due
to its low pKa ( 8.2), makes it an ideal handle for site-selectively con-
jugating proteins to groups of interest via alkylation or crossed-disulfide
formation. An advantage of the disulfide bond is that intracellular release
of the moiety of interest is possible.[2] For effective reaction to occur, the
protein’s reaction partner needs to harbour a thiol group for oxidative re-
action with the cysteine. In general, in order to reduce the formation of
homodimeric disulfide species, either the protein cysteine or thiol partner
is activated. We report herein a remarkably simple strategy for conjugating
proteins bearing accessible cysteines to unprotected peptides containing a
Cys(Scm) (Carbomethoxysulfenyl) protecting group. The Scm group was
introduced on-resin via a Cys(Acm) (Acetamidomethyl) building block.[3]
The peptides employed for this proof of principle study were highly varied
and structurally diverse and underwent multiple on-resin decoration steps
prior to protein conjugation. The methodology was applied to three dif-
ferent proteins and proved to be site-selective. Moreover, the overall syn-
thesis is facile, efficient and versatile, and takes advantage of solid phase
peptide chemistry strategies for the decoration of proteins with free Cys
residues. On the peptide partner, the Acm protecting group is stable to nu-
merous conditions, allowing different functionalisations to be carried out
on-resin, prior to quantitative conversion to Scm. The use of Fmoc-(Cys)
(as opposed to Boc-MTS or Boc-DTNP) allows the use of milder peptide
synthesis conditions. Conjugations of the resulting unprotected peptides
to proteins are carried out in ambient conditions, and protein-peptide con-
jugates are easily isolated from excess peptide for characterisation. In ad-
dition, we found that for some peptides synthesised, prior purification was
not required pre-disulfide formation, and pure protein conjugate was ob-
tained. Obviously, where strictly homogeneous conjugates are required,
employed peptides can be purified. The methodology should be generally
applicable to many systems, as evidenced by our use of multiple proteins
and peptides. Crucially, Cys can be introduced into proteins by simple site-
directed mutagenesis. Further biological applications of the conjugates
formed are currently being explored in our group, as well as application of
the method to other biomolecules.
References: [1] Smita B. Gunnoo, Annemieke Madder, Org. Biomol.
Chem. 14, 8002 (2016). [2] Saito, G.; Swanson, J. A.; Lee, K. D. Adv.
Drug Deliv. Rev. 55 (2), 199–215 (2003) [3] Daniel G. Mullen, Mark D.
Distefano, J. Pept. Sci., 16, 219 (2010)
OP68
Use of selenoester for the efficient synthesis of protein
Toshiki Takei1, Michio Iwaoka2, Hironobu Hojo1
1Osaka University, Japan
2Tokai University, Japan
We have been developing efficient methods for protein synthesis based
on the ligation methods, such as the native chemical ligation [1] and the
thioester method [2]. One of the remaining issues in these methods is that
it is necessary to isolate the intermediate segments after each ligation reac-
tions, which leads to the low recovery yield from the HPLC column as well
as the low efficiency of the entire synthetic process. Many researchers are
engaged in developing the one-pot ligation method, which can eliminate
this problem. We have developed one-pot four-segment ligation without
requiring any purification and any protecting group-removal, combining
the use of peptide seleno and thioester. The efficiency of the method was
demonstrated by the synthesis of human superoxide dismutase composed
of 153 amino acid residues [3]. Another topic of this presentation is the
synthesis of selenocysteine-containing protein, such as selenoinsulin [4]
and selenoferredoxin. The synthesis of the segments, ligation and folding
reaction will be described.
[1] Dawson, P.E., Muir, T.W., Clark-Lewis, I., Kent, S.B.H., Science 1994,
266, 776-779. [2] Hojo, H., Aimoto, S. Bull. Chem. Soc. Jpn. 1991,
64, 111-117. [3] Takei, T., Andoh, T., Takao, T., Hojo, H., Angew. Chem.
Int. Ed., 2017, 56, 15708-15711. [4] Arai, K. Takei, T., Okumura, M.,
Watanabe, S., Amagai, Y., Asahina, Y., Moroder, L., Hojo, H., Inaba, K.,
M. Iwaoka, Angew. Chem. Int. Ed., 2017, 56, 5522–5526.
OP69
Eukaryotic macrocyclases enhance biocatalytic
production of cyclic peptides
Hannes Ludewig1, Clarissa M. Czekster1, James H.
Naismith2
1University of St Andrews, United Kingdom
2University of Oxford, United Kingdom
Peptide macrocycles display enhanced structural rigidity, protease resis-
tance cell membrane permeability as well as ability to modulate protein-
protein interaction. Thus, rendering a major interest in drug development.
Chemically diverse cyclic peptides can be challenging to synthesis chemi-
cally. In vitro approaches using biosynthetic enzymes have been proven
successful in combining cyclic peptide biosynthesis with solid phase
peptide synthesis accessing cyclic peptides containing non-proteinogenic
amino acids. However, macrocyclization of these compounds has been
the bottle-neck within this process. PCY1 from Saponaria vaccaria and
GmPOPB from Galerina marginata are recently discovered macrocyclases
involved in the biosynthesis of segetalins and amanitin toxin, respectively,
belonging to the class of prolyl-oligo peptidases (POPs). Extensive struc-
tural characterization of substrate complexes of both enzymes coupled
with kinetic and thermodynamic studies shed light on mechanistic insights
which informed the design of substrates with a minimal C-terminal recog-
nition sequence, allowing a more effective usage of these two enzymes as
biocatlytic tools in the (bio)synthesis of cyclic peptides.
OP70
Cost Effective peptide Purification via ZEOsphere
DRP Mixed-Mode Chromatography
Alessandro Butté1, Jurgen Machielse2, Andrea Wild2, Timo
Nuijens3, Marcel Schmidt3
1DataHow AG, Switzerland
2Zeochem AG, Switzerland
3EnzyPep BV, Netherlands
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Cost Effective Peptide Purification via ZEOsphere DRP Mixed-Mode
Chromatography Alessandro Butté [1], Jürgen Machielse [2], Andrea Wild
[2], Timo Nuijens [3], Marcel Schmidt [3] 1. ETH-Zürich / DataHow,
Zürich, Switzerland 2. Zeochem AG, Rüti, Switzerland 3. EnzyPep BV,
Geleen, The Netherlands
Peptides are important API’s for modern pharmaceuticals and have to
be produced on preparative scale with increasing demand on separation
costs. RPC and Ion Exchange are well-established chromatographic modes
within the available tool-box of methods and procedures for the purifica-
tion of this class of compounds in preparative scale production.
The presentation will show the beneficial use of ZEOsphere DRP (Doped
Reversed Phase) Mixed-Mode stationary phases in the repulsive-attractive
mode compared to non-doped RP or IEX stationary phases on crude pep-
tides. The orthogonal Doped Reversed Phase materials combines the dual
action of strong IEX groups (acidic or basic) and Reversed Phase ligands
like octyl chains on the packing surface.
Usually, Mixed-Mode stationary phases are applied under conditions
which add the retention power of IEX groups by electrostatic attractive
forces to the retention received from hydrophobic surface groups to the
solutes. Both species, e.g. the peptide and the IEX group carry opposite
charges.
It can be shown that in the majority of real life cases tested so far with
ZEOsphere DRP in repulsion-attractive mode, improved selectivities and
increased resolution at decreased retention time and solvent consumption
can be obtained.
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MS1
Generation and characterisation of novel antibodies
from selectively Advanced Glycation Endproduct
(AGE) modified Collagen Model Peptides (CMPs)
Jakob Gaar
The University of Auckland, New Zealand
Advanced Glycation Endproducts (AGEs) are naturally occurring protein
modifications found in humans that are derived from the non-enzymatic
reaction of sugars with proteins which alters the structure and biological
properties of modified peptides. AGEs accumulate over time in long-lived
peptides, particularly in diabetes patients due to persistent high blood-
sugar levels. A positive relationship between increased AGE formation
and pathological disease state has been established for diabetes, cancer,
cardiovascular and Alzheimer’s diseases, making AGEs a group of highly
interesting biomarkers. Collagen is one of the most abundant proteins
in humans, and is the main component of skin, cartilage, bones and
blood vessels. Cross-linking via uncontrolled glycation in collagen alters
the structural and biological properties of the native peptide contributing
to diabetes-related failure of tissue, arteriosclerosis and oxidative stress.
Selective AGE modification of Collagen model peptide (CMPs) can be
achieved by utilizing Fmoc based solid phase peptide synthesis (SPPS).
The target AGE need to be synthesised first and similar to common SPPS
protected. AGEs such as glyoxal lysine-dimer (GOLD) and methylglyoxal
lysine-dimer (MOLD) have already been successfully incorporated into
collagen peptides in a site-selective matter by our group, whereas more
complex AGEs (Pentosidine, Vesperlysine) have only been described as
nonspecific protein modifications in the literature to date. Our group is in-
terested in investigating the effect of different cross-linking AGEs on the
structural and biological properties of CMPs. Furthermore, we are focus-
ing on new methods to detect these modifications using second generation
antibodies derived from these biomimetic haptens. Pentosidine and Ves-
perlysine cross-linked CMPs are the most attractive target as both AGEs
have been frequently used as a biomarker for pathological conditions asso-
ciated with hyperglycaemia. Therefore, a reliable and accessible method
to measure and investigate AGEs in complex biological samples is needed.
Several techniques are available to determine the quantity and identity of
AGEs in biological samples, with the most prominent being UV-Vis, fluo-
rescence spectroscopy and HPLC analysis. These methods require highly
specialised equipment and personnel and are thus expensive in terms of
both time and cost. Selective antibodies, generated to recognize AGE mod-
ifications in peptides, offer a more versatile alternative. However, the an-
tibodies currently available are primarily generated from a direct but unse-
lective AGE modification of carrier proteins such as bovine serum albumin
(BSA) or keyhole limpet hemocyanin (KLH), raising the question of their
epitope specificity. Designing a biomimetic immunogen is crucial for the
generation of highly specific antibodies that are capable of recognising an
AGE on a particular human protein. Particularly since the epitope of an an-
tibody is likely to encompass not only the AGE modification but also the
modified protein, making the backbone of the peptide an important factor
for antibody generation.
MS2
Light-controlled inhibition of MLL1 methyltransferase
by azo-containing peptides: towards optoepigenetic
leukemia regulation
Lea Albert1, Jing Xu2, Vasundara Srinivasan1, Yali Dou2,
Olalla Vázquez1
1Philipps-Universität Marburg, Germany
2University of Michigan, United States
Epigenetics is the study of changes in gene expression unrelated to changes
in the DNA sequence. Since genetics alone cannot explain human variation
and disease, epigenetics is one of the most promising fields in biomedicine.
Combinatorial post-translational modifications (PTMs) on histones, often
referred to as the histone language,[1] regulate the structure of chromatin
and affect transcriptional activity by recruiting a large variety of proteins
through protein-protein interactions (PPIs). One widely studied PTM is the
specific methylation at lysine 4 of histone 3 (H3K4) by the mixed-lineage
leukemia (MLL) enzymes. MLL1 is an H3K4 methyltransferase enzyme
and a promising cancer therapeutic target since its deregulation has been
implicated in various cancers and solid tumors.[2] MLL1 exists as a part
of a protein-core complex that enhances its activity. Particularly, the pro-
tein WD40-repeat protein 5 (WDR5) controls MLL1 activity by forming
a bridge between units and via binding to the argenine 3765 of MLL1,
which is essential for methylation activity. Therefore, blocking WDR5-
MLL1 interaction is an effective strategy for its inhibition. There are some
precedents of small molecules[3,4] and peptides[5] as potent MLL1 an-
tagonists. However, all these precedents do not offer the possibility to
exert spatiotemporal control over the highly dynamic epigenetic signalling
processes. To solve this, our group has recently synthetized and studied
cell-permeable photoswitchable peptidomimetics that are able to target the
key WDR5-MLL1 interaction[6] with high affinity (Ki = 1.25 nM). Impor-
tantly, upon irradiation, the change of conformation of our peptidomimet-
ics triggers a significant difference in MLL1 activity, leukemia cell prolif-
eration and even transcription of the MLL1-target gene Deptor.
References: [1] B. D. Strahl, C. D. Allis, Nature 2000, 403, 41–45. [2]
M. S. Cosgrove, A. Patel, FEBS J. 2010, 277, 1832–1842. [3] H. Karatas,
E. C. Townsend, F. Cao, Y. Chen, D. Bernard, L. Liu, M. Lei, Y. Dou, S.
Wang, J. Am. Chem. Soc. 2013, 135, 669–682. [4] H. Karatas, Y. Li, L.
Liu, J. Ji, S. Lee, Y. Chen, J. Yang, L. Huang, D. Bernard, J. Xu, et al.,
J. Med. Chem. 2017, 60, 4818–4839. [5] H. Karatas, E. C. Townsend,
D. Bernard, Y. Dou, S. Wang, J. Med. Chem. 2010, 53, 5179–5185. [6]
L. Albert, J. Xu, R. Wan, V. Srinivasan, Y. Dou, O. Vázquez, Chem. Sci.
2017, 8, 4612–4618.
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Development of NaV-Selective Agonists with Potential
for Treatment of Dravet Syndrome Epilepsy
Chun Yuen Chow1, Linlin Ma2, Eivind Undheim3, Yanni
Chin1, Steve Petrou4, Glenn King1
1Institute for Molecular Bioscience, Australia
2Flinders University, Australia
3Centre for Advanced Imaging, Australia
4Florey Institute of Neuroscience and Mental Health, Australia
Dravet syndrome (DS) is a catastrophic epileptic encephalopathy char-
acterised by childhood-onset polymorphic seizures, multiple neuropsy-
chiatric comorbidities, and increased risk of sudden death. Most DS
cases result from de novo loss-of-function mutations in one allele of the
SCN1A gene that encodes the ion-conducting α-subunit of the voltage-
gated sodium channel 1.1 (NaV1.1). In the brain, NaV1.1 is primarily
found in the axon initial segment of fast-spiking GABAergic inhibitory in-
terneurons; selective deletion of NaV1.1 in these interneurons in mice re-
capitulates the symptoms of DS. Thus, the principle mechanism proposed
to underlie seizure genesis in DS is loss of inhibitory input due to dysfunc-
tional firing of GABAergic interneurons. In support of this hypothesis,
antiepileptic drugs such as phenytoin, lamotrigine and carbamezipine that
non-selectively inhibit NaV channels are contraindicated in DS, whereas
compounds that enhance GABAergic neurotransmission such as benzodi-
azepines are therapeutically beneficial.
We hypothesised that DS symptoms could be ameliorated by a drug that
activated the reduced population of functional NaV1.1 channels in DS in-
terneurons. Toward this end, we identified and characterised two homol-
ogous disulfide-rich spider-venom peptides (Hm1a and Hm1b) that selec-
tively potentiate NaV1.1. Hm1a rescues DS interneurons from action po-
tential collapse, while i.c.v. infusion of Hm1a abolishes seizures in DS
mice and rescues them from premature death. However, Hm1a is unstable
in vivo and difficult to produce via both recombinant and chemical meth-
ods. We therefore produced recombinant Hm1b using periplasmic E. coli
expression system and examined its selectivity against a panel of human
NaV subtypes using whole-cell patch-clamp recordings. Hm1b is a potent
and highly selective agonist of NaV1.1 (EC50 12 nM). Hm1b is a gat-
ing modifier that shifts the voltage dependence of channel activation and
inactivation to hyperpolarised and depolarised potentials respectively, pre-
sumably by interacting with the channel’s voltage-sensor domains. It has
minimal effect on peak current amplitude but robustly inhibits fast inacti-
vation to cause a large increase in sustained currents. Hm1b has no effect
on other Nav subtypes except NaV1.3. Like Hm1a, the structure of Hm1b
determined using NMR revealed a classical inhibitor cystine knot motif in
which the peptide is cross-braced by three disulfide bonds. However, we
show that Hm1b is an order of magnitude more stable than Hm1a in hu-
man cerebrospinal fluid. Taken together, our data suggest that Hm1b is an
exciting lead for a precision therapeutic targeted against DS.
MS4
Exploiting thioamide reactivity in peptide synthesis
Varsha Thombare, Craig Hutton
The University of Melbourne, Australia
Over recent decades, the preparation of proteins and long peptides has
been achieved using either recombinant methods or total chemical synthe-
sis employing native chemical ligation (NCL). These methods each have
limitations; recombinant expression techniques cannot be used for unnatu-
ral amino acids and modified amino acids, while native chemical ligation
requires cysteine at the ligation site. To overcome limitations of NCL, sev-
eral methods have been developed including desulfurization of cysteine to
alanine. Nevertheless, all NCL-type methods rely on thioester (or sele-
noester) exchange with an N-terminal residue possessing a thiol or selenol
functional group as the critical step. To overcome the limitation of NCL
methods we are developing new residue-independent ligation strategies.
Previous work in the Hutton group developed novel chemoselective reac-
tions of thioamides with peptide C-terminal carboxylic acids, which has
been exploited in the synthesis of peptide imides and enables coupling of
amino acids for N-C direction peptide synthesis. The N-C direction pep-
tide synthesis involves the generation of isoimide intermediates, which can
rearrange to imides via an O-N acyl transfer.1 We have now developed a
novel chemoselective peptide ligation strategy that further exploits the re-
activity of peptides containing backbone thioamides. We have successfully
synthesized madanin-1 (60 amino acid peptide) using this thioamide-based
ligation method. Further, we are exploiting the thioamide-based ligation
in an intramolecular reaction to synthesize naturally occurring cyclic pep-
tides, including gramicidin S and mahafacyclin B.
1. Pourvali, A.; Cochrane, J. R.; Hutton, C. A., Chemical Communications
2014, 50 (100), 15963-15966.
MS5
Zn-catalyzed tert-butyl nicotinate-directed amide
cleavage for applications in peptide synthesis and
peptidomimetic design
Karlijn Hollanders1, Charlène Gadais1, Evelien Renders2,
Laurent Van Raemdonck2, Clarence Wybon2, Bert Maes2,
Steven Ballet1
1Research Group of Organic Chemistry, Departments of Chemistry and
Bioengineering Sciences, Vrije Universiteit Brussel, Belgium
2Organic Synthesis, Department of Chemistry, University of Antwerp,
Belgium
An amide is the key functional group that makes up the backbone of pep-
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tides and proteins. Consequently, the selective formation of this group has
been extensively studied by peptide scientist with the development of a
well-established catalogue of so-called coupling reagents as a result. Nev-
ertheless, the general method remains the direct acylation of an amine by
means of an in situ activated carboxylic acid.[1] In endeavors to overcome
the inherent limitations associated with these coupling reagents, chemical
ligation involving the assistance of other functional groups or amine rather
than carboxylic acid activation has been explored.[2] To date, amides have
rarely been considered as a carboxylic acid surrogate because of their poor
electrophilicity and intrinsic stability. While the activation of secondary
amides via Bocylation delivers substrates which are cleavable with alco-
hols and amines under Ni-catalysis,[3] our research focused on the cleav-
age of primary amides via directing group activation. This directing group
is easily introduced onto primary amides via Pd-catalyzed amidation with
tert-butyl 2-chloronicotinate. Zinc(II)acetate was identified as a suitable
catalyst for nicotinate directed amide cleavage with alcohols.[4] The ac-
tivation mechanism can be regarded as ‘biomimetic’: the C3-ester sub-
stituent of the pyridine in the directing group populates the trans-conformer
suitable for Zn-chelation, C=O(amide)-Zn-N(directing group), and Zn-
coordinated alcohol is additionally activated as a nucleophile by hydrogen
bonding with the acetate ligand of the catalyst. Additionally, the acetate
ligand assists in intramolecular O-to-N proton transfer. The method could
be extended to amines. Nicotinate activated amino acid amides proved
to be suitable substrates. Transamidations with amino acid esters/amides
allow diverse applications in peptide research, exemplified by segment con-
densations and macrocyclisations.
References [1] A. El-Faham, F. Albericio, Chem. Rev., 2011, 111, 6557-
6602 [2] R. M. de Figueiredo, J.-S. Suppo, J.-M. Campagne, Chem. Rev.,
2016, 19, 12029-12122 [3] G. Meng, S. Shi, M. Szostak, Synlett 2016,
2530–2540; J.E. Dander, N.K. Garg, ACS Catal. 2017, 7, 1413–1423 [4]
C.C.D. Wybon, C. Mensch, K. Hollanders, C. Gadais, W.A. Herrebout, S.
Ballet, B.U.W. Maes, ACS Catal., 2018, 8, 203-218.
MS6
Synthesis of peptides glycated at Lys residues
Daria Roshchupkina, Yulia Filatova, Tatana Melnikova,
Alexey Chistov, Ekaterina Kolesanova
Institute of Biomedical Chemistry (IBMC), Moscow, Russia
Glycated proteins are considered putative triggers of diabetes complica-
tions. Glycated peptides are needed as standards for proteomic studies of
pathological protein glycation and as antigens for producing specific an-
tibodies. We studied several approaches for the preparation of peptides
containing glycated (1-deoxyfructosyl-, or Amadori product (AM), car-
boxymethylated (CM) and carboxyethylated (CE)) Lys residues: 1) modi-
fication by glucose in water solution; 2) Schiff base formation with further
reduction; 3) alkylation (for CM-and CE-modifications). Peptide modifi-
cation versus Fmoc-Lys modification with further application of the latter
in SPPS was evaluated. Yields and purity of glycated peptides obtained
with the use of different approaches were compared and yields and pu-
rity achieved by the tested approaches were compared. The suitability of
each studied approach (except the 1st one) was shown to depend upon the
type of the glycation and the position of the modified Lys residue in pep-
tide chains. Modification of peptides by glucose in solution resulted in
low yields and a mixture of various glycation products difficult to sepa-
rate selectively by HPLC. The study was performed in the framework of
the Program for Basic Research of State Academies of Sciences for 2013-
2020. Peptide synthesis was done with the use of the equipment of the
“Human Proteome” Core Facility of the Institute of Biomedical Chemstry
(Moscow, Russia) supported by Ministry of Education and Science of the
Russian Federation (unique project ID RMEFI62117X0017).
MS7
Targeting Ghrelin Receptor Homodimer: Bivalent
Ligands with Exceptional Binding Affinity and
Potency
Tyler Lalonde, Jinqiang Hou, Pierre Thibeault, Savita
Dhanvantari, Rithwik Ramachandran, Len Luyt
University of Western Ontario, Canada
The ghrelin receptor (GHS-R1a) is a 7-transmembrane G protein-coupled
receptor (GPCR) that is activated by a 28-amino acid peptide, ghrelin.
GPCRs are known to form dimers and the literature investigating ghre-
lin receptor dimerization has largely focused on heterodimerization with
other GPCRs. The formation of GHS-R1a homodimers is less studied
and chemical tools to explore this phenomena would allow for a better
understanding of mechanism and functional relevance of homodimeriza-
tion. In the present study we report the design, synthesis, and binding
affinity evaluation of bivalent ligands targeting GHS-R1a. Bivalent lig-
ands, based on the peptidomimetic G7039, were designed through a ra-
tional structure-based design approach. The optimal linker length was de-
termined through the synthesis of eight bivalent ligand variants and these
were evaluated using an in vitro competitive binding assay. Our studies
showed that the bivalent ligand B5-58 possesses exceptionally high bind-
ing affinity (IC(50high) = 0.43 nM; IC(50low) = 0.42 pM) and can bind to
both receptors within the GHS-R1a homodimer in HEK293 cells, which
is indicated by a bivalent binding curve. In addition, we demonstrated
that B5-58 is a strong agonist by its activation of beta-arrestin-1 and beta-
arrestin-2 recruitment in the low nanomolar range (EC(50) = 1.81 nM for
beta-Arr-1 and EC(50) = 2.09 nM for beta-Arr-2). The monomeric version
S5-58 (the single peptidomimetic with the linker attached), the unmodified
G7039 peptidomimetic, and the natural ligand for the receptor, ghrelin, are
2-15x less potent then B5-58 based on EC(50) values for beta-arrestin-1
and beta-arrestin-2 recruitment. GHS-R1a was then inserted into both a
yellow fluorescent protein (YFP) vector and Renilla luciferase (rluc) vec-
tor for use in a BRET assay to assess the induction of the homodimer with
the addition of B5-58. We determined that there was 3-fold increase in ho-
modimerization BRET response with B5-58 compared to ghrelin, G7039,
and the monomer. Currently, B5-58 is being evaluated in cell signaling
assays and confocal experiments to visualize the induction of the homod-
imer. Ghrelin receptor activation triggers several signaling pathways that
can be harnessed for therapeutic response in disease states (i.e. inflamma-
tion, diabetes, and hypotensive effects), leading to the potential for B5-58
to be used as a therapeutic agent. Therefore, we conclude that B5-58 is
able to induce GHS-R1a homodimer formation and is a bivalent ligand
that has high binding affinity and receptor activation. The bivalent ligand
described herein is a powerful tool to explore the functions of the GHS-
R1a homodimer and constitutes a novel therapeutic entity for GHS-R1a
related pathological conditions and diseases that can be controlled through
the activation increase of the ghrelin receptor.
MS8
De novo designed proteins catalyzing amide bond
forming reactions
Elise Naudin1, William DeGrado2, Vladimir Torbeev1
1University of Strasbourg, France
2University of California San Francisco, United States
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Chemical synthesis of peptides and proteins is of great interest as a tool
for studying protein structure and function and as a method for prepara-
tion of biomedically important proteins.[1] Our goal is to design de novo
proteins which can accelerate the amide bond forming reactions and can
be used as peptide ligases or for peptide/protein labelling. In this study,
we explored N-terminus of α-helix with unpaired hydrogen-bond donors
as a structural motif to stabilize negatively charged tetrahedral interme-
diates of nucleophilic addition-elimination reactions at carbonyl group.
The catalytic cysteine residue acting as a principal nucleophile was en-
gineered at either of the two key positions, so-called Ncap (residue pre-
ceding the first amino acid that adopts α-helical conformation) and N2
(second residue at N-terminus of α-helix) in a designed Domain-Swapped
Dimer (DSD) three-α-helix protein scaffold.[2] We demonstrated efficient
transthioesterification of peptide-αthioesters and, subsequently, aminol-
ysis of the thioester intermediate in the presence of a large excess of
tris(hydroxymethyl)aminomethane (Tris), an amine with pKa similar to
N-terminal amino group of peptides. To improve catalytic parameters, the
iterations of computational design, X-ray crystallographic structural stud-
ies, as well as combinatorial synthesis of libraries of variants are currently
undergoing.
References [1] D. J. Craik, D. P. Fairlie, S. Liras, D. Price, Chem. Biol.
Drug Des. 2013, 81, 136–147. [2] N. L. Ogihara, G. Ghirlanda, J.W.
Bryson, M. Gingery, W. F. DeGrado, D. Eisenberg, Proc. Natl. Acad. Sci.
2001, 98, 1404–1409.
MS9
Synthesis and biochemical evaluation of
GnRH-III-drug conjugates
Sabine Schuster1, Beáta Biri-Kovács1, Adina Borbély2,
Norbert Sewald2, Ines Neundorf3, Cesare Gennari4, Gábor
Mezó1
1Eötvös Loránd University, Faculty of Science, Institute of Chemistry,
Research Group of Peptide Chemistry, Budapest, Hungary
2University of Bielefeld, Department of Chemistry, Organic and
Bioorganic Chemistry, Bielefeld, Germany
3University of Cologne, Institute of Biochemistry, Cologne, Germany
4Università degli Studi di Milano, Dipartimento di Chimica, Milano, Italy
Gonadotropin releasing hormone-III (GnRH-III, <EHWSHDWKPG-NH2;
<E – pyroglutamic acid, isolated from sea lamprey), a native isoform of
the human peptide hormone GnRH-I, represents a promising starting point
for the development of efficient peptide-based drug delivery systems for
targeted cancer therapy. Beneficially hereby is that GnRH-III specifically
binds to GnRH receptors on cancer cells without revealing a significant
endocrine effect [1]. Based on these findings, a variety of GnRH-III-drug
conjugates have been developed and characterized in our laboratories. We
could demonstrate that the side chain of 8Lys provides a suitable ligation
site for cytotoxic agents without substantial decrease of receptor binding
affinity or antiproliferative activity [1]. Moreover, we developed an ef-
ficient strategy to link the anthracycline daunorubicin (Dau) to GnRH-
III via oxime bond by insertion of an aminooxyacetyl moiety [1]. To
achieve an improved antitumor activity, we designed and synthesized a
series of oxime linked GnRH-III-Dau conjugates in which the targeting
peptide sequence was modified by different unnatural amino acids [2]. Ini-
tially, the cytostatic effect of the 20 novel bioconjugates was studied on
MCF-7 breast and HT-29 colon cancer cells revealing an enhanced an-
tiproliferative activity for one of the compounds. Due to this, the best
candidates were chosen for further biochemical evaluation like cellular
uptake studies, plasma stability or lysosomal degradation. Furthermore,
the two most promising peptide carriers of these studies were selected
as targeting moiety for the development of novel drug conjugates. Thus,
the classical anticancer drugs Dau and paclitaxel (PTX) have been suc-
cessfully linked to GnRH-III derivatives by using a self-immolative p-
aminobenzyloxycarbonlyl (PABC) spacer between a cathepsin B cleavable
dipeptide (Val-Ala, Val-Cit) and the drug. For comparative purpose, the
non-cleavable GnRH-III-drug conjugates were also synthesized. The re-
sulting bioconjugates have been analyzed for their in vitro cytostatic effect
on A-2780 ovarian and Panc-1 pancreatic cancer cells and the release of
the drug was followed by lysosomal degradation studies in presence of rat
liver lysosomal homogenate. Next to this, the highly efficient drug candi-
date cryptophycin was conjugated to a GnRH-III homing device by using
different cleavable and non-cleavable linker systems [5]. The correspond-
ing in vitro evaluation including the antitumor activity of the compounds
as well as stability and drug-release studies are ongoing. This project has
received funding from the European Union’s Horizon 2020 research and
innovation program under the Marie Sklodowska-Curie grant agreement
No 642004, and from the National Research, Development and Innovation
Office (NKFIH K119552), Hungary.
[1] G. Mezó, et al. Peptides (2007), 28, 806-820 [2] S. Schuster et al. Beil-
stein J. Org. Chem. (2018), 14, 756-771 [3] A. Dal Corso et al Chem. Eur.
J. (2015), 21, 6921-6929 [4] G.M. Dubrowchik et al. Bioconjugate Chem.
(2002), 13, 855-869 [5] C. Weiss et al. J. Pept Sci. (2017), 23, 514-531
MS10
Directing PYY3-36 internalization through half-life
extenders
Esben Matzen Bech1, Anette Kaiser2, Kathrin
Bellmann-Sickert2, Søren Ljungberg Pedersen3, Annette G.
Beck-Sickinger2, Knud J. Jensen4
1Gubra ApS and University of Copenhagen, Denmark
2University of Leipzig, Germany
3Gubra ApS, Denmark
4University of Copenhagen, Denmark
Peptide YY3-36 (PYY3-36) is an endogenous ligand of the neuropeptide
Y2 receptor (Y2R), on which it act to reduce food intake. Accordingly,
PYY3-36 analogues are interesting as potential anti-obesity pharmaceuti-
cals. However, native PYY3-36 is rapidly cleared from circulation, and
half-life extension is thus a prerequisite for PYY3-36 based pharmaceu-
ticals. This is typically achieved by covalent attachment of PYY3-36 to
macromolecules (e.g. PEG) or through lipidation which promotes non-
covalent interactions to albumin. Many peptide drugs, like PYY3-36, re-
quire binding to a specific G protein coupled receptor (GPCR) to exert
their effect. GPCRs are desensitized and internalized following intracellu-
lar binding of arrestins, which bind to the ligand-activated conformation of
the receptor.[1] GPCR-bound arrestins can in some cases confer signalling
with distinct and important biological consequences, but will also inhibit
G-protein signalling, which is often the primary signalling pathway.[1]
Beck-Sickinger and co-workers recently reported how PEGylation and lip-
idation differentially direct arrestin-3 (Arr3) recruitment and receptor in-
ternalization of pancreatic polypeptide (PP), another peptide of the neu-
ropeptide Y receptor system.[2] Hence, the half-life extender selected for
PYY3-36 therapeutics may alter its efficacy. Accordingly, we aimed to
investigate how PEGylation (PEG20), hexadenoic acid (C16), and octade-
canedioic acid (C18 di-acid) lipidation, direct Y2R-mediated internaliza-
tion of PYY3-36. We report how PEGylation, confer a G-protein bias and
a reduced Y2R internalization. We further report how lipidation with both
C16 and C18 di-acid confer a slight Arr3 bias, whereas only C16 increase
Y2R internalization. Next, the mechanism underlying the half-life exten-
der’s control of receptor-internalization were investigated through Y2R
binding studies. We report how affinity alone cannot explain differences
in internalization. Moreover, we demonstrate how binding kinetics may be
the root-cause of internalization differences, with increased koff leading to
reduced internalization.
In summary, peptides including PYY3-36 may achieve enhanced
pharmacodynamic- and pharmacokinetic properties, if receptor-mediated
internalization is minimized. Half-life extending techniques can differen-
tially direct signalling bias and internalization of the Y2R-PYY3-36 com-
plex. Here, we demonstrate for the first time, how binding kinetics under-
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lay these differences.
1) Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching Old Receptors New
Tricks: Biasing Seven-Transmembrane Receptors. Nat. Rev. Drug Discov.
2010; 9: 373–386
2) Mäde V, Babilon S, Jolly N, Wanka L, Bellmann-Sickert K, Diaz
Gimenez LE, Mörl K, Cox HM, Gurevich V V., Beck-Sickinger AG. Pep-
tide Modifications Differentially Alter G Protein-Coupled Receptor Inter-
nalization and Signaling Bias. Angew. Chemie - Int. Ed. 2014; 53:
10067–10071;
MS11
Mechanisms of bacterial membrane permeabilization
of snake venom-derived peptides crotalicidin (Ctn) and
Ctn[15-34]
Clara Pérez-Peinado1, Susana Almeida Dias2, Marco M.
Domingues2, Aurélie H. Benfield3, João Miguel Freire2,
Gandhi Rádis-Baptista4, Diana Gaspar2, Miguel Castanho2,
David Craik5, Sónia Troeira Henriques5, Ana Salomé
Veiga2, David Andreu1
1Universitat Pompeu Fabra, Spain
2Instituto de Medicina Molecular, Portugal
3Institute for Molecular Bioscience, Australia
4Laboratory of Biochemistry and Biotechnology, Brazil
5The University of Queensland, Australia
Against the alarming rise of multi-resistant bacteria, antimicrobial peptides
(AMPs) have emerged as a promising therapeutic choice, due to their po-
tency, broad spectrum and mechanisms of action that minimize the appear-
ance of resistance. In this context, we recently identified a new cathelicidin-
like AMP from the venom gland of the South American Crotalus durissus
terrificus rattlesnake, named crotalicidin (Ctn), which demonstrated potent
antimicrobial and antitumoral properties. Subsequent studies allowed us
to identify a minimal motive, Ctn[15-34], with enhanced selectivity and
serum stability while preserving activity. In the present study we investi-
gate the antibacterial mechanism of both Ctn and Ctn[15-34], focusing on
their membrane-disruptive properties. Although both peptides are shown
to permeabilize E. coli membranes in a three-step process, i.e., (i) recruit-
ment, (ii) accumulation, (iii) membrane disruption, slight differences be-
tween them were detected by time-resolved flow cytometry, suggesting
different modes of action. Additionally, the effect of the peptides on bac-
terial cells was directly visualized by atomic force microscopy, and their
bacterial surface localization by confocal microscopy. Ctn[15-34] demon-
strated preference for vesicles that mimic bacterial or tumoral cell mem-
branes, confirming its potential as an anti-infective lead.
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P1
Convenient method of peptide hydrazide synthesis
using a new hydrazone resin
Thomas Bruckdorfer1, Pavel S. Chelushkin2, Ksenia V.
Polyanichko2, Maria Leko2, Marina Dorosh2, Sergey V.
Burov2
1Iris Biotech GmbH, Germany
2Institute of Macromolecular Compounds, St. Petersburg State University,
Russia
Peptide hydrazides can be easily synthesized using a new hydrazone resin,
obtained via acylation of aminomethyl polystyrene by Fmoc-hydrazone of
pyruvic acid. It was shown that the hydrazone linker is completely stable
in the course of standard Fmoc SPPS. Moreover, it can tolerate a treatment
with 5% TFA/DCM thus permitting selective removal of Mtt or related
acid-labile protecting groups. Subsequent application of cleavage cock-
tails containing net TFA permits to obtain the desired peptides in a reason-
able yields and purity. Synthesized peptide hydrazides can be applied as
building blocks for the conjugation with different carrier molecules using
hydrazone ligation technique.
P2
On the challenge of cysteine-rich peptide synthesis:
the heat-stable toxin from Enterotoxigenic Escherichia
coli (STh) and its toxoids
Françoise Baleux1, Yves-Marie Coïc1, Ephrem Zegeye2,
Yuleima Diaz2, Pål Puntervoll2, Laurence Mulard1
1Institut Pasteur, France
2Uni Research Environment, Norway
Enterotoxigenic Escherichia coli (ETEC), and in particular those that ex-
press the heat-stable toxin (ST), with or without the heat-labile toxin (LTB),
are an important cause of diarrheal disease and death in children under five
years of age.1 Porcine and human ST (STp and STh) are antigens of in-
terest in the search for a broad coverage ETEC vaccine. Owing to their
similarity with guanylin and uroguanylin (Figure 1), toxoid analogues are
the only option when considering STh as antigen. In this context, selected
mono- and double mutants of STh have emerged as lead candidate STh
toxoids.2 STh and selected analogues are 19 amino acid peptides encom-
passing three disulfide bridges, the synthesis of which is a challenging is-
sue. Correct cysteine pairing is of upmost importance for antigenicity, and
therefore for immunogenicity. A panel of toxoids and reference STh were
produced either by recombinant synthesis or solid phase peptide synthesis
combined to direct air-oxydation folding or to site-selective cysteine pair-
ing. Whilst native STh adopted the right cysteine pairing independently of
the protocol, important divergences have been observed for toxoids, with
a strong impact on their antigenic properties. Using selected toxoids, the
various synthesis strategies and their outcome are discussed in line with
the antigenicity profiles of the obtained peptides. Our data suggest that
the fully orthogonal chemical strategy is the only way to ensure that the
isolated peptides are the properly folded STh toxoid isomers.
References 1. Liu, J. et al, Use of quantitative molecular diagnostic meth-
ods to identify causes of diarrhoea in children: a reanalysis of the GEMS
case-control study. Lancet, 2016, 388, 1291-1301. 2. Taxt, A. M., Diaz,
Y., Aasland, R., Clements, J. D., Nataro, J. P., Sommerfelt, H., and Punter-
voll, P., Towards rational design of a toxoid vaccine against the heat-stable
toxin of Escherichia coli, Infect Immun, 2016, 84, 1239-1249.
Figure 1. The STp and STh toxins and their sequence similarities with
uroguanylin and guanylin.
P3
Photo induced electron transfer across transmembrane
peptides
Samantha Wörner, Hans-Achim Wagenknecht, Anne Ulrich
Karlsruhe Institute of Technology, Germany
Electron transfer through proteins is a controlled process playing an im-
portant role in biological processes such as photosynthesis and respiration.
But it still remains to be investigated in detail which of the 20 natural
amino acids are present or influence the electron pathways and what role
transmembrane peptides play. Previous investigations of ribonucleotide re-
ductase , DNA photolyase , and photosystem II have shown the importance
of aromatic amino acids like tyrosine (TyrOH) and tryptophan (TrpH) for
electron transfer in these proteins. To gain better insight about electron
transfers across peptides as key components of biological energy conver-
sion systems our idea is to create a transmembrane peptide in which by
pulsed laser excitation the progress of electron transfer through the vari-
ous amino acids can be monitored by time resolved spectrophotometry. At
first, a polyproline peptide model was chosen to confirm the stepwise elec-
tron transfer across the peptide using TrpH and TyrOH as electron stepping
stones and a Flavin modified amino acid as electron acceptor. This model
showed a fluorescence quenching dependent on the distance between the
Flavin amino acid at the N terminus and the first Trp stepping stone. Fur-
thermore, a polyproline II as secondary structure was found in dependency
on the amount of neighbouring prolines for the peptide models. These re-
sults already indicate an electron transfer which has to be confirmed by
transient absorption spectroscopy. Hereafter, the system can be transferred
to the transmembrane peptide EGFR and electron transfer across mem-
branes can be achieved.
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P4
Multivalent Ligand Design – Chemistry and
Applications
Markus Muttenthaler
University of Vienna, Austria
Multivalent interactions are widely observed in nature yet relatively un-
derexplored in ligand design and drug development. Dendritic structures
of neurons, vasculature, viral surface proteins, roots and river deltas are
just a few examples where biological function is transferred in a branched
fashion. Chemically, multivalent interactions and dendritic structures have
been explored in biomaterials, catalysis, gene delivery and vaccine devel-
opment, however, the therapeutic prospect of multivalent ligands has yet
to be established. Our lab is interested in chemical strategies to efficiently
assemble a diverse range of monodisperse, well-defined, multifunctional
peptide dendrimers, so we can explore their potential as a novel class of
molecular probes, drug leads and theranostics.
Here we present our synthetic strategies to produce different sets of mul-
tivalent (2x, 4x, 8x, 16x) peptide ligands. Design rationale, the different
chemistries employed, pharmacological and biophysical characterisation,
and the synthetic challenges that were faced will be discussed. Biological
applications of these multivalent ligands include G protein-coupled recep-
tor interaction which resulted in substantial potency improvements, and the
use of poly-arginine peptide dendrimers to improve intracellular delivery
of nanoparticles decorated with drug cargo. The chemical strategies em-
ployed in this work are broadly applicable for the synthesis of other com-
plex peptide constructs, and our biological results strongly highlight the
versatility of multivalent ligands as molecular probes and potential drug
leads.
P5
Peptide Couplings by Reactive Extrusion: Efficient,
Continuous and Green
Thomas-Xavier Métro1, Yves Yeboue1, Benjamin Gallard2,
Nicolas Le Moigne2, Jean Martinez1, Frédéric Lamaty1
1Institut des Biomolécules Max Mousseron, France
2IMT Mines Ales, France
Peptides play a central role in the therapeutic solutions of the future. Unfor-
tunately, conventional peptide production techniques (i.e. solution-phase
and supported-phase) suffer from both very long reaction times and huge
amounts of toxic solvents and reactants that are required during synthesis.
These limitations have a highly negative influence on environmental im-
pact and cost of production, thereby inhibiting economical attractiveness
of peptide production. Therefore, the development of efficient and envi-
ronmentally sound processes for the production of peptides is of utmost
priority. To reach this goal, we have developed innovative peptide synthe-
sis technique based on the use of a twin-screw extruder. Thus, by using this
equipment that enables mixing of extremely concentrated solid-containing
reaction mixtures, peptide couplings could be performed solvent-free in a
continuous way, thereby offering a direct and scalable approach to efficient
and sustainable production of peptides at the industrial scale.[1]
References:
[1] Y. Yeboue, B. Gallard, N. Le Moigne, F. Lamaty, J. Martinez, T.-X.
Métro, submitted.
P6
Ribosomal Synthesis of a Thioamide Bond
Rumit Maini1, Ryo Takastuji2, Yuki Goto2, Hiroaki Suga2
1Merck Sharp & Dohme (MSD), United States
2The University of Tokyo, Japan
In the past few years, numerous reports of ribosomal synthesis of polypep-
tides containing non-natural peptide backbones including N-alkyl-amide
or ester backbones have appeared in the literature, where the amine nu-
cleophile was modified to either N-substituted amine or hydroxyl group
without changing the carbonyl carbon electrophile. In the present study,
we demonstrated the catalysis of a thioamide bond by the ribosome, where
a thiocarbonyl carbon was utilized as an electrophile. First, we developed a
strategy for the preparation of amino(thio)acyl-tRNAs using the flexizyme
technology developed in the Suga lab, which allowed for reassignment of
the genetic code to a thio-amino acid. Later, by using the amino(thio)acyl-
tRNAs in flexible in vitro translation (FIT) system, linear and cyclized
peptides having one thioamide backbone were synthesized by the ribo-
some. Moreover, ribosomal synthesis of an N-methyl-thioamide bond was
shown for the first time. Many examples have demonstrated the applica-
tion of thioamide backbone in improving the pharmacological properties
of a peptide as well as in studying protein folding and dynamics. So far,
polypeptides bearing thioamide backbones are accessible by synthetic or
semi-synthetic methods. Using the method described in this study, direct
ribosomal translation of peptides and proteins with thioamide backbones
is now possible. This method will enable the generation of an mRNA dis-
played peptide library containing one or more thioamide backbone, that
will possibly lead to the discovery of biologically active macrocyclic pep-
tides with improved pharmacological properties
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P7
New Synthesis of Stapled Peptide Alcohols and Their
Activity as Mdm2 Inhibitor
Fernando Jose Ferrer Gago, Gayathri S, David P Lane
BMSI/P53, Singapore
The use and testing of peptide alcohols (PAs) in SAR are limited because
of the lack of commercially available resins that enable their reliable and
fast synthesis. At A*STAR, we have developed a set of resins that enable
the synthesis of PAs using the conventional 9-fluorenylmethoxycarbonyl
(Fmoc)/tBu SPPS strategy.
It is well known that peptide C-terminus can have a strong influence on the
activity. These new resins provide a great opportunity to evaluate the effect
of changing the amide or carboxylic group to their reduced form (alcohol).
Here we are presenting the first solid phase synthesis of stapled PAs and
a comparison with their peptide amide counterparts. The change of the
C-terminal amide to alcohol increases the hydrophobicity and doubles the
p53 activation over their C-terminus amide counterparts. Even though the
amide and PAs have similar Kd, an increase in hydrophobicity can enhance
the activation of p53 by making the PAs more cell permeable.
P8
One-Pot Assembly of Oligopeptides in Solution-Phase
Ivo E. Sampaio-Dias1, Sara C. Silva-Reis1, Xerardo
García-Mera2, José E. Rodríguez-Borges1
1LAQV/REQUIMTE, Department of Chemistry and Biochemistry,
Faculty of Sciences, University of Porto, Portugal, Portugal
2Department of Organic Chemistry, Faculty of Pharmacy, University of
Santiago de Compostela, Spain, Portugal
Synthetic peptide chemistry in solution-phase makes use of two main
strategies for peptide coupling: the use of pre-activated peptide frag-
ments and in situ activation procedures. These strategies are being em-
ployed throughout the peptide chemistry disjointedly. This work describes
a methodological advancement in solution-phase peptide synthesis via
the development of a convenient and operational protocol to synthesize
oligopeptides in a one-pot three-step cascade method, in which two pep-
tide bonds are introduced chemoselectively. This protocol comprises the
coupling between a fully deprotected peptide fragment and a pre-activated
fragment in its succinimide ester form, followed by in situ activation of car-
boxylic acid moiety of the intermediate which undergoes aminolysis with
last amino-peptide fragment. Following this protocol, tri- to hexapeptides
were obtained in high global yields (80–95%) with no need of purifica-
tion of intermediates and with virtually no epimerization as determined
via HPLC and variable-temperature NMR experiences. This methodol-
ogy represents a faster, easier and milder approach to the synthesis of pep-
tides, and it operates at equimolar amounts. In this study, we checked the
compatibility with common N-protecting in peptide chemistry (Z, Boc and
Fmoc) the formation of secondary and tertiary amides as well as the use
of D/L and non-proteinogenic amino acids. This protocol may represent
an attractive alternative to the preparation of larger peptides by facilitating
convergent synthesis which otherwise would entail in exhaustive cycles of
protection/deprotection and coupling steps.
P9
The Thioamide Ligation: A Residue-Independent
Peptide Ligation
Varsha Thombare, Carlie Charron, Craig Hutton
The University of Melbourne, Australia
The most widely used peptide ligation strategy is native chemical ligation
(NCL). The requirement for ligation at cysteine – the least common of the
proteinogenic amino acids – has led to the development of modified liga-
tion methods. Thiol- or selenol-functionalized amino acid derivatives have
been employed in NCL, which after dechalcogenation facilitate ligations
at a variety of amino acid residues. However, all NCL-type approaches
require a side-chain functionalized N-terminal amino acid residue. We
have developed a residue-independent ligation process in which a back-
bone thioamide group is incorporated at the N-terminal amide position.
This thioamide directs a chemoselective reaction with a peptide carboxylic
acid to generate, after O–N acyl transfer of an isoimide intermediate, the
ligated peptide.
P10
Inhibitory Effect of 4 Novel Synthetic Peptides on
Food Spoilage Yeasts
Laila Shwaiki, Thibaut Thery, Elke K.A. Arendt
University College Cork, Ireland
The spoilage of foods caused by the growth of undesirable yeast species
is a problem in the food industry. Yeast species such as Zygosac-
charomyces bailii, Zygosaccharomyces rouxii, Debaryomyces hansenii,
Kluyveromyces lactis and Saccharomyces cerevisiae have been encoun-
tered in foods such as high sugar products, fruit juices, wine, mayonnaise,
chocolate and soft drinks. The demand for new methods of preserva-
tions have increased because of the negative stigma attached to chemical
preservatives. A novel peptide sequence (KKFFRAWWAPRFLK-NH2)
was modified to generate three versions of this original peptide. These
peptides were tested for the inhibition of the yeasts mentioned above, al-
lowing us to better understand their residue modifications. The range of the
Minimum Inhibitory Concentration was between 25 and 200 µg/mL. Zy-
gosaccharomyces bailii was the most sensitive strain to the peptides, while
Zygosaccharomyces rouxii was the most resistant. Membrane permeabil-
isation was found to be responsible for yeast inhibition to some extent at
a two-fold concentration (400 µg/mL) of the MIC. The possibility of the
overproduction of Reactive Oxygen Species was also assessed but was not
recognised as a factor involved for the peptides’ mode of action. Cyto-
toxicity and haemolytic activity of the peptides were assessed to address
the safety concern of using synthetic peptides in food products. This con-
cern was dismissed as the rate of haemolysis (less than 10% at the highest
concentration) and cytotoxicity were found to be relatively low. These ef-
ficient novel peptides represent a new source of food preservation that can
be used as an alternative for current controversial preservatives used in the
food industry.
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P11
Improving Throughput in Therapeutic Peptide
Manufacturing with Parallel Automated SPPS
Andrew Kennedy1, James Cain2, Cyf Ramos-Colon2,
Daniel Martinez2
1Gyros Protein Technologies, Sweden
2Gyros Protein Technologies, United States
Process development for the manufacture of therapeutic peptides remains
a vital part of the commercial peptide production process. An optimized
solid-phase synthesis protocol can be challenging to develop, however the
benefits range from increased crude product purity and yield to reduced
synthesis time and reduced production costs. Many of the recent advances
in peptide therapeutics focus on peptides with greater structural complex-
ity compared to naturally occurring peptides, allowing for the design of
more physiologically stable products with increased target specificity and
membrane permeability [1]. Examples of more complex peptides include
cyclic, hydrophobic and chemically modified peptides, both of which can
be difficult to synthesize and subsequently purify, which calls for more effi-
cient synthesis protocols to overcome these manufacturing challenges. The
advent of the neoantigen and personalized medicine sectors adds a further
requirement for faster peptide synthesis protocols and reduced processing
times, including adherence to regulatory guidelines and GxP requirements
during manufacture.
Solid-phase peptide synthesis (SPPS) of linear peptides using heat (>50
°C) and highly reactive coupling reagents have resulted in products with
increased crude purities and yields when using significantly shorter cou-
pling cycles compared to room-temperature methods [2]. Some structural
modifications such as cyclizations have traditionally been performed post-
SPPS using solution-phase methods, however factors such as ring size and
sequence can compromise reaction efficiency. Development of automated
solid-phase (on-resin) protocols for cyclization, potentially using heat, may
provide numerous advantages for the development of complex peptide
products [3]. Parallel automated synthesis is a useful tool for quickly
and efficiently synthesizing multiple peptide analogs simultaneously for
structure-activity relationship (SAR) studies of synthetically challenging
sequences.
Here we describe the process development and parallel optimization of
SPSS relating to different biologically relevant peptides. Solid-support
screening, reagent screening and temperature screening are demonstrated
using an automated peptide synthesizer as part of the optimization pro-
cess for difficult peptides such as Aib-Enkephalin (90% optimized crude
purity vs 21% crude purity) and JR 10-mer (67% optimized crude purity
vs 21% crude purity). A number of automated solid-phase protocols are
also shown to be more efficient replacements for traditionally manual or
solution-phase manipulations, resulting in reduced processing times and
high crude product purities and yields. We report the use of heat to in-
crease the crude purity of Melanotan II peptide from 43% to 60% using
solely on-resin synthetic methods.
[1] S. H. Joo, “Cyclic peptides as therapeutic agents and biochemical
tools,” Biomol. Ther., 20, 1, 19-26, 2012. [2] T. Redemann and G. Jung,
Proc. 24th Eur. Pep. Symp., 1996, 749. [3] N. Tsomaia, “Peptide thera-
peutics: Targeting the undruggable space”, 2015.
P12
An Alternative Disconnection for Native Chemical
Ligation
Rita Petracca, Lauren McSweeney, Eoin Scanlan
Trinity College Dublin, Ireland
Chemical modification of proteins is a powerful tool for the investigation
of natural systems and the development of therapeutic conjugates. The re-
finement of methods for protein total synthesis remains a key objective of
synthetic organic chemistry. To date, Native Chemical Ligation (NCL)
represents the gold standard for the thioester-mediated, chemoselective
peptide bond-forming condensation of unprotected peptide residues.[1a]
Despite its widespread use, NCL still has certain limitations, such as
the essential requirement for an N-terminal cysteine (Cys) at the liga-
tion site.[1a] Although several synthetic advancements have been reported
over the years,[1b] the development of efficient alternatives to NCL is an
expanding area of research.[2] The recent emergence of the dehydroala-
nine aminoacid (DAla) and its successful application in protein modifica-
tion,[3] prompted us to develop a novel ligation methodology based on the
DAla chemical reactivity. DAla is an excellent electrophilic moiety, which
can rapidly react with sulphur nucleophiles to generate alkyl cysteine ana-
logues; the ligation with a specific amino thio-acid gives a stable thioester
intermediate, which spontaneously undergoes to an S-to-N acyl shift forg-
ing a native peptide bond (Figure 1). The reported methodology enriches
the state-of-the-art protein ligations set and undoubtedly represents a valid
alternative disconnection approach within the NCL strategy.
1. (a) Kent, S. Biopolymers, 2010, 94, 4-9; (b) Dawson, P. E. at al. J. Am.
Chem. Soc. 1997, 119, 4325-4329; 2. Burke, H. M. et al. Nat. Comm.
2017, 8, 15655. 3. Davis, B. G. et al. Nat. Comm. 2014, 5, 4740.
P13
Chemical synthesis of venom peptides using
directed-disulfide bond formation
Claude Zoukimian1, Didier Boturyn2
1Département de Chimie Moléculaire, UMR CNRS 5250 - Smartox
Biotechnology, France
2Département de Chimie Moléculaire, UMR CNRS 5250, France
Venoms come from thousands of years of evolution that allowed venomous
species to develop complex mixtures of peptides and proteins known as
toxins. Such molecules have received a growing interest due to their poten-
tial power as drugs in the medical field or even as eco-friendly insecticids .
These toxins are particularly well folded due to the natural high abundance
of cysteine which form several disulfide bonds and give to these molecules
their specificity and robustness in organisms. Usually, toxins are first iso-
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lated from venoms, but the low quantity of material that can be produced
remains a major hurdle to overcome. To address this issue, chemical pep-
tide synthesis is typically used. Nowadays, numerous synthesis techniques
and automated synthesizers permit the preparation of the linear sequence
of a toxin without major difficulties. The key step is then to correctly fold
the biomolecule. Oxidative buffers are the easiest way to fold a cysteine-
containing peptide, but generally lead to a complex mixture of the desired
product with peptide misfolding, and sometimes to exclusively undesired
disulfide bond configurations. In order to selectively synthesize the de-
sired pattern, we herein describe chemical scheme to direct disulfide bond
formations. This strategy uses a combination of orthogonally protected
cysteines which are successively deprotected and oxidized in cystine and
can be applied to venom peptides that contain up to three disulfide bonds.
This approach has been applied with success to several toxins. Moreover,
the directed-disulfide bond formation has been demonstrated in one-pot,
then avoiding fastidious and time-consuming purifications of intermedi-
ates. This also enables the access to numerous analogues and modified
toxins that cannot be extracted from venoms.
P14
Incorporation of Cystine and its Mimetics in Insulin
and other Disulfide-rich Peptides
John Karas1, Frances Separovic1, John Wade2, Mohammed
A Hossain2
1The University of Melbourne, Australia
2Florey Neurosciences Institute, Australia
Disulfide bonds are important structural elements in peptides and proteins
and play a critical role in maintaining their biologically active confor-
mation. Chemical synthesis of peptides can enable sequential formation
of multiple cystine bonds through exploitation of judiciously chosen re-
gioselective thiol protecting groups. The ortho-Nitroveratryl moiety can
be utilised as an orthogonal cysteine protecting group and is efficiently
cleaved via photolysis under ambient conditions. In combination with
complementary S-pyridinesulfenyl activation, disulfide bonds are formed
rapidly in situ. We also report the efficient incorporation of lactam and cys-
tathionine bridges in insulin and related peptides as stable cystine mimetics
for the development of peptide-based therapeutics with enhanced thermal
stability.
P15
Revisiting ligation at selenomethionine: insights into
native chemical ligation at selenocysteine and
homoselenocysteine
Rebecca Dardashti, Norman Metanis
The Hebrew University of Jerusalem, Israel
Selenomethionine (Sem), though not present naturally in human proteins,
can serve as a structural probe in NMR and X-ray crystallography. Sem
has been incorporated recombinantly into proteins many times to eluci-
date their structure and function. We revisited incorporation via chemical
protein synthesis to shed light on the mechanism of native chemical lig-
ation. The effect of chalcogen position on ligation was investigated, and
selenium-containing peptide ligation was optimized. Additionally, selec-
tive methylation was performed on selenolates in a peptide in the presence
of unprotected thiols.
P16
Synthesis of RGD Peptides Inducing Multicellular
Spheroids Formation
Maria Leko1, Anna Pokhvoshcheva1, Marina Dorosh1,
Roman Akasov2, Elena Markvicheva2, Markus Weishaupt3,
Thomas Bruckdorfer3, Sergey Burov1
1Medical-Biological Research-Industrial Complex CYTOMED, Russia
2Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, RAS, Russia
3Iris Biotech GmbH, Germany
The 2D monolayer cell culture model widely applied for drug screening
is not able to adequately mimic the in vivo response. Sutherland et al.[1]
were the first to propose multicellular tumor spheroids as 3D model of
small solid tumors. Later, multicellular spheroids (MS) composed of nor-
mal cells were applied for the screening of neuroprotective agents, 3D bio-
printing and tissue regeneration. Recently we demonstrated the practical
utility of a cyclic RGD peptide containing a triphenylphosphonium (TPP)
moiety, namely cyclo-RGDfK(TPP), in a novel and highly reproducible
one-step approach for MS formation [2]. Here we describe an optimized
procedure for the synthesis of cyclo-RGDfK(TPP) and related peptides
using our novel hydrazone resin [3]. In order to compare the efficiency
of various reaction protocols, the synthesis was performed in parallel on
different polymer supports, namely Wang resin, MBH-Br resin and Fmoc-
hydrazono-pyruvoyl-aminomethylpolystyrene resin. In preliminary exper-
iments it was shown that attachment of the TPP moiety to the cyclic pep-
tide in solution complicated the purification of the final product. Therefore,
it was achieved by selective deprotection of Lys(Mtt)-containing peptidyl
resin, followed by acylation with 4-carboxybutyltriphenyl phosphonium
bromide. Unexpectedly, using MBH resin the Mtt-deprotection with 1%
TFA in DCM resulted in peptide cleavage from the polymer support, while
application of a mixture of AcOH/TFE/DCM (1:2:7) was inefficient. Syn-
thesis on Wang resin provided linear peptide in reasonable purity. Its cy-
clization with HCTU proceeded smoothly without significant formation of
dimeric side product. However, subsequent removal of the OBzl group
from the aspartic acid residue by catalytic hydrogenolysis showed very
low efficiency. The final peptide deprotection requires two successive treat-
ments with HBr/TFA for 30 min and 1 h. The best results were obtained us-
ing hydrazone resin. Selective removal of the Mtt group had no influence
on the stability of the hydrazone bond. Peptide cleavage from the solid
support and removal of all protecting groups proceeded in one step. Cy-
clization of the resulting peptide hydrazide was achieved in good yield and
purity using the azide method. These data evidence the practical utility of
hydrazone resin for the synthesis of cyclic RGD peptides or their analogs
containing cargo molecules. The biological experiments have shown that
cyclo-RGDfK(TPP) is able to generate MS formation from tumor, normal
or stem cell lines of various origin. This methodology can be applied in
the design of efficient in vitro models for the screening of novel drugs and
drug delivery systems.
References
1. Sutherland R.M., McCredie J.A., Inch W.R. J. Natl. Cancer. Inst., 1971,
46, 113–120. 2. Akasov R., Zaytseva-Zotova D., Burov S., Leko M., Don-
tenwill M., Chiper M., Vandamme T., Markvicheva E. Int. J. Pharm. 2016,
506, 148–157. 3. Chelushkin P.S., Polyanichko K.V., Leko M.V., Dorosh
M.Yu., Bruckdorfer T., Burov S.V. Tetrahedron Lett. 2015, 56, 619–622.
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P17
Solid-phase peptide synthesis: the Greener, the Better
Beatriz G. de la Torre1, Ashish Kumar1, Yahya Jad1,
Jonathan M. Collins2, Simona Serban3, Othman
Almusaimi1, Fernando Albericio1
1UKZN, South Africa
2CEM Corporation, United States
3Purolite, Ireland
The concept of solid-phase peptide synthesis (SPPS) pioneered by Merri-
field in the 60s and the later development of the Fmoc/tBu strategy are the
cornerstones that have made peptides the subject of study in many research
areas. Thus, the demand for synthetic peptides is increasing, and consid-
erable efforts have been channelled into optimizing the synthetic process
itself, i.e. the coupling reagents, protecting groups, automatization of the
process, etc. However, little attention has been paid to making the process
greener. The concept of “solid-phase” itself is green in that, for instance,
the synthesis of a peptide comprising 20 amino acids involves 41 chemical
steps in only one reactor, and there is a clear minimization of mechanical
losses and mass transfer. However, SPPS involves the use of large ex-
cesses of reagents, which are removed by simple filtration and exhaustive
washing steps between each reaction, and therefore the consumption of sol-
vents the main impediment to it being considered an eco process. DMF, the
main solvent used in SPPS, is a highly reprotoxic solvent and is classified
as a Substance of Very High Concern (SVHC). However, it is considered
to be difficult to replace because of its properties. Our research demon-
strates that the complete substitution of DMF by the biomass-derived or-
ganic solvent GVL in all the steps of SPPS, coupling, deprotection and
washes can be achieved. Moreover, GVL is compatible with the appli-
cation of microwave-assisted automated SPPS because it is stable at high
temperatures. This solvent has been tested in the synthesis of peptides with
a wide range of lengths and using polystyrene- and polyethylene glycol-
based resins. The peptides were obtained in high purity, comparable to that
achieved using standard methodologies. Although, the incorporation of the
first protected amino acid into most resins is carried out by carboxylic acid
activation, this reaction on CTC resin takes place by a SN reaction, which
is normally done in DCM, a solvent called to be removed from practical
use. We propose to replace DCM with the green solvent 2-MeTHF. We
have also studied the peptide precipitation step after peptide cleavage from
the resin. Diethyl ether (DEE) is the solvent used for this purpose and it
is classified as a highly hazardous chemical. It is highly flammable and
is sensitive to light and air, and it tends to form explosive peroxides. We
propose to replace DEE with cyclopenthylmethyl ether (CPME), which is
not hampered by the aformentioned previous hazards and is considered a
green solvent. CPME gave similar performance to DEE. In general, the
work we will present is a first and important step toward greener SPPS in
terms of the use of solvent, waste generated, and energy efficiency.
P18
The Attempt of Solid-Phase Peptide Synthesis of
Lassopeptides - Part 1
Mateusz Waliczek, Piotr Stefanowicz
University of Wroclaw, Poland
Lassopeptides are specific class of peptides characterized by „knot” struc-
ture motif. These compounds are synthesized rybosomally and post-
translationally modified. These peptides are built from macrolactam ring
formed from isopeptide bond between N-terminal amino acid residue (e.g.
glycine, alanine) and the side chain of aspartic or glutamic acid. The re-
maining C-terminal chain is threaded and divided into a loop and tail.[1]
The broad interest of lassopeptides results from their biological activity.
Recently, the biological study of lassomycin showed the activity against
Mycobacterium tuberculosis.[2] The previous attempts of chemical syn-
thesis of natural lassopeptides have been unsuccessful due to the lack of
specific “knot” structure. The access to these compounds obtained by
chemical synthesis would allow in our opinion to design the new analogs
and study on their biological activity. In our research group we have made
attempt to synthesize a natural lassopeptide Sungsanpin using solid-phase
peptide synthesis. This is 15-amino acids peptide, which was discovered
from Streptomyces in Korea.[3] For this purpose we synthesized a linear
precursor of Sungsanpin, which was then subjected to on-resin cyclization
using several solvent and elevated pressure during the coupling. The ob-
tained products were controlled by LC-MS using selected ion monitoring
mode. According to literature data, the threaded and unthreaded form of
lassopeptide exhibit different chromatographic behavior, which in general
leads to clear separation of these two form. Our recent study revealed, that
the application of high pressure and non-polar solvent during the synthe-
sis of Sungsanpin leads to formation of two form of peptide. The LC-MS
analysis of the product showed the presence of two separated signals in the
chromatogram, characterized by the same molecular mass. Additionally,
these two forms of peptides exhibit different fragmentation properties dur-
ing the MS/MS analysis. These facts are consistent with the literature data
and may indicate the formation of threaded peptide. Moreover, the large
scale purification of these two forms using high-pressure liquid chromatog-
raphy was feasible.
This work was supported by Grant No.UMO-2015/19/B/ST5/00659 from
the National Science Centre, Poland
[1] S. S. Elsayed, F. Trusch, H. Deng, A. Raab, I. Prokes, K. Busarakam,
J. A. Asenjo, B. A. Andrews, P.West, A. T. Bull, M. Goodfellow, Y. Yi,
R. Ebel, M. Jaspars, M. E. Rateb, J. Org. Chem, 80, 10252 (2015) [2] E.
Gavrish, C. S. Sit, S. Cao, O. Kandror, A. Spoering, A. Peoples, L. Ling,
A, Fetterman, D. Hughes, A. Bissell, H. Torrey, Tatos Akopian, Andreas
Mueller, S. Epstein, A. Goldberg, J. Clardy, K. Lewis, Chemistry & Biol-
ogy, 21, 509 (2014). [3] S. Um, Y.J Kim, H. Kwon, H. Wen, S.H Kim,
H.C. Kwon, S. Park, J. Shin, and D.C Oh: Nat. Prod. 76, 873 (2013)
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The Attempt of Solid-Phase Peptide Synthesis of
Lassopeptides - Part 2
Piotr Stefanowicz, Mateusz Waliczek
Faculty of Chemistry, University of Wroclaw, Poland
Lasso peptides are recently discovered class of natural peptides of ribo-
somal origin [1]. These compounds exhibit a wide range of biological
functions. The most striking feature of lasso peptides is topology of these
compounds. They are composed of a loop - macrocyclic ring stabilized
by amide bond and peptide tail which is threaded through the loop. The
unique structure of lasso peptides is formed in the enzyme active centre
during posttranslational modification of precursor peptide. The effect of
high pressure on the solid phase cyclization of linear lassomycin precur-
sor was investigated. The synthesis of linear analogue of natural peptide
lassomycin was performed on ChemMatrix® resin using the combination
of protecting groups (2-phenylisopropyl ester group for carboxylic group
in sidechain and FMOC for N-terminal amino group) allowing the solid
phase cyclization [2]. The cyclization at various pressures was monitored
by LC-MS and MS/MS techniques. However the chromatographic prop-
erties and fragmentation pattern of synthetic lassomycin obtained under
atmospheric pressure and the sample cyclized under high pressure were
identical. This behavior is distinct from the Sungsanpin which during cy-
clization under high pressure forms of two isomers with different retention
times.
References [1] J. D. Hegemann, M. Zimmermann, X. Xie, M. A. Marahiel,
Acc. Chem. Res. 48, 1909 (2015) [2] P. W. R. Harris , G. M. Cook , I. K.
H. Leung and M. A. Brimble, Aust. J. Chem. 70, 172 (2017)
Acknowledgments: This work was supported by Grant No.UMO-
2015/19/B/ST5/00659from the National Science Centre, Poland
P20
Green Chemistry Approach for Peptide Synthesis
Kim Manzor, Ewa Kowalska, Katarzyna Wegner
Ipsen Manufacturing Ireland Limited, Ireland
‘Green chemistry is the utilisation of a set of principles that reduces or
eliminates the use or generation of hazardous substances in the design,
manufacture and application of chemical products.’ (Anastas and Warner,
Oxford University Press, 1998).
Peptide synthesis involves amide bond formation between protected amino
acids. The synthesis of peptides is a vital process in biological, medical
and pharmaceutical research, however it usually employs the use of haz-
ardous solvents and reagents which are used in large excess. REACH, a
European Union regulation concerning the Registration, Evaluation, Au-
thorisation & restriction of Chemicals, has identified aprotic solvents
such as N,N-Dimethylformamide (DMF), dimethylacetaamide (DMAc),
N-methyl pyrrolidone (NMP) and halogenated solvent dichloromethane
(DCM), which are the most widely used solvents for peptide synthesis,
as hazardous and problematic for pharmaceutical process scale-up. DMF,
DMAc and NMP have been identified as reprotoxic and are classified un-
der REACH regulations as a Substance of Very High Concern (SVCH) and
is included in the Candidate list for Authorisation.[1,2,3] The classification
of these solvents has highlighted the necessity to find alternative greener
solvents and processes for peptide synthesis.
Currently, we are investigating alternative solvents for peptide synthesis
and introducing continuous flow chemistry into our processes with the aim
of reducing solvent/reagent consumption and improving the ’greenness’ of
our processes. We are also concerned with educating and training the sci-
entific community with regards to green chemistry. All of our efforts to
date are presented in our poster.
[1] Lawrenson, S.; North, M.; Peigneguy, F.; Routledge, A.: Green Chem.,
2017, 19, 952-962 [2] Prat, D.; Wells, A; Hayler, J.; Sneddon, H.; McEl-
roy, R.; Abou-Shehada, S.; Dunn, P. : Green Chem., 2016, 18, 288-296
[3]www.echa.europa.eu/candidate-list-table
P21
Peptides going sweet: Synthesis of glycopeptide
hybrid structures using Passerini and Ugi reactions
Andreja Jakas, Aleksandar Višnjevac, Ivanka Jeric´
Rudjer Boškovic´ Institute, Croatia
α-Acyloxy and α-acylamino carboxamides are the building blocks for the
synthesis of various natural products such as peptide and peptoide deriva-
tives. Multicomponent reactions (MCRs) offer an attractive one-pot strat-
egy for generating a library of these highly functionalized and complex
organic compounds. The Passerini and Ugi reactions are isonitrile-based
MCR that yields α-acyloxy and α-acylamino carboxamides, respectilvely.
Passerini reaction involves an aldehyde, an isonitrile, and a carboxylic
acid while Ugi reaction involves an aldehyde, an isonitrile, a carboxylic
acid and an amine component. Utilization of carbohydrates and their
derivatives in MCRs is based on their polyfunctional character and stere-
ochemical diversity.[1] Carbohydrates represent the most abundant class
of natural products with distinctive role in different biological processes
and they are highly valuable pool of chiral molecular scaffolds.[2] Our
efforts were directed toward exploitation of carbohydrate derivatives as
components in the Passerini and Ugi reactions. We used for the first time
highly strained carbohydrate-derived aldehydes, isocyanides and amines
in the Passerini and Ugi reaction with different commercially available
carboxylic acids. As acidic non-sugar components acetic acid, benzoic
acid and Boc-protected phenylalanine were used, and as a sugar compo-
nent isopropylidene protected gulonic acid (GulA) was used. Three dif-
ferent sugar moieties were used as isopropylidene protected carbohydrate-
derived components (aldehydes, isocyanide, and amine) in the Passerini
and Ugi reaction: fructose (Fru), galactose (Gal) and sorbose (Sor). The
prepared Passerini products bear up to three sugar components, while Ugi
products comprise up to four sugar components. The Passerini reactions
conducted with prepared sugar aldehydes were highly diastereoselective,
with d.r. 90:10, and the crystal structure analysis revealed that the stereo-
chemistry of newly formed chiral center is S. The diastereoselectivity of
Ugi reactions depends on component’s structure and varies from d.r. 1:1
to d.r. 90:10 with S isomer being predominant one.
1. Neochoritis, D., Zhang, J. & Dömling, A. Synthesis 2015; 47(16): 2407-
2413. 2. Ernst, B., Magnani, J. L. Nat. Rev. Drug Discovery 2009; 8:
661-677.
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Introducing the Petasis Reaction for Multicomponent
Peptide Labeling and Stapling
Manuel Garcia Ricardo, Daniel García Rivera, Ludger
Wessjohann
Leibniz Institute of Plantbiochemistry, Germany
Multicomponent reactions have lately evolved from versatile methods for
the synthesis of small molecules to powerful tools for the post-synthetic
derivatization of peptides and proteins. Among the relevant multicom-
ponent transformations recently conducted with peptides are cyclization,
lipidation and labeling. The possibility of implementing these transforma-
tions in a multicomponent manner opens new venues of applications, as
e.g., multiple reactive handles, affinity or fluorescent tags, and even ad-
ditional biomolecular fragments can be simultaneously incorporated while
conducting the desired transformation. Here, multicomponent labeling and
stapling of peptides by means of the Petasis reaction is described. The
Petasis reaction, also known as the borono-Mannich reaction, is a three-
component process comprising the condensation of an aldehyde or ketone,
an amine and an aryl/vinyl boronic acid or ester. The report includes the
solid-phase derivatization of peptides at Lys and Nε-MeLys side chains
and its simultaneously functionalization with boronic acids containing flu-
orescent tags, lipidic or biotin moieties in conjunction with relevant oxo-
components such as dihydroxyacetone, glyceraldehyde, glyoxylic acid and
aldoses, thus encompassing a powerful complexity-generating derivatiza-
tion procedure. The multicomponent stapling is conducted in solution by
linking Nε-MeLys or Orn side chains – positioned at i, i+7 and i, i+4 – with
(bi)aryl tethers forcing the peptide to adopt helical conformations, while
the hydroxyl-carbonyl moieties were introduced as exocyclic fragments.
This multicomponent method enables the simultaneous incorporation of
aryl/vinyl moieties and aldoses and ketoses at the peptide side chain. In ad-
dition, the solution-phase multicomponent stapling proves highly efficient,
enabling the installation of rigid aryl tethers and hydroxylated exocyclic el-
ement. This successful application of the Petasis reaction in peptide chem-
istry shows promise for the future development of peptide pharmaceuticals.
P23
Bioactive fluorescent cyclopeptides through on-resin
Suzuki cross-coupling reaction
Elmira Ghabraie, Nicolo Tonali, Isabell Kemker, Norbert
Sewald
Department of Organic and Bioorganic Chemistry, Bielefeld University,
Germany
RGD containing peptides can be used as potential drugs for the treatment
of osteoporosis, restenosis, ocular disease, and cancer [1]. Cyclic RGD
peptides based on the tripeptide sequence Arg-Gly-Asp (RGD) are well-
known to bind preferentially to the αVβ3 integrin and in particular have
been shown to exhibit improved affinity, receptor selectivity, and enzy-
matic stability relative to their parent linear peptides. Recently labeling
RGD-peptides with a variety of fluorescent probes have been reported for
imaging [2, 3]. A series of phenothiazine derivatives with carboxylic acid
and boronic acid substituents was produced and introduced in the RGD
peptide coupled to the enzymatically synthesized 7-Br tryptophan (W(7-
Br)) [4], using solid phase peptide synthesis (SPPS). Successively, a new
on resin Suzuki cross-coupling procedure was developed and allowed to
obtain new fluorescent RGD cyclopeptides, presenting an absorption max-
ima at 303 nm and an emission maxima at 460 nm. The investigation of
the cyclopeptide structure by NMR spectroscopy demonstrated the axial
diastereoselection of the cyclization. The affinity of the cyclopeptides to
bind with αvβ3 integrin was evaluated by Enzyme-Linked Immunosor-
bent Assay (ELISA) [5]. This assay showed a relatively good activity only
for the cyclopeptide containing oxidized form of phenothiazine (IC50=52
nM). In conclusion, we developed a new method that allows to modulate
the inhibitory activity and the fluorescent property of RGD cyclopeptides,
by using various synthesized phenothiazin and 7-Bromo tryptophan.
Acknowledgments: This work was supported by Alexander von Humboldt
foundation Reference [1] Dayam, R.; Aiello, F.; Deng, J.; Wu, Y.; Garo-
falo, A.; Chen, X.; Neamati, N. J. Med. Chem. 2006, 49, 4526–4534.
[2] Götzinger, A.C.; Michaelis, C. S.; Müller, T. J. J. Dyes and pigments,
2017, 143, 308-316. [3] Belei, D.; Dumea, C.; Samson, A.; Farce, A.;
Dubois, J.; Bîcu, E.; Ghinet, A. Bioorg. Med. Chem. Lett. 2012, 22,
4517-4522. [4] Frese, M.; Sewald, N. Angew. Chem. Int. Ed. 2015, 54,
298-301. [5] Kapp, T, G.; Rechenmacher, F.; Neubauer, S.; Maltsev, O. V.;
Cavalcanti-Adam, E. A.; Zarka, R. Sci. Rep. 2017, 7, 39805.
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A Photolabile Backbone Amide Linker for the
Synthesis of Cyclic and C-terminal Modified Peptides
Mark Lipton1, Matthew Hostetler1, Soo Sung Kang2
1Purdue University, United States
2Ewha Womans University, South Korea
Photolabile linkers provide an alternative to the classic acidic or basic
cleavage protocols used in solid phase organic synthesis. The backbone
amide linker (BAL) approach involves a solid-phase linker for providing
free C- and N-termini of a resin-bound peptide by anchoring the resin to
the amide backbone of a peptide. Traditional BAL, an acid labile linker,
is not orthogonal with any acid sensitive functional groups, which makes
application to multi-dimensional solid phase synthesis difficult. Here our
efforts focus on the developmnent of a photolabile BAL (pBAL), whereby
the synthesized peptide is released only by UV irradiation, therefore per-
mitting the general compatibility to the attachment and detachment of
amino acids as well as tolerance of diverse functional groups. Initially, p-
oxyphenacyl (Op), alpha-Methyl-p-oxyphenacyl (Mop), alpha,o-Dimethyl
phenacyl (Dmp), alpha-Phenyl-p-oxyphenacyl (Pop), and 6-nitroveratryl
(Nve) functional groups were screened, and o-nitrobenzyl such as Nve was
found to be the most efficient functional group at the photolytic release of
the backbone amide. To improve the efficiency of loading amino acids
to the linker, a hydroxy group was added to the other ortho position of
the o-nitrobenzyl group. A carboxylate was added to the para position of
the 2-hydroxy-6-ntrobenzyl group to provide a resin attachment point as
well as an additional electron withdrawing group to increase photoreactiv-
ity and tramsamidation. Finally, the 2-hydroxy-4-carbonyl-6-nitrobenzyl
(Hcnb) linker was chosen as the optimal pBAL motif. Its reactivity was
tested with more than eight amino acids in solution with respect to am-
ination, amidation, and photolysis. The synthesis of several cyclic and
C-terminally modified peptides will be discussed.
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Total chemical synthesis of hyper-phosphorylated p53
Transactivation Domain
Aromal Asokan, Abhishek Baral, Vladimir Torbeev
Institut de Science et d’Ingénierie Supramoléculaires, Université de
Strasbourg, France
Chemical synthesis is a systematic tool for the creation of protein
molecules with desirable characteristics as it allows enormous variations
in the covalent structure resulting in protein molecules with precisely in-
troduced site-specific modifications (1). Our goal is to develop novel and
efficient chemical methods for the synthesis of post-translationally modi-
fied protein molecules. In this study, we chose the 61 residue N-terminal
transactivation domain (TAD) of the human tumour suppressor p53, which
contains a total of 9 phosphorylation sites (2). Phosphorylation along with
acetylation, acts as a switch between the degradation and activation of the
p53 (3). We devised one-pot, three fragment sequential ligation strategy
towards the synthesis of the full length hyper-phosphorylated TAD. The
fragments were synthesized using Fmoc-SPPS and the phospho residues
were incorporated using building block approach. Through our strategy,
we demonstrated the synthesis of the hyper-phosphorylated TAD contain-
ing 9 phosphorylations. Future directions include the optimization and
development of efficient ligation strategies towards the synthesis of the
combinatorial library of p53 TAD variants.
References 1. Chuh KN, Batt AR, Pratt MR., Cell Chem Biol. 2016; 23(1):
86–107 2. Lisa M. Miller Jenkins Stewart R. Durell Sharlyn J. Mazur Et-
tore Appella., Carcinogenesis. 2012; 33(8): 1441–1449. 3. Ferreon JC1,
Lee CW, Arai M, Martinez-Yamout MA, Dyson HJ, Wright PE., Proc Natl
Acad Sci U S A. 2009;106(16):6591-6
P26
Enhancing Affinity of RGD Peptides by Incorporation
of Bromotryptophan obtained by Enzymatic
Halogenation
Isabell Kemker, Norbert Sewald
Universität Bielefeld, Germany
Halogenases are a powerful tool to incorporate halogens (Br, Cl) into
indol derivatives as tryptophan under mild reaction conditions requir-
ing only oxygen and halide salts. Enzymatic halogenation has recently
emerged as a method to introduce halogen substituents that are known to in-
crease biological activity in natural products.[1-2] For preparative synthe-
sis of halotryptophans immobilization by cross-linked enzyme aggregates
(CLEAs) gave higher enzyme stability and allowed gram scale synthesis
of 7-bromotryptophan.[3] This lead us to apply this method for introduc-
ing bromotryptophan residues into RGD peptides to increase their biolog-
ical activity. The lead structure c(RGDwV) is derived from Cilengitide,
c(RGDf(NMe)V), and displays similar low nanomolar affinities to differ-
ent integrins (αvβ3: 1.6 nM, α5β1: 9.2 nM).[4] The affinity to αvβ3 (0.4
nM) is increased fourfold by incorporating D-Trp(7Br) and a superior se-
lectivity against α5β1 (6112 nM) is observed. We elaborated our approach
to synthesize a library of RGD derivatives containing different halogens (F
,Cl,Br,I) in different positions using halogenases and tryptophan synthase.
P27
Combining Synthetic Biology and Synthetic
Chemistry to Dial in to New to Nature Peptidic Natural
Products in vitro and in vivo
Christopher Cartmell, Sunil V. Sharma, Tong Xiaoxue,
Cristina Pubill-Ulldemolins, Emma Bogosyan, Emma J.
Rackham, Enrico Morelli, Michael Corr, Rebecca J. M.
Goss
University of St Andrews, School of Chemistry, St Andrews, KY16 9ST,
United Kingdom
Peptidic natural products and peptide-polyketide hybrid natural products
play a central role in medicine, key examples include daptomycin, a drug
used to treat skin and skin structure infections1 as well as vancomycin2, a
last resort antibiotic. The GenoChemetic approach that we are developing
affords access to diverse series of natural product analogues. One approach
that we have been employing, within the GenoChemetics framework, is the
utilization of halogenation and cross-coupling, in concert, to enable C-H
activation. This poster focuses on applying this strategy to the peptidic nat-
ural product pacidamycin4. GenoChemetics involves the introduction of
a gene into the natural product generating host. This gene acts in concert
with the existing biosynthetic pathway, installing a chemically orthogonal
handle. By developing mild chemistries and compatible fermentation me-
dia we can selectively carry out chemical diversification in the presence of
the living cultures. For example we have constructed a bacterial host that
can produce bromopacidamycin and have developed air and water tolerant
Suzuki-Miyaura chemistry for its diversification in vivo. This exciting new
approach draws flux through the system, enables labeling and tagging for
tracking and purification and could potentially enable the production and
testing of antibiotics in 1 step.
References 1. R. L. Nichols., Journal of Antimicrobial Chemotherapy.,
1999, 19-23 2. C. Liu, A. Bayer et al., Clinical Infection Diseases., 2011,
52, 285-292 3. M. Corr, S. V. Shama, C. Cartmell, R. J. M. Goss et al.,
Chem. Sci., 2017, 8, 2039-2046
P28a
Quality Peptide Versus Speed: Conventional Synthesis
Versus Microwave
Hossain Saneii, Farshad Karimi, William Bennett, Mandar
Maduskar, Mostafa Hatam
AAPPTec, United States
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Purification of crude peptides is time consuming. Utilizing methods that
produce higher quality crude peptides can reduce the over-all production
time of pure peptides and reduce costs. We have compared conventional
synthesis with microwave synthesis for a number of peptides. In general,
conventional methodology takes 32% longer, but the higher quality crude
peptide reduces purification time by 200% to 500%.
P28b
Most Efficient Method For Synthesis and Purification
of Peptides
Hossain Saneii, Farshad Karimi, William Bennett, Mandar
Maduskar
AAPPTec, United States
Many peptides are produced and marketed by pharmaceutical companies
and the number is growing. In addition, peptides are utilized in increasing
quantities in cosmetics, the food industry and other applications. Current
methods for synthesis and purification of peptides are slow and costly. The
increasing demand for large quantities of high purity peptides makes the
development of fast, low cost, highly efficient methods of synthesizing and
purifying peptides essential. We disclose a most efficient method of puri-
fying peptides. By this method, the majority of impurities are extracted
from the crude peptide before final purification. As a result, purification
is accelerated and costs are reduced to approximately one seventh of stan-
dard HPLC purification costs. A further advantage of our method is that
highly hydrophobic peptides with poor solubility can be purified readily.
Additionally, because the extraction and HPLC processes rely on different
methods of purification, our method can resolve impurities that overlap or
co-elute with the desired peptide product in HPLC.
P29
Studies on the Regeneration of Aged DMF for Use in
Solid-Phase Peptide Synthesis
Fintan Kelleher1, Marc Devocelle2, Jordan Kevin Magtaan1
1ITT Dublin, Ireland
2Royal College of Surgeons in Ireland, Ireland
Peptide therapeutics have immense commercial value that is estimated
to reach $46.6 billion USD by 2024 (Al Musaimi et al. 2018).
Fluorenylmethyloxycarbonyl-based solid-phase peptide synthesis (Fmoc-
SPPS) is one of the main techniques used for the synthesis of peptides,
with dimethylformamide (DMF) as one of the most widely used solvents.
However, it has long been known that DMF is not stable over time and
degrades to dimethylamine (DMA) which can remove the Fmoc protect-
ing group (van Regenmortel et al. 1988). The initial loading (mmol/g)
has been identified as a critical parameter in SPPS since its magnitude
ultimately dictates the maximum possible yield of a synthesised peptide
(Forns & Fields 2000). Photometry-based resin loadings typically involve
the quantification of dibenzofulvene-piperidine adduct which is formed
during Fmoc removal with piperidine in DMF (Eissler et al. 2017). Signif-
icant amounts of DMA in aged DMF can lead to unwanted Fmoc removal
and ultimately, inaccurate loading measurements.
During our studies, we treated aged DMF to reduce DMA content and
compared the initial resin loading between treated aged DMF and newer
DMF samples. Within the last decade, several research groups have pro-
posed possible greener alternative solvents, which do not have the issue of
DMA contamination, for SPPS (Kumar et al. 2018). For comparison, the
loading values when using greener solvents for the initial loading step of
SPPS, were also determined. Our studies show that the use of aged DMF
can lead to a significant reduction in initial resin loading and the use of
treated aged DMF can improve the measured loading. Our results thus far
on the comparative initial loading measurements, when using aged DMF,
treated aged DMF and greener solvent systems, will be presented.
P30
Solid-phase Synthesis of Tyrosine Cyclic
DepsiPeptides from Fmoc-MeDbz-resin
Gerardo Acosta Crespo1, Laura Maria Murray2, Shimaa
A.H. Adbel Monaim3, Miriam Royo1, Ayman El-Faham4,
Beatriz G. de la Torre5, Fernando Albericio6
1CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and
Nanomedicine, Barcelona Science Park, Spain
2Dublin Institute of Technology, Ireland
3Catalysis and Peptide Research Unit, School of Health Sciences,
University of KwaZulu-Natal, Durban 4001, South Africa
4Chemistry Department, Faculty of Science, Alexandria University, P.O.
Box 426, Ibrahimia, Alexandria 12321, Egypt
5KRISP, College of Health Sciences, University of KwaZulu-Natal,
Westville, Durban 4001, South Africa
6Barcelona, Spain & Chemistry Deparment, University of
KwaZulu-Natal, South Africa
Desipeptides are peptides that, within their structure, at least one of the
amide links has been replaced with ester, thioester or amide links with
molecules that are not amino acids. In general, they are cyclic compounds
that are found as natural products in different living organisms of marine
origin amongst others. They present themselves with a wide spectrum of
biological activity, they have reported that depsipeptides act as enzyme in-
hibitors that are used as anti-tumour agents such as Romidepsin1 (FK228);
antiviral properties such as Neamphamide2 and antibacterial or antibiotic
properties such as Etamycin3 amongst others. In this work we studied the
conditions to obtain cyclic depsipeptides from Tyrosine in solid phase us-
ing the MeDbz-resin that permitted after activation, in a single step, the
formation of the ester and the cleavage from the resin.
1.-J. Med. Chem. 2007, 50, 5720-5726; 2.- J. Org. Chem. 2005, 70,
6842-6847; 3.- J. Antibiotics, 2010, 63, 219–224
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Fluorogen-based amino acids with
Aggregation-Induced Emission features for bioprobes
design
Mathieu Arribat1, Emmanuelle Rémond1, Sébastien
Richeter2, Philippe Gerbier2, Sébastien Clément2,
Florine Cavelier1
1IBMM, France
2ICGM, France
Fluorescently labelled peptides are widely used as tool for molecular imag-
ing to provide biological information on living systems. However, most
of the conventional organic fluorophores used for such purpose aggregate
when dispersed in aqueous media.1 This aggregation generally implies a
self-quenching and thus, a drastic decrease of the fluorescence (“turn-off”)
which is a thorny problem for developing efficient bioprobes. At the op-
posite, luminophores such as tetraphenylethylene (TPE) and silole deriva-
tives with unique aggregation-induced emission (AIE) features have been
reported.2 These dyes are found to be non-emissive when molecularly dis-
solved but highly emissive when aggregated, which is due to a restriction
of the intramolecular rotations (RIR) in these dyes, a well-known source
of nonradiative deactivation. Unlike conventional organic fluorophores,
they also exhibit higher photobleaching resistance.3 Among the AIEgens,4
siloles exhibit great light emission and are used for preparation of organic
light-emitting diodes and optoelectronic devices. The silole core is a di-
enic five membered ring containing a silicon atom. The low-lying of the
LUMO favoured interaction between the σ* and the pi*, conferring fast
electron mobility and remarkable fluorescent properties to silole moiety.5
Hence, the unusual fluorescence and higher photostability of siloles make
them excellent candidates to develop a new class of fluorescently labelled
peptides.
Based on our previous work on silylated amino acids,6,7 we describe here
the synthesis of the first silole-based amino acids and their corresponding
fluorescent properties. After selective deprotection of carboxylic or amine
functions, C- or N- peptide coupling with alanine proved their possible
incorporation into peptides. The synthesis of a model tripeptide was also
achieved by SPPS with the N-Fmoc protected silole amino acid derivative.
As expected, such silole amino acids and peptides exhibit AIE properties
with λem around 500 nm and large Stokes shift (∆λ 100 nm) offering
new opportunities to design AIE fluorogens-peptides conjugates.
[1] J. B. Birks , Photophysics of Aromatic Molecules , Wiley , London
1970. [2] Tang, B.; Zhan, X.; Yu, G.; Lee, P.; Liu, Y.; Zhu, D. J. Mater.
Chem, 2001, 11, 2974-2978. [3] Ding, D.; Li, K.; Liu, B.; Tang, B. Z.
Acc. Chem. Res. 2013, 46, 2441. [4] Mei, J.; Legung N.; Kwok, R.; La,
J.; Tang, B. Chem. Rev., 2015, 115, 11718. [5] Zhao, Z; He, B.; Tang,
B. Chem. Sci. 2015, 6, 5347. [6] Marchand, D.; Martinez, J. ; Cavelier,
F., EurJOC, 2008, 3107. [7] Fanelli, R.; Berthomieu, D.; Didierjean, C.;
Doudouh, A.; Lebrun, A.; Martinez, J. ; Cavelier, F. Org. Lett., 2017, 19,
2937.
P32
Stabilization of Secondary Structures by
Cross-Coupling Reactions
Hendrik Gruß, Norbert Sewald
Organic and Bioorganic Chemistry, Department of Chemistry, Bielefeld
University, Germany
Protein-protein interactions (PPi) related to signal transduction are in-
volved in many biological processes. Hence, dysregulated PPi’s are re-
sponsible for the origin of many diseases such as cancer, infections or
neurological disorders. In particular, peptides as potential therapeutics
are very promising due to their high selectivity. However, small peptides
often suffer from low conformational stability and stability against prote-
olytic digestion as well as poor membrane permeability. In contrast, cyclic
peptides have a more constrained conformation resulting in better binding
affinities to their target and moreover, cyclization improves the stability
against proteases.[1] The cyclization can be performed by backbone or
side chain to side chain connection. For side chain to side chain crosslinks,
reactions such as ring closure metathesis,[2] cycloadditions,[3] lactam-,[4]
disulfide-[5] and thioether-formation[6] are described and can be used for
stabilization of secondary structures such as α-helices or β -sheets. The
availability of C5-, C6- and C7 regioisomers of bromotryptophan on a
preparative scale using FAD-dependent tryptophan halogenases gave rise
to utilize Pd-catalyzed cross-couplings for stabilization of secondary struc-
tures by side chain to side chain connection.[7] A main advantage of Pd-
catalyzed bioorthogonal reactions is the selective derivatization in presence
of a broad range of functional groups in biomolecules. The intramolecu-
lar SUZUKI-MIYAURA cross-coupling between bromotryptophan and a
suitable aryl boronic acid provides a promising tool for those crosslinks,
because it was shown to facilitate the derivatization of bromotryptophan
and bromotryptophan containing peptides and natural products.[8] More-
over, other cross coupling reactions such as MIZOROKI-HECK reaction
are investigated as suitable approaches.
References [1] Craik et al., Chem. Biol. Drug Des. 2013, 81, 136–147
[2] a) Schafmeister et al., J. Am. Chem. Soc. 2000, 122, 5891–5892, b)
Blackwell et al., Angew. Chem. Int. Ed. 1998, 37, 3281–3284 [3] a)
Scrima et al., Eur. J. Org. Chem. 2010, 2010, 446–457, b) Hanold et al.,
PloS one, 2015, 10, e0118796 [4] Felix et al., Int. J. Pept. Protein Res.
1988, 32, 441–454 [5] a) Jackson et al., J. Am. Chem. Soc. 1991, 113,
9391–9392, b) Toyama et al., Bioorg. Med. Chem 2016, 24, 3406–3412
[6] Brunel et al., Chem. Commun. 2005, 2552–2554 [7] a) Frese et al.,
Angew. Chem. Int. Ed. 2015, 54, 298–301, b) Frese et al., ChemCatChem,
2016, 8, 1799–1803 [8] Willemse et al., Catalysts 2017, 7, 74
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Synthesis of A-ring Analogues of the Bioactive
Peptide Nisin
Agnieszka Wadolowska, Fintan Kelleher
Institute of Technology Tallaght, Ireland
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Significant numbers of bacteriocins have recently been discovered with
high potential for use as human therapeutic agents [1]. Nisin, the most
common lantibiotic, which has a polycyclic structure consists of 34 amino
acids, is currently used worldwide as a food preservative in dairy, meat
and tinned food products. It is a potent antimicrobial agent against Gram-
positive bacteria and contains unusual amino acids like dehydroalanine
(Dha) and dehydrobutyrine (Dhb) within its structure [2]. An interesting
feature of many lantibiotics, from very diverse sources, is the similarity of
their A and B ring fragments (Figure 1). They contain the same number
of amino acid residues, with the Dha and (methyl)lanthionine (thioether
links) residues present in all the structures. The major difference between
the various A-rings is the amino acids residues flanking the Dha moiety.
The strategy towards the synthesis of different analogues of the A-ring of
nisin, and other type A lantibiotics, will be presented.
References 1 P. Singelton, Bacteria in Biology, Biotechnology and
Medicine, 6th Ed., Wiley, New York, 1995, 139-142. 2 C. Chatterjee, M.
Paul, L. Xie, W. van der Donk, Chem. Rev., 2005, 105, 633–684.
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Synthesis of different lengths of highly monodisperse
cholesteryl-PEGn-peptide conjugates
Edgar Cristóbal-Lecina1, Daniel Pulido1, Pau
Martin-Malpartida2, Maria Macias2, Fernando Albericio3,
Miriam Royo1
1Centro de Investigación Biomédica en Red (CIBER-BBN), Spain
2Institute for Research in Biomedicine, Spain
3Chemistry Department, University of KwaZulu-Natal South África &
Barcelona, Spain
Cholesterol (Chol) is an essential component of eukaryotic cell plasma
membrane and has multiple functions regulating fluidity and permeability
of the membrane structure. In lipid-based nanovesicles (L-NVs) such as
liposomes, Chol is used as a key component stabilizing these nanostruc-
tures, reducing the permeability of encapsulated drugs, and enhancing li-
posome drug loading.1 In this sense, cholesteryl-polyethylenglycol (Chol-
PEG) conjugates are usually employed as stabilizing anchors for liposomes
favouring the increase of their circulation time.2 Chol-PEG conjugates also
behave as solubilizing surfactants which serve to prevent aggregation of
vesicles. In this sense, the use of monodisperse PEGs (M-PEGs) has a bur-
geoning interest in therapeutic delivery systems due to the well stablished
correlation between erratic biological activities and polydispersity. This
issue can originate a range of problems in their applications in regulatory
phases. Herein, we describe the synthesis of highly monodisperse Chol-
PEGn derivatives (n=200-1000) by iterative introduction of macrocyclic
tetraethylenglycolsulphate.3 As a proof of concept, we have conjugated a
cyclic (RGDfK) peptide, a well known integrin ligand, to all these Chol-
PEGn moieties with good yields and excellent purities (up to 99%). The
versatility of this platform has been demonstrated by chemoselective lig-
ation of other peptides to Chol-PEGn maleimide derivatives. All these
Chol-PEGn-peptide conjugates can be achieved with good yields, high pu-
rity and showing highly monodispersity.
References 1) I. Cabrera et al. Nano Lett. 2013, 13, 3766-3774. 2) I.
Cabrera et al. Adv. Healtcare Mater. 2016, 5, 829-840. 3) H. Zhang et al.
Angew. Chem. Int. Ed. 2015, 54, 3763-3767.
Acknowledgements This study was funded by the Spanish government
(RTC-2014-2207-1), CIBER-BBN (Lipocell, CB06-01-0074) and Euro-
pean Community (Smart4Fabry).
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Design and Synthesis of a µ-KIIIA Conotoxin
Peptidomimetic that Blocks Human Nav1.6
Laura McDougall
University of Glasgow, United Kingdom
The conotoxins are a family of naturally occurring peptides which are used
as defensive and offensive neurotoxic agents by predators, such as the cone
snail. These disulfide containing mini-proteins act by blocking ion chan-
nels and disrupting normal cell membrane potentials. Selective inhibition
of ion channels has the potential to treat conditions such as epilepsy and
chronic pain. Previous studies into these compounds have elucidated the
active region of the peptide which is important for activity and have re-
placed the disulfide networks with other covalent constraints which are
more stable and synthetically accessible. 1
Physical constraints for peptide backbones have been well studied with
a variety of strategies employed. Hydrocarbon staples have undergone
significant investigation due to the relative ease of incorporating alkene
bearing amino acids and performing a ring closing metathesis reaction.
A unique and emerging chemical constraint is a diyne bridge formed by
a Glaser coupling of two unnatural amino acids bearing terminal alkyne
groups. This strategy produces no cis/trans isomers, gives a more rigid
cross bridge and has the potential for label free imaging using Raman spec-
troscopy. 2,3
This work focuses on the asymmetric synthesis of alkyne bearing amino
acids and investigation of Glaser coupling conditions for intramolecular
diyne formation. Electrophysiological data using a patch clamp assay
showed it to be a good inhibitor of human Nav1.6.
References
1. R. S. Norton, Expert Opin. Drug Discov., 2017, 12, 611–623. 2. C. E.
Schafmeister et al., J. Am. Chem. Soc., 2000, 122, 5891–5892. 3. P. A.
Cistrone et al., ChemBioChem, 2018, 19, 1031-1035.
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High-throughput parallel synthesis optimization of
Glucagon-like Peptide 1 receptor agonists
Cyf Ramos-Colon1, Andrew Kennedy2, Daniel Martinez1,
James Cain1
1Gyros Protein Technologies, United States
2Gyros Protein Technologies, United Kingdom
Type 2 diabetes represents a major health burden, with over 400 million pa-
tients worldwide [1]. Glucagon-like Peptide 1 (GLP-1) agonists are an im-
portant treatment for the management of Type 2 Diabetes. GLP-1 agonists
improve glycemic control through multiple mechanisms with a low risk
of hypoglycemia [2]. Type 2 diabetes is usually coupled with obesity and
thus molecules targeting both GLP-1 receptor, mediating food intake sup-
pression and the glucagon receptor, which modulates energy expenditure,
are of great interest and some have progressed into the clinic1. Many SAR
studies have been completed on GLP-1 related peptides in the search for
stability and increased target affinity, with improvement via modifications
such as peptide cyclizations and the attachment of PEG-based monomers.
These peptides have been prepared by fragment synthesis and solution
phase condensation in order to reduce impurities and maximize yields for
pharmaceutical manufacturing. Recently, dual GLP-1/glucagon receptor
peptide agonists have been described by Evers et al.[1] Here we show the
synthesis optimization in parallel of GLP-1 related peptides and dual GLP-
1/glucagon receptor agonists, testing multiple resins and coupling reagents
searching for optimal crude purity that may translate into ease of purifica-
tion during the manufacturing process.
References: [1] Evers, A. et al. Dual Glucagon-like Peptide 1 (GLP-
1)/Glucagon Receptor Agonists Specifically Optimized for Multidose For-
mulations. J. Med. Chem. 1, (2018). [2] Kalra, S. et al. Glucagon-
like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past,
present, and future. Indian J. Endocrinol. Metab. 20, 254–67 (2016).
P37
Synthesis of an HIV-targeted stapled peptide: Fully
automated on-resin peptide cyclization via olefin
metathesis
James Cain1, Daniel Martinez1, Andrew Kennedy2, Cyf
Ramos-Colon1
1Gyros Protein Technologies, United States
2Gyros Protein Technologies, United Kingdom
Cyclic peptides are an important tool for development of peptide therapeu-
tics. Their increased rigidity allows for increased membrane permeability
and increased stability to proteases, two major drawbacks of peptide drug
development. Peptide cyclization can be achieved several ways, includ-
ing head-to-tail cyclizations or side chain-to-side chain cyclizations, which
can be done by lactam bridge formation, disulfide bonds or hydrocarbon
stapling via olefin metathesis, to name a few. Hydrocarbon stapling sta-
bilizes a-helical structures and thus increases cell permeability and stabil-
ity. Other advantages of stapled peptides include the targeting of protein-
protein interactions, important for targeting many disease states such as
cancer. Zhang et al. have described the synthesis and properties of an i,
i+4 stapled peptide, NYAD-1, which targets the capsid and inhibits HIV-1
in cell culture [1]. Here we show the fully automated synthesis, from linear,
on-resin cyclization, and resin cleavage, of NYAD-1 and other examples.
Reference:
[1] Zhang, H. et al. Dual-acting stapled peptides target both HIV-1 entry
and assembly. Retrovirology 10, 1–20 (2013).
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Non-natural Amino Acid and Peptoid Building Blocks
for Optimization of the Cell-Penetrating (R-X-R)n
Motif
Anita Wester, Fredrik Björkling, Peter Nieslen, Henrik
Franzyk
University of Copenhagen, Denmark
Facilitating efficient cell membrane permeability is a crucial step in un-
locking the therapeutic potential of drug candidates that are otherwise lim-
ited by poor inherent cellular uptake. Cell-penetrating peptides (CPPs)
are short peptides that most often are cationic in nature, which confers a
propensity to enable efficient intracellular delivery of a variety of cargo
molecules (e.g. other peptides) across the cell membrane. CPPs contain-
ing the (R-X-R)n motif have proved to be among the most effective in
facilitating membrane penetration.
Herein, we report the optimized synthesis of a number of non-natural
amino acid and peptoid building blocks that are ideally suited for the syn-
thesis of analogues of the (R-X-R)n motif. The cationic character of typ-
ical CPPs is resulting from the presence of both Lys and Arg residues.
However, especially the guanidino functionality of the arginine residues
has been found to be crucial for the cell-penetrating properties of highly
cationic CPPs. The ideal presentation of guanidinium groups as well as
an optimal ratio of hydrophobic-hydrophilic character was shown to be
critical for the modulation of their activity. Incorporation of the described
non-natural amino acid building blocks allows for the synthesis of a va-
riety of analogues aiming at optimization of the hydrophobic-hydrophilic
components and the spacing between guanidinium groups, which both are
expected to influence the cellular uptake properties. Furthermore, incorpo-
ration of related peptoid building blocks is expected to increase proteolytic
stability of the resulting analogues.
All building blocks can be synthesized and purified in large scale, and
they are compatible with use in microwave-assisted automated solid-phase-
peptide synthesis (SPPS). They can be used efficiently with standard cou-
pling protocols and the resulting peptides are obtained in very high purity.
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Disulphide cyclization of somatostatin and its
analogues with selected oxidizing agents
Damian Neubauer, Natalia Cie˛z˙ka, Wojciech Kamysz
Medical University of Gdan´sk, Poland
Somatostatin is a peptide hormone produced by hypothalamus, thyroid,
placenta, and mucous membranes of the stomach and small intestine. It
is a cyclic peptide with a disulphide bridge that occurs in two forms, the
14- and 28-amino acid residue long. Somatostatin regulates the endocrine
system and affects neurotransmission and cell proliferation. Moreover, it
inhibits the secretion of growth hormone (GH), serotonin, insulin, and
glucagon. Radiolabelled analogues of somatostatin can be used to local-
ize scintigraphically neuroendocrine tumours on account of the increase in
expression of somatostatin receptors on tumour cells. Hence, it seemed ex-
pedient to obtain a peptide analogue, octreotide with extended biological
half-life, conjugated with a chelator (hydrazinonicotinic acid - HYNIC). A
co-ligand and a radionuclide are added to the peptide before use. The aim
of this study was to examine the potential of selected oxidizing agents in
intramolecular disulphide bridge formation.
Somatostatin and octreotide analogues – HYNIC-TOC and HYNIC-TATE,
were obtained by manual synthesis on solid support using Fmoc/tBu strat-
egy. Coupling reactions were carried out for 1.5 h in DMF and DCM mix-
ture using a fourfold excess of substrates (Fmoc-AA : DIC : Oxyma Pure,
1:1:1, mol/mol) based on the resin. Deprotection step was accomplished
with a 20% piperidine in DMF for 15 min. The peptides were cleaved form
the resin in TFA and a scavengers mixture (TFA : EDT : TIS : water : phe-
nol, 90:2.5:2.5:2.5:2.5, v/v) for 1 h. Iodine, ozone, and CLEAR-OX™ (a
polymer-supported oxidant) were examined as oxidizing agents in peptide
cyclization. Oxidation was performed in peptide solution (1 mg/mL) in
20% acetic acid in water. To monitor the progress of oxidation reaction the
Ellman test and LC-MS analyses were performed.
In this study we determined the efficiency of different oxidizing agents. At
early stages of oxidation, the cyclized peptide was identified in all sam-
ples. However, ozone rapidly degraded the desired product. On the other
hand, iodine provided an efficient and fast oxidation. It was found to be
an appropriate agent for cyclization of somatostatin, but HYNIC-TOC and
HYNIC-TATE were degraded. Only CLEAR-OX™, as a mild oxidant,
did not degrade the peptides. Nonetheless, one of the weaknesses of the
procedure is that CLEAR-OX™ requires a relatively long time (2 h) to
cyclize the peptides. Air appears to be the most universal oxidizing agent.
However, after two days of oxidation there was still a few percent of free
sulphydryl groups left in the samples.
Acknowledgements This study was supported by the statutory found from
Medical University of Gdansk (Project No. ST-02-0087/07/508).
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Evaluation of the ”ResPep continuous flow synthesizer”
with real-time UV-monitoring, automated feedback &
heating in solid phase peptide synthesis
Felix Niethammer, Daniel Maisch, Marcus Rothe
INTAVIS Bioanalytical Instruments AG, Germany
Automation in assembly of peptides via solid phase synthesis following
the Fmoc-strategy [1] is a well-established method and commonly used for
peptide synthesis today. Mostly due to length of the peptide, the presence
of hydrophobic stretches and sterically hindered amino acids, difficulties
during peptide synthesis are sequence inherent. Therefore, the choice of
the proper conditions like coupling reagent and temperature have tremen-
dous influence on the stepwise amide bond formation yielding the crude
product in the highest purity possible. Here, we present examples of au-
tomated peptide syntheses of so called “difficult sequences” [2], [3] us-
ing different coupling reagents and varying temperature on the new Re-
sPep continuous flow synthesizer with real-time UV monitoring and feed-
back. Four classes of coupling reagents were applied: triazine-, uronium-,
phosphonium- and carbodiimide-based reagents were used in solid phase
peptide synthesis. The results were discussed and compared in terms of
quality of the crude product, coupling efficiency, costs and cycle times.
[1] Atherton, E.; Sheppard, R.C., Solid phase peptide synthesis: a practical
approach, Oxford, England: IRL Press , (1989) [2] Redemann, T., Jung, G.,
Peptides 1996. Proceedings of the 24th European Peptide Symposium, Ra-
mage, R., Epton, R., Eds., Mayflower Scientific Ltd: Kingswinford, UK,
749 (1998) [3] Carpino, L. A., Krause, E., Sferdean, C. D., Schümann, M.,
Fabian, H., Bienert, M., Beyermann, M., Tet. Lett., 45, 7519 (2004)
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A simple method for raising the temperature in manual
peptide synthesis
Wojciech Kamysz, Damian Neubauer
Medical University of Gdan´sk, Poland
Methods for obtaining synthetic peptides have undergone only a few
changes over many years. Chemists do not like to modify synthesis pro-
tocols. This involves the need to change reagents and re-training employ-
ees. With the emergence of the Fmoc methodology, peptides have been
obtained in the same way for over 30 years. After the success of mi-
crowave devices, many synthesizer manufacturers return to heating tech-
niques in peptide synthesizers. The present research shows how to easily
implement heating to the manual synthesis without the need to use water-
heated vessels. Synthesis of three model peptides were performed using
two reference methods (either the classic synthesis at room temperature or
automatic synthesis on a microwave synthesizer) and two classic methods
with dry heating blocks. The classic experiments were performed using
the device Skiller 1 (heating block with a magnetic stirrer) and in the lab-
oratory heating clamp. The syntheses with the heating block were carried
out in a glass vessel enabling thermostatting with air (the Kamysz vessel).
Synthesis with Skiller 1 and heating clamp was performed at 60°C. The
reference syntheses were carried out either at room temperature (classic
synthesis) or following the synthesizer protocol. All peptides were synthe-
sized using the Wang resin and a threefold excess of reagents (Fmoc-AA :
DIC : OxymaPure, 1:1:1, mol/mol) dissolved in DMF based on the resin.
Coupling was carried out for 2 h in the classic method and for 15 min
when heated. Deprotection was performed with a 20% piperidine in DMF
for 2 and 10 min in the classic method and for 2×2 min when heated. The
peptides were cleaved form the resin in TFA and a scavengers mixture
(TFA : TIS : water : phenol, 94:2:2:2, v/v) for 1 h. The quantity of the
crude peptides was determined and their purity was tested by HPLC. The
resins used in the experiment were examined independently for their me-
chanical degradation. The results clearly indicate that the heating in dry
heating blocks is an effective method to accelerate peptide synthesis. This
approach does not require specialized equipment and the temperature used
(60°C) is not dangerous for the user. At the same time, it was found that
the synthesis of long peptides using a magnetic stirrer is either not recom-
mendable (although possible) or demand the use of mechanically resistant
resin (TentaGel type).
Acknowledgements This study was supported by the statutory found from
Medical University of Gdansk (Project No. 02-0087/07/508).
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Peptide Production from mg to Kg with Automation
and Microwave Assisted Heating
Keith A. Porter, Jonathan M. Collins, Sandeep K. Singh,
Michael Karney
CEM, United States
Peptide therapeutics are an attractive alternative to their small molecule
drug counterparts [1]. With several high revenue peptide drugs on the mar-
ket and a pipeline full of potential candidates [2], the demand for highly
robust and efficient synthetic methods is of great importance. Microwave
assisted SPPS has established itself as the primary chemical method to pro-
duce high quality peptides while drastically reducing synthesis time and
waste [3]. This poster will highlight new R&D and technology which en-
compasses GMP peptide production from mg to Kg scale. On the R&D
scale, our research team has developed a standardized methodology for
synthesis of varied peptides, providing a powerful tool that simplifies pep-
tide therapeutic research. To validate this comprehensive strategy that uti-
lizes microwave (MW) heating and rapid automation, a variety peptides
from current literature were linearly synthesized. Key features of this
methodology include:
- Improved carbodiimide coupling which increases purity and suppresses
side reactions such as epimerization - One-pot coupling and deprotection
process for increased efficiency - Reduction of up to 95% generated waste
compared to conventional methods
Rapid scale-up for clinical trials and peptide production has been accom-
plished using similar technology with a focus on elevated temperatures.
Crude purity from R&D to production scale is preserved if not improved
and unwanted side reactions such as epimerization and aspartimide forma-
tion are easily controlled. The result, easier purification and reduced labor
cost. Cycle times at the production scale range from 10 – 60 min with the
capability to produce up to 1 KG crude peptide in a single batch. Several
examples, including process development, will be presented.
[1] D. J. Craik, D. P. Fairlie, S. Liras, D. Price, Chem Biol Drug Des 81,
136 (2013). [2] K. Fosgerau, T. Hoffman, Drug Discov Today 20, 122
(2015). [3] J. M. Collins, K. A. Porter, S. K. Singh, G. S. Vanier, Org. Lett.
16, 940 (2014).
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Microwave-Assisted Synthesis of Symmetrically and
Unsymmetrically Branched Peptides
Isaiah Gober, Sandeep K. Singh, Jonathan M. Collins,
Michael Karney
CEM, United States
Branched peptides represent a class of peptides with highly desirable
physio-chemical and biological properties. For example, peptides with
symmetrically branched cores such as multiple antigenic peptides (MAPs)
or peptide dendrimers have been shown to have increased biological ac-
tivity compared to their linear counterparts due to multivalent binding to
a protein target or due to an improved resistance to proteases.1 On the
other hand, unsymmetrical branching allows for the synthesis of chimeric
peptides that contain different peptide sequences in a single structure. As
a result of their useful properties, branched peptides have found use in a
variety of applications including the development of antimicrobial and an-
tiviral drugs2–4, tumor-targeting agents5,6, drug delivery vehicles7, and
other novel applications8,9.
Synthesis of branched peptides via SPPS is often challenging because of
the inherent close proximity of the elongating peptide chains on a branched
scaffold, which leads to steric clashes and poor peptide coupling. Here we
report on the application of microwave-assisted SPPS to the synthesis of
branched peptides. Microwave energy helps overcome steric challenges,
allowing for more efficient coupling and the rapid synthesis of difficult
branched peptides with fewer deletion products.
(1) Falciani, C.; Lozzi, L.; Pini, A.; Corti, F.; Fabbrini, M.; Bernini, A.;
Lelli, B.; Niccolai, N.; Bracci, L. Chem. Biol. Drug Des. 2007, 69 (3),
216–221. (2) Haney, E. F.; Nazmi, K.; Bolscher, J. G. M.; Vogel, H. J.
Biochim. Biophys. Acta - Biomembr. 2012, 1818 (3), 762–775. (3) Liu,
S. P.; Zhou, L.; Lakshminarayanan, R.; Beuerman, R. W. Int. J. Pept. Res.
Ther. 2010, 16 (3), 199–213. (4) Wynn, J. E.; Santos, W. L. Org. Biomol.
Chem. 2015, 13 (21), 5848–5858. (5) Falciani, C.; Pini, A.; Bracci, L. Ex-
pert Opin. Biol. Ther. 2009, 9 (2), 171–178. (6) Minervini, A.; Siena, G.;
Falciani, C.; Carini, M.; Bracci, L. Expert Rev. Anticancer Ther. 2012, 12
(6), 699–701. (7) Brunetti, J.; Pillozzi, S.; Falciani, C.; Depau, L.; Tenori,
E.; Scali, S.; Lozzi, L.; Pini, A.; Arcangeli, A.; Menichetti, S.; Bracci, L.
Sci. Rep. 2015, 5, 17736. (8) Haj-Yahya, M.; Eltarteer, N.; Ohayon, S.;
Shema, E.; Kotler, E.; Oren, M.; Brik, A. Angew. Chemie Int. Ed. 2012,
51 (46), 11535–11539. (9) Vera-Bravo, R.; Scotter, A. J.; Davies, P. L.;
Blanco, L. H. Rev. Colomb. Química 2012, 41 (1), 133–157.
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Automated Synthesis of Cyclic Disulfide-Bridged
Peptides
Isaiah Gober, Sandeep K. Singh, Jonathan M. Collins
CEM, United States
Cyclic peptides containing disulfides represent a class of compounds with
a profound array of biological functions ranging from venoms to integral
hormones(1). The disulfide bonds help stabilize the secondary structure
and conformation of peptides, which can contribute favorably to prote-
olytic stability and target affinity(2). Because of their promising therapeu-
tic potential, interest in the synthesis of cyclic disulfide-bridged peptides
has grown steadily. Peptides with disulfide bridges can be prepared by
SPPS by using orthogonally-protected cysteine amino acids such as Fmoc-
(S)-Cys(Mmt)-OH and Fmoc-(S)-Cys(STmp)-OH. The Cys(Mmt) group
can be deprotected using a dilute solution of trifluoroacetic acid (TFA),
whereas the Cys(STmp) group is orthogonally deprotected using dithio-
threitol (DTT) as a reducing agent. After deprotection, disulfide bond
formation can be achieved using N-chlorosuccinimide (NCS) as a mild
oxidant(3).
Here, we report that cyclic disulfide-bridged peptides can be prepared
rapidly with good purity using automated microwave-enhanced SPPS. Syn-
thesis of the peptide hormone oxytocin4 was achieved in under 3 h with
69% purity. Preparation of a peptide agonist of BMP receptor activin-like
kinase 3 (Alk3), THR-1235, was completed in 3 h with 77% purity. Fi-
nally, a peptide venom from cone snails containing two disulfide bridges
(conotoxin-SI)6 was synthesized in under 4 h with 67% purity.
(1) Góngora-Benítez, M.; Tulla-Puche, J.; Albericio, F. Chem. Rev. 2014,
114 (2), 901–926. (2) Adessi, C.; Soto, C. Curr. Med. Chem. 2002, 9
(9), 963–978. (3) Postma, T. M.; Albericio, F. Org. Lett. 2013, 15 (3),
616–619. (4) Lee, H.-J.; Macbeth, A. H.; Pagani, J. H.; Young, W. S.; 3rd.
Prog. Neurobiol. 2009, 88 (2), 127–151. (5) Sugimoto, H.; LeBleu, V. S.;
Bosukonda, D.; Keck, P.; Taduri, G.; Bechtel, W.; Okada, H.; Carlson, W.;
Bey, P.; Rusckowski, M.; Tampe, B.; Tampe, D.; Kanasaki, K.; Zeisberg,
M.; Kalluri, R.; Kalluri, R. Nat. Med. 2012, 18 (3), 396–404. (6) Azam,
L.; McIntosh, J. M. Acta Pharmacol. Sin. 2009, 30 (6), 771–783.
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3-Substituted isocyanopyridines as mildly convertible
isocyanides
Mathias Elsocht1, Karlijn Hollanders1, Olivier Van der
Poorten1, Mouhamad Jida2, Bert Maes3, Steven Ballet1
1Vrije Universiteit Brussel, Belgium
2University of Strasbourg, France
3Universiteit Antwerpen, Belgium
A powerful tool to generate peptidomimetics are multicomponent
reactions, such as the Ugi reaction, often combined with post-
condensation modifications. An Ugi reaction typically gives an α-
acylaminocarboxamide that has a dipeptide like structure. The down-
side of the Ugi reaction is the formation of a stable amide bond at the
C-terminus of the product, which cannot be cleaved under mild reaction
conditions. This limitation can be circumvented by the use of convert-
ible isocyanides that allow the chemoselective transformation of this amide
bond.[1] Throughout the years, different convertible isocyanides have been
developed all with their advantages and restrictions such as low stabil-
ity, cleavage requires acidic or basic conditions or a multistep procedure.
There is, however, still a need for efficient convertible isocyanides that
can easily be cleaved under neutral conditions. With this in mind, we set
out to develop a convertible isocyanide that can be cleaved using a Zn-
catalyzed nicotinate-directed transamidation. Hence, the synthesis of dif-
ferent 3-substituted-2-isocyanopyridines was pursued. To compare their
efficiency towards the amide cleavage, all isocyanides were subjected to
the Ugi-4C conditions. These Ugi products were in turn used in the zinc
catalyzed transamidation reaction. It was demonstrated that the 3-methyl
ester generates the most labile amide bond, followed by the bromo and
chloro directing groups, which resulted in comparable conversions, while
the least labile amide is obtained for the methoxy substituted directing
group. Nevertheless, the amide bond at the C-terminus was easily and
selectively cleaved in all cases.
References [1]. van de Heijden et al. Org Lett 2016, 18, 984-7.
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Strategies toward optimizing automated on-resin
disulfide bond formation in disulfide rich peptides
Elizabeth Denton1, Amit Mehrotra2, Cédric Rentier3
1Biotage, United States
2Biotage, Sweden
3Biotage, Japan
Disulfide rich peptides exhibit exquisite stability due to the covalent stabi-
lization of their secondary structure mediated by disulfide bonds. While
many of these compounds already display bioactivity, they have also
demonstrated a unique plasticity when alternative sequences are grafted
into various loop regions. After a particular sequence has been identified,
these peptides are often folded in solution under redox conditions, assum-
ing that the thermodynamically stable conformation will be the predom-
inant species. However, there are many scenarios that multiple disulfide
bonding patterns are observed upon folding completion, demanding addi-
tional purification and characterization before any biological assays can
be performed. A simplified on-resin synthesis strategy is attractive as the
purification and characterization steps can be minimized, if not completely
eliminated, increasing the overall yield of the peptide with the proper disul-
fide bond pattern. Herein we describe a fully automated, optimized solid
phase synthesis of apamin, an 18 amino acid peptide conformationally
constrained by two disulfide bonds. Using Branches™, the synthesis and
on-resin disulfide bond formation was readily visualized and programmed,
simplifying the total synthesis and ensuring that the proper disulfide bond
pattern was achieved.
P47
Synthesis and characterization of new Hemorphin-5
analogues containing azobenzene units with potential
optical switching properties
Petar Todorov, Petia Peneva, Stela Georgieva-Kiskinova,
Anton Georgiev
University of Chemical Technology and Metallurgy, Sofia, 1756,
blvd.Kliment Ohridski 8, Bulgaria
The development of agents to control bio macromolecular function with
light offers the potential to change the properties of defined molecules in bi-
ological systems with minimal disturbance to the rest of the system. Photo-
dynamic control of peptides, proteins or drugs provides a non-invasive way
to disorder these networks to investigate their effect or cause a defined out-
come. Azobenzene containing peptides could be acting as photoswitches
that interconvert between E and Z isomers around –N=N– group offer
highly predictable light state structural properties. These molecules are
relatively small and adopt predictable conformations they are well suited
as tools to interrogate cellular function in a spatially and temporally con-
trolled fashion and for applications in photopharmacology and nanotech-
nology. In order to elucidate the influence of azobenzene-peptides we intro-
duced the different substitution azobenzenes to the N-side of Hemorphin-
5 peptide analogues. This report refers to the solid-phase synthesis and
characterization of novel azobenzene containing Hemorphin-5 analogues.
Hemorphin-5, also known as Valorphin, is a naturally occurring, endoge-
nous opioid peptide of the Hemorphin family with affinity for opioid re-
ceptors and morphinomimetic properties. These neuropeptides are increas-
ingly being used in the treatment of various diseases such as hypertension,
epilepsy, chronic pain, cancer, and etc. The synthesis and characterization
of a photochromic compound, in which Valorphin analogues are linked
through their N-terminal amino group by an azobenzene units, are reported.
The synthesis was achieved by a modified solid-phase peptide synthesis
by Fmoc-strategy, based on the reaction between different substitution
azobenzenes with N-terminal amino group of heptapeptide Hemorphin-5
(Val-Val-Tyr-Pro-Trp-Thr-Gln) directly to the resin. The crude neuropep-
tides were purified on an RP-HPLC and the molecular weights were deter-
mined, using ES-MS, and also determining of the specific angles of optical
rotation and photoisomerization.
Acknowledgment: This work was financial supported by the Bulgarian
National Scientific Fund project 18/5 of the Ministry of Education and
Science, Bulgaria.
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A preparation of isopeptide mimetics by the peptide
ligation using a thiirane linker
Toru Kawakami, Yuichi Mishima, Hironobu Hojo, Isao
Suetake
Osaka University, Japan
The site specific modification of proteins such as post-translational mod-
ification (PTM) and fluorescence labeling is important for studies of pro-
tein functions. Histone proteins form an octamer as a core of the nucleo-
some, which is a basic unit of chromatin and which consists of two copies
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of each four different core histones, H2A, H2B, H3, and H4 with DNA.
The PTMs of histones, such as acetylation, methylation, phosphorylation,
and so on, play an important role in the epigenetic regulation of gene ex-
pression. We previously reported on the preparation of histones H3 and
H4 containing a trimethylated Lys residue [1,2]. Ubiquitination is also
one of important PTMs, in which the C-terminus of ubiquitin (Ub), a 76
amino acid residue peptide, is attached to the side-chain amino group of
Lys residues by an isopeptide bond. Histone H3 was reported to be ubiqui-
tinated at Lys18 or 23 to regulate maintenance DNA methylation by DNA
methyltransferases [3]. Here we report on a convenient method for prepar-
ing an isopeptide-mimetic structure, in which thiiran-2-ylmethanamine (2-
aminomethylthiirane) is used as a linker for peptide ligation [4]. Using this
procedure the ubiquitinated histone H3 was prepared [5].
[1] T. Kawakami, Y. Akai, H. Fujimoto, C. Kita, Y. Aoki, T. Konishi, M.
Waseda, L. Takemura, S. Aimoto, Bull. Chem. Soc. Jpn. 2013, 86, 690-
697. [2] T. Kawakami, R. Yoshikawa, Y. Fujiyoshi, Y. Mishima, H. Hojo,
S. Tajima, I. Suetake, J. Biochem. 2015, 158, 403-411. [3] S. Ishiyama, A.
Nishiyama, Y. Saeki, K. Moritsugu, D. Morimoto, L. Yamaguchi, N. Arai,
R. Matsumura, T. Kawakami, Y. Mishima, H.; Hojo, S. Shimamura, F.
Ishikawa, S. Tajima, K. Tanaka, M. Ariyoshi, M. Shirakawa, M. Ikeguchi,
A. Kidera, I. Suetake, K. Arita, M. Nakanishi, Mol. Cell 2017, 68, 350-
360. [4] T. Kawakami, Y. Mishima, M. Kinoshita, Y.-H. Lee, I. Suetake,
Tetrahedron Lett. 2016, 57, 2112-2115. [5] T. Kawakami, Y. Mishima, H.
Hojo, I. Suetake, I., J. Pept. Sci. 2017, 23, 532-538.
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Synthesis of Homogeneously Glycosylated Soluble
Fas Ligand Variants
Alanca Schmid1, Claudia Bello2, Christian F.W. Becker1
1University of Vienna, Department of Chemistry, Institute of Biological
Chemistry, Austria
2University of Florence, Department of Chemistry, Fiorentino, Italy
Glycosylation is one of the most abundant and complex posttranslational
modifications of proteins. Since its alteration is frequently observed in
many pathogenic conditions [1-3], it is crucial to be able to investigate the
impact of individual glycan structures at specific positions in proteins and
access to homogeneously glycosylated protein variants is urgently needed
[4]. To obtain such homogeneously N-glycosylated variants of soluble Fas
ligand (sFasL), an important player in cancer proliferation, a chemoenzy-
matic approach was chosen. The protein will be assembled from three
segments, each of them synthesized by Solid Phase Peptide Synthesis
(SPPS), using Native Chemical Ligation (NCL). The C-terminal peptide,
containing two native N-glycosylation sites, will be equipped with an N-
terminal selencocysteine for NCL and subsequent selective deselenisation
and a polyethyleneglycol (PEG) chain attached to a tobacco etch virus
(TEV) protease cleavage site to facilitate peptide purification between cy-
cles of enzymatic carbohydrate chain elongation [5]. After the incorpora-
tion of asparagine-N-acetyl-glucosamine building blocks by SPPS at the
sites of N-glycosylation, glycan extension is achieved by using glycosi-
dases/glycosynthases and a homogeneous, activated N-glycan core struc-
ture isolated from egg yolk [6]. Subsequent elongation with suitable gly-
cosyltransferases increases the number of accessible glycopeptide variants
[7]. These glycopeptide variants will be linked to the larger N-terminal
segment, which in turn is synthesized from two smaller SPPS fragments
by NCL. In this way, several N-glycan variants of soluble Fas ligand will
be obtained and subjected to further chemical and biological investigation.
Here, the latest results on the synthesis of all three peptide segments and
different ligation reactions will be presented.
1. Ferris, S.P., et al., Dis Model Mech, 2014, 7 (3): 331-41. 2. Ohtsubo, K.
and Marth, J.D., Cell, 2006, 126 (5): 855-67. 3. Stowell, S.R., et al., Annu
Rev Pathol, 2015, 10: 473-510. 4. Kajihara, Y., Murakami, M., Unverzagt,
C., Chemical Glycoprotein Synthesis. In Glycochemical Synthesis (eds S.
Hung and M. M. Zulueta), 2006. 5. Bello, C., et al., Chem. Sci., 2014, 5:
1634–1641. 6. Seko, A. et al., Biochimica et Biophysica Acta, 1995, 1335:
23–32. 7. Gamblin, D.P., et al, Chem. Rev., 2009, 109 (1): 31–163
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Pd-catalyzed cysteine modification of peptides and
proteins
Julia Kriegesmann1, Thomas Schlatzer2, Rolf Breinbauer2,
Christian F.W. Becker1
1University of Vienna, Faculty of Chemistry, Institute of Biological
Chemistry, Währinger Str. 38, 1090 Vienna, Austria
2Graz University of Technology, Institute of Organic Chemistry,
Stremayrgasse 9, 8010 Graz, Austria
Posttranslational modifications such as phosphorylation, acylation and lip-
idation play an important role for the control of protein function and lo-
calization. Among these, prenylation is especially important for the asso-
ciation of certain proteins to specific membranes.[1] The current knowl-
edge about the physiological function of many of these proteins is mostly
based on the use of prenylated peptides that are linked to a target protein
by chemoselective modification reactions in order to obtain prenylated
protein variants. For these semisynthetic approaches especially proteins
where almost all lipidations occur within the last C-terminal amino acids
are well suited. As the attachment of lipid chains to C terminal peptides
occurs mostly via thioethers and thioesters, chemistry not easily compati-
ble with standard Fmoc-based solid phase peptide synthesis and cleavage
conditions, complex synthesis strategies were developed.[1,2] Another ap-
proach to prepare protein variants with either natural or synthetically mod-
ified residues is the use of chemical protein modification. This allows to
decide which modification should be attached to which residue in order to
create proteins with the desired properties such as natural posttranslational
modifications, fluorophores or reactive tags.[3] But the synthesis of chemi-
cally modified proteins still represents an important challenge due to prob-
lems with selectivity, reaction conditions and yield.[3,4] Here we show ini-
tial experiments that support our hypothesis that Pd-catalyzed Tsuji-Trost-
allylation can be used for the prenylation of Cys-containing peptides and
proteins, thereby allowing direct access to prenylated peptides and proteins
with high n/iso ratio and excellent chemoselectivity. Furthermore, peptides
with other modifications such as a fluorophore and an affinity tag can be
synthesized.
[1] L. Brunsveld, J. Kuhlmann, K. Alexandrov, A. Wittinghofer, R. S.
Goody, H. Waldmann, Angew. Chem. Int. Ed. 2006, 45, 6622–6646.
[2] B. Ludolph, H. Waldmann, Chem. Eur. J. 2003, 9, 3683–3691. [3] O.
Boutureira, G. J. L. Bernardes, Chem. Rev. 2015, 115, 2174-2195. [4] J.
M. Chalker, G. J. L. Bernardes, Y. A. Lin, B. G. Davis, Chem. Asian J.
2009, 4, 630-640.
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Accessing semisynthetic Hsp27 carrying site-specific
non-enzymatic post-translational modification
implicated in disease
Somnath Mukherjee1, Maria Matveenko2, Christian F.W.
Becker1
1Institute of Biological Chemistry, University of Vienna, Austria
2Life Science Editors, Australia
Non-enzymatic posttranslational modifications (nPTMs) are believed to af-
fect at least 30% of human proteins, many of which are implicated in var-
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ious pathological conditions e.g. cataract, diabetes, neurodegenerative dis-
eases and cancer. A general lack of structural information of many of such
nPTM target proteins coupled with the difficulty in pin-pointing the site of
such modifications impede further studies and development of therapeutics
against such modifications. Since most of these nPTMs are not included
in the available chemical libraries or protein expression systems, semi-
synthesis remains to be the only feasible way to access such proteins carry-
ing site-specific and homogeneous modifications. Methylglyoxal (MG), a
reactive electrophilic species formed during glycolysis is known to modify
proteins at amino acids carrying nucleophilic side chains (e.g Arg, Lys etc).
One of such modifications, argpyrimidine (Apy) has been detected in hu-
man small heat shock protein Hsp27 (HSPB1) in various tissues of patients
suffering from pathological conditions, such as hyperglycemia, cataract
and cancer. Although, there are as many as 16 arginines in this 205-amino
acid long protein susceptible to Apy modification, previous studies based
on mutating arginines in Hsp27 to glycine residues followed by expres-
sion in HEK-293 cells and subsequent immunoblot analyses, revealed that
only mutation at Arg188 leads to loss of recognition by an anti-Apy anti-
body. This particular point mutation also results in partial dissociation of
the usual higher order oligomeric structure of Hsp27 to lower order ones,
accompanied with a loss of chaperone activity, as we have previously ob-
served with a semisynthetic Hsp27 analogue carrying an R188Apy mu-
tation. We were interested to understand the impact of such individual
point mutations of arginine residues to Apy, precisely, how it influences
the quaternary structure and thus associated functions of Hsp27. Herein,
we present a study combining semisyntheses and biophysical as well as bio-
chemical assays on Hsp27 analogues with single point Apy mutations at
five different arginine sites (R4, R5, R12, R20, R27) within the N-terminal
domain of Hsp27.
P52
Deciphering the interplay role of phosphorylation and
glycosylation on the aggregation of tau proteins by
using semi-synthesis
Wenyi Li1, Kristina Siebertz2, Caroline Smet-Nocca3,
Christian Hackenberger2
1Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP),
Germany
2Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP),
Humboldt-Universität zu Berlin, Institut für Chemie, Germany
3Université de Lille 1, UMR8576 CNRS, France
The tau protein is a major target in Alzheimer disease (AD) research, since
it was found to be the main component of insoluble, aggregated neurofib-
rillary tangles (NFTs) in the brains of AD patients [1]. It was observed
that phosphorylation and glycosylation played an important role during tau
aggregation process, where the pattern of modification suggests that some
motifs are unique to the disease [2]. Among these are the post-translational
modifications (PTMs) on the AT-8 epitope within the proline-rich domain
[3] and on the PHF-1 epitope in the microtubulin-binding domain [4], both
of which are recognised by several disease-relevant antibodies [5] and are
consequently of high interest for tau aggregation studies. While biochem-
ical methods, like pseudo-phosphorylation and enzymatic modifications,
are valuable tools to evaluate the effect of these motifs on the structure
and function of tau, none of them can produce homogeneously modified,
natural protein.
By utilising native chemical ligation (NCL) [6] and expressed protein lig-
ation (EPL) [7], Haj-Yahya and Lashuel have recently demonstrated the
preparation of full-length native tau[8]. Currently, we aim to produce
homogeneously PTM tau proteins bearing phosphorylation and glycosyla-
tion, both of which were already successfully applied in the semi-synthesis
of tau fragments and proteins [9,10]. In this study, we will present our re-
cent efforts to obtain new tau constructs and show the potential interplays
between phosphorylation and glycosylation on the aggregation of tau pro-
tein.
[1] L. Matin et al. Neurochem. Int. 2011, 58, 458. [2] S. Yuzwa et al. Nat
Chem Biol. 2012, 8, 393 [3] K. C. Walls et al. Neurosci. Lett. 2014, 575,
96. [4] L. Otvos Jr et al. J. Neurosci. Res. 1994, 39, 669. [5] L. Amniai
et al. FASEB J. 2009, 23, 1146. [6] P. E. Dawson et al. Science 1994,
266, 776. [7] T. W. Muir et al. PNAS 1998, 95, 6705. [8] Haj-Yahya et al.
JACS, 2018, in press [9] M. Broncel et al. Chem. Eur. J. 2012, 18, 2488.
[10] O. Reimann et al. Angew. Chem. Int. Ed. 2015, 54, 306.
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cysteine-independent native chemical ligation and
chemoenzymatic modification
Maximilian Schrems1, Christian F.W. Becker1, Claudia
Bello2
1University of Vienna, Department of Chemistry, Institute of Biological
Chemistry, Vienna, Austria
2University of Florence, Department of Chemistry “Ugo Schiff”,
Fiorentino, Italy
From expanding the spectrum of biological and chemical tools for the
synthesis of complex modified proteins, various fields of research would
greatly benefit. Semisynthesis in combination with auxiliary-mediated na-
tive chemical ligation methods present an incredibly valuable tool for this
purpose. [1] A recently developed PEGylated auxiliary by Bello et. al. ex-
ploits the advantages of ligation auxiliaries and adds functionality by intro-
ducing a polyethylene glycol (PEG) polymer to its scaffold. Thereby, the
fast and quantitative recovery following repeating rounds of enzymatic gly-
cosylation of a glycopeptide was possible. [2] Here we present a synthesis
route for a new generation of this ligation auxiliary. Its modified structure
enables investigation of alternative coupling strategies, with the prospect
of expansion of the auxiliary’s versatility beyond glycine residues. Further-
more, a straightforward and short synthesis scheme improves its applicabil-
ity and allows us to extend its usage in semisynthesis and chemoenzymatic
modification reactions of peptides. We were able to couple this newly gen-
erated auxiliary to a peptide N-terminus by Mitsunobu-Fukuyama alkyla-
tion, via the newly introduced hydroxyl moiety. The conditions employed
are mild, in agreement with standard Fmoc peptide chemistry and tolerate
the presence of O-linked N-acetylgalactosamine. In combination with the
general strategy of a PEGylated photocleavable auxiliary, this revisited ap-
proach should enable further expansion of its application to previously not
accessible ligation sites.
[1] S. S. Kulkarni, J. Sayers, B. Premdjee and R. J. Payne, Nat. Rev. Chem.
2018, 2, 0122. [2] a) C. Bello and C. F. W. Becker, Biorg. Med. Chem.
2017, 25, 5016-5021; b) C. Bello, S. Wang, L. Meng, K. W. Moremen and
C. F. W. Becker, Angew. Chem. Int. Ed. 2015, 54, 1-6.
P54
Chemical synthesis of transactivation domain (TAD)
of tumor suppressor protein p53
Abhishek Baral1, Aromal Asokan1, Valentin Bauer1, Bruno
Kieffer2, Vladimir Torbeev1
1Institut de Science et d’Ingénierie Supramoléculaires, Université de
Strasbourg, France
2Institut de Genetique et de Biologie Moleculaire et Cellulaire (IGBMC),
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Abstract: Intrinsically disordered proteins (IDPs) have evolved as a key
structural component of functional proteins in the last decade in the midst
of traditional fixed 3D protein structure.1 The intrinsic disorder enables
flexibility in the protein which helps it to attain different conformations for
interacting with distinct biomolecules subject to different biological con-
ditions and functions. The tumor suppressor protein p53, whose incorrect
behavior is responsible for many cancers,2 possesses an intrinsically disor-
dered transactivation domain (TAD) in its N-terminus.3 Chemical synthe-
sis of this full-length TAD, rarely reported in the literature, is extremely
important to address the questions of the role of the combinations of post-
translational modifications (PTMs) in p53 function as most PTM sites of
the full-length p53 are located in this domain.4,5 To achieve this, a de-
tailed synthetic procedure for preparation of TAD p53 is presented in this
work based on the combination of Fmoc/tBu-solid phase peptide synthesis
(SPPS) and native chemical ligation (NCL). Both the C-to-N and N-to-C
one-pot three-segment strategies were applied and three different thioesters
of the middle segment (PEP2) were used for the N-to-C native chemical
ligation during the synthesis and their comparative yields are presented.6,7
The chemically synthesized negatively charged TAD interacts with a pos-
itively charged nuclear receptor coactivator binding domain (NCBD) of
CREB-binding protein as clearly visible from the NMR and CD experi-
ments which are in concurrence with the previous reports.4,5
References 1. H. J. Dyson and P. E. Wright, Nat. Rev., 2005, 6, 197-2008.
2. M. Olivier, M. Hollstein and P. Hainaut, Cold Spring Harb Perspect
Biol, 2010, 2, a001008. 3. J. C. Ferreon, C. W. Lee, M. Arai, M. A.
Martinez-Yamout, H. J. Dyson and P. E. Wright, Proc. Natl. Acad. Sci.
USA, 2009, 106, 6591-6596. 4. D. P. Teufel, M. Bycroft and A. R. Fersht,
Oncogene, 2009, 28, 2112-2118. 5. M. Wells, H. Tidow, T. J. Rutherford,
P. Markwick, M. R. Jensen, E. Mylonas, D. I. Svergun, M. Blackledge and
A. R. Fersht, Proc. Natl. Acad. Sci. USA, 2008, 105, 5762-5767. 6. J.-S.
Zheng, S. Tang, Y.-K. Qi, Z.-P. Wang and L. Liu, Nat. Protoc., 2013, 8,
2483-2495. 7. J. B. Blanco-Canosa, B. Nardone, F. Albericio and P. E.
Dawson, J. Am. Chem. Soc., 2015, 137, 7197-7209.
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Calibration of analytical HPLC to generate preparative
LC gradients for peptide purification
Jack Silver
Teledyne ISCO, United States
Preparative LC (liquid chromatography) is widely used to purify synthe-
sized peptides. One bottleneck in the purification process is method devel-
opment. Significant time can be required to produce an efficient prepara-
tive purification method that resolves the desired peptide from impurities
and minimizes both time and solvent usage. This work describes a simple
method of calibrating analytical HPLC systems to match the preparative
LC system using the existing scouting gradients typically employed by a
research group. After the calibration is complete, the determined delay vol-
ume is applied to the scouting gradient. This delay volume encompasses
any dwell volumes, column volumes, mixing volumes, solvent mispropor-
tioning, and other corrections that are needed to match the analytical sys-
tem to the preparative system. After the calibration is complete, the user
only needs to enter the retention time of the desired compound from the
analytical HPLC scouting run to calculate a preparative method. Although
the calculated gradient is designed to run over 12 minutes with targeted
peptides eluting at 6 minutes, other gradient lengths may be run.
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Development of a strategic and quantitative route for
the chemical synthesis of membrane-associated
proteins
Lena Steinacker, Andreas Baumruck, Alesia Tietze
TU Darmstadt, Germany
Membrane proteins are vitally important for cells providing communica-
tion between outer and inner compartment, the transfer of ions, small
molecules and the transduction of stimuli.[1] These numerous compe-
tences make them a suspenseful drug target leading to an increased demand
on models for fundamental as well as individual research. Membrane pro-
teins are embedded and integrated into a lipid bilayer, thus displaying a
highly hydrophobic behavior. This feature consequently leads to difficul-
ties in handling not only the protein itself during experiments and recrystal-
lization but also during synthesis, that being either expression or chemical
synthesis. The synthetic production of membrane proteins features many
benefits. These involve obtaining amounts of product in the milligram
range which can further be used for structural analysis as well as the abil-
ity to rather easily insert mutations, isotopic labels and other desired post-
translational modifications. To obtain the demanded membrane protein,
solid phase peptide synthesis (SPPS) reaches its limit with the elongation
of the peptide sequence. To date the synthetic production of sequences of
membrane-associated proteins containing more than 50 – 60 amino acids
are still a great challenge. Native chemical ligation (NCL) is the method
of choice whereupon at least two fragments are needed, one displaying a
N-terminal cysteine and the other a C-terminal thioester.[2] Modern-day
research focuses on the C-terminal part with the integration of rearrange-
ment groups which generate thioesters during NCL through O- to S or N-
to S-acyl shifts. This approach represents the basis for our research on the
Hmp (2-hydroxy-3-mercaptopropionic acid) rearrangement group.[3] Us-
ing this building block to evade difficulties that come along with thioester-
groups and integrating solubilizing tags that facilitate handling as well as
solubility, NCL of several membrane proteins was successful leading to the
development of unique strategies given from the requirements of different
membrane protein sequences. Herein we present the synthesis of the struc-
turally unsolved part of the M2 proton channel from influenza B virus as
well as results towards the smallest known viral potassium channel.
[1] A. Engel and H. E. Gaub, Annu Rev Biochem 2008, 77, 127-148. [2] L.
Raibaut, N. Ollivier and O. Melnyk, Chem Soc Rev 2012, 41, 7001-7015.
[3] F. Liu and J. P. Mayer, J Org Chem 2013, 78, 9848-9856.
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Second generation N-2-hydroxybenzyl-cysteine
peptide crypto-thioesters for native chemical ligation
Mehdi Amoura1, Victor Terrier1, Agnès Delmas2,
Vincent Aucagne3
1Centre de Biophysique Moléculaire, CNRS UPR 4301, Orléans, France
2CNRS, France
3CNRS Center for Molecular Biophysics, France
Recent advances in Fmoc-based solid phase synthesis of peptide α-
thioesters for the convergent synthesis of proteins via native chemical lig-
ation (NCL) significantly contributed to push up the boundaries of the
field. In particular, promising beta-mercapto amide-based thioesterifica-
tion devices have emerged. If most systems require an acid catalysis, a
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few of them can undergo an N → S acyl shift under NCL conditions
(neutral pH): peptide bearing such devices are called crypto-thioesters.1
We recently reported an N-(2-hydroxy-4-nitrobenzyl)cysteine-based de-
vice (N-Hnb-Cys),2-5 which allows routine automated synthesis of crypto-
thioesters from inexpensive building blocks. Conveniently, no post-SPPS
steps are required, and these thioester surrogates are perfectly stable to
handling, storage and purification. This strategy is thus easily and readily
usable by non-specialists. We illustrated the potential of this methodol-
ogy for the synthesis of long,2,3,5 cyclic4 and N-terminal Cys-containing3
disulfide-rich peptides. To assess the scope and limitations of the method,
we undertook systematic kinetic studies that showed that NCL reactions
using N-Hnb-Cys-based crypto-thioesters are only 4-to-5 fold slower than
those using a benchmark preformed alkyl thioester. These relatively fast ki-
netics are thought to arise from a bio-inspired design, aimed at mimicking
intein-like intramolecular catalysis with a well-positioned phenol group.2
In order to rationally design further optimized second-generation devices,
we aimed at finely understand the molecular basis underlying the fast rear-
rangement. These efforts gratifyingly led to a promising second generation
device with a 2 fold increase of the NCL kinetics.
[1] T. Kawakami, S. Aimoto, Chem. Lett., 2007, 36, 76–77; (b) S. Tsuda,
A. Shigenaga, K. Bando, A. Otaka, Org. Lett., 2009, 11, 823–826; (c) N.
Ollivier, J. Dheur, R. Mhidia, A. Blanpain, O. Melnyk, Org. Lett., 2010,
12, 5238–5241; (d) W. Hou, X. Zhang, F. Li, C.-F. Liu, Org. Lett., 2011,
13, 386–389; (e) F. Burlina, G. Papageorgiou, C. Morris, P. D. White, J. Of-
fer, Chem. Sci., 2014, 5, 766–770; (f) Y. Asahina, K. Nabeshima, H. Hojo,
Tetrahedron Lett., 2015, 56, 1370–1373; (g) S. Tsuda, M. Mochizuki, K.
Sakamoto, M. Denda, H. Nishio, A. Otaka, T. Yoshiya, Org. Lett., 2016,
18, 5940–5943; (h) M. Eto, N. Naruse, K. Morimoto, K. Yamaoka, K.
Sato, K. Tsuji, T. Inokuma, A. Shigenaga, A. Otaka, Org. Lett., 2016, 18,
4416–4419. [2] V. P. Terrier, H. Adihou, M. Arnould, A. F. Delmas, V.
Aucagne, Chem. Sci., 2016, 7, 339–345. [3] D. Lelièvre, V. P. Terrier, A.
F. Delmas, V. Aucagne, Org. Lett., 2016, 18, 920–923. [4] V. P. Terrier, A.
F. Delmas, V. Aucagne, Org. Biomol. Chem. 2017, 15, 316–319. [5] G.
Martinez et al. Mol. Hum. Rep., 2017, 23,116–131.
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Gold-Titania Nanocatalyst Generated by
Mineralization Using Two Artificial Peptides with
DNA
Makoto Ozaki1, Kin-Ya Tomizaki2, Yoshio Hamada1, Kenji
Usui1
1Faculty of Frontiers of Innovative Research in Science and Technology
(FIRST), Konan University, Japan
2Department of Materials Chemistry, Ryukoku University, Japan
Organic-inorganic hybrid nanostructures[1] could be used in diverse appli-
cations in nanotechnology, nanoelectronics and biotechnology. However,
their production method by general top-down and bottom-up strategies is
unsatisfactory. Biomineralization (precipitation of inorganic compounds)
in a biological system is one of the most powerful approaches for over-
coming this problem. However, inorganic compounds formed by mineral-
ization precipitate randomly in solution. This system’s function is to cre-
ate inorganic compounds on organic compounds such as proteins and pep-
tides[2]. Therefore, the mineralization control at nanometer level is nec-
essary for the manufacture of functional organic-inorganic hybrid nanos-
tructures. Our previous study, we had developed a site-specific control of
an inorganic compound (silica) on DNA using an artificial peptide[3]. Fur-
thermore, we succeeded in a limited site-specific precipitation of multiple
inorganic compounds (silica and calcium carbonate) using a DNA and an
artificial peptide[4]. However, there were some problems of direct multiple
inorganic precipitation using one DNA and one peptide. 1) DNA can pre-
cipitate only a specific inorganic compounds with positive charge. 2) Di-
rect inorganic precipitation on DNA constructs only rod or fiber like nanos-
tructures. Therefore, by using template DNA and two precipitating pep-
tides corresponding to two inorganic compounds, we attempted to produce
more complicated organic-inorganic hybrid nanostructures as nanobuild-
ingblocks were built. In this study, focusing on construction of gold-titania
nanocatalyst with VIS light excitation, we demonstrated more complicated
site-specific precipitation control of gold and titania on DNA using two ar-
tificial peptides. At first, we performed micro-scale techniques such as
atomic force microscopy (AFM) and transmission electron microscopy-
energy dispersive X-ray microscopy (TEM-EDX) and macro-scale tech-
niques such as dynamic light scattering (DLS) and UV-VIS spectroscopy
for the nanocomposite. These results suggested that the site-specific pre-
cipitation of titania and gold on DNA was successfully achieved. Addi-
tionally, we evaluated their visible light excitation characteristic by UV-
VIS diffuse reflectance spectroscopy (UV-VIS DRS) and photocatalytic
activity under visible light irradiation using photodegradation reaction of
methylene blue (MB). As a result, the generated gold-titania nanocatalyst
had visible light excitation characteristic. Our method for site-specific pre-
cipitation thus represents a powerful and fundamental tool for use in nan-
otechnology.
Reference [1] J. Shi et al., Chem. Soc. Rev., 43, 5192-5210 (2014). [2] M.
B. Dickerson et al., Chem. Rev., 108, 4935-4978 (2008). [3] M. Ozaki et
al., Chem. Commun., 52, 4010-4013 (2016). [4] K. Usui et al., Nanoscale,
8, 17081-17084 (2016).
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Shin-Ichiro Yokota1, Yasumasa Mashimo2, Yoshio
Hamada1, Youji Harada3, Masayasu Mie2, Eiry Kobatake2,
Kenji Usui1
1Faculty of Frontiers of Innovative Research in Science and Technology
(FIRST), Konan University, Japan
2Department of Life Science and Technology, School of Life Science and
Technology, Japan
3Clean Chemical Co., Ltd, Japan
Amyloid fibril formed by aggregation of amyloid bata peptide (Aβ ) have
been involved Alzheimer’s disease [1]. The Aβ -nanomaterials studies
have been demonstrated because amyloid possesses high regularity of
molecular structure, thermodynamic stability and stiffness [2-4]. In ad-
dition, some studies showed that the morphologies in mixture of Aβ and
another peptide were changed from fibrils of Aβ . [5] Focusing on ap-
plication to cell culture substrate, we attempted to generate nanostructure
(digested Aβ s:dAβ s) composed of some Aβ fragments by protease diges-
tion of fibrils formed by aggregation of Aβ . Furthermore, we identified
Aβ fragments in dAβ s and synthesized these Aβ fragments. Finally, we
performed cell adhesion assay using these Aβ fragments to compare with
dAβ s. We first generated amyloid fibrils by aggregation of Aβ (1-40) and
performed digestion of the amyloid fibrils using three proteases (trypsin,
chymotrypsin and subtilisin). The results of TEM (transmission electron
microscopy) showed that the morphologies of dAβ s samples remarkably
were different from fibril structure of Aβ without digestion. We performed
cell adhesion assay using three dAβ s. The results showed that the number
of adhered cells in Tryp-dAβ s (Aβ digested by trypsin)-coating well is
larger than that in other dAβ s-coating wells. Then, we identified some Aβ
fragments in Tryp-dAβ s using HPLC and MALDI-TOF MS. The results
showed that Tryp-dAβ s included Aβ (17-28) and Aβ (6-40). Futhermore,
we synthesized identified Aβ fragments and performed monitoring by ThT
(Thioflavin-T) of aggregation using these Aβ fragments. The ThT moni-
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toring showed that Aβ (17-28) does not form amyloid-like nanostructure
as amyloid fibril. Finally, we demonstrated the cell adhesion assay using
these Aβ fragment samples. Wells with Tryp-dAβ s showed better cell
adhesion than wells with Aβ (17-28) or with Aβ (6-40). Throughout this
study, we successfully produced nanostructures (dAβ s) consisting of some
Aβ fragments and Tryp-dAβ s (mixture of Aβ fragments) was more useful
than Aβ fragment in cell culture substrate. Our method thus was indicated
as a powerful and fundamental tool for use in nanomaterials.
Reference [1] K. usui et al., Proc. Natl. Acad. Sci. USA., 106, 18563-
18568 (2009) [2] R. S. Jacob, et al., J. Biol. Chem., 291, 5278-5298 (2016).
[3] B. Dai, et al., Proc. Natl. Acad. Sci. USA., 112, 2996-3001 (2015).
[4] D. Li, et al., Proc. Natl. Acad. Sci. USA., 111, 191-196 (2014). [5] J.
Sato, et al., Chem. Eur. J., 13, 7745-7752. (2007).
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1University of Montpellier, France
2University of Lorraine, France
The development of organocatalysts, which are metal-free organic cata-
lysts, has shown a great potential in the last decade for various asymmetric
transformations such as aldol, Mannich and Michael reactions. [1] Asym-
metric aldol reaction provides chiral β -hydroxy carbonyl units and consti-
tutes one of the most important and useful carbon-carbon bond-forming re-
action. Among the various organocatalysts, bifunctional catalysts bearing
both free secondary amine and carboxylic acid functions that are involved
in the enamine activation and in the control of the geometrical position of
the reagents, are particularly relevant. In particular, short peptides lead to
efficient catalysts when both the amino and carboxylic acid functions are
correctly positioned, which makes the secondary structure of such peptides
an important characteristic. [2]
In the work presented here, a series of N-pyrrolidine-based α ,β -
peptide catalysts incorporating a constrained aminobicyclo[2.2.2]octane-
2-carboxylic acid (ABOC) residue were synthesized and evaluated in the
asymmetric aldol reaction from acetone and some p-substituted benzalde-
hydes. Their catalytic properties were shown to be highly dependent on
the amino acid sequences and on the absolute configuration of the ABOC
residue that played a determinant role. DFT calculations helped to ratio-
nalize this role. Among the peptides tested, the heterochiral tripeptide H-
Pro-(R)-ABOC-Asp-OCH3, that adopts a turn conformation in the solid
state, proved to be the most efficient catalyst affording β -hydroxy ketones
in high yields and good enantioselectivities (up to 87%). [3]
References: [1] Bertelsen, S.; Jørgensen, K. A., Chem. Soc. Rev. 2009,
38, 2178-2189; [2] Trost, B. M.; Brindle, C. S., Chem. Soc. Rev. 2010,
39, 1600-1632. [3] Milbeo, P.; Maurent, K.; Moulat, L.; Lebrun, A.; Di-
dierjean, C.; Aubert, E.; Martinez, J.; Calmès, M., Tetrahedron 2016, 72
(13), 1706-1715.
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scaffolds
Franziska Thomas
Georg-August-Universität Göttingen, Germany
De novo designed biomolecules have a tradition in being applied as mod-
els to mimic natural systems or to create new functional assemblies, which
work under physiological conditions. Among the explored protein folding
motifs the coiled coil is probably best understood, and designs for a variety
of coiled-coil assemblies are available.
We aim to use well-understood small self-assembling protein folding mo-
tifs as scaffolds to mediate chemical reactions. In this respect, the parallel
heterodimeric coiled coil is highly interesting. Due to its heterogeneity it
is not simply a dimerization tool but also provides control over the associa-
tion process. By now, the specificity of the interaction between the two coil
strands can be fine-tuned via the sequence pattern or chain lengths of the
individual coil strands.[1-3] Furthermore, we found that based on the dif-
ferences in strength of association, coil strands can be readily exchanged
to form the more stable coiled-coil assembly.[4] These properties make the
heterodimeric coiled coil a perfect building block to develop strategies for
proximity-induced reactions and even reaction sequences.
Another protein structure of interest is the WW domain, a small β -sheet
structural motif, which mediates protein-protein interaction. As the WW
domain is not as well-understood as the coiled-coil motif, we envisioned a
combinatorial approach to modulate function. We use fragmented WW do-
mains and link the fragments on the strands of an antiparallel heterodimeric
coiled coil, respectively. The three-dimensional structure of the split-WW
domain is reconstituted upon coiled-coil association. With this tool in
hand, we plan to establish the WW-domain-scaffold as platform for the
design of small peptide-based catalytic entities.
References: [1] Bromley, E. H. C.; Sessions, R. B.; Thomson, A. R.;
Woolfson, D. N., J. Am. Chem. Soc. 2009, 131, 928. [2] Gradisar, H.;
Bozic, S.; Doles, T.et al., Nat. Chem. Biol. 2013, 9, 362. [3] Thomas, F.;
Boyle, A. L.; Burton, A. J.; Woolfson, D. N., J. Am. Chem. Soc. 2013,
135, 5161. [4] Groth, M. C.; Rink, W. M.; Meyer, N. F.; Thomas, F., Chem.
Sci. 2018, DOI: 10.1039/C7SC05342H.
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Functionalizable oligoprolines as a platform for the
development of extended self-assemblies with tunable
morphologies
Nellie Ochs, Helma Wennemers
ETH Zurich, Switzerland
Self-assembly of pi-conjugated building blocks has become increasingly
important for the fabrication of functional nanostructures. Towards this
goal, peptides, which readily adopt well-defined secondary structures and
are highly modular, have been used to direct chromophore self-assembly
into well-organized, chiral nanostructures. The assembly of these conju-
gates has primarily been controlled by exploiting hydrogen-bonding net-
works within the peptides. Here we will present the formation of highly
ordered supramolecular structures built on non-self-assembling peptidic
scaffolds. Using oligoprolines as scaffolds to direct the self-assembly of
conjugated systems, we achieved the hierarchical self-assembly of pery-
lene monoimides into fibrils, sheets, and advanced, novel topologies, and
the self-assembly of quaterthiophenes into extended sheets and ribbons
wrapped in a double helix.[1, 2] This work culminated in the discovery of
the first extended triaxial supramolecular weave, which consists of wholly
organic threads. The weave proved to be more robust than non-woven
self-assemblies of the same building block and is capable of hosting irid-
ium nanoparticles.[3] Variation in length of the oligoproline and choice
of chromophore and linker has allowed for facile access to a variety of
supramolecular structures that do not rely on H-bonding between peptides.
Thus, oligoproline pi-system conjugates constitute novel and efficient tools
for self-assembly towards functional nanostructures.
+This work was performed in collaboration with Prof. K. Müllen (Max
Planck Institute, Mainz) and Prof. Peter Bäuerle (University of Ulm)
[1] Lewandowska, U., Zajaczkowski, W., Chen L., Bouillière, F., Wang D.,
Koynov, K., Pisula, W., Müllen, K., Wennemers, H. Angew. Chem. Int.
Ed. 2014, 53, 12537 [2] *Ochs, N. A. K., *Lewandowska, U., *Corra, S.,
*Zajaczkowski, W., Shoshan, M.S., Tanabi, J., Yashima, E., Stappert, S.,
Pisula, W., Müllen, K., Wennemers, H., to be submitted [3] Lewandowska,
U., *Zajaczkowski, W., *Corra, S., Tanabe, J., Borrmann, R., Benetti,
E.M., Stappert, S., Watanabe, K., Ochs, N. A. K., Schaeublin, R., Li, C.,
Yashima, E., Pisula, W., Müllen, K., Wennemers, H., Nat. Chem., 2017, 9,
1068–1072
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Single step recombinant human follicle stimulating
hormone purification by peptide affinity
chromatography
Juan M. Gurevich Messina1, Silvana L. Giudicessi1, María
C. Martínez-Ceron1, Nicolás Urtasun1, Guillermina Forno2,
Laura Mauro2, Osvaldo Cascone1, Silvia A. Camperi1
1Universidad de Buenos Aires. FFyB. Cát. Biotecnología.
CONICET-UBA, Inst. NANOBIOTEC. Junín 956, 1113, Bs As. ,
Argentina
2R&D Zelltek S.A., UNL, FBCB, Ciudad Universitaria, Paraje el Pozo,
CC 242, Santa Fe, Argentina
Human Follicle Stimulating Hormone (hFSH) is used clinically for women
ovulation and men spermatogenesis induction, in assisted reproduction
technologies. As FSH-based biopharmaceuticals are parenterally admin-
istered, their purity must be high. Current methods for hFSH purification
include several chromatographic steps to reach the required purity. How-
ever, these involve a decrease of the hFSH total yield, thus rising the cost
of the process. Short peptides have been described as useful ligands for
AC because of their low cost, simple chemical synthesis and high stabil-
ity in comparison to protein-based ligands. In previous works, Ryu et al
(1998) and Sohn et al. (2002) studied the hFSH receptor and examined
the interaction of its exoloop 3 with the hormone, testing each amino acid
of that exoloop by Ala substitutions. From those works, the mutant with
higher affinity: (580)KVPLITVSKAK(590) was selected to design a syn-
thetic ligand for affinity chromatography (AC): Ac-KVPLTVSKAKVAC-
NH2. The peptide was synthesized as amide and was acetylated to avoid
its polymerization during the coupling to the chromatographic support and
to improve its stability to degradation by exopeptidases. A Cys was incor-
porated at the C-termini to facilitate its subsequent immobilization to the
chromatographic activated SulfoLink agarose resin. A sample of crude re-
combinant FSH (rhFSH) was loaded to the peptide affinity column using
20 mM sodium phosphate, 0.5 mM Met, pH 5.6 and 7.2 as adsorption and
elution buffers respectively. The column was overloaded, and the dynamic
capacity obtained was 54.6 mg rhFSH/mL chromatographic resin. The pu-
rity obtained after AC purification was 95 %. Purified rhFSH quality was
analyzed: the percentage of oxidized rhFSH was 3.4 % and the percentage
of free subunits was 1 %, both of them in the range established by the Eu-
ropean Pharmacopeia, as also were the sialic acid content and the isoforms
profile. The method here designed allows obtaining a high quality rhFSH
using a low-cost affinity matrix based on a short peptide ligand.
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Chromatography
Gabriela R. Barredo1, Silvana L. Giudicessi1, María C.
Martínez-Ceron1, Soledad L. Saavedra1, Gustavo Mahler2,
Fernando Albericio3, Osvaldo Cascone1, Silvia A.
Camperi1
1Universidad de Buenos Aires. FFyB. Cát. Biotecnología.
CONICET-UBA, Inst. NANOBIOTEC. Junín 956, 1113, Bs As. ,
Argentina
2AGC Biologics. 22021 20th Avenue SE. Bothell, WA 98021. USA,
United States
3School of Chemistry, University of KwaZulu-Natal, Durban 4001, South
Africa
Therapeutic Monoclonal Antibodies (mAbs) are widely used in many dis-
eases’ treatments such as cancer, rheumatoid arthritis, multiple sclerosis,
among others. Bevacizumab (trade name: Avastin) inhibits the vascu-
lar endothelial growth factor and hence the angiogenesis process and it
is applied to treat brain, breast, colorectal, lung and renal cancers. Its
biotechnological production process involves host cell optimization, culti-
vation and mAb biosynthesis (upstream processing) and finally, the mAb
recovery and purification from the culture broth (downstream processing).
Due to its parenteral administration, its degree of purity must be extremely
high. Nowadays, that is achieved with affinity chromatography (AC) with
immobilized protein A, a highly expensive ligand that increases the cost
of the process. In addition, due to the high affinity between antibodies
and protein A, harsh elution conditions are required, impairing the protein
ligand and reducing the chromatographic matrix half life. On the other
hand, short peptides are ideal ligands for AC due to their higher stability,
easier synthesis and lower cost in comparison to protein A. In this work,
short peptide ligands with affinity for Bevacizumab were selected from a
short one-bead-one-peptide combinatorial library obtained by the divide-
couple-recombine method using the HMBA-ChemMatrix resin and using
the Fmoc strategy. Bevacizumab (AGC Biologist (USA) was labeled with
Texas-Red, and after mixing it with the library, fluorescent beads were se-
lected and the peptide immobilized in each bead was identified by MALDI-
TOF MS/MS. Those peptides that appeared most frequently were synthe-
sized in larger quantities on Rink Amide resin by Fmoc strategy, separated
from the solid support with TFA cocktail, and afterwards immobilized on
NHS-activated agarose. The affinity chromatographic matrices were evalu-
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ated by measuring the adsorption isotherms and affinities between 105-106
M were obtained. Those peptides that selectively adsorbed Bevacizumab
without interacting with the CHO cell supernatants proteins were selected
for future process scale-up. In conclusion, an efficient one-step-method
based on AC with an immobilized short peptide allows the purification of
the mAb Bevacizumab not only in a single step, but also at low cost.
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Switch of DNA G-wire Formation Using a PNA
Peptide by Protease Activity
Shungo Sakashita, Arisa Okada, Yoshio Hamada, Kenji
Usui
Konan University, Japan
Switchable molecular devices whose structure and function can be dy-
namically regulated are necessary for nanomedicine, nanomaterials and
nanomachines. DNA molecules and their derivative such as PNA (peptide
nucleic acid) [1] are attractive for the design of such as nanodevices be-
cause they have nanostructures, and they can be easily designed logically
and systematically based on complementary binding. Guanine nanowire
(G-wire) [2], one of the DNA nanostructure, is based on a four-stranded
DNA helix called a G-quadruplex and is growing interest as functional el-
ements in molecular electronics and nanotechnology. We previously con-
structed a regulating system for the G-rich DNA sequences, using a PNA
peptide (Lmyc) that could switch the DNA secondary structures through
protease (calpain I) activity [3]. In this study, we tried to develop a DNA
nanostructural switch system (G-wire <-> particles) using Lmyc with cal-
pain I toward nanotechnological applications [4]. First of all, Lmyc was
synthesized. Lmyc consists of a G-rich PNA sequence for inducing G-rich
DNA to form DNA-PNA hybrid structures and a calpain I substrate se-
quence for switching moiety that is depending on the activity of calpain I.
Thus, Lmyc would induce the DNA to form hybrid secondary structures
resulting in forming nano particles, and once calpain I existing the peptide
would be digested and simultaneously loose the induction ability resulting
in forming G-wire in the presence of calcium ion. We used the micro-scale
analyses such as AFM and TEM, and the macro-scale analyses including
zeta potential and DLS, to demonstrate the nanostructural switching of
a DNA. AFM and TEM showed that the DNA alone formed G-wires in
the presence of calcium ion, and that the peptide disrupted this formation
and formed particles with the DNA. In the addition of calpain I, the pep-
tide was digested and G-wire was regenerated. The results of macro-scale
analyses agree with those of the micro-scale analyses. Our findings imply
that a secondary structural change in the G-wires (higher-order structure)
using the peptide provides the conformational change of DNA into a differ-
ent nanostructure (higher-order structure). Throughout this study, we have
constructed a switching system of nanostructural morphology through en-
zyme activity using a PNA peptide. This system would be promising tool
for controlling the formation of DNA nanostructures for various applica-
tions, including electronic circuits for use in nanotechnologies.
Reference: [1] Nielsen, P, E., Egholm, M., et al., Science, 1991, 1497-
1500, 253. [2] Marsh, T. C., et al., Nucleic Acids Res., 1995, 696-700, 23.
[3] Usui, K. et al., Org. Biomol. Chem, 2015, 7, 2022. [4] Usui, K et al.,
Molecules, 2017, 22, 1991.
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Hugh Glossop1, Gayan Heruka De Zoysa1, Celine Valery2,
Yacine Hemar1, Viji Sarojini1
1The University of Auckland, New Zealand
2RMIT University, Australia
Supramolecular chemistry was defined by the Nobel Laureate Jean-Marie
Lehn as ‘Chemistry beyond the molecule’ and deals with complex molecu-
lar architectures that result when two or more species organize into higher
order structures which are held together by intermolecular forces [1]. A
common example of biopolymer self-assembly is the formation of amy-
loid fibrils, which are implicated in several diseases [2]. However, the
importance of self-assembled peptides as nanomaterials for technological
applications has also been realized [3-4]. Ultrashort peptides as well as
designed beta peptides have been investigated for their self-assembly prop-
erties and as biomaterials with intrinsic antimicrobial activity [5-7]. Pep-
tides can assemble into beta-sheets and form entangled fibrillar networks,
resulting in water-trapping hydrogels [8]. Hydrogels have several poten-
tial applications such as drug delivery vectors, wound healing treatments
and tissue engineering matrices [9]. Additionally, self-assembly in water
provides a green chemistry approach towards generating soft biomaterials.
We have designed and characterized a new class of ultrashort peptides (3 to
5 residues) that rapidly form hydrogels and possess promising broad spec-
trum antimicrobial activity. Modifying key amino acid residues enhances
the self-assembly potential of these peptides resulting in improved kinetics
and biophysical properties. Results from extensive biophysical and imag-
ing techniques indicate that these peptides self-assemble into extended β -
sheet nanofibrils. Investigations into the potential biomedical applications
of these peptides are currently underway.
References
1. Jean-Marie L, Angew. Chem. Int. Ed. Engl. 1988, 27 (1), 89-112. 2.
Harper JD, Lansbury PT, Jr., Annu. Rev. Biochem. 1997, 66, 385-407. 3.
Thomas F, Burgess NC, Thomson AR, Woolfson DN, Angew. Chem. Int.
Ed. Engl. 2016, 55 (3), 987-91. 4. Moore AN, Hartgerink JD, Acc .Chem.
Res. 2017, 50 (4), 714-722. 5. Schnaider L, Brahmachari S, Schmidt
NW, Mensa B, Shaham-Niv S, Bychenko D, Adler-Abramovich L, Shi-
mon LJW, Kolusheva S, DeGrado WF, Gazit E, Nat. Commun. 2017, 8
(1), 1365. 6. Rua F, Boussert S, Parella T, Diez-Perez I, Branchadell V, Gi-
ralt E, Ortuno RM, Org. Lett. 2007, 9 (18), 3643-5. 7. A. MT, Anasztázia
H, Lívia F, M. MI, K. TG, Imre D, Ferenc F, Angew. Chem. Int. Ed. Engl.
2006, 45 (15), 2396-2400. 8. Du X, Zhou J, Shi J, Xu B, Chem. Rev. 2015,
115 (24), 13165-13307. 9. Seow WY, Hauser CAE, Mater. Today 2014,
17 (8), 381-388.
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Nora Schönberger1, Robert Braun2, Sabine Matys2,
Franziska Lederer2, Katrin Pollmann2
1Technische Universität Bergakademie Freiberg, Germany
2Helmholtz Institute Freiberg for Resource Technology, Germany
High-tech metals are almost ubiquitous in our everyday lives. Due to
their great importance for the electronics industry, the demand is contin-
uously growing. The supply of these important raw materials is currently
mainly covered by primary raw material sources. However, with increas-
ing technological progress, the supply situation on the global market be-
comes tense. The recovery of high-tech metals from secondary raw mate-
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rial sources could help to ease the situation. This task is a major challenge
due to a strongly mixed matrix and sometimes low concentrations of valu-
able metals from such sources. However, highly innovative strategies are
required to meet this challenge. Modern biotechnology offers promising
concepts for the efficient, economical and sustainable recycling of high-
tech metals [1]. Recently we’ve established a phage display technology
platform for the highly specific recognition of mineral particles as well as
of metal ions in polluted water streams. This is escorted by a newly devel-
oped system for the heterologous expression of identified peptides [2-4].
Here we report in detail about the development of high-affinity peptide
ligands for the recovery of gallium from industrial wastewater. Various
gallium binding peptide sequences were identified by applying a commer-
cial dodecamer peptide library (Ph.D.-12, NEB, US). Biopanning condi-
tions were optimized for the enrichment of metal ion binding phage clones,
which allows a more precise selection process. By single clone binding
studies and competitive binding experiments, 3 sequences were character-
ized to show high binding affinity and selectivity for gallium above other
metals, especially arsenic. Gallium binding peptides are now produced for
further spectroscopic characterization and evaluation of binding properties.
In addition immobilization strategies to create peptide-based materials for
the recovery of gallium binding peptides will be discussed.
[1] K. Pollmann, S. Kutschke, S. Matys, J. Raff, G. Hlawacek, F.L. Led-
erer, Bio-recycling of metals: Recycling of technical products using bi-
ological applications, Biotechnology Advances, (2018) [2] R. Braun, S.
Matys, N. Schönberger, F.L. Lederer, K. Pollmann, Simplified Expres-
sion and Production of Small Metal Binding Peptides, Solid State Phe-
nomena, (2017) [3] S. Matys, F.L. Lederer, N. Schönberger, R. Braun, F.
Lehmann, K. Flemming, S. Bachmann, S. Curtis, R.T.A. MacGillivray, K.
Pollmann, Phage Display - A Promising Tool for the Recovery of Valu-
able Metals from Primary and Secondary Resources, Solid State Phenom-
ena, (2017) [4] F.L. Lederer, S.B. Curtis, S. Bachmann, W.S. Dunbar, R.T.
MacGillivray, Identification of lanthanum-specific peptides for future recy-
cling of rare earth elements from compact fluorescent lamps, Biotechnol
Bioeng, (2017)
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Designing a Minimal Synthetase
Radoslaw Piast
Warsaw University, Poland
Minimal enzymes are enzymatic units reduced to the bare essential with
a preservation of their initial catalytic activity. The most famous exam-
ple is SerHis dipeptide - a minimal hydrolase. Such minimal enzymes are
thought to be a missing link between chemistry and the first organisms
in the abiotic Earth environment and hold potential to use instead of en-
zymes in the future. As far as SerHis dipeptide can be used to condensate
substrates, this reaction is unfavorable by the environment. In aqueous
conditions direction of the reaction will be shifted from polymerization
to hydrolysis. There is, however, another type of enzymes that deal with
this problem by coupling unfavorable reactions with promoted ones. Syn-
thetases are driven by hydrolysis of the pyrophosphate bond which they
couple with the reaction of synthesis.
By studying the active sites of various enzymes belonging to the class of
synthetases we have extracted crucial residues in their active sites and sub-
sequently transferred them onto smaller, peptidic units.
In my presentation, I will present the inside to the structure of minimal en-
zymes we have designed and discuss features behind their activity. I will
also compare peptides with synthetase-like activity with peptides without
any desired properties yet similar sequence.
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Functionalized coiled-coil peptide hydrogels as
potential ECM mimics
Katharina Hellmund, Nan Ma, Beate Koksch
Freie Universität Berlin, Germany
Biomaterials have numerous applications in the fields of tissue engineer-
ing and regenerative medicine, which rely on the use of stem cells or pro-
genitor cells. Various approaches using peptides as Extracellular Matrix
(ECM) mimics for directing stem cell differentiation have been reported.
Coiled-coil peptides have been increasingly investigated as highly suitable
substrates for stem cell culture applications due to their self-assembly prop-
erties, which allow multivalent ligand presentation.[1] To date, however,
there are very few examples of 2D and 3D coiled-coil based substrates pre-
senting functional ligands of ECM proteins and subgroups of glycosamino-
glycans (GAGs) to mimic proteoglycans and glycoproteins and further in-
fluence stem cell behavior.[2] GAGs for example play crucial roles in a
variety of biological processes and are found covalently attached to proteo-
glycans, a critical biomacromolecule of ECM in mammalian tissues.[3,4]
Herein we present a self-assembling coiled-coil peptide hydrogel which is
modified with a carbohydrate moiety to evaluate whether this peptide is
a suitable substrate for stem cell culture applications. The impact of the
nature and density of GAG or other ligands on stem cell proliferation and
differentiation is currently evaluated and will allow tailoring of the ECM
for a variety of applications.
[1] E. Zacco, C. Anish, C. E. Martin, H. v. Berlepsch, E. Brandenburg,
P.H. Seeberger, B. Koksch, Biomacromolecules 2015, 16, 2188-2197. [2]
J. Hu, P. H. Seeberger, J. Yin, Org. Biomol. Chem. 2016, 14, 8648-8658.
[3] A. D. Theocharis, S. S. Skandalis, C. Gialeli, N. K. Karamanos, Adv.
Drug Deliv. Rev. 2016, 97, 4-27. [4] O. Yasa, O. Uysal, M. S. Ekiz, M. O.
Guler, A. B. Tekinay, J. Mater. Chem. B 2017, 5, 4890-4900.
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Bioactivity of silicate foams selectively and covalently
functionalized with protease-resistant adhesive
peptides
Annj Zamuner1, Paola Brun1, Hamada Elsayed1, Francesca
Ravanetti2, Antonio Cacchioli2, Enrico Bernardo1, Monica
Dettin1
1University of Padova, Italy
2University of Parma, Italy
Bioceramic foams, based on as wollastonite and diopside, can be pre-
pared from the thermal treatment of preceramic polymers (silicone resins)
containing micro- and nano-sized filler powders [1]. This novel process
presents limited processing temperature, microstructural homogeneity and
leads to foams that can simulate the natural porous internal structure of hu-
man bones [2]. Currently the discovery of many physiological molecules
with an active role on cell behaviour, opens the perspective to create
biomimetic materials. In our studies, we demonstrated that the nonapep-
tide (HVP) from the h-Vitronectin is able to enhance human (h)-osteoblast
adhesion through an osteoblast-specific mechanism [3-4]. In this work,
polymer-derived silicate foams were covalently and selectively function-
alized with adhesive peptides. In addition to HVP sequence, a dimeric
analogue (2HVP) has been prepared in order to increase ionic interactions
with cellular GAGs, together with two retro-inverted sequences (DHVP
and D-2HVP) [5] in an effort to avoid the enzymatic degradation of HVP
peptide in serum-containing medium. Both mechanical and biological as-
S105
Po
st
e
rs
says were carried out to compare the differently decorated bioactive foams.
The mechanical strength at crushing remained unchanged after functional-
ization. All functionalized samples showed increased cell proliferation at
2, 4 and 6 days from the seeding with respect to the control and silanized
foams. In particular, retro-inverted sequences doubled the proliferation
with respect to HVP and 2HVP at 2 days; D-2HVP gave a dramatic pro-
liferation increase (more than 15 times) at 6 days. All anchored peptides
enhanced mRNA specific transcript levels coding IBSP, VTN, RUNX2 and
OPN. LDH test confirmed the absence of cytotoxicity. In vivo assays were
performed inserting samples/controls under-skin in a murine model for 45
days. D-2HVP functionalized foams enhanced calcium deposition in vivo
and histological analysis revealed the presence of new calcium deposits in-
side the pores only on functionalized bioceramics. In vivo assays demon-
strated the osteoconductive and osteoinductive properties of D-2HVP pep-
tide grafted to bioceramic foams.
References. [1] Fiocco L, Elsayed H, Ferroni L, Materials 2015; 8: 2480-
2494. [2] Fiocco L, Li S, Bernardo E, Biomed Mater 2016; 11: 025016.
[3] Dettin M, Herath T, Gambaretto R, J Biomed Mater Res Part A 2009;
91A: 463-479. [4] Brun P, Scorzeto M, Vassanelli S, Acta Biomater 2013;
9: 6105-6115. [5] Liu Y, Mei L, Yu Q, Amino Acids 2007; 47: 2533-2539.
P71
Catalytically Active Peptides for Conjugate Addition
Reactions
Greta Vastakaite, Helma Wennemers
ETH Zurich, Switzerland
Peptides of the type H-Pro-Pro-Xaa (Xaa = any amino acid) are highly reac-
tive and stereoselective catalysts for organocatalytic C-C bond formations,
such as aldol reactions (H-Pro-Pro-Asp-NH2)[1] as well as conjugate ad-
dition reactions of aldehydes to nitroolefins (H-D-Pro-Pro-Glu-NH2)[2]
and unprotected maleimide (H-D-Pro-Pro-Asn-NH2), respectively.[3] The
peptide catalysts are so reactive that loadings of less than 1 mol% suffice
to obtain the products in high yields, enantio- and diastereoselectivities
and the peptides can be immobilized and used in flow chemistry.[4] ESI
MS, React-IR and NMR spectroscopic studies allowed for detailed insight
into the mechanism.[5] Recently, our interests focused on the structural
features of H-Pro-Pro-Xaa type peptides and in particular the trans/cis con-
former ratio and hence its consequence for reactivity and stereoselectivity
of the catalyst.[6] The poster will focus on the expansion of the scope of
peptide catalyzed conjugate addition reactions to even more challenging
substrates.
[1] P. Krattiger, R. Kovasy, J. D. Revell, S. Ivan, H. Wennemers, Org. Lett.
2005, 7, 6, 1101. [2] a) M. Wiesner, M. Neuburger, H. Wennemers, Chem.
Eur. J. 2009, 15, 10103. b) J. Duschmalé, H. Wennemers, Chem. Eur. J.
2012, 18, 1111. c) R. Kastl, H. Wennemers, Angew. Chem. Int. Ed., 2013,
52, 7228. [3] C. Grünenfelder, J. Kisunzu, H. Wennemers, Angew. Chem.
Int. Ed. 2016, 55, 8571. [4] Y. Arakawa, H. Wennemers, ChemSusChem,
2013, 6, 242. [5] a) F. Bächle, J. Duschmale, C. Ebner, A. Pfalz, H. Wen-
nemers, Angew. Chem. Int. Ed. 2013, 25, 4511. b) J. Duschmalé, J. Wiest,
M. Wiesner, H. Wennemers, Chem. Sci. 2013, 4, 1312. [6] T. Schnitzer,
H. Wennemers, J. Am. Chem. Soc., 2017, 139, 15356.
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Peptidic Stabilization of Gold Nanoparticles for
Biological Applications
Elena Egorova, Aimee Boyle, Alexander Kros
Leiden University, Netherlands
Peptide-capped gold nanoparticles (GNPs) offer a multitude of possible
bio-based applications including imaging, labelling, electron contrast en-
hancement, bio-sensing, photothermal therapy or as a drug delivery plat-
form. GNPs act as a defined solid core, providing a tunable size and shape
template for peptide-functionalized particle formation, and can serve as an
optical read-out1. Peptides provide biocompatibility, solubility, stability
under physiological conditions, and allow for the possibility of function-
alization with drugs or other small molecules2-3. The peptide sequence
CALNN was proposed by Lévy4, and was designed for GNPs to be used
for photothermal therapy. The use of this peptide produced the highest
grafting density ever reported, which ensured GNP stability in vivo. In
this study, we modified the CALNN sequence to obtain a small peptide
library and employed this to determine optimal peptide sequences for sta-
bilizing different in respect to the GNPs sizes. All the peptide sequences
are a short beta-structured unit, forming a shell of 1 nm thickness around
the GNPs, and contain a free thiol at the N-terminus to covalently bind to
the GNP surface. By adding or substituting a beta-sheet forming residue,
we managed to stabilize a range of differently-sized GNPs. The effect of
surface curvature defined the composition of the peptide required, with the
inclusion of bulkier residues necessary for the stabilization of large GNPs.
Our peptide-capped GNPs can be modified with extra moieties to demon-
strate their potential as imaging and therapeutic agents. For example, a
click-handle can be attached to enable orthogonal cell-labeling, and to act
as an imaging tool. Alternatively, the stabilizing peptide can be extended to
incorporate a therapeutic sequence, thus yielding bioactive peptide-capped
GNPs capable of generating immunogenic, bio-sensing, or specific target-
ing properties.
1. A. Parnsubsakul et al., Nanoscale, 2018, 10, 5466-5473. 2. Q. Li et
al., Nanoscale, 2018, 10, 10166-10172. 3. J.L. Daniels, Biochemistry and
Biophysics Reports, 2017, 10, 62-69. 4. E. Colangelo et al., Langmuir,
2017, 33, 428-449.
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Tyrocidines and the creation of antimicrobial cellulose
Wilma van Rensburg, Marina Rautenbach
Stellenbosch University, Department of Biochemistry, BIOPEP Peptide
Group, South Africa
Agriculture and processing sectors are plagued with continual bacterial
and fungal infections that lead to great losses in terms of product spoilage
and costs of recall. Since treatment and factory reset can be costly, it is
favourable to invest in the prevention of surface infection. This can be
done by creating antimicrobial surfaces by covalently or non-covalently at-
taching an antimicrobial agent to a surface. Antimicrobial peptides have
been identified as possible candidates for this purpose. Tyrocidines (Trcs),
antimicrobial cyclodecapeptides, have a broad spectrum of activity, as well
as a limited resistance potential. Moreover, its inherent bio-stability and
tendency to adhere to various surfaces make Trcs ideal peptides for cre-
ating antimicrobial materials. We observed that these peptides have a
preference to bind to celluloses while still maintaining its activity against
Gram-positive bacteria. Furthermore, it was shown that Trc-treated cellu-
lose would maintain activity over broad pH and temperature ranges, as well
as after multiple water washes. Which begs the question: How does the
Trcs associate so tightly with cellulose? The inherent fluorescence of Trp
residues in the Trcs was used to study the peptide association/dissociation
to cellulose. Quenching of the fluorescence at low acetonitrile (ACN) was
observed, indicated the stacking of the tryptophan aromatic rings eluding
to the peptides forming high order structures. Trcs also only bound to the
cellulose at 5-10% ACN (v/v). After binding, only a third of the bound
Trcs could be removed over 20 minutes of washing with 50-60% ACN
(v/v). Trc binding to the cellulose is driven by the concentration of pep-
tide available usually binding half of the peptide in the first hour, regard-
less of the starting concentration, indicating layering by self-association or
oligomerisation. The oligomerisation of the Trcs was studied with circular
dichroism (CD) and ion-mobility mass spectroscopy (IMMS), specifically
comparing 5% and 50% ACN to mimic a polar and amphipathic environ-
ment. As IMMS is performed in vacuo, only polar interactions remain.
Similar oligomeric structures, from dimers to octamers, were observed for
both conditions. The Trcs displayed CD spectra with a pronounced deep-
ening of the minima at 206±2 nm and 215±2 nm from 5% to 50% ACN.
Based on the results obtained and known amphipathic nature of the dimeric
Trcs, the current hypothesis is that if higher order oligomers occur, it will
selectively bind to the hydrophilic cellulose. We further propose that the
first layer of peptide could bind covalently to the cellulose via the Mailard
reaction between the Lys/Orn residue and glucose moieties. The Trcs are
then layered via self-assembly in higher order oligomers and the amount
of deposited Trcs is depended on concentration. The antimicrobial Trcs-
containing cellulose can be utilised in agriculture, paper industry and food
packaging, ultimately limiting surface contamination and product spoilage.
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Modification of metal surfaces using TCM-derived
cyclotides: an antibacterial and antibiofilm study
Pan Cao1, Ying Yang2, Fidelia Ijeoma Uche2, Sarah Hart2,
Chengqing Yuan1, Wen-Wu Li2
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Technology, China
2Institute for Science and Technology in Medicine, Keele University,
United Kingdom
Modification of metal surfaces with antimicrobial peptides is a promis-
ing approach to reduce bacterial adhesion. Here, cyclic peptides or cy-
clotides, possessing remarkable stability and antimicrobial activities were
extracted and purified from a traditional Chinese Medicine (TCM)- Viola
philippica Cav., and identified using mass spectrometry. Cyclotides were
subsequently utilized to modify stainless steel surfaces via polydopamine-
mediated coupling. The resulting cyclotide-modified surfaces were charac-
terized by Fourier transform infrared (FTIR) spectroscopy and contact an-
gle analysis. The antibacterial capacity of these cyclotides against Staphy-
lococcus aureus was assessed by Alamar blue assay. The antibiofilm ca-
pacity of the modified surfaces was assessed by crystal violet assay, and
scanning electron microscopy (SEM). A composite of Varv A, Kalata b1,
Viba 15 and Viba 17 (P1), Varv E (P2), and Viphi G (P3) was isolated
and identified. FTIR analysis of the modified surfaces demonstrated that
cyclotides bound to the surfaces and induced reduction of contact angles.
Antimicrobial effects showed an order P3 > P1 and P2, with P3-treated sur-
faces demonstrating the strongest antibiofilm capacity. SEM confirmed re-
duced biofilm formation for P3-treated surfaces. This study provides novel
evidence for cyclotides as a new class for development of antibacterial and
antibiofilm agents.
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Selective gold recovery by peptides from homogenous
aqueous solutions containing noble metal ion
contaminants
Kin-Ya Tomizaki, Takuya Okamoto, Takahito Imai,
Masahiro Asano
Ryukoku University, Japan
In these days, noble metals are used as decorative items, electrodes, etc.
However, because of limited production of noble metals, recovering no-
ble metals from electronic materials and liquid wastes are quite important.
For instance, liquid-liquid extraction method enables to stepwise recovery
of noble metal species from liquid waste, but it uses large amount of or-
ganic solvents and extracting agents, and takes time for completion due
to biphasic reaction. In the previous studies, it was found that RU006, a
9-residue-peptide formed self-assembled nanostructures and reduced gold
ions to afford metallic gold [1, 2]. The mechanism would be applicable
to selective gold recovery from homogeneous aqueous solution contain-
ing metal ion contaminants. In this study, aromatic ring-containing RU006
and its derivatives were employed to develop selective and stepwise separa-
tion/recovery of gold ions in the presence of platinum ions. These peptides
were allowed to self-assembly in the mixture of HAuCl4 and H2PtCl6 at
40°C for 24 hours. Formations of metallic particles were detected by UV-
vis spectroscopy. Elemental analysis of the precipitates after centrifugation
of the reaction mixtures was conducted by EDS-FE-SEM. Efficiency of no-
ble metal recovery by peptides was conducted by ICP-OES. We found that
all peptides successfully recovered gold ions in 90% efficiency from the
mixtures and one of them enabled recovery of gold in 7.5 times more se-
lectively than platinum from homogeneous aqueous solutions. It would
contribute to the development of sustainable society.
This study was financially supported in part by The Joint Research Center
for Science and Technology, Ryukoku University (Japan).
[1] Tomizaki, K.-Y. et al. Langmuir 2014, 30, 846-856. [2] Tomizaki, K.-Y.
et al. Bioorg. Med. Chem. 2015, 23, 7282-7291.
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Detection and characterization of new blood peptide
analogues using different voltamperometric techniques
Stela Georgieva-Kiskinova, Petar Todorov, Petia Peneva
University of Chemical Technology and Metallurgy, Bulgaria
The oxidation and adsorption reactions of the peptides at an electrode sur-
face in different electrolyte media are relevant in order to be investigating
the interfacial behavior of these compounds and to be calculating their acid-
base dissociation constants. In this regard the voltamperometric properties
of some analogues of valorphin (Val-Val-Tyr-Pro-Trp-Thr-Gln) have been
studied using hanging mercury drop electrode (HMDE) and a platinum
electrode as working electrodes, Ag/AgCl, (3 mol l-1) KCl electrode as a
reference electrode and a carbon electrode as an auxiliary electrode. The
redox potentials and dissociated constants of the compounds were deter-
minated under various experimental conditions, e.g. pH of the electrolyte
solution, scan rate and mode of sweep (differential pulse DP and cyclic
voltamperometry CV). Electrochemical oxidation of peptides at two type
working electrodes have shown that there is strong adsorption of all species
at anodic potentials in neutral solution (phosphate buffer solution: pH =
7.0 ± 0.1). Analysis of the wave shape, pH dependence, and concentra-
tion dependence of the oxidation process leads to the conclusion that the
overall reaction of the peptides at mercury electrode could be described by
the equation 2Vlf(Trp) + Hg←→ Hg(Trp)2 + 2H+ + 2e- where Vlf(Trp) is
valorphine containing tryptophan: Val-Val-Tyr-Pro-Trp-Thr-Gln. The fact
that the mercury complex of Vlf(Trp) derivatives are strongly adsorbed at
mercury electrodes leads to the possibility of employing differential pulse
polarography with deposition of the mercury drop for the determination
of low concentrations of this class of peptides. Limits of detection in the
1x10-6 to 1x10-5 mol L-1 concentration range are available.
Acknowledgements: Financial support from BG05M20P001-2.009-0015
“Support for the development of capacity of doctoral students and young
researcher in the field of engineering, natural and mathematical sciences”
funded by the operational programme “Science and Education for Smart
Growth” 2014–2020 the co-financed by the European Union through the
European Social Fund is gratefully acknowledged.
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Peptidyl Microbeads for Modification of a Direct
Peptide Reactivity Assay (DPRA) in Skin
Sensitization Assessment
Kenji Usui1, Hiroshi Miyazaki2, Hidefumi Ikeda3,
Kunihiko Yamashita2, Yoshio Hamada4
1Faculty of Frontiers of Innovative Research in Science and Technology
(FIRST), Konan University, Japan
2Daicel Corp., Japan
3Mandom Corp., Japan
4Konan University, Japan
A direct peptide reactivity assay (DPRA) is one of the most promising
method as a robust alternative to animal testing for skin sensitization anal-
ysis. In DPRA, a chemical substance is mixed with peptides. After 24 h re-
action, HPLC is used to measure unreacted peptides, and skin sensitization
is predicted based on the percent decrease in unreacted peptides [1]. Since
the test substance and peptides are both in aqueous solutions during DPRA,
DPRA cannot appropriately assess poorly water-soluble substances. In ad-
dition, HPLC measurement has relatively cumbersome procedures. This
precludes the ready assessment of numerous types of samples in a short
period of time. In this study, we immobilized the DPRA peptides to am-
phiphilic microbeads. Then using these peptidyl microbeads, two modified
skin sensitization assay systems were developed in order to address these
limitations in DPRA. We utilized a photo-labile linker [2, 3] and an unre-
acted peptide sequence as an internal standard in the first system, and thiol
or amino group indicators [4, 5] for detecting amount of unreacted peptides
were used in the second system. We examined test chemicals including
poorly water-soluble substances by our two modified methods. The results
indicated that the both two methods were able to appropriately assess all
test chemicals including poorly water-soluble substances that conventional
DPRA was unable to assess. Additionally, our method offered easy han-
dling and general versatility, and more reproducibility and accuracy than
the conventional DPRA. Thus, these studies successfully improved the con-
ventional DPRA. Our method provides a high-throughput testing for skin
sensitization with easy handling.
[1] OECD Test Guideline 442C, In Chemico Skin Sensitisation: Direct
Peptide Reactivity Assay (DPRA) (2015). [2] Usui, K. et al. (2013) Chem.
Commun., 49, 6394-6396. [3] Usui, K. et al. (2016) Methods. Mol. Biol.,
1352, 199-210. [4] Ellman, G. L. (1959) Arch. Biochem. Biophys. 82,
70-77. [5] Mekkaoui Alaoui, I. and Menzel, E. R. et al. (2005) Forensic
Sci. Inter., 152, 215-219.
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Label-free analysis of proteins in human cells in
relation to cytotoxicity, viability and differentiation
processes
Maria Ricci1, Paola Sassi2, Assunta Morresi2
1Research Center for Natural Sciences, Hungarian Academy of Sciences,
Institute of Materials and Environmental Chemistry, Hungary
2Department of Chemistry, Biology and Biotechnology, University of
Perugia, Italy
In the last years, vibrational spectroscopies have been increasingly used
to investigate a large variety of biological samples, from complex tissues
to single living cells. The label free nature of these techniques, together
with their applicability in physiological environments, allows to study bio-
chemical variations occurring in biological processes without damaging or
altering the cell status. Following characteristic bands, we studied alter-
ations of the protein content of different cell types. We used attenuated
total reflection infrared spectroscopy (ATR-FTIR) to study the formation
of prefibrillar aggregates in cord blood samples and HuDe (Human Der-
mal) adherent fibroblasts related to the cytotoxic effect of dimethyl sul-
foxide (DMSO) (1). Due to superior spatial resolution and reduced back-
ground signal from the culture medium and intracellular water, Raman
microspectroscopy allows the analysis of single living cells in their physi-
ological environment. We were, thus, able to follow variations of the pro-
tein content without cell fixation and staining in single neuroblastoma and
glioblastoma cells in adhesion on substrates of interest in neurosciences
(2). Moreover, using a 532 nm exciting wavelength, it was possible to
observe the strong resonant Raman scattering of cytochrome c. Since it
acts as a trigger of caspase cascade activation resulting in the disassem-
bly of proteins, the observation of the dynamics of cytochrome c reveals
the initiation of the apoptotic process before morphological changes are
visible. Therefore, the analysis of the cytochrome c band provided impor-
tant information regarding cell viability in stress conditions and during the
differentiation process. This work confirms the potential of Infrared and
Raman spectroscopies to detect protein alterations that are indicative of
the cell status and that can be possibly used for diagnostics or as a tool
for evaluating new therapies. This research project was supported by PAT
(Autonomous Province of Trento) (GP/PAT/2012) “Grandi Progetti 2012”
Project “MaDEleNA”, “Fondo d’Ateneo per la ricerca di base 2014” -
D.D.N. 40/2015 DCBB-UniPG and by Fondazione Cassa di Risparmio
– Perugia with the project 2015.0332.021 ”Analisi ed ottimizzazione del
processo dicrioconservazione di linee cellulari mediante tecniche spettro-
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scopiche”.
1. Giugliarelli A, Urbanelli L, Ricci M, Paolantoni M, Emiliani C, Sac-
cardi R, et al. Evidence of DMSO-induced protein aggregation in cells.
The Journal of Physical Chemistry A. 2016;120(27):5065–70. 2. Ricci
M, Sagini K, Caponi S, Urbanelli L, Cornella N, Macchi P, et al. Micro-
Raman detection of the differentiation state of SH-SY5Y cells grown on
silicon and aluminium substrates. Journal of Raman Spectroscopy. 2018;
1-10
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Extracellular vesicles oriented by shear force can be
studied using polarized light spectroscopy
Imola Szigyarto, Priyanka Singh, Robert Deak, Judith
Mihaly, Ferenc Zsila, Zoltan Varga, Tamas Beke-Somfai
Research Centre for Natural Sciences, Hungarian Academy of Sciences,
Hungary
Extracellular vesicles (EVs) are currently in the scientific focus showing
a great potential to revolutionize the diagnosis and therapy of various dis-
eases. Despite intense investigation, however, many properties and mecha-
nisms remain indefinable due to the lack of standardization of isolation and
characterization methods which hinders the translation of EV-based diag-
nostics into clinical use. Our knowledge may rapidly increase on EVs if
these systems could be the subject of additional structural methods used
commonly for lipid systems. Research of EVs, having lipid composi-
tion very similar to those of the secreting cells have opened the way to
potentially use complex lipid vesicles in biophysical characterization of
biomolecules, such as antimicrobial peptides or membrane associated pro-
teins. Monitoring the orientation of biomolecules associated to EVs can
provide valuable information on their structure and interaction with the
lipid membrane.
Extracellular vesicles were isolated from human erythrocytes and char-
acterized by flow-linear and circular dichroism spectroscopy (flow-LD,
CD), freeze-fracture electron microscopy (FF-TEM), dynamic light scatter-
ing (DLS) and attenuated total reflection Fourier-transform infrared spec-
troscopy (ATR-FTIR). The Soret-band of the LD spectra demonstrates that
hemoglobin molecules are attached to the lipid bilayer in freshly released
EVs. During storage this interaction ceases coupled to major protein con-
formational changes relative to the initial state. In overall, we propose
that both LD and circular dichroism (CD) spectra provide simple, rapid,
yet efficient ways to track changes in membrane-protein interactions of
EV components at the molecular level which may also give insight to pro-
cesses occurring during vesiculation.
References:
1. Szigyártó I.Cs., Deák R., Mihály J., Rocha S., Zsila F., Varga Z, Beke-
Somfai T.: Flow-alignment of extracellular vesicles: structure and orien-
tation of membrane associated biomacromolecules studied with Polarized
Light, CHEMBIOCHEM, 19(6), 545-551 (2018) 2. Mihály J., Deák R.,
Szigyártó I.Cs., Bóta A., Beke-Somfai T., Varga Z.: Characterization of
extracellular vesicles by IR spectroscopy: Fast and simple classification
based on amide and C-H stretching vibrations, Biochimica et Biophysica
Acta-Biomembreanes, 1859 (3), 459-466 (2017)
Acknowledgment:
This work was funded by the Momentum programme (LP2016-2), and by
the National Competitiveness and Excellence Program (NVKP_16-1-2016-
0007).
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Modulating peptide hydrogel strength through
halogenation
Wouter Vandeplassche1, Steven Ballet1, Charlotte Martin1,
Richard Hoogenboom2, Annemieke Madder2
1Vrije Universiteit Brussel, Belgium
2Ghent University, Belgium
Due to their biocompatibility, low toxicity and physical properties, peptide
hydrogels represent a promising class of biomaterials for medical appli-
cations. Previously, we investigated amphipathic peptide sequences able
to form hydrogels [1]. The developed hexamer sequences possess alter-
nating hydrophilic and hydrophobic residues. Because earlier findings
have shown that the hydrophobicity of the composing amino acids plays
a key role in the gelation process, further elaboration of the hydropho-
bic amino acid was scoped to improve the strength of the peptide fibers,
while keeping the peptide length to a minimum. Preliminary in-house cal-
culations and quantifications of the non-covalent interactions index (NCI)
[2] between halogenated aromatic amino acids, have determined a signif-
icant increase of the NCI once the aromatic amino acids phenylalanine
(Phe) and tryptophan (Trp) are halogenated. To experimentally validate
the calculations, commercially available halogenated Phe were directly in-
corporated into SPPS and selected halogenated Trp residues were synthe-
sized, via chemical synthesis followed by an enzymatic deconvolution and
Fmoc-protection, yielding building blocks compatible with SPPS. Conse-
quently, a library of halogenated Phe and Trp-based peptides was synthe-
sized. Subsequently, quantitative results were needed to confirm the hy-
pothesis and the rigidity of the peptide hydrogels was evaluated through
dynamic rheometry. These measurements indicated that the halopeptides
have a higher rigidity, in comparison with the non-halogenated lead se-
quences, with up to a hundred-fold increase in the storage modulus G’.
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A Self-assembling Peptide Hydrogel for Ultrarapid 3D
Immunoassays
Alessandro Gori, Paola Gagni, Greta Bergamaschi,
Alessandro Romanato, Marina Cretich
National Research Council of Italy, Italy
Diagnostic array platforms rely on the intimate structure-function relation
of immobilized probes. In this context, hydrogels are appealing semi-wet
systems to locally confine biomolecules while preserving their structural
integrity and function. Yet, limitations on biomolecule diffusion rates or
fabrication difficulties have hampered their broad application. Here, us-
ing micromolar concentrations of a self-assembling peptide, a printable
and self-adhesive hydrogel was obtained and applied to the 3D immobi-
lization of biomolecules on microarray slides. This soft matrix represents
a robust and versatile material allowing selective tuning of analytes diffu-
sion, that is here exploited to run in-gel immunoassays under solution-like
conditions in an unprecedented (<10 min) time frame. The developed ma-
terial overcomes major limitations associated to hydrogel for immunoas-
says, widening the perspectives of easy fabrication of multifunctional bio-
interfaces for high-throughput, molecular recognition assays.
P82
Development of new supramolecular nanostructured
materials based on peptide hydrogelator
Ac-L-Phe-L-Phe-L-Ala-NH2 with embedded
liposomes for potential biomedical application
Ruža Frkanec1, Karmen Radoševic´2, Adela Štimac1, Lucija
Horvat3, Leo Frkanec4
1University of Zagreb,Centre for Research and Knowledge Transfer in
Biotechnology, Croatia
2Department of Biotechnology, University of Rijeka, Croatia
3Division of Molecular Biology, Rud¯er Boškovic´ Institute, Croatia
4Department of Organic Chemistry and Biochemistry, Rud¯er Boškovic´
Institute, Croatia
In recent years design and synthesis of self-assembled nanomaterials with
diversified structures and functionalities via fine tuning of supramolecular
building blocks increased rapidly (1). Self-assembling peptides have been
widely recognized as nanomaterials with high potential for a extensive
range of biomedical applications from drug delivery to tissue enginering,
owing to their hydrophilic character and biocompatibility (2,3). The aim
of the present study was preparation and characterization of supramolecu-
lar systems based on peptide hydrogelator(4) Ac-L-Phe-L-Phe-L-Ala-NH2
and liposomes with incorporated model proteins. The gelling properties of
the hydrogelator Ac-L-Phe-L-Phe-L-Ala-NH2 with addition of liposomes
and proteins were studied. Liposome formulations of BSA and FITC-BSA
incorporated in the hydrogel were characterized by electron and confocal
microscopy. Transmission electron microscopy (TEM) confirmed incorpo-
ration of liposomes into the hydrogel. In gel samples with built-in BSA,
the gel network preserved integrity, but it was noticed that the gel fibers
were thinner and thicker. Confocal microscopy proved the incorporation
of liposome formulations of FITC-BSA in the hydrogel. It was also shown
that liposomes do not impair the gel network of hydrogelator at lipid con-
centrations lower than the gelator concentration. We confirmed that use
of higher amounts of protein albumin (BSA)/FITC-BSA resulted in slower
gel formation or inability to transition into gel. In order to investigate the
potential of using the prepared nanostructured supramolecular systems in
immunodiagnostic and immunotherapy, complex protein mixture isolated
from allergen pollen of Ambrosia elatior plant was successfully incorpo-
rated into the tested system. References: 1. J. Boekhoven , W. E. Hen-
driksen , G. J. M. Koper , R. Eelkema , J. H. van Esch , Science 2015
, 349 , 1075 2. X. Du, J. Zhou, J. Shi, B. Xu, Chem. Rev. 2015, 115,
13165−13307,DOI: 10.1021/acs.chemrev.5b00299 3. R. Dong, Y. Pang,
Y. Su, X. Zhu, Biomater. Sci., 2015, 3, 937. 4. T. Pospišil, L. Ferhatovic´
Hamzic´, L. Brkic´ Ahmed, M. Lovric´, S. Gajovic´, L. Frkanec, Biomater
Sci. 2016; 4: 1412–1416.
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Improving Peptide Studies with Miniaturised Mass
Spectrometry
Christopher Harris
Microsaic Systems plc, United Kingdom
Peptides are important building blocks of many biologically active com-
pounds so they must be carefully characterised, and their quality checked
throughout processing. Mass Spectrometry (MS) has always been a well-
used tool in the analysis of peptides, however not always accessible at the
point-of-need. Miniaturised MS allows the capability of mass detection to
be available for real-time, on-line analysis. This study shows the integra-
tion of a miniaturised Mass Spectrometer (MS) with a Nano-LC system.
The data obtained of the commonly studied cytochrome C digest, shows
an order of magnitude increase in sensitivity compared with traditional UV
detection. This study showcases the possibility to improve analytical ca-
pabilities in peptide studies with little increase in footprint or resources
required.
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Correlation between the structure and oligomerisation
of the three main cyclodecapeptides from the
tyrocidine group
J. Arnold Vosloo1, Vikas Kumar1, Ramesh Singh2, Marina
Rautenbach1
1Stellenbosch University, South Africa
2Dr Harisingh Gour Central University Sagar, India
The tyrocidines (Trcs) are a group of cyclodecapeptides [cyclo(D-Phe1-
L-Pro2-L-X3-D-X4-L-Asn5-L-Gln6-L-Tyr7-L-Val8-L-X9-L-Leu10] pro-
duced by the soil bacterium Brevibacillus parabrevis. The three major
analogues, TrcA, TrcB and TrcC, contain an ornithine residue in posi-
tion X9 and vary at the aromatic dipeptide moiety (L-X3-D-X4) with
TrcA containing L-Phe3-D-Phe4, TrcB L-Trp3-D-Phe4 and TrcC L-Trp3-
D-Trp4. These Trcs have potent but differential antimicrobial activity to-
ward a broad range of pathogens including Gram-positive bacteria, fungi
and protozoa (Plasmodium falciparum). Differences in antimicrobial ac-
tivity seem to be dependent on the identity of the aromatic amino acid
residues in L-X3-D-X4. Trc dimers have been proposed to be the mem-
brane active moieties. Electrospray mass spectrometry (ESMS) analysis
and ion mobility mass spectrometry (IMMS) supported the formation of
highly stable dimers by all three Trcs. However, the Trcs oligomerise
into high order structures and we detected up to octamers with ESMS and
IMMS. Analysis of 24-hour incubated Trc samples by circular dichroism
(CD) indicated differences between the three Trcs regarding their hydrogen
bonded structures. All three Trcs displayed CD spectra with a pronounced
deep minimum at 206±2 nm and shallower minimum at 215±2 nm in
50% trifluoreoethanol (TFE). However, the ellipticity minima of TrcC was
significantly less than that of TrcA and TrcB, both in water and in 50%
TFE. Visualisation of nanostructures formed by the Trcs through scanning
electron microscopy showed freshly prepared TrcA formed well defined
vesicles, in contrast to aggregated vesicles observed for TrcB, while vesi-
cles were only detected for TrcC after 24 hours of incubation. Comparison
of the nanostructures formed by the three peptides after 24 hours by atomic
force microscopy showed both TrcA and TrcB formed vesicles with a di-
ameter of ±0.3 µm while the TrcC vesicles were smaller than 0.1 µm.
The nanostructures could be related to the activity of the peptides with
the more hydrophobic TrcA that rapidly forms higher order and nanostruc-
tures being more active against slower growing fungi and protozoa. TrcB
forming abundant dimers, but less defined macrostructures have good ac-
tivity against protozoa, but much weaker activity against fungi, while being
much more active against bacteria. TrcC forming less dimers and smaller
nanostructures has appreciable activity against fungi and bacteria, but low
activity against protozoa. These data show the importance of D-Phe4 in ac-
tivity and the association of the Trcs into higher order structures by forming
pi-pi stacking interactions complementing the anti-parallel β -sheet struc-
tures formed by the Trcs.
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Label-free detection of high-density peptide arrays
Alice Mueller1, Natalie Jahn1, Peter Fechner1, Guenther
Proll1, Jigar Patel2
1Biametrics, Germany
2Roche Diagnostics, United States
Protein-protein or protein-peptide interactions are crucial for most cel-
lular and biochemical processes. Especially peptides represent interest-
ing emerging drug targets. Therefore, the demand for high-throughput
screenings of large peptide libraries is rising. In this study, we used high-
throughput label-free screening technology to analyse the binding of a tar-
get to a large number of peptides in a fast and simultaneous assay. The
high-density peptide array consisting of two different FLAG epitope vari-
ants and five different streptavidin-binding peptides was generated through
photolithographic immobilisation. Each of those different peptides was
generated in different spot sizes (7.4 – 111 µm) and multiple replicates
among the array to evaluate data reproducibility. We then observed the
binding of an anti-FLAG antibody to the two FLAG epitopes and the bind-
ing of streptavidin to the five streptavidin-binding peptides by using label-
free single colour reflectometry (SCORE). Kinetic analysis on all binding
events was performed to further characterise the protein-peptide interac-
tions. We could show that this technology enables a precise, fast, and reli-
able characterisation of protein-protein interactions and represents a novel
and unique combination of high-density peptide microarrays with label-
free read-out.
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Chemical labeling associated to Mass spectrometry as
a powerful tool for peptide detection and quantification
in biology
Sonia Cantel, Mathieu Maingot, Maxime Rossato,
Guillaume Miralles, David Paramelle, Didier Gagne, Jacky
Marie, Guillaume Cazals, Jean Martinez, Muriel Amblard,
Gilles Subra, Christine Enjalbal
IBMM, France
Mass spectrometry represents a method of choice to identify and charac-
terize peptides and proteins present in complex biological mixtures at low
concentrations. In the attempt to develop potent MS methodologies, we
work to the design and synthesis of chemical tags able to increase detec-
tion sensitivity and specificity through direct MS detection and/or directed
fragmentation. On one hand, we aim at developing a novel approach that
relies on the joint use of MALDI mass spectrometry and original labeling
chemistries designed to specifically enhance the ionization of the tagged
molecules. MALDI is well-known to provide very sensitive detection but
not commonly used for quantitative measurements. Using MALDI for
such purposes is challenging and has been successfully applied to track
peptides at low concentrations in various media. We developed a method-
ology associating HCCA-targeted peptide to be analyzed by MALDI-MS
in a matrix such as HCCE. This original approach allowed to selectively en-
hance and discriminate the MALDI-MS signals of targeted peptides. This
concept was successfully applied to protein structure issues illustrated by
the cross-linking of a model protein and peptide quantification for phar-
macological studies of receptor/ligand systems. On the other hand, we
focused on N-terminal positively charged peptide derivatization as effi-
cient agents for directed ESI MS fragmentation. We explored labeling by
pyridinium-based molecules, well known in chemistry literature, generally
for enantio-separation, pharmaceutical or biochemical analysis, showing a
great tendency to meet some of the desired requirements to investigate the
field of ESI-MS qualitative and quantitative analysis of biomolecules like
proteins or peptides. This technology should have a great impact in bio-
sciences, in particular in research laboratories dealing with pharmacology.
We will give you an account on the development of these methodologies.
1- G. Subra, D. Paramelle, S. Cantel, C. Enjalbal, M. Amblard, E. Forest,
M. Heymann, C. Geourjon, J. Martinez, Proteomics 2009, 9, 5384–5388.
2- X. Qiao, Y. Yang, S. Liu, S. Chen, X. Wang, G. Li, H. Yana and X. Yang,
Analyst, 2015, 140, 407-413. 3- M. Rossato G. Miralles, C. M’Kadmi, D.
Gagne, M. Maingot, M. Amblard, B. Mouillac, J. Martinez, G. Subra, C.
Enjalbal and S. Cantel, ChemMedChem, 2016, 11 (23), 2582-2587.
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Dynamic stereoselection of kinetically-inert
DNA-binding metallopeptide cylinders
Jacobo Gomez Gonzalez, Eugenio Vázquez Sentís, Miguel
Vázquez López
University of Santiago de Compostela, Spain
Helicates, discrete metal complexes in which one or more organic ligands
are wound around and coordinate two or more metal ions. Helicates are
inherently chiral species that can appear as right-handed, or left-handed
helicity, according to the orientation in which the ligands coil around the
helical axis defined by the metal centers. Indeed, the supramolecular chiral-
ity of helicates represents an additional challenge for the synthesis of these
complexes and, despite some noteworthy examples, no general approach
for the efficient and versatile stereoselective synthesis of helicates is yet
available. We propose that peptides represent ideal platforms for the pro-
grammed assembly of helicates—and, in general, of supramolecular met-
allostructures. In this context, we present the synthesis and study of pep-
tide helicate precursors featuring 2,2’-bipyridine ligands that predictably
fold into complexes with defined chirality in the presence of metal ions.
The folding of the peptide ligands into bimetallic helicates is directed by
a particular heterochiral combination residues in the loops connecting the
coordinating bipyridines that induce a tight turn in the sequence and allow
the thermodynamic control over the supramolecular chirality of the final
three-stranded metallocylinders after the coordination of Co (II) or Fe (II)
ions. Furthermore, the Co(II) peptide helicates can be locked into defined
configurations by oxidative treatment with cerium(IV) ammonium nitrate,
thus providing a straightforward method for stereoselective selection of ki-
netically inert metallopeptides in aqueous media. The DNA-binding prop-
erties of these labile Co(II), Fe(II), and inert Co(III) peptide helicates was
studied by fluorescence titrations and electroforetic mobility shift assays
with three-way junctions and double-stranded DNAs. Both the labile and
the inert complexes display good DNA-binding properties and selectivity
towards three-way junction DNA.
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Peptide Segments of Type I Collagen Preferably
Preserved in Archaeological Bones and Animal Glues
Yuji Kobayashi1, Kazuki Kawahara2, Takashi Nakazawa3
1Osaka University, Japan
2Graduate School of Pharmaceutical Sciences, Osaka University, Japan
3Faculty of Science, Nara Women’s University, Japan
Collagen is arguably one of the oldest proteins found to survive in archae-
ological specimens. In the tryptic digest of α1 and α2 chains of type I
collagen, each of which has 1,000-amino acid-long triple helical region,
our mass spectrometric study has identified a few peptides almost invari-
ably appeared irrespective of the animal species and the ages as old as
10,000 years before present (BP). These include a peptide with the se-
quence GLTGPIGPPGPAGAPGDKGEAGPSGPAG PTGAR correspond-
ing to residue 763-795 of bovine α1 chain (C763A1). We also identi-
fied the sequence GAPGAIGAPGPAGANGDRGEAGPAGPAGPAGPR of
bovine α2 chain (C763A2), which is precisely the same length (33-amino
acid-long) as that of C763A1 and homologous, characteristically conserv-
ing the pair of acidic and basic amino acids DK and DR in the middle of
the peptide chain. The similar pair of α1 and α2 sequences has been found
for those of GETGPAGPPGAPGAPGAPGPVGPAGK (bovine α1, 1036-
1061; C1036A1) and GYPGNAGPVGAAGAPGPQGPVGPVGK (bovine
α2; C1036A2). The peptides in each pair C763A1/A2 and C1036A1/A2
are homologous but definitely contain different amino acids. Furthermore,
mutations at a few amino acid residues in the sequences, or the difference
in animal species, did not affect the detection of the respective peptides.
These features allowed us to identify the animal species by amino acid
sequencing. In fact, the peak of peptide C763A1 in the mass spectra of
collagen digest is particularly useful as a marker in zoological mass spec-
trometry of archaeological specimens in which collagen is often the sole
protein surviving while DNA has been diminished. It is most likely that
these peptides are involved in considerably stable triple helical regions in
which two α1 chains and one α2 chain are contacting very tightly to form
the triple helix. Considering that these collagen peptides have been identi-
fied not only in archaeological animal bones up to 10,000 years BP but also
animal glues dated to more than 4000 years BP, we could assume that the
stability of the triple helix is responsible for the resistance of the respective
peptide against degradation due to ageing. Note that animal glues in mu-
ral paintings used as a binder are exposed to natural environment without
being protected from chemical and biological degradation. In particular, a
tightly folded structure can serve to avoid digestion by proper proteases by
shielding the peptide bonds in an interior of the triple helix. We will dis-
cuss the relationship between the amino acid sequences of these peptides
and the stability of collagen.
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Use of Peptide Nucleic Acids for the Chemoselective
Ligation of Biomolecules
Jannis Beutel, Johannes Lach, Jutta Eichler
Friedrich Alexander Universität Erlangen-Nürnberg, Germany
The DNA-like, base-pair-specific hetero-dimerization of peptide nucleic
acids (PNA) has been utilized for a range of applications, including the
alignment and pre-organization of biomolecules, generating spatial prox-
imity, and enabling otherwise unlikely covalent reactions. Here, we ex-
plore the possibility of using complimentary PNAs as adapter domains for
the chemoselective, site-directed covalent ligation of intrinsically multi-
reactive molecules, such as peptides. In a first study using match and
mismatch 5-mer to 10-mer PNAs, we could show that hybridization of
matching sequences, with subsequent covalent stabilization of the result-
ing heterodimer via thioether bond, is a promising strategy for the highly
selective and site-directed ligation of biomolecules.
P90
Chemoselective Modifications of Elastin-like
Polypeptides Towards Synthetic Glycoconjugates
Marie Rosselin, Elisabeth Garanger, Sébastien
Lecommandoux
Université Bordeaux/LCPO/CNRS, France
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There are relevant opportunities to develop innovative biomaterials at the
frontier between biotechnology, peptide chemistry and traditional organic
chemistry. The main challenge relies in the design of a robust and repro-
ducible synthetic approach that will allow the establishment of structure-
activity relationships. In this project, protein-engineering techniques are
used to access functional precision polypeptide scaffolds with exquisite
control over monomer sequence and length, namely with an exact “pri-
mary structure” [1]. Orthogonal bioconjugation strategies are subsequently
applied to chemoselectively modify specific residues of the genetically-
engineered polypeptides so as to introduce biologically relevant motifs,
as a means to access thermoresponsive, well-defined and high molecular
weight multivalent bioconjugates.
This project is specifically applied to the synthesis of chemical tools for
glycobiology, where there is a critical need for the rational design of gly-
copolypeptides mimics for drug-targeting and vaccination strategies. To
achieve this goal, a set of elastin-like polypeptide (ELPs) scaffolds was de-
signed and produced recombinantly in Escherichia coli bacteria. Precision
functional ELPs and diblock ELPs are subsequently modified chemoselec-
tively onto specific residues lateral chain (i.e., methionine and lysine) to
introduce pendant carbohydrate motifs at defined positions within the ELP
backbones [2]. Thanks to their perfectly defined primary structures, these
will be subjected to structure-activity relationship studies. Their propen-
sity to recognize and bind specific lectins and receptors will be assayed
as soluble chains and self-assembled nanoparticles in order to determine
optimal ligand design for receptor binding and answer relevant biological
questions.
References [1] Van Hest J. C. M. and Tirrell D. A., Chemical Commu-
nications, 2001, 1897-1904. [2] Gharakhanian E. G. and Deming T. J.,
Biomacromolecules, 2015, 16(6), 1802-18.
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Interactions of fructosyllysine and phenylboronic
moieties in amphipathic peptides
Monika Kijewska1, Angelika Czerwin´ska1, Alicja
Kluczyk1, Mariusz Jaremko2, Lukasz Jaremko2, Piotr
Stefanowicz1, Zbigniew Szewczuk1
1University of Wrocław, Faculty of Chemistry, Poland
2KAUST: King Abdullah University of Science and Technology, Saudi
Arabia
Glycation, one of the post-translational modifications of proteins, is a
nonenzymatic reaction of amino groups of proteins and peptides with
glucose yielding Amadori products (fructosyllysine derivatives).[1] These
derivatives are the key intermediates in the formation of advanced glyca-
tion end products (AGEs).[2] Fructosyllysine moieties interact selectively
with phenylboronic acids[3] as well as borate ions[4]. The affinity of
phenylboronic acids towards Amadori products found the application in
enrichment and isolation of glycated peptides as well as their selective de-
tection.[5] Herein we designed and synthesized series of penetrating pep-
tide (MAP) analogues. MAP (Ac-KLALKLALKALKAALKLA-NH2) is
an α-helical amphipathic peptide that shows high cellular uptake.[6] The
designed analogues contain in the sequence both the glycated lysine moi-
ety and phenylboronic acid. We investigated the intramolecular interac-
tions between the fructosyl moiety and phenylboronic acid incorporated in
various positions of peptide chain using high-resolution mass spectrometry
(HR-MS). Additionally, we studied the influence of these interactions on
secondary structure of peptides using circular dichroism (CD) and nuclear
magnetic resonance (NMR).
[1] Amadori M. Atti Accad. Naz. Lincei, Cl. Sci. Fis., Mat. Nat.,
Rend., 1925, 2, 337. [2] Ulrich, P., Cerami, A. Recent. Prog. Horm.
Res., 2001, 56, 1. [3] Kijewska, M., Kuc, A., Kluczyk, A., Waliczek,
M., Man-Kupisinska, A., Łukasiewicz, J., Stefanowicz, P., Szewczuk, Z.
J. Am. Soc. Mass Spectrom., 2014, 25, 966. [4] Kijewska, M., Kluczyk,
A., Stefanowicz, P., Szewczuk, Z. Rapid Commun. Mass Sp., 2009, 23,
4038. [5] Soboleva, A., Modzel, M., Didio, A., Płóciennik, H., Kijewska,
M., Grischina, T., Karonova, T., Bilova, T., Stefanov, V., Stefanowicz, P.,
Frolov, A. Anal. Methods, 2017, 9, 409. [6] Oehlke, J.1., Scheller, A.,
Wiesner, B., Krause, E., Beyermann, M., Klauschenz, E., Melzig, M., Bi-
enert, M. Biochim. Biophys. Acta, 1998, 1414, 127.
P92
Double-head lipopeptide surfactants as potential
antimicrobial agents
Izabela Małuch, Oktawian Stachurski, Paulina
Kosikowska-Adamus, Dariusz Wyrzykowski, Adam Prahl,
Emilia Sikorska
Faculty of Chemistry, University of Gdan´sk, Poland
Short cationic lipopeptides are an interesting group of antimicrobial com-
pounds. They satisfy the amphipathicity and total positive charge condi-
tions, essential features of antibiotic peptides. Additionally, due to the
surfactant-like structure they exhibit surface-active properties. Thus, they
can act as both preservatives and stabilizers in multiphase systems. A
group of compounds of our particular interest are double-head lipopep-
tide surfactants. This class of compounds can be obtained by lipidation of
the side chain of one of the middle lysine or its shorter homologs (Fig. 1).
To our knowledge, such peptide-like compounds have not been tested as
antimicrobials so far.
The lipopeptides studied are expected to undergo self-assembly in solution
above a certain concentration referred to as the critical micelle concentra-
tion. Both the larger headgroup charge and size enhance electrostatic repul-
sions among surfactant molecules. Consequently, a larger micellar surface
is required, and progressively fewer surfactant molecules can be accommo-
dated in a single micellar aggregate. Therefore, double-head lipopeptides
are expected to form smaller and more dynamic aggregates in comparison
with the single-head ones. It is believed that smaller aggregates of an-
timicrobial amphiphiles can penetrate more deeply into the bacterial cell
surface that the large ones, this resulting in enhanced antimicrobial activity.
Smaller aggregates are also expected to bind to a greater number of bacte-
rial cells, and consequently operate more efficiently. All the lipopeptides
were tested for antimicrobial activity. The isothermal titration calorime-
try (ITC) was employed to determine thermodynamic parameters of the
binding of the lipopeptides to anionic liposomes being a model of bacte-
rial membrane. Molecular dynamic simulations were used to visualize the
self-assembly properties. The results of our studies were discussed with
regard to the parameters involved in the potency and cell specificity of
cationic lipopeptides and their potential to be developed as antimicrobial
agents.
Acknowledgments This work is supported by the National Science Center
in Poland, contract No. UMO-2016/21/B/ST5/01375.
Figure 1. Double-head lipopeptide and schematic representation of the
double-head surfactant.
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Studies of Bio-orthogonal self-assembled
peptide-carbohydrates
Shunliang Wu, Mads Østergaard, Knud J. Jensen
University of Copenhagen, Denmark
Oligogalacturonic acid (OGA) is known to dimerize into “egg-box” like
structure in the presence of suitable amount of Ca(II).1 The dimerization
between OGAs can be used as an intermolecular Ca(II) bridge to connect
peptide units in order to form Ca(II) sensitive nanoassemblies, where the
bridge can be disrupted again by adding monovalent cations or chelating
agents. Here, we conjugated a 10-mer OGA chain at the N-terminus of
a 23-mer and a 30-mer α-helical coiled coil peptide through an oxime
linkage.2,3 The peptide-carbohydrate conjugate can assemble via two bio-
orthogonal self-assembly principles; hydrophobic collapse between pep-
tides, and egg-box dimerization between OGAs triggered by Ca(II). The
dynamic light scattering studies showed that the size of self-assembly is
affected by two important factors; the ratio between divalent and mono-
valent cations, and the number of heptad repeats in the peptide sequence.
The size change of the nanoassemblies inspired us to redesign our peptide-
carbohydrate conjugates by chromophore labeling. The chromophore will
be labelled on the outer face of the coiled coil unit which allows us to study
the shape of the nanoassemblies by using stochastic optical reconstruction
microscopy.
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Synthesis of Aryl-Thioglycopeptides Through
Chemoselective Pd-Catalyzed Conjugation
Thimmalapura Marulappa Vishwanatha1, David Montoir2,
Mehdi Amoura1, Zine El Abidine Ababsa2, Expédite
Yen-Pon2, Vincent Robert3, Massimiliano Beltramo3,
Véronique Piller4, Mouâd Alami2, Vincent Aucagne4,
Samir Messaoudi2
1Centre de Biophysique Moléculaire, CNRS, France
2BioCIS, Univ. Paris-Sud, CNRS, Univ. Paris-Saclay, Châtenay-Malabry,
France
3UMR Physiologie de la Reproduction et des Comportements, INRA,
CNRS, Univ. Tours, IFCE, Nouzilly, France
4Centre de Biophysique Moléculaire, CNRS, Orléans, France
We describe herein a methodology for the thioglycoconjugation of p-
iodophenylanaline (p-IPh) containing-peptides and aminoacids through
palladium-catalyzed coupling with glycosyl thiols. Palladacycle pre-
catalyst G3-XantPhos[1] was found to be highly efficient for the C¬S bond
formation under semi-aqueous conditions. The S-glycoconjugation is op-
erationally simple and displays broad substrate scope. A wide range of
thioglycosylated amino acids building blocks were synthesized with com-
plete control of anomeric stereochemistry. We studied the suitability of
the synthesized building blocks in standard Fmoc-based SPPS protocols.
Thioglycoconjugation was carried out at Tyr1 of a lipo-triazolo-peptide
analogue of the neuropeptide kisspeptin-10 (KP10)[2] with the aim to im-
prove its physicochemical properties (low water solubility, unwanted gel
formation[3]). The expected thioglyco-lipo-triazolopeptide was obtained
in similar yields as for the parent compound, demonstrating the compat-
ibility of our N-Fmoc thioglucoaminoacid building block with standard
Fmoc-SPPS protocols, including couplings, piperidine-mediated Fmoc de-
protections and TFA-based cleavage. The thioglycopeptide was tested for
its agonist activity towards the GPCR KiSSR, and showed similar sub-
nanomolar EC50 as the parent compound. Its physicochemical properties
were also briefly evaluated, however, no marked differences were observed
as compared to the non-glycosylated peptide.[4] The strategy was also suc-
cessfully applied to the thioglycoconjugation of unprotected peptides: to
demonstrate the broad potential of this technique for late stage function-
alization, we incorporated challenging β -S-GlcNAc- and α-S-GalNAc-
derivatives into very long unprotected peptides derived from the mucin
MUC1. The generated thioglycoconjugates were used as biochemical tools
to study their recognition by O-GalNAc-specific lectins, suggesting future
in applications of this method in chemical (glyco)biology. References: 1.
See for example: (a) A. Bruneau, M. Roche, A. Hamze, J.-D. Brion, M.
Alami and S. Messaoudi, Chem. Eur. J. 2015, 21, 8375–8379; (b) N.
Probst, R. Lartia, O. Thery, M. Alami, E. Defrancq, S. Messaoudi, Chem.
Eur. J. 2016, 22, 15006–15010. 2. (a) M. Beltramo, V. Robert, M. Galib-
ert, J.-B. Madinier, P. Marceau, H. Dardente, N. De Roux, D. Lomet, A. F.
Delmas, A. Caraty and V. Aucagne, J. Med. Chem., 2015, 58, 3459−3470;
(b) C. Decourt, V. Robert, K. Anger, M. Galibert, J. B. Madinier, X. Liu, H.
Dardente, D. Lomet, A. F. Delmas, A. Caraty, A. E. Herbison, G. M. An-
derson, V. Aucagne and M. Beltramo M. Sci. Rep. 2016, 6, 26908–26918.
3. N. Nishizawa, Y. Takatsu, S. Kumano, A. Kiba, J. Ban, S. Tsutsumi,
H. Matsui, Shin-ichi Matsumoto, M. Yamaguchi, Y. Ikeda, M. Kusaka, T.
Ohtaki, F. Itoh, and T.Asami J. Med. Chem.2016, 59, 8804–8811. 4. The
article of this work has been submitted
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Verification of mannan (polymannose)-peptide
conjugation by SDS-PAGE
Areti Gkika1, Maria-Eleni Androutsou2, Iro
Triantafyllakou1, Alexios Vlamis-Gardikas1, Theodore
Tselios1
1University of Patras, Greece
2Vianex S.A., Greece
Myelination of the nerve axons ensures the unhindered transmission of
neuron impulses. Multiple sclerosis (MS) is an autoimmune disease
whereby the myelin of the central nervous system (CNS) is destroyed,
leading to paralysis and serious health problems. Myelin consists of pro-
teins and lipids while in CNS, myelin basic protein (MBP), proteolipid
protein (PLP), myelin oligodendrocyte glycoprotein (MOG) and myelin-
associated glycoprotein (MAG) are the main proteins of the membrane
sheath of myelin. MOG is an autoantigen associated with the pathogene-
sis of MS and experimental autoimmune encephalomyelitis (EAE, animal
model of MS). The 35-55 epitope of MOG has been implicated in the in-
duction of EAE in mice. Conjugation of this epitope with mannan polysac-
charides via Schiff base has been extensively studied in our laboratory with
the conjugates showing potential against EAE. In the presented study, the
conjugation reaction and the quantification of the unconjugated peptide
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were followed and verified by SDS-PAGE and high-performance liquid
chromatography (HPLC). The optimum time needed for complete conju-
gation was six hours (yield of more than 95 %). The developed analytical
methodology could prove useful for the study of conjugation between pep-
tides and polysaccharides.
P96
Nucleus penetrating peptidomimetic synthesis and
application
Magdalena Wysocka, Anita Romanowska, Irena
Audzeyenka, Adam Lesner
University of Gdansk, Poland
Arginine rich peptides, belong to class of cell penetrating peptides that
are able to transport the wide variety of attached chemical entities (car-
gos) through the cell membrane. Diversity of transported molecules is
impressive and includes: DNAs, siRNAs, peptides, proteins and small
drugs. Polyarginines comprise over five residues of L-arginine efficiently
penetrate the cell membrane, and in some instances are part of more com-
plex molecule which is able to deliver cargos to nucleus through nuclear
localisation signal (NLS). The general aim of this work is to reveal the
mechanism and properties of novel cell penetrating peptidomimetic. Such
molecule contains six instances of L-2,3-diaminopropionic acid (DAP)
connected through the peptide bond and modified on its side chain amino
groups by substitution of 8-amidino-3,6-dioxaoctanoic acid (PEG) fur-
ther abbreviated as (GO2). For group of compound we proposed the ab-
breviation DAPEG that is merged DAP and PEG. Such compound was
synthesized on solid phase using Fmoc/Mtt chemistry by applying semi-
monomeric approach. Obtained peptidomimetic is labelled by fluorophore
moieties efficiently penetrates cell membrane and is transported directly
to nucleus of primary and transformed cell without significant toxicity.
Such compound is also resistant to protease action inside the cells. Such
compound forming strong non covalent complex with DNA, which is re-
sistant to nuclease action. In this work the panel of techniques aiming
to deeply characterized novel nuclear penetrating peptidomimetics with
different types of cargo moieties will be presented including DNA bind-
ing constant (thermophoresis, nanocalorimetry and surphase plasmon res-
onanse) and interactions with cell membrane.
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Design and Synthesis of Novel Silicon-containing
Small Molecule Peptidomimetics with Nanomolar
Anticancer Activities
Lajos Gera1, Peter Hegyes2, Daqing Wu3, Robert Hodges1
1University of Colorado Denver, Anschutz Medical Campus, Aurora, CO,
80045, United States
2Avidin Kft, Szeged, H-6726, Hungary
3Augusta University, Augusta, GA, 30912, United States
The problems associated with existing anticancer drugs are that many pa-
tients are unable to tolerate the high toxicities associated with chemother-
apy (serious side-effects and toxicity-associated death). Thus, there is
an urgent need to develop new first-line agents with reduced toxicity and
side-effects. There is also a need for new drugs for cancer prevention in
high-risk patients. More than a decade ago we developed a highly potent
bradykinin (BK) antagonist peptide dimer, B9870 (also known as B201,
CU201 and Breceptin) with excellent anticancer activity against small cell
lung cancer (SCLC) [1]. The transformation of our B9870 BK anticancer
peptide dimer into peptidomimetics led us to the discovery of BKM570,
the first generation of our small molecule peptide mimetic with a simple 3
component “A-B-C” structure [1]. Structural optimization of BKM570 re-
sulted our new generation of peptidomimetics with aminobisphosphonate
and NSAID components [2,3]. In this presentation, we will discuss the
synthesis and the structural modification of our anticancer “A-B-C” small
molecules introducing silicon-containing components [4]. Using silicon
over carbon has many advantages: a) compounds are more lipophilic than
their carbon equivalent, b) silicon can improve compound permeability, c)
silicon can lower compound toxicity, d) silicon can change receptor se-
lectivity, e) silicon can enhance anticancer activity of compounds, f) sili-
con compounds can treat drug- resistant tumors. In our new compounds,
GH1501, GH1503 and GH1504, the “A” component was modified to con-
tain a silicon atom. These compounds were tested by the National Cancer
Institute (NCI) in vitro against 60 human tumor cell lines. The NCI re-
sults showed that these small molecules are potential anticancer drug can-
didates with specificity against prostate and colon cancer cell lines. These
compounds were less active against other cancer types including breast,
central nervous system (CNS), leukemia, melanoma, non-small cell (NSC)
lung, ovarian, and renal cell lines. GH1503 is the best silicon contain-
ing compound to date for prostate cancer cell lines (average IC50 less
than 500 nM). GH1501, GH1503 and GH1504 are all active against colon
cancer with similar activity (IC50 less than 500 nM). The Eli Lilly Open
Innovation Drug Discovery Program suggested the target for GH1503 is
EZH2, a Histone H3 Lys 27 (H3K27) Methyltransferase. These new sili-
con containing peptidomimetics were synthesized in solution phase using
Boc-chemistry. They were purified by Reversed-phase high-performance
liquid chromatography (RP-HPLC) and characterized by LC-MS. Our an-
ticancer results will be discussed.
[1] Whalley, E.T., Figuerora, C.D., Gera, L., Bhoola, K.D. Expert Opin.
Drug Discovery, 7, 1129 (2012). [2] Seo, S.I. Gera, L., et al. Clin. Cancer
Res. 14, 6198 (2008). [3] Gera, L., et al. In Peptides: Proc. 24th APS,
American Peptide Society and Prompt Scientific Publishing, San Diego,
241 (2015). [4] Gera, L., et al. US 9828393 B2, Nov. 28, 2017.
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Pyrrole-based Macrocyclic Small-Molecule Inhibitors
Targetting Oocyte Maturation
Pethiah Gunasekaran, Jeong Kyu Bang
Korea Basic Science Institute, South Korea
Polo-like kinase 1 (PLK1) plays crucial roles in various stages of oocyte
maturation. Recently, we reported that the peptidomimetic compound
AB103-8, which targets the polo box domain (PBD) of PLK1, affects
oocyte meiotic maturation and the resumption of meiosis[1]. However, to
overcome the drawbacks of peptidic compounds, we designed and synthe-
sized a series of pyrrole-based small-molecule inhibitors and tested them
for their effects on the rates of porcine oocyte maturation. Among them,
the macrocyclic compound (E/Z)-3-(2,16-dioxo-19-(4-phenylbutyl)-3,19-
diazabicyclo[15.2.1]icosa-1(20),6,17-trien-3-yl)-propyl dihydrogen phos-
phate (4) showed the highest inhibitory activity with enhanced inhibition
against embryonic blastocyst formation. Furthermore, the addition of this
compound to culture media efficiently blocked the maturation of porcine
and mouse oocytes, indicating its capacity to penetrate the zona pellucida
and cell membrane. We investigated mouse oocytes treated with com-
pound 4, and the resulting impairment of spindle formation confirmed
PLK1 inhibition. The molecular modeling studies with PLK1 PBD also
confirmed the presence of significant interactions between compound 4
and PLK1 PBD binding pocket residues, including those in the phosphate,
tyrosine-rich, and pyrrolidine binding pockets. Collectively, these results
suggest that the macrocyclic compound 4 may serve as a promising tem-
plate for the development of novel contraceptive agents. [2]
References: [1] Jia, J. L., Han, Y. H., Kim, H. C., Ahn, M., Kwon, J. W.,
Luo, Y., Gunasekaran, P., Lee, S. J., Lee, K. S., Bang, J. K., Kim, N. H.,
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Namgoong, S. (2015) Sci. Rep. 2015, 13, 14626. [2] Gunasekaran, P., Lee,
S., Jeong, S., Takei, T., Asahina, Y., Bang, G., Kim, S., Ahn, M., Ryu, E.
K., Kim, H. N., Nam, K. Y., Shin, S. Y., Hojo, H., Namgoong, S., Kim, N.
H., Bang, J. K. (2017) ChemMedChem, 12, 580-589 (Cover page article).
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Amphipathic Triazine based small molecules with
Potent Anti-bacterial and Anti-atopic Dermatitis
Properties
Jeong Kyu Bang
Korea Basic Science Institute, South Korea
The steady rise of drug resistant bacteria remains the major threat to the
public health.1 Even though cationic peptide antibiotics (CPAs) found to
be a potential source of treating the drug resistant bacteria, their trans-
formation into a therapeutic is hindered by series of disadvantageous in-
cluding, high protection cost, proteolytic stability, poor cell permeability
and salt resisitance.2 To overcome this,we report the development of tri-
azine based amphiphilic small molecular antibacterial agents as a mimics
of lysine- and arginine-based cationic peptide antibiotics (CPAs). From
the antimicrobial screening of these compounds against a panel of both
Gram-positive and Gram-negative bacterial strains, we identified some
potent compounds. Further, evaluation of these compounds against anti-
inflammatory studies led to an array of four efficient compounds, DG-
5, DG-6, DL-5, and DL-6. Moreover, these molecules displayed good
potency against drug-resistant bacteria, including MRSA, MDRPA, and
VREF. In addition, they inhibit the biofilm formation, and also maintains
their antimicrobial activity in the presence of physiological salts and serum.
Mechanistic studies, including cytoplasmic membrane potential, confocal
imaging and flow cytometry suggest that DG-5, DG-6, and DL-5 kill bac-
teria by targeting bacterial membrane, while DL-6 follows intracellular tar-
geting mechanism. We also demonstrate that these molecules are having
therapeutic potential by showing the efficiency of DG-5 in preventing the
lung inflammation of LPS-induced ALI mouse model. More intriguingly,
DL-6 exhibited impressive potency on atopic dermatitis (AD)-like skin le-
sions in BALB/c mice model by displaying the proficiency in suppressing
the pro-inflammatory cytokines. Collectively, these results suggest that
they can serve a new class of antimicrobial, anti-inflammatory and anti-
atopic agents with promising therapeutic potential.
References 1. C. L. Ventola, Pharm. Ther. 2015, 40, 277−28 2. B. M. Pe-
ters, M. E. Shirtliff, M. A. Jabra-Rizk, PLOS Pathog. 2010, 6, e1001067.
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Synthesis & Analysis of β -Peptides For The Specific
& Non-specific Aggregation On Model Membranes
Markus Wiegand, Geralin Höger, Ulf Diederichsen
University Göttingen, Germany
In biological systems protein-membrane interactions form complex struc-
tures, which fulfill numerous functions such as signaling, regulation and
domain formation. Furthermore, these interactions are of great importance
to the functional and structural integrity of bio-membranes.1 Yet many
aspects of the mechanism and dynamics of the protein-membrane inter-
actions remain unknown, therefore artificial model systems might give
an insight into the complex nature of protein-membrane interactions.2,3
The goal of this study is to establish model systems of aggregational
peptide-membrane interactions by exploiting β3-peptide scaffolds. These
scaffolds are known to form stable, well-defined 14-Helices as secondary
structures and can be obtained via manual Solid Phase Peptide Synthesis
(SPPS).6,7 These peptides are modified with molecular recognition units
to enable specific and non-specific aggregation among each peptide, as
well with hydrophobic moieties to achieve membrane interactions. These
lipid-like modifications can be alkyl chains as well as cholesterol, which
are able to insert into membranes spontaneously.8,9 The Peptide aggre-
gation is achieved by pursuing two approaches. One approach is the in-
corporation of a chelating agent like a bipyridine derivative. These non-
specific aggregation can be achieved by the addition of metal cations.10,11
The other approach is the use of nucleobase modifications, which offers a
means of specific aggregation by Watson-Crick base pairing.12
References 1. J. Bonifacino, J. Lippincott-Schwartz, Nat. Rev. Mol. Cell.
Biol. 2003, 4, pp. 409-14. 2. G. Ebert, Biopolymere: Struktur und Eigen-
schaften, B.G. Teubner, Stuttgart, 1993, 1992. 3. W. S. Horne, S. H. Gell-
man, Acc. Chem. Res. 2008, 41, 1399–1408 4. S. Suetsugu, Microscopy
2016, pii: dfw002. [Epub ahead of print] 5. S. Suetsugu , S. Kurisu , T.
Takenawa, Physiol. Rev. 2014, 94, 1219-48 6. D. Seebach, D.F. Hook, A.
Glättli, Biopolymers 2006, 84, 23-37. 7. R.P. Cheng, S.H. Gellmann, W.F.
DeGrado, Chem. Rev. 2001, 101, 3219-32 8. S. Bourgault, M. Létourneau,
A. Fournier, Peptides 2007, 28, 1074-1082. 9. Y.-L. Yu, J.-W. Bai, J.-H.
Zhang, J. Mol. Struct. 2012, 1019, 1-6. 10. G.R. Newkome, A.K. Patri,
E. Holder, U.S. Schubert, Eur. J. Org. Chem. 2004, 2, 235-54. 11. C.S.
Pilz, C. Steinem, Eur. Biophys J. 2008, 37, 1065-71 12. P. Chakraborty, U.
Diederichsen, Chem. Eur. J. 2005, 11, 3207-16.
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Enopeptin A analogs: Synthesis & Activity
Sacha Stadelmann, Stéphane Mayor, Vincent Pilloud, Marti
Roger, Marc Mathieu
HESSO, Switzerland
The therapy of life-threatening infections significantly weakened by the
global spread of antibiotic resistance has prompted a need for the de-
velopment of novel, effective, and safe antibiotics. Novel antibacterial
agents with unprecedented mechanisms of action, which are devoid of
pre-existing cross-resistances, are therefore very necessary [1]. Natural
products from soil bacteria (Actinomycetes), have served as a promising
source of new structural leads in this area [2], in particular the cyclodidep-
sipeptides (CDP). CDP’s show promising pharmacological activities and
meet all criteria for good solubility and permeability. CDP’s are capa-
ble like natural peptides, to interact with numerous proteins and show a
large panel of activities (antitumor, anthelmintic, insecticidal, antibiotic,
antifungal, immunosuppressant, antiinflammatory and antimalarial). We
will present most recent achievments with our novel solid-phase assem-
bled Enopeptin A analogs varying the R and R’ positions, and discuss
their structure-activity relationship following cell bio-activity screening as-
says. (1) Hinzen B. et al., Med. Chem. 2006, 1, 689 – 693 (2) Jordan D.
Goodreid, J. Nat. Prod. 2014, 77, 2170−2181
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Immobilization by Surface Conjugation of Cyclic
Peptides for Effective Mimicry of the HCV-Envelope
E2 Protein as a Strategy toward Synthetic Vaccines
Theodorus Meuleman1, James Dunlop2, Anna Owsianka2,
Helmus Van de Langemheen1, Arvind Patel2, Rob
Liskamp1
1School of Chemistry, University of Glasgow, United Kingdom
2MRC-University of Glasgow Centre for Virus Research, United
Kingdom
Mimicry of the binding interface of antibody−antigen interactions us-
ing peptide-based modulators (i.e., epitope mimics) has promising appli-
cations for vaccine design. These epitope mimics can be synthesized
in a streamlined and straightforward fashion, thereby allowing for high-
throughput analysis. The design of epitope mimics is highly influenced
by their spatial configuration and structural conformation. It is widely as-
sumed that for proper mimicry sufficient conformational constraints have
to be implemented. This paper describes the synthesis of bromide deriva-
tives functionalized with a flexible TEG linker equipped with a thiol-
moiety that could be used to support cyclic or linear peptides. The cyclic
and linear epitope mimics were covalently conjugated via the free thiol-
moiety on maleimide-activated plate surfaces. The resulting covalent, uni-
form, and oriented coated surface of cyclic or linear epitope mimics were
subjected to an ELISA to investigate the effect of peptide cyclization with
respect to mimicry of an antigen−antibody interaction of the HCV E2 gly-
coprotein. To the best of our knowledge, the benefit of cyclized peptides
over linear peptides has been clearly demonstrated here for the first time.
Cyclic epitope mimics, and not the linear epitope mimics, demonstrated
specificity toward their monoclonal antibodies HC84.1 and V3.2, respec-
tively. The described strategy for the construction of epitope mimics shows
potential for high-throughput screening of key binding residues by simply
changing the amino acid sequences within synthetic peptides. In this way,
leucine-438 has been identified as a key binding residue for binding mon-
oclonal antibody V3.2.
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Trifluoromethylated proline surrogates as part of
‘Pro-Pro’ turn-inducing templates for the design of
β -hairpin mimetics.
Charlène Gadais1, Kevin Van Holsbeeck1, Samuel Moors2,
Krisztina Fehér3, Julien Pytkowicz4, José Martins3, Frank
De Proft2, Dirk Tourwé1, Thierry Brigaud4, Charlotte
Martin1, Grégory Chaume4, Steven Ballet1
1ORGC - Vrije Universiteit Brussel, Belgium
2ALGC - Vrije Universiteit Brussel, Belgium
3NMR department - Universiteit Gent, Belgium
4LCB - Université de Cergy-Pontoise, France
Proline is often found as a turn inducer in protein domains. Exploitation
of its restricted conformational freedom led to the development of a D-Pro-
Pro (pP) segment as a ‘templating’ unit, frequently used in the design of β -
hairpin peptidomimetics. Recent studies revealed the stabilizing effect of
CF3-proline surrogates on β -turn conformation, especially by controlling
the cis-trans isomerization of the amide bond. In view of finding alterna-
tive templates with a stronger capacity to fix the β -hairpin conformation,
we investigated different fluorinated analogs of the well-established D-Pro-
Pro segment as β -turn promoter. A conformational study was performed
on a set of 12 non-natural variants of pP hairpin sequence, incorporating
TfmPro and TfmOxa. Out of the investigated combinations only TfmPro-
Pro, TfmPro-TfmPro, TfmOxa-Pro, D-Pro-TfmPro, D-Pro-TfmOxa exhib-
ited a strongly stabilized β -turn conformation, relative to the ‘parent’ pP.
Considering synthetic feasibility, D-Pro-TfmOxa was selected for the in-
corporation into peptides. The increased preference of the selected peptide
for the β -hairpin conformation was confirmed by molecular dynamics. To
support those calculations, synthetic methodology was elaborated to pre-
pare the peptide Fmoc-DPro-TfmOxa-Val-OH as a suitable building block
for incorporation by SPPS in a cyclic β -hairpin mimetic sequence. Sub-
sequent NMR conformational study is carried out to evaluate the β -turn-
inducer propensity of these trifluoromethylated diproline surrogates.
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Functionalized Collagen Model Peptides
Jasmine Egli, Helma Wennemers
Department of Chemistry and Applied Bioscience, ETH Zurich,
Switzerland
Collagen is the most prevalent protein in mammals.[1] The protein has
a fibrous structure that arises from right-handed triple helices that are
formed from three, parallel, left-handed all-trans polyproline (II)-like sin-
gle strands. Studies with short-chain collagen model peptides (CMPs)
showed that the cis/trans isomerization of the amide bonds is the rate-
limiting step for triple helix formation.[2] Preorganization of the amide
bonds within collagen single strands into trans conformation is therefore
expected to accelerate triple helix folding and result in increased triple he-
lix stability. In 2015, our group showed that an apolar environment favors
the trans isomer of acetylated dimethylamide of proline over the cis iso-
mer.[3] Based on this result, we reason that a hydrophobic environment
pre-organizes the single strands in a trans conformation and should result
in stable, fast-folding triple helices. To create such a hydrophobic microen-
vironment, we covalently linked hydrophobic residues to CMPs, while still
maintaining the solubility in an aqueous environment. Thermal denatura-
tion experiments and temperature jump experiments showed that the CMPs
with the hydrophobic attachment are remarkably more stable and faster-
folding than CMPs without a hydrophobic moiety. NMR studies and native
MS confirmed the observations. The results of these experiments as well
as those obtained with other functionalized CMPs[4,5] will be presented.
Literature: [1] M. D. Shoulders, R.T. Raines, Annu. Rev. Biochem. 2009,
78, 929. [2] H. P. Bächinger, J. Engel., P. Brucker, Eur. J. Biochem. 1978,
90, 605. [3] C. Siebler, B. Marysin, M. Kümin, R.S. Erdmann, C. Rigling,
C. Grünenfelder, C. Ochsenfeld, H. Wennemers, Chem. Sci. 2015, 6,
6725. [4] J. Egli, C. Siebler, B. Maryasin, R. S. Erdmann, C. Bergande,
C. Ochsenfeld, H. Wennemers, Chem. Eur. J. 2017, 23, 7938-7944. [5] J.
Egli, R. S. Erdmann, P. Schmid, H. Wennemers, Org. Bio. Chem. 2017,
53, 11036-11039.
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Design of new cyclic plasmin inhibitors
Yuko Tsuda1, Koushi Hidaka1, Keiko Hojo1, Keigo
Gohda2, Naoki Teno3, Keiko Wanaka4
1Kobe Gakuin University, Japan
2Computer-Aided Molecular Modeling Research Center, Kansai, Japan
3Hiroshima International University, Japan
4Research Projects on Thrombosis and Haemostasis, Japan
Plasmin (Plm) is involved in the fibrinolysis pathway and pathologic events
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including angiogenesis, tumor invasion, metastasis, and alters the expres-
sion of cytokines. A growing body of data suggests that a Plm inhibitor is a
potential candidate as an anti-inflammatory and anti-cancer agent. The X-
ray crystal structure of YO-2 [trans-4-aminomethylcyclohexanecarbonyl-
Tyr(Opicolyl)-NH-Octyl: IC50 = 0.53 µM for Plm] [1] in complex with
microPlm (serine protease domain of Plm) reveals its binding mode [2], in
which the cyclohexylmethylamine moiety inserts into the S1 subsite. At
the S1’ subsite, the Tyr moiety forms a hydrogen bond with K607, and
the pyridine moiety forms an imperfect pi-pi stacking. Contrarily, the hy-
drophobic octyl moiety does not have extensive interaction with the S2’
subsite; it points away from the protease surface. In this work, we describe
cyclic Plm inhibitors, in which YO-2 was cyclized between the side chains
of P2’and P3’site residues with the aim of creating extensive interactions
at the S2’site. The ring segment of the inhibitor could fit well into the
S2’site to enhance the binding affinity. The cyclization was performed via
ring closing metathesis (RCM) or lactam formation: 16-, 18-, 20-, and
22-membered ring compounds were obtained. The cyclic compounds in-
hibited Plm more strongly than the corresponding liner compounds. Fur-
thermore, the compounds having an olefin exhibited stronger Plm inhibi-
tion than that bearing a lactam. Among compounds, the cyclic compound
possessing an olefin with 20-membered ring showed the strongest Plm in-
hibition (IC50 = 3.68 µM), which was ten-times weaker than YO-2. It
implies that the ring structure is useful to occupy the S2’ site; however the
other elements such as hydrophobic interaction are required to increase the
contact points.
[1] Okada, Y., Tsuda, Y., et al. (2000) Chem. Pharm. Bull., 48, 1964-1972.
[2] Law, R.H.P., Wu, G., et al. (2017) blood advances, 1, 766-770.
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ON/OFF repetitive control of protease activity using
peptidomimetic ligands through biotin-streptavidin
affinity
Koushi Hidaka, Keiko Hojo, Yuko Tsuda
Kobe Gakuin University, Japan
Peptidomimetic protease inhibitors targeting the enzyme active site are use-
ful as research tools and drugs. Such small compounds are difficult to
remove from the proteases once they bind, requiring dilution or protein
denaturation procedures. Our research group developed “removable in-
hibitors” that was designed with a direct conjugation of biotin and a strip-
pable property, through extremely strong affinity to streptavidin (SA) even
after the binding to the target protease, in which the methodology was
named ISAAC. To extend the utility of removable inhibitors, we studied
the ON/OFF repetitive control of enzymatic activity derived from affinity-
purified proteases.
Protease inhibitors containing an amino group were coupled with biotin
using mixed anhydride method. Peptidomimetics with a carboxylic acid
were biotinylated through an additional hydrazide bond. The target pro-
teases were purified from human serum or cellular lysate using magnetic
beads possessing the conjugated inhibitors with a long spacer. The bound
protease was eluted by a solution containing removable inhibitors and the
eluate was examined for activity detection using the corresponding FRET
substrates along with SA addition.
Enzymatic activity of HIV-1 protease was inhibited by a removable in-
hibitor, bPI-11, which was sufficiently recovered by SA addition, and
then inhibited again by extra addition of the inhibitor. The result showed
ON/OFF/ON/OFF repetitive control of the enzymatic activity of HIV pro-
tease. Based on this result, we performed the activity detection of the wild-
type protease purified from human serum. The substrate cleavage was con-
firmed by addition of SA and suppressed by following addition of clinical
protease inhibitor drugs such as darunavir, lopinavir and atazanavir. Sim-
ilar experiments using the mutated protease, A17m5, which is lopinavir-
resistant, were performed, revealing its lower enzymatic activity and dif-
ferent inhibition by the clinical drugs from that of the wild-type protease.
Some biotinylated derivatives of pepstatin A, were also utilized to detect
cathepsin D activity purified from HCT116 cells and the activity was in-
hibited by addition of pepstatin.
These results showed the ON/OFF repetitive control of proteases using
removable inhibitors, suggesting useful applications for susceptibility or
drug resistance testing before treatment with protease inhibitor drugs.
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Polymer-based peptidomimetics of Cell Penetrating
Peptides and Antimicrobial Peptides
Marc Devocelle, Alan Hibbitts, Aoife O’Connor, Sally-Ann
Cryan, Deirdre Fitzgerald-Hughes
RCSI, Ireland
Peptides are an emerging class of new therapeutic candidates. The total
peptide drug market was estimated at $50 billion in 2015 and, with a pro-
jected annual growth rate of approximately 10%, is expected to exceed
$70 billion by 2019. They are approved/in development in a large num-
ber of therapeutic areas, including metabolic diseases, endocrinology, on-
cology, gastroenterology, cardiovascular, neurology. . . Antimicrobial Pep-
tides (AMPs) and Cell Penetrating Peptides (CPPs) are also promising pep-
tide candidates for therapeutic applications, as active entities and delivery
agents, respectively. Peptides, however, have a number of limitations im-
pending their direct clinical application. They are essentially a lack of oral
bioavailability and metabolic stability; a reduced serum half-life; an inabil-
ity, generally, to reach intracellular targets; a potential toxicity; a high cost
of production. Accordingly, the chemical and drug developments of ther-
apeutic peptides generally require a technology addressing these clinical
shortcomings.
Peptidomimetic conversion and conjugation to biocompatible polymers
are archetypal techniques of pharmacokinetic and pharmacodynamic
properties improvement for peptide therapeutics. The combination of
these two techniques in a method to generate polymeric mimics of
peptides has successfully been applied for the peptidomimetic con-
version of CPPs and AMPs (deRonde BM and Tew GN, Biopoly-
mers, 2015, 104(4), 265-280; Lienkamp K and Tew GN, Chemistry,
2009, 15(44), 11784-11800). These peptidomimetics include guany-
lated poly((oxa)norbornenes), polymethacrylamides and oligocarbonates,
as well as a guanylated polymethacrylates, for CPPs, and poly(acrylics),
nylon-3 and poly(norbornenes), for AMPs. Novel polymeric mimics of
CPPs and AMPs, based on a biocompatible polymer backbone not previ-
ously exploited in peptidomimetics, have also been prepared and will be
presented. Their activities as transfection reagents (CPP mimetics) or an-
timicrobial/antibiofilm agents (AMP mimetics) surpass, or match those of
the parent peptides, respectively, while being metabolically stable. Also, as
demonstrated with the CPP mimetics, these polymer-based peptidomimet-
ics are devoid of toxicity and cheaper (30 fold) to produce than the parent
peptide.
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Comparison of the Cell Permeability of Linear and
Cyclic Peptoids
Daseul Ko1, Min-Kyong Shin1, Yu-Joung Hyun1, Ji Hoon
Lee2, Hyun-Suk Lim1
1POSTECH, South Korea
2New Drug Development Center, Medicinal Chemistry Support
Department Daegu Gyeongbuk Medical Innovation Foundation, South
Korea
Cyclic peptoids are emerging as powerful class of peptidomimetics. Pep-
toids are known to have enhanced of cell permeability compared to pep-
tides, which means that they could serve as enhanced cell permeable
molecules. Also, cyclic peptoids, which have increased rigidity compared
to linear peptoids, could exhibit increased binding affinity against target
protein compared to linear counterparts due to reduced entropy penalty
when forming complex with the target. [1] However, no studies have
shown the experimental results of enhanced cell permeability of cyclic pep-
toids compared to linear peptoids that contain same residues. Here, we, for
the first time showed that the cell permeability of cyclic peptoids are more
cell permeable irrespective of side chains and size. Peptoids that were
used in the experiment were designed to be compatible with combinatorial
library and high-throughput screening technologies. Thus, cyclic peptoids
will serve as a promising protein binding molecules with high affinity that
could target intracellular proteins without the matter of cell permeability
and proteolytic ability.
References [1] Scharn, D.; Germeroth, L.; Schneider-Mergener, J.; Wen-
schuh, H. “Sequential nucleophilic substitution on halogenated triazines,
pyrimidines, and purines: a novel approach to cyclic peptidomimetics”, J.
Org. Chem. 2001, 66, 507−513.
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Incorporation of trifluoromethylated pseudoproline in
an entomotoxic knottin: effects on oxidative folding,
3D structure and biological activity
Franck Coste1, Grégory Chaume2, Madinier Jean-Baptiste1,
Isabelle Rahioui3, Bertrand Castaing1, Pedro Da Silva3,
Thierry Brigaud2, Vincent Aucagne1, Agnès Delmas4
1CNRS, France
2Cergy-Pontoise university, France
3INSA Lyon, France
4CNRS CBM, France
Chemical tools to explore the trans/cis isomerization of the peptide bond
have been studied for decades. Trans/cis Pro isomerization is known to
be a late and relatively slow event on the oxidative folding time scale,
and is considered a rate-limiting step in the folding of cis bond-containing
proteins. Cis bond-inducing (4S)-fluoro-proline and 5,5-dimethyl proline
were shown to accelerate the folding of cis bond-containing proteins [1].
We recently reported on the incorporation of a trifluoromethylated proline
surrogate (CF3-ΨPro) into short peptide sequences and its positive impact
on the stabilization of a cis peptide bond [2]. To enlarge the scope of CF3-
ΨPro to finely tune physicochemical and biological properties of polypep-
tides, we incorporated CF3-ΨPro in PA1b (37 residues), an entomotoxin
effective per os, isolated from pea seeds. PA1b is cross-linked by three
interlocked disulfide bridges, and contains a cis amide bond suspected to
slow down its oxidative folding [3]. CF3-ΨPro-containing PA1b was syn-
thesized by Fmoc solid phase peptide synthesis and CF3-ΨPro was incor-
porated as a Fmoc-Ala-CF3-ΨPro dipeptide. The oxidative folding was
conducted under thermodynamic control in the presence of a redox couple
as optimized [3a] and compared to native PA1b. The biological activity
of CF3-ΨPro-containing PA1b is of the same order of magnitude as that
of native PA1b. To evaluate subtle modifications introduced by a non nat-
ural amino acid, we solved by quasiracemate crystallography [4] the 3D
structure of a mixture of L-CF3-ΨPro-containing PA1b and a D-form in-
corporating D-Pro instead of D-CF3-ΨPro. This 1.1 Å resolution structure
allowed us to unambiguously attribute the cysteine pairing of interlocked
disulfide bridges and to gain atomic-level insight of CF3-ΨPro modified
knottin derivatives.
[1] (a) Arnold U., Hinderaker M. P., Köditz J., Golbik R., Ulbrich-
Hofmann R., Raines R. T. J. Am. Chem. Soc. (2003) 125, 7500. (b)
Boulègue C., Milbradt A. G., Renner C., Moroder L. J. Mol. Biol. (2006)
358, 846. [2] (a) Chaume G., Simon J., Caupène C., Lensen N., Miclet
E., Brigaud T. (2013) J. Org. Chem., 78, 10144. (b) Simon J, Pytkow-
icz J, Lensen N, Chaume G, Brigaud T. J. Org. Chem. (2016) 81, 5381.
(c) Chaume G., Simon J., Lensen N., Pytkowicz J., Brigaud T., Miclet E.
(2017) J. Org. Chem., 82, 13602. [3] (a) Da Silva P., Strzepa A., Jouvensal
L., Rahioui I., Gressent .F, Delmas A.F. (2009) Biopolymers. 92, 36. (b)
Da Silva P., Rahioui I., Laugier C., Jouvensal L., Meudal H., Chouabe C.,
Delmas, Gressent F. J. Biol. Chem. (2010) 285, 32689. [4] (a) Wukovitz
S.W., Yeates T.O., Nat. Struct. Biol. (1995) 2, 1062. (b) Mandal K., Pen-
telute B.L., Tereshko V., Kossiakoff, Kent S.B. J. Am. Chem. Soc. (2009)
131, 1362. (c) Mortenson D.E., Satyshur, Guzei I.A., Forest K.T., Gellman
S.H. J. Am. Chem. Soc. (2012) 134, 2473.
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Evaluation of Cell Permeability of Bicyclic Peptoids
Chang Deok Seo, Hee Myung Wang, Hyun-Suk Lim
POSTECH, South Korea
Macrocyclic peptoids, in particular bicyclic peptoids are of considerable
interest as a promising class of potential protein capture agents. Com-
pared to their linear and monocyclic counterparts, bicyclic peptoids have
significantly increased conformational rigidity and preorganized structures,
thereby enabling them to bind more tightly to the target proteins without
a major entropy loss. Owing to their relatively large size and conforma-
tional constraint, bicyclic peptoids might be well-suited molecules to tar-
get many challenging protein targets such as protein−protein interactions,
which cannot be easily modulated by traditional drug-like small molecules.
Because macrocyclic peptoids lack the amide protons in their backbones
like linear peptoids, it was perceived and recently investigated that cyclic
peptoids are more cell permeable than linear counterparts. However, de-
spite the cell permeability of monocyclic peptoids were studied, that of
bicyclic peptoids have not been investigated yet. Here, we compared the
cell permeability of bicyclic peptoids and their linear counterparts from
6mer to 10mer. Halotag-labeled linear and bicyclic peptoids were syn-
thesized and their penetration into the cell was analyzed by chloroalkane
penetration assay (CAPA). We could conclude that the bicyclic peptoids
are quite more permeable than linear peptoids. This result suggests that
compared to the linear peptoids, bicyclic peptoids will be a useful source
of protein binding molecules, especially for targeting intracellular proteins,
given their excellent cell permeability in addition to their conformational
rigidity and proteolytic stability.
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Structure-Activity Study of α-Peptoid/α-Peptide
Peptidomimetics: Influence of Hydrophobicity on
Antimicrobial Activity and Cytotoxicity
Nicki Frederiksen, Fredrik Björkling, Peter Nielsen, Henrik
Franzyk
University of Copenhagen, Denmark
Bacterial resistance to conventional antibiotics is a rising global challenge
and discovery and development of novel classes of antimicrobial agents are
urgently needed. In particular, multidrug-resistant Gram-negative strains
resistant to all currently used clinical antibiotics constitute a severe health
problem, since the new classes of antibiotics, launched in the period 2000-
2012 primarily target Gram-positive infections.
Antimicrobial peptides (AMPs) have in the last decades produced promis-
ing leads, as they often exhibit broad-spectrum activity and high selectivity
towards bacteria over mammalian cells. However, their therapeutic poten-
tial is generally limited by several disadvantages e.g., low plasma stability
due to proteolytic susceptibility and decreased activity in vivo due to bind-
ing to serum proteins. To circumvent these drawbacks, several types of
peptidomimetics with a high content of unnatural residues have been inves-
tigated as potent AMPs. Peptoid-containing peptidomimetics constitute an
interesting class of such compounds as they have been found to possess
high antimicrobial activity, while being stable and display increased activ-
ity in plasma.
Previously, lysine-based alpha-peptide/beta-peptoid hybrid oligomers
were found to display activity against multidrug-resistant bacteria. Gen-
erally, a 1:1 ratio of lysine to hydrophobic peptoid residues were found to
result in the highest antibacterial activity and lowest toxicity, but only a
small number of hydrophobic peptoids have been investigated. Previous
studies have shown that phenylalanine analogues and substituted variant
are favorable. Thus a more comprehensive investigation of the role of
hydrophobic residues for activity of peptoid-peptide hybrids with an alter-
nating cationic-hydrophobic design appeared to be lacking in literature.
In the present study, it was decided to explore a reversed design with the
cationic residues being the alpha-peptoid anologue lysine (i.e., NLys) since
we found that the corresponding Fmoc-protected building block readily
could be obtained in multigram scale without chromatography. Thus, a
wide range of polarity could be investigated by complementing the nat-
ural hydrophobic amino acids with unnatural alpha-amino acid display-
ing appropriate side chains. Thus, a library of >20 α-peptoid/α-peptide
hybrid oligomers were obtained by automated microwave-assisted solid-
phase synthesis using the Fmoc-protected peptoid building block Fmoc-
NLys(Boc)-OH and various Fmoc-protected amino acids. Subsequently,
the antimicrobial activity (MIC) of the compounds was tested against
a panel of pathogenic Gram-negative bacteria (Escherichia coli, Kleb-
siella pneumoniae, Acinetobacter baumannii, and Pseudomonas aerugi-
nosa). Somewhat surprisingly, most compounds displaying hydrophobic
aliphatic side chains proved to be inactive, with the exception of cyclo-
hexyl, while most compounds with hydrophobic aromatic side chains ex-
hibited moderate to high activity.
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Synthesis of novel arylazepinone dipeptide mimetics
and 1,5-benzothiazepinones as local constraints in
peptidomimetic design
Robin Van Den Hauwe1, Olivier Van der Poorten1, Steven
Ballet1, Emilie Eiselt2, Phillipe Sarret2, Louis Gendron2,
Dirk Tourwé1
1Vrije Universiteit Brussel, Belgium
2Université de sherbrooke, Canada
Incorporation of conformationally constrained amino acids is a well-
known technique to design peptides that are more potent and/or selective
towards their targeted receptors. Moreover, these modified peptides or pep-
tidomimetics display an increased metabolic stability, as compared to their
natural counterparts.[1] For this reason, many research groups direct their
attention to the application of conformationally constrained amino acids in
the development of novel peptide therapeutics. Presented herein is the use
of novel conformationally constrained arylazepinone dipeptidomimetics to
screen the χ-space of the aromatic Phe3 side chain within dermorphin’s se-
quence. 4-Amino-8-bromo-2-benzazepin-3-one (1) (8-Br-Aba), 3-amino-
3-4-dihydroquinolin-2-one (Dhq, not shown), and regioisomeric 4-amino-
naphthoazepinone (2-3) (1/2-Ana) scaffolds were synthesized in solution
via N-acyl iminium ion cyclization. These conformationally constrained
scaffolds were incorporated into dermorphin-like tetrapeptides, evaluated
in vitro and resulted in compact and high affinity MOP/DOP opioid recep-
tor ligands.[2] Secondly, 3-amino-1,5-benzothiazepin-4(5H)-One dipep-
tidemimetics (5) were constructed through an Ugi-4CR-Ullmann Cross-
Coupling sequence. The seven dipeptides were conformationally investi-
gated in silico and by NMR analysis, all lowest energy conformers stabilize
γ-and β -turn structures.[3]
References [1]. Van der Poorten, O. et al. J. Med. Chem. 2016, 59, 10865-
10890. [2]. Van der Poorten, O. et al. ACS Medicinal Chemistry Letters
2017, 8, 1177-1182. [3]. Van der Poorten, O. et al. Organic & Biomolecu-
lar Chemistry 2018, 16, 1242-1246
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Impact of Bulky Dehydroamino Acids on the Structure
and Proteolytic Stability of Peptides
Ankur Jalan, David W Kastner, Kei G I Webber,
Steven Castle
Brigham Young University, United States
New strategies for increasing the stability of peptides to proteolysis are
needed in order to facilitate the translation of bioactive peptides into phar-
maceutical agents. The inherently high levels of A1,3 strain present
in bulky alpha,beta-dehydroamino acids such as dehydrovaline and de-
hydroethylnorvaline make them promising candidates for rigidifying the
backbones of peptides and increasing their proteolytic stability. However,
synthetic challenges have hindered investigations of the impact of bulky
dehydroamino acids on peptide structure and stability. Recent advances
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from our laboratory have enabled the construction of peptides containing
dehydroVal or dehydroEnv. We have shown that these bulky dehydroamino
acids can substantially increase the stability of model beta-hairpin peptides
to degradation by Pronase, an aggressive mixture of nonspecific proteases.
We have correlated this enhanced proteolytic stability to an increased pref-
erence for the folded state versus random coil states. A summary of these
findings will be presented along with new data describing the effect of
bulky dehydroamino acids on other secondary structures. We envision a
host of exciting future applications for dehydroVal, dehydroEnv, and other
bulky dehydroamino acids as stabilizing and constraining elements of pep-
tides.
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Study of β -sheet Helix Interactions Based on
Conformational Properties of Synthetic
D,L-alternating Decapeptides
Emma Fenude, Michele Saviano
ICB-CNR, Department of Chemical Science and Material Technology-
Italy, Italy
De novo peptide design is based on the ability to construct peptide se-
quences with predictable folding patterns. Helices and β -sheet have been
the focus of considerable synthetic attention in attempts to assemble mim-
ics for helical bundles and all β -motifs. In contrast, strategies for construc-
tion of β -sheet helix have been less widely explored. The β -sheet helical
architecture is constructed from polypeptides that are coiled into a large
helix, formed by stacks of β -sheets separated by loops. β -Sheet helices
are present in the fibrous form of transyretin, that play an important role in
bovine spongiform encephalopathy (BSE) and form the crucial structural
elements in insect antifreeze proteins. We report on synthetic analogues
able to form β -sheet helices and on the structural comparison with β -
helices formed by D,L-alternating peptides. Alternating D,L peptides are
able to assume very specific conformations, including, among others, vari-
ous kinds of single and double stranded β -helical structures. β -Helix con-
formations share an important number of structural features with β -sheet
ones, as a set of hydrogen bonds between amino and carbonyl backbone
groups and ΦL, ΨL,ΦD, and ΨD values in poly-L- and poly-D-peptides.
Double stranded β -helices, both parallel and antiparallel, are stabilized by
systematic interchain NH-CO hydrogen bonds between adjacent peptide
chains and by intrachain hydrogen bonds equivalent in pairs. They are
symmetrical structures in which the backbone CO and NH groups are ori-
ented quasi-parallel to the helical axis but in alternating opposite directions.
The side chains are oriented perpendicular to the helical axis on the outside
of the helix. Insertion of proline residues within a homochiral segment has
been used to nucleate β -sheet helical conformation. The juxtaposition of
proline within repetitive motifs supports the formation of β -turns which
are labile and impart dynamic and flexibility upon sliding between succes-
sive Pro-containing repeats. Furthermore, the periodicity with which Pro
and Xaa amino acid are arranged with the peptide directs the formation
of specific secondary structures. We have observed –XPXPXPXP- peri-
odicity with the synthetic homologous of β -casomorphin-8 and a -PXXP-
periodicity using a synthetic, homochiral sequence having X=F with 13
amino acid. Here we report about synthesis and conformational behaviour
of both peptides.
References [1] Nowick J.S. Acc. Chem. Res. (2008) 41(10),1319-1330
[2] O’Neil K.T., DeGrado W.F., Science (1990) 250, 646-651 [3] Lorenzi
G.P., Gerber C., Jackle H., Macromolecules (1985) 18, 154-159
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Modulation of the properties of elastin-like
polypeptides by structure variations
Katerina Sancova1, Lucie Bednarova2, Romana Sulakova1,
Sergej Karel1, Barbora Brtkova3, Martin Flegel4, Vladimír
Velebný1
1Contipro a.s., Czechia
2Institute of Organic Chemistry and Biochemistry of the CAS, Czechia
3Contipro a.s., Slovakia
4University of Chemistry and Technology Prague, Czechia
Elastin-like polypeptides (ELPs) are artificial biomacromolecules derived
from hydrophobic VPGVG sequence of extracellular matrix protein tropoe-
lastin. Their ability to form coacervates at specific temperature has huge
potential in drug delivery, ELPs are also used in areas of protein purifi-
cation or tissue engineering. Non-natural, synthetic ELPs consist of re-
peating pentapeptide motives VPGXG, where X is represented by any of
encoded aminoacids except proline to preserve β -turn conformation [1].
Phase transition behavior is significant feature of this type of peptides. Un-
der transition temperature, these molecules are soluble in water. On the
other hand they form unsoluble clusters above the transition temperature.
Subsequent cooling under their transition temperature results in the res-
olution of ELPs. The transition temperature can be influenced by both
extrinsic and intrinsic factors. The intrinsic factors include changing pri-
mary sequence and chain length, whereas extrinsic variables comprise pH,
ionic strength or solvents [2]. We present the set of new pentacontapep-
tides H-(VPGLG)2(VPGXG)2(VPGLG)6-H prepared using SPPS proto-
col by Fmoc/tBu strategy, where as the variable element X the hydrophobic
(Gly, Ala, Leu), hydrophilic (Gln, Asn, Tyr), acidic (Glu) as well as basic
aminoacids (His, Lys) were used. Transition temperatures of our peptides
set mainly obtained using CD spectroscopy were defined and discussed
with respect to their primary structure.
[1] A. Chilkoti et al. Curr. Opin. Chem. Biol.10 (2006) 652–657. [2] F.
Aladini et al. J. Pep. Sci. 22 (2016) 334–342.
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Heme binding beyond Cys-Pro-motifs? – A systematic
Analysis of His/Tyr-Based Motifs in Heme Binding
peptides and proteins
Benjamin Syllwasschy, Marie-Thérèse Hopp, Ajay A. Paul
George, Amelie Wißbrock, Diana Imhof
University of Bonn, Germany
The porphyrin derivative heme (Fe(III)-PPIX) is vital to the survival of
all eukaryotic organ-isms, which mainly exploit its gas and electron trans-
porting properties in hemoproteins such as hemoglobin, myoglobin, and
cytochromes. In addition, a pool of biologically available heme has been
recognized to regulate biological processes such as transcription, ion trans-
port, circa-dian rhythm and inflammation.[1] Considering the amino acid
sequence responsible for such a regulatory interaction it is meanwhile
established that solvent-exposed sequence stretches pos-sessing distinct
features including coordination site(s) for the iron ion (termed heme-
regulatory motifs (HRMs)) are an indispensable prerequisite for heme
binding. Apart from the known Cys-Pro (CP)-dipeptide motifs less was
known with respect to consensus sequences for spe-cific HRMs beyond
CP. Thus, we established an approach which facilitates the detection of
heme-binding sequences and, in turn, novel heme-regulated proteins based
on combinatorial peptide library screening.[2-6] In these earlier studies,
we first focused on Cys-, His- and Tyr-containing sequences with a pri-
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mary interest in CP-motif containing peptides and proteins.[7-9] However,
a deeper analysis of the hit sequences revealed the frequent occurrence of
multiple tyrosines and/or histidines in peptides with strong heme-binding
affinities and in several well-known proteins.[10] Therefore, we hypothe-
sized that distinct combinations of His and Tyr may depict a novel HRM
beyond the well-established CP-motif. Here, we report a detailed struc-
tural analysis of the heme-binding capacity of a subset of H/Y-containing
peptides and their inverted sequences using spectroscopic methods. In ad-
dition, we will introduce a web-based tool, which enables the user to screen
protein sequences for HRMs, based on our findings. The presented study
will provide insight into this new class of HRMs and explore the under-
lying structure-binding relationship. It will provide an improved under-
standing of the molecular mechanism of regulatory heme binding and may
allow for the discovery of novel heme-regulated proteins based on defined
H/Y-motifs.
REFERENCES: [1] Kühl, T., et al. Chembiochem, 15(14), 2024-2035
(2014). [2] Wißbrock, A., et al. submitted to Mol. Gen. Metab. (2018).
[3] Brewitz, H. H., et al. Biochim. Biophys. Acta – Gen. Subj., 1860(6),
1343-1353 (2016). [4] Brewitz, H. H., et al. Chembiochem, 16(15), 2216-
2224 (2015). [5] Kühl, T., et al. ACS Chem. Biol., 8(8), 1785-1793 (2013).
[6] Kühl, T., et al. Chembiochem, 12(18), 2846-2855 (2011). [7] Brewitz,
H. H., et al., Biochim. Biophys. Acta – Gen. Subj., 1861(3), 683-697
(2017). [8] Hagelueken, G., et al., Biophys. J., 110(12), 2642-2650 (2016).
[9] Peherstorfer, S., et al. BBA-General Subjects, 1862(9), 1964-1972
(2018). [10] Wißbrock, A., et al. J. Med. Chem., 60(1), 373-385 (2017).
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The ever-growing spread of antimicrobial resistance among bacterial
pathogens is one of the major threats to public health. Especially con-
cerning is the case of Gram-negative multi-resistant bacteria, intrinsically
resistant to many hydrophobic molecules, due to the presence of a highly-
packed extra membrane system, the outer membrane (OM). Antimicro-
bial peptides (AMPs) are interesting candidates to fight bacterial infec-
tions, including those caused by Gram-negative bacteria, as the antimicro-
bial activity is exerted through membrane disruption, a mechanism that is
thought to be unlike to elicit resistance. We have studied the membrane
activity and selectivity of EcAMP1R2, a designed AMP highly specific
towards Escherichia coli. As model membrane systems, we have used
large unilamellar vesicles (LUVs) of different lipid compositions, includ-
ing those mimicking the outer (OML) and inner (IML) membranes of
E. coli, and actual E. coli cells. Using a combination of fluorescence
spectroscopy, flow cytometry and light scattering spectroscopy, we have
found that EcAMP1R2 discriminates between zwitterionic (mammalian-
like) and anionic (bacterial-like) membranes. Interestingly, the peptide
causes hyperpolarization of E. coli cells, indicating inability for pore for-
mation. Moreover, we have found that EcAMP1R2 promotes a cardiolipin-
dependent (hemi)fusion of IML vesicles, without a concomitant neutral-
ization of the zeta-potential. This result suggests that the interaction of
EcAMP1R2 with IML vesicles results in major membrane lipid rearrange-
ments able to alter the membrane curvature, with interesting mechanic im-
plications. We propose that the peptide can induce cardiolipin demixing
at the plasmatic membrane level, hampering the activity of the respira-
tory machinery, thereby causing membrane hyperpolarization. Molecular
dynamics (MD) simulations with the Martini force field were performed
to shed some light on the validity of our hypothesis, gathering additional
information that could explain the fusogenic ability of EcAMP1R2. Sim-
ulations indicated dimer formation on the membrane, which prompted ex-
perimental validation by NMR.
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Conformational dynamics of an intrinsically
disordered protein controlled by alpha-methylation of
amino acid residues
Vladimir Torbeev1, Valentin Bauer1, Boris Schmidtgall1,
Bruno Kieffer2
1Institut de Science et d’Ingénierie Supramoléculaires, University of
Strasbourg, France
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Intrinsically disordered proteins (IDPs) or protein domains readily fold
into well-defined secondary and/or tertiary structures upon binding to their
targets whereas in isolation they remain largely unfolded. Determining
the mechanistic pathways that lead to well-structured complexes involving
IDPs is a challenge. Here we demonstrate that mechanism of binding-
induced folding of an IDP can be elucidated by using site-specific incorpo-
ration of alpha-methylated amino acids that locally stabilize alpha-helical
conformations. Combinatorial chemical protein synthesis was applied to
prepare protein library that contained more than fifty alpha-methylated
variants of the p160 transcriptional co-activator ACTR and possessed up
to six alpha-methylated amino acids incorporated at various positions.
Complexation between ACTR variants and nuclear co-activator binding
domain NCBD was studied using various biophysical techniques in con-
junction with molecular dynamics simulations. Thermodynamic data for
complexation between ACTR variants and nuclear co-activator binding do-
main (NCBD) revealed presence of entropy-enthalpy compensation, such
that local conformational constrains (loss of entropy) resulted in more
stable intra- and intermolecular contacts (gain of enthalpy). Anomalous
compensation corresponded to functionally most important residues at
ACTR/NCBD interface. Furthermore, several alpha-methylated analogs
of ACTR have higher affinities to NCBD than wild type highlighting
their potential for development into efficient inhibitors for cancer-related
ACTR/NCBD interaction.
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Selective Metal-Ion Induced Folding of a Coiled-Coil
Peptide
Aimee Boyle1, Niek Crone1, Martin Rabe2, Guto Rhys3,
Patrick Voskamp1, N. Raj Pannu1, Alexander Kros1
1Leiden University, Netherlands
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A variety of small, well-defined, peptide scaffolds based on α-helices and
β -strands have been engineered to produce metal-binding peptides. These
designed metallopeptides have allowed researchers to probe the relation-
ship between peptide-folding and metal-binding. One such scaffold, used
to generate several metallopeptides, is the α-helical coiled coil.1 Coiled
coils are attractive design scaffolds as the majority have a defined sequence
repeat and several studies have uncovered rules enabling coiled-coils with
specific oligomeric states and orientations to be reliably designed.2-4 For
this study an existing, well-folded, trimeric coiled coil was employed,3
and histidine residues were introduced into different positions within the
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hydrophobic core. Analysis of the resulting peptides using circular dichro-
ism (CD) spectroscopy showed that the inclusion of one histidine per helix
was well tolerated but when two histidine modifications were introduced,
folding of the coiled coil was obliterated. However, folding could be in-
duced in a selective manner when divalent metal ions were added to the
peptide; Cu(II) and Ni(II) promoted folding of the peptide, while Co(II)
and Zn(II) did not. A combination of CD spectroscopy, NMR studies, and
analytical ultracentrifugation (AUC) revealed more about how the metal
ions and the peptides interact to form a folded construct. In addition, the
X-ray crystal structure of the Cu(II)-peptide complex was obtained and
this revealed an unusual coordination mode of the Cu(II), which provided
insights as to the reason for the observed metal-binding selectivity. It is
envisaged that further modification of this scaffold would allow for other
metals to be coordinated and potentially for metal-binding specificity to be
achieved.
1 A.J. Doerr & G.L. McLendon, Inorg. Chem., 2004, 43, 7916. 2 P.B.
Harbury, T. Zhang, P.S. Kim & T. Alber, Science, 1993, 262, 1401. 3 J.M.
Fletcher, A.L. Boyle, M Bruning, G.J. Bartlett, T.L. Vincent, N.R. Zaccai,
C.T. Armstrong, E.H.C. Bromley, P.J. Booth, R.L. Brady, A.R. Thomson
& D.N. Woolfson, ACS Synth. Biol., 2012, 1, 240. 4 A.R. Thomson, C.W.
Wood, A.J. Burton, G.J. Bartlett, R.B. Sessions, R.L. Brady D.N. Woolf-
son, Science, 2014, 346, 485.
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The multiHis-cyclopeptide as ligands for metal ions
Justyna Brasun, Aleksandra Kotynia
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Wide spectrum of biological processes involving metal ions fuels the in-
tensive research aimed at their detailed characterization. This research are
generally carried out with the use of biomimetic systems which mimicking
the structure and/or the activity of natural systems. These studies are con-
ducted primarily on protein and/or peptide systems, because they allow to
the introduction of a large number of modifications and tracking of their
impact on efficiency of metal ion binding and its coordination sphere. The
use of the linear models is restricted by high liability of their chain. This
restriction may be waived by the cyclization of the peptide chain. The
antibiotics, hormone peptides, toxins or transporters of metal ions though
the membrane can be found among of the naturally occurring cyclopep-
tides. Additionally the cyclic structure influences the sterical arrangements
of the side chains of the amino acid residues, which is significant for the
interactions with metal ions or for the receptor binding in the biological
systems.
The donor atoms for metal ions in the cyclopeptide molecule are nitrogens
form peptide bonds and donors from the side chains of the amino acid
residues as imidazole nitrogen of His or oxygen carboxylate side chain of
the Asp residue. The binding mode of the metal ion depends on the number
structural modifications e.g.: optical isomerism and acid-base properties of
side chain group [1], the ring size [2] or presence of Pro residue in the pep-
tide sequence [3]
We focused on the specially created cyclopeptides able to form bi-metallic
systems mimicking the active centers of metalloproteins. The new cy-
clopeptides with two prolines in the peptide cycle have been designed. The
insertions of two prolines allowed to create of two well defined metal bind-
ing sites. The performed studies have shown that these compounds are the
promising tool for the creation of the biomimetic systems as e.g. active
site of the superoxide dismutase (SOD). Due to the complexity of the bind-
ing processes and action of the metal ions in the living systems, presented
studies are still continued.
Literature 1. J. Brasun´, A. Matera, S. Ołdziej, J. Swiatek-Kozlowska, L.
Messori, C. Gabbiani, M. Orfei, M. Ginanneschi, J. Inorg. Biochem. 2007,
101, 452, 2. H. Czapor, S. Bielin´ska, W. Kamysz, Ł. Szyrwiel, J. Brasun´,
J. Inorg. Biochem., 2011, 105, 297–302 3. A. Kotynia, S. Bielin´ska, W.
Kamysz, J. Brasun´, Dalton Trans., 2012, 41, 12114
Acknowledgements: The presented work was supported by Wroclaw Med-
ical University (ST.D080.16.006).
P121
Elucidating the effect of membrane composition on the
structure of antimicrobial peptide
Hala Youssef, Christine Dewolf
Concordia University, Canada
GL13K is a thirteen residue, cationic antimicrobial peptide that is highly
selective for both Gram-positive and Gram-negative bacteria. Monolayer
studies coupled with spectroscopic techniques provide insight into the be-
haviour of the peptide at the outer leaflet of the membrane biointerface.
We probe the impact of membrane packing on the behaviour of GL13K
by incorporating cholesterol (Ch) or branched diphytanoylphosphatidyl-
glycerol (DPhPG) into negatively-charged dioleoylphosphatidylglycerol
(DOPG) model membranes. At the interface the peptide organizes into
crystalline β -sheets. The membrane composition significantly impacts the
depth of peptide insertion as well as the size of the inter-peptide β -sheet
structures.
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Methylene thioacetal bond substitution reveals a new
hidden pathway in BPTI folding mechanism
Reem Mousa, Shifra Lansky, Gil Shoham, Norman Metanis
The Hebrew University of Jerusalem, Israel
Bovine pancreatic trypsin inhibitor (BPTI) is a 58 residues protein that
is stabilized by three disulfide bonds at positions 5-55, 14-38 and 30-51
(right). BPTI folding mechanism was extensively studied since it repre-
sents a folding model for many disulfide-rich proteins. The reduced pro-
tein folds via bifurcated pathway, roughly half of the reduced BPTI reach
the native state via two intermediates: N’ that lacks the 5-55 disulfide and
N* that lacks the 30-51. Formation of the fully oxidized BPTI requires
partial unfolding that reduces the solvent exposed disulfide bridge 14-38
and rearrangement to form another intermediate NSHSH . Therefore, we
hypothesized that replacing the 14-38 disulfide bond with highly stable
methylene thioacetal (MT), will cause the protein to be trapped at the two
stable intermediates N’ and N*, preventing the formation of the native state
(N). We performed this experiment and found that this is not the case! The
methylene thioacetal substitution revealed a hidden pathway involving di-
rect reaction between N* and GSSG. This experiment revealed that the
previously published mechanism does not present a complete picture of
BPTI folding.
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The use of natural products isolated from microorganisms is becoming a
promising alternative approach to control plant diseases caused by phy-
topathogens. In this respect, cyclic lipodepsipeptides (CLPs) are a diverse
group of secondary metabolites produced by various bacteria with inter-
esting biological functions. However, they have yet unresolved molecular
mechanisms. CLPs are made up of an amino acid sequence consisting of
both D- and L-amino acids. At the N-terminus, they are capped by a fatty
acid moiety, in most cases a hydroxydecanoic acid. Depending on chem-
ical properties, such as the amino acid sequence length, the CLPs can be
classified into different groups. Our previous efforts have gone towards
characterizing the three-dimensional conformations of several CLP groups
using liquid-state NMR spectroscopy, X-ray crystallography or both. It
is believed that CLPs exert their biological functions through interactions
with the cellular membrane. However, a full understanding of their mem-
brane interactions is essential to elucidate the exact working mechanism
of CLPs. To obtain comprehensive structural information in a membrane
environment, we have used various, complementary techniques including
liquid-state NMR spectroscopy. Using this technique, the affinity, orien-
tation and insertion depth of CLPs in a membrane environment can be
investigated using diffusion NMR and paramagnetic relaxation enhance-
ment measurements. The latter is achieved by introducing paramagnetic
probes at various locations. By introducing a water-soluble paramagnetic
complex, NMR signals from nuclei closer to the aqueous phase can be
identified. Adding lipid molecules with covalently linked paramagnetic
radicals at various positions deliver the orientation and the insertion depth
of the peptides in the bilayer. The NMR results are complemented with
other experimental techniques, including fluorescence spectroscopy, circu-
lar dichroism and infrared spectroscopy. We have also performed all-atom
molecular dynamics (MD) simulations of CLPs within lipid membranes,
which can be confronted with the experimental results.
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4Université de Cergy Pontoise, France
Collagen, the most abundant protein in the animal kingdom, is also an im-
portant biomaterial owing to its great mechanical strength and its excellent
thermal stability. This last decade, both the industry and the academia have
been involved in the development of new collagen-related biomaterials.[1]
One common strategy consists in using Collagen Model Peptides (CMP)
as collagen surrogates. Numerous studies have demonstrated that short se-
quences, based on the repetition of the Pro-Hyp-Gly triplet, can be used
to mimic the primary sequence of collagen.[2] Using such peptides, we
have developed an approach combining CD and NMR spectroscopies in
order to characterize the formation of the triple helix (TH) and its struc-
tural features in solution. MD simulations and NMR spectroscopy have
allowed us to gain insights into the conformational ensembles explored by
the monomeric CMP peptides and their conversion into larger oligomeric
species. Innovative 13C, 15N strategies and NMR developments have
been carried out to obtain structural information on these assemblies at
the atomic scale. In addition, we have been able to introduce 19F nuclei
in model CMP using previously reported strategies.[3-6] Kinetic and struc-
tural effects of this insertion onto the collagen triple helix will be discussed
using the developed biophysical tools and MD simulations.
[1] Koide, T., Philos. Trans. R. Soc. B. 362, 1281-1291 (2007). [2] Shoul-
ders, M. D., Raines, R. T., Annu. Rev. Biochem. 78, 929-958 (2009). [3]
Feytens, D., Chaume, G., Chassaing, G., Lavielle, S., Brigaud, T., Byun,
B. J., Kang, Y. K., Miclet, E. J. Phys. Chem. B 116, 4069-4079 (2012). [4]
Chaume, G., Simon, J., Caupene, C., Lensen, N., Miclet, E., Brigaud, T., J.
Org. Chem. 78, 10144-10153 (2013). [5] Chaume, G., Feytens, D., Chas-
saing, G., Lavielle, S., Brigaud, T., Miclet, E. New J. Chem. 37, 1336-38
(2013). [6] Chaume, G., Simon, J., Lensen, N., Pytkowicz, J., Brigaud, T.,
Miclet, E. J. Org. Chem. 24, 13602-13608 (2017).
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peptide brevinin-1BYa and its analogue
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Brevinin-1BYa (FLPILASLAAKFGPKLFCLVTKKC), first isolated from
skin secretions of the foothill yellow-legged frog Rana boylii, is partic-
ularly effective against C. albicans, and is also active against E. coli
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and S. aureus. The structures of brevinin-1BYa and its less-potent ana-
logue [C18S,C24S]brevinin-1BYa were investigated in various solution
and membrane-mimicking environments by 1H-NMR spectroscopy and
molecular modelling. Brevinin-1BYa possesses two cysteine residues, one
at the C-terminal end of the peptide and the other 6 residues prior to it,
joined by a disulphide bridge. The peptide does not appear to possess a sec-
ondary structure in aqueous solution. In a 33% 2,2,2-trifluoroethanol (TFE-
d3)-H2O solvent mixture, as well as in membrane-mimicking sodium dode-
cyl sulphate micelles, and dodecylphosphocholine micelles, however, the
structure is characterised by a helix-hinge-helix motif, with a hinge located
at the Gly13/Pro14 residues, and the two α-helices extending from Ile4 to
Lys11 and from Lys15 to Thr21. Positional studies of both the native peptide
and its serine analogue in sodium dodecyl sulphate micelles using 5-doxyl
labelled stearic acid and manganese chloride paramagnetic probes show
that the N-terminal helical segment of the peptide lies parallel to the micel-
lar surface, with the residues of the hydrophobic side of the amphipathic
helix facing towards the micelle core and the hydrophilic residues pointing
outwards, with similar results obtained for the C-terminal segment of the
native peptide.
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Understanding how antimicrobial peptides interact
with membranes
Glen van den Bergen, Alan Mark
School of Chemistry and Molecular Bioscience, The University of
Queensland, Australia
Antimicrobial peptides (AMPs) are a first line of defence against many
pathogens in a diverse range of organisms, including humans. The ma-
jority of AMPs act by disrupting the plasma membrane. Many models of
membrane disruption have been proposed (e.g. barrel-stave pores, toroidal
pores, disordered toroidal pores, carpet-like, micelle formation, etc.). This
makes predicting whether a given peptide sequence will be antimicrobial
highly challenging. Using the assumption that membrane disrupting pep-
tides optimise the amphipathic arrangement of amino acids, I have exam-
ined the ability of evolutionary algorithms to predict the structures of 44
membrane-bound AMPs. I have compared the predicted structures to con-
formations determined by solution NMR in membrane mimetic environ-
ments and explored how these structures might be used to predict activity
and mechanism of action.
Many of the structures predicted were curved helices, with alignment of
hydrophobic residues on the concave surface of the peptide. For example,
the curvature and the amphipathic arrangement predicted for crotalicidin
matched well with the curvature and residue alignment observed by solu-
tion NMR. However, in the case of dermadistinctin K, the hydrophobic
residues faced the convex surface; opposite to the alignment of residues
seen by solution NMR. To investigate this disparity, the precise details of
how dermadistinctin K and crotalicidin disrupt lipid bilayers were stud-
ied with molecular dynamics simulations. The antimicrobial activity of
Dermadistinctin K is claimed to act by a carpet-like mechanism and cro-
talicidin is proposed to form pores. The implications of how these con-
trasting mechanisms would effect their interaction with the membrane, the
membrane-bound structures and how they compare to the results of opti-
mising amphipathicity, are investigated.
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Targeting Peptide Secondary Structures with
Multicomponent Ligation and Cyclization Strategies
Aldrin Vasco Vidal1, Daniel García Rivera2, Ludger
Wessjohann1
1Leibniz Institute of Plant biochemistry, Germany
2Center for Natural Products Research. University of Havana, Cuba
This work discloses how peptide secondary structures (i.e., helices, beta-
strands and beta-turns) can be either induced or stabilized in short pep-
tide sequences with the use of isocyanide-based MCRs. Two different
multicomponent strategies are described: i) the side chain-to-side chain
macrocyclization of peptides to stabilize helices, bulges and turn struc-
tures, and ii) the ligation of a small peptide to a rigid, bulky template ca-
pable to fold back the peptide chain into a beta-turn. Applications of such
strategies on the synthesis of biologically relevant peptide structures(e.g.,
beta-hairpins) are presented, together with the determination of the solu-
tion three-dimensional structures of the peptides by means of NMR and
molecular dynamics simulation.
P128
Alpha-methylation scan of an intrinsically disordered
protein to study and control its conformational
dynamics and binding
Valentin Bauer, Boris Schmidtgall, Bruno Kieffer, Vladimir
Torbeev
Université de Strasbourg, France
The activation domain from p160 transcriptional co-activator for thyroid
hormone and retinoid receptors (ACTR, 47 amino acids) was found to be
highly unstructured with only the N-terminal part partially adopting α--
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helical conformation. It is a well-known intrinsically disordered protein
which binds with high specificity and affinity to nuclear co-activator bind-
ing domain (NCBD, 47 amino acids) from the CREB protein forming a
well-structured complex which exhibits six α-helices (PDB 1KBH).
In this work, we present a new way to study IDPs conformation dynamics
and complex formation. The incorporation of non-canonical α-methylated
amino acids, which are conformationally constrained with (ϕ/ψ) back-
bone dihedral angles corresponding to 310/α-helical conformation, was
performed on ACTR at multiple sites using Fmoc/tBu-Solid Phase Peptide
Synthesis (SPPS) and Native Chemical Ligation (NCL)(1). In total we
synthesized more than 50 methylated variants of ACTR. By incorporation
of α-methylated amino acids we were able to modify the conformation of
ACTR variants in the free state and, furthermore, to alter the energetic land-
scape of binding-induced folding with NCBD. To observe changes in α--
helical content and conformational changes upon α-methylation, nuclear
magnetic resonance (NMR) and circular dichroism (CD) measurements
were performed. To dissect the thermodynamics and kinetics of complex
formation, isothermal titration calorimetry (ITC) and surface plasmon res-
onance (SPR) were used, respectively.
We confirmed that incorporation of α-methyl amino acids leads to the en-
hancement in α-helical content of ACTR, and that the α-helical content
plays a key role in complex formation with NCBD.
(1) Dissecting Mechanism of Coupled Folding and Binding of an In-
trinsically Disordered Protein by Chemical Synthesis of Conformation-
ally Constrained Analogues. B. Schmidtgall, O. Chaloin, V. Bauer, M.
Sumyk, C. Birck,and V. Torbeev. Chemical Communications, (2017) DOI
: 10.1039/C7CC02276J
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Activation of the Chemokine-like Receptor 1 by
Cyclic Chemerin-9 Analogs
Tobias Fischer, Tristan Zellmann, Annette G.
Beck-Sickinger
Faculty of Life Sciences, Universität Leipzig, Germany
The chemokine-like receptor 1 (CMKLR1) is a G protein-coupled recep-
tor (GPCR), which is expressed mostly on the surface of cells of the innate
immune system like macrophages and dendritic cells. Since activation of
CMKLR1 by its endogenous ligand chemerin results in the chemotaxis of
these cells, chemerin has been proposed to be an important regulator of
inflammation. Detailed knowledge of receptor binding and activation at
a molecular level is crucial for the development of agents that could be
used in the treatment of diseases like psoriasis or inflammatory bowel dis-
ease. Wittamer et al. discovered in 2004 that a small nonapeptide derived
from the C-terminus of chemerin, named chemerin-9, is able to activate
the CMKLR1 with nanomolar potency similar to the full-length protein.
Previous work in our group indicated that this peptide binds to its recep-
tor in a hairpin-like conformation. Exploiting this information we could
synthesize cyclic chemerin-9 analogs that have the same potency and in-
creased stability compared to the native peptide. Running molecular dy-
namics (MD) simulations of these novel cyclic peptides in combination
with signal transduction studies helped gaining a more detailed insight into
the conformation necessary for receptor activation, which might be benefi-
cial for the development of even more potent analogs.
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Synthesis and conformation of short peptides modeled
after peptide LL-37
Barbara Biondi1, Silvia Millan2, Fernando Formaggio2,
Alessandra Semenzato3, Cristina Peggion2
1ICB, Padova Unit, CNR, Department of Chemistry, University of
Padova, Italy, Italy
2Department of Chemistry, University of Padova, Italy
3Department of Pharmaceutical Sciences, University of Padova, Italy
Numerous tissues and cells of our body (e.g., epithelial or innate im-
mune cells) are able to produce the 37-residue peptide cathelicidin LL-
37 [1]: -LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES- LL-37
plays important roles in the innate immune system as it acts as a natural
antibiotic against Gram-positive and Gram-negative bacteria, fungi, and
even viruses [1,2,3]. Also, it can inhibit the viral replication [1], promote
wound healing [1,4] and kill tumor cells [4,5]. Its possible mechanisms
of action, based on the disruption of cell membranes, were recently re-
viewed [3,6]. LL-37 is an amphipathic, α-helical peptide with an over-
all positive charge (+6). The helical structure promotes cell killing by
binding to the negatively-charged bacterial membrane. To make LL-37
industrially appealing as a drug, we started a program aimed at individuat-
ing shorter segments endowed with the same potency of LL-37. We syn-
thesized short, helical peptides stabilized by one or two helix-promoting
Aib (alpha-aminoisobutyric acid) residues: 1 Pal-RKSKEKIG-NH2 (Pal
= palmitoyl) 2 Pal-KSKEKIG-NH2 3 Ac-RKUKEKIG-NH2 (Ac = acetyl;
U = Aib)) 4 Pal-RKUKEKIG-NH2 5 Ac-KRUVQRUKDFLR-NH2 6 Pal-
KRUVQRUKDFLR-NH2 Peptides 1 and 2 correspond to segments 7-14
and 8-14, respectively, of LL-37. To protect them from the enzymatic
degradation we added at the N-terminus a palmitoyl moiety, able also to
promote membrane insertion. In peptides 3 and 4 the helix-promoting and
hydrophobic Aib residue replaces Ser9. We came to this choice after hav-
ing observed that the hydrophilic Ser9 is located on the hydrophobic face
of the alpha-helical LL-37. With peptides 5 and 6 we focused on the 18-29
segment of LL-37, known to be quite active. Also in this case we aimed
at assessing the possible beneficial effects of palmitoylation and Aib inser-
tion. All peptides were synthesized by the solid phase approach and puri-
fied by reverse-phase HPLC. Their 3D-structures were assessed by means
of circular dichroism and 2D-NMR. For all peptides we observed alpha-/3-
10-helix equilibria, strongly dependent on the solvent used. Preliminary
experiments of interactions with model membranes reveal an interesting
selectivity for peptide 4.
References: [1] P. Chieosilapathama, S. Ikedab, H. Ogawab, F. Niyons-
abab, Cur. Pharm. Design 2018, 24, 1079-1091. [2] M. E. Pachón-Ibáñez,
Y. Smani, Jerónimo Pachón, J. Sánchez-Céspedes, FEMS Microbiol. Rev.
2017, 41, 323-342. [3] K. Zeth, E. Sancho-Vaello, Front. Chem. 2017, 5,
art. 86. [4] A. A. Baxter, F. T. Lay, I. K. H. Poon, M. Kvansakul, M. D.
Hulett, Cell. Mol. Life Sci. 2017, 74, 3809-3825. [5] E. Ogawa, Y. Sato,
A. Minagawa, R. Okuyama, J. Dermat. 2018, 45, 264–272. [6] Z. Khur-
shid, M. Naseem, F. Y. I. Asiri, M. Mali, R. S. Khan, H. A. Sahibzada, M.
S. Zafar, S. F. Moin, E. Khan, Biomolecules 2017, 7, art. 80.
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Synthesis and conformational investigation of
hetero-chiral sequential oligopeptides based on the
(alphaMe)Aze/Ala dyad
Bruno Drouillat1, Cristina Peggion2, Barbara Biondi2,
Karen Wright1, François Couty1, Marco Crisma2, Fernando
Formaggio2, Claudio Toniolo2
1Institute Lavoisier de Versailles, UMR CNRS 8180, Université de
Versailles, France
2ICB, Padova Unit, CNR, Department of Chemistry, University of
Padova, Italy
Conformationally restricted alpha-amino acids are able to promote spe-
cific main-chain conformations in peptides. One of them, (S)-2-
methylazetidine-2-carboxylic acid [(S)-(alphaMe)Aze], when combined in
homo-chiral dipeptide sequences with (S)-Ala, has been shown to produce
multiple gamma-turns.[1] Recently, some of us developed a practical syn-
thesis of both (alphaMe)Aze enantiomers.[2] By use of (R)-(alphaMe)Aze
we synthesized the hetero-chiral sequential oligopeptide series listed be-
low:
Boc-[(S)-Ala-(R)-(alphaMe)Aze]n-OMe (n = 1-3) Boc-[(R)-
(alphaMe)Aze-(S)-Ala]n-OMe (n = 2,3) Boc-[(S)-Ala-(R)-
(alphaMe)Aze]n-(S)-Ala-OMe (n = 1,2)
An X-ray diffraction analysis unambiguously showed that in the crystal
state the hetero-chiral tripeptide Boc-(S)-Ala-(R)-(alphaMe)Aze-(S)-Ala-
OMe adopts a regular type-II beta-turn conformation. However, FT-IR ab-
sorption and 2D-NMR data provide evidence that in deuterochloroform so-
lution the tripeptide is mainly folded in a gamma-turn conformation. Tran-
sition from the former conformation to the latter requires only a variation
of the (alphaMe)Aze psi torsion angle from the crystallographically ob-
served value of 3.8° to -45°. As for the higher homologs, the combined re-
sults of our conformational investigation in solution (by FT-IR absorption,
NMR, and CD spectroscopies) strongly suggest that they are involved in
conformational equilibria to which both beta- and gamma-turns may con-
tribute. The relative weight of the beta-turn conformers seems to increase
with increasing main-chain length. This outcome, quite unexpected if com-
pared to the preference for multiple, non-consecutive gamma-turns dis-
played by the corresponding homo-chiral peptides, suggests that sequence
chirality might be a dominant feature in directing type of backbone folding
in these sequential oligopeptide series.
References [1] M. Crisma, M. De Zotti, A. Moretto, C. Peggion, B. Drouil-
lat, K. Wright, F. Couty, C. Toniolo, New J. Chem. 2015, 39, 3208. [2] B.
Drouillat, K. Wright, J. Marrot, F. Couty, Tetrahedron Asymmetry 2012,
23, 690.
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Synthesis of Fluorinated Ubiquitin Variants
Valentina Stulberg, Beate Koksch
Freie Universität Berlin, Institute for Chemistry and Biochemistry,
Takustr. 3, 14195 Berlin, Germany
Ubiquitin is a structurally conserved protein found in many eukaryotic tis-
sues. In the process called ubiquitination this protein is covalently attached
to diverse target peptides and proteins, which is important in numerous
biological processes, for example, proteolytic degradation.[1] Due to its
highly conserved globular structure ubiquitin is an interesting model for
an investigation of the effects that modifications in the primary structure
have on protein stability, structure, and function. The incorporation of flu-
orinated amino acids into peptides and proteins has attracted broad interest
due to the unique properties of fluorine (e.g., high electronegativity, low
polarizability and small size). [2] In this context, our goal is to establish
ubiquitin as a biologically relevant model for studying fluorine-specific
interactions, in particular their impact on protein folding. To this end a
protein library of site-specifically fluorinated ubiquitin monomers will be
synthesized and ligated in different combinations with similarly fluorinated
or not fluorinated variants. These complexes will be investigated regarding
the role of fluorine-fluorine interaction in protein folding. [1] D. Koman-
der, M. Rape, Annu. Rev. Biochem. 2012, 81, 203–29. [2] A. A. Berger,
J- S. Völler, N. Budisa, B. Koksch, Acc. Chem. Res. 2017, 50, 2093-2103.
P133
Solution Studies of the Bioactive Peptide Nisin
Wayne Travers, Fintan Kelleher
Institute of Technology Tallaght, Dublin, Ireland
Nisin, a 34 amino acid lanthipeptide, is currently used as a food preserva-
tive worldwide and has been used for decades without significant bacterial
resistance being reported.1 It is an extremely active molecule which kills a
range of different Gram-positive bacterial species, in the nano-molar range.
However, nisin, along with some other similar peptides, suffers from low
stability at physiological pH, which severely restricts its possible use as a
therapeutic in human and veterinary medicine.2
Above pH 6 nisin suffers from a dramatic decrease in both solubility and
stability. The two histidine residues (27 and 31) may be involved in the
dramatic decrease in solubility due to the side-chain pKa values being in
this pH range. Nisin is supplied commercially with a very high NaCl con-
tent (>70% w/w), which may have an effect on both its conformational
stability and bioactivity. NMR and Circular Dichroism (CD) studies of
both naturally occurring forms of Nisin (A and Z) will be presented.
References 1 W. Liu and J. N. Hansen, Appl. Environ. Microbiol., 1990,
56, 2551–8. 2 E. Breukink and B. de Kruijff, Biochim. Biophys. Acta -
Biomembr., 1999, 1462, 223–234.
P134
The 1,3-diyne linker as a tunable tool for peptide
secondary structure stabilization
Steven Verlinden1, Niels Geudens2, José Martins2, Steven
Ballet1, Guido Verniest1
1Vrije Universiteit Brussel, Belgium
2Ghent University, Belgium
In search of new, mild and functional group tolerant cyclization strategies
towards novel constrained cyclopeptidomimetics, oxidative alkyne-alkyne
coupling reactions were proposed as a straightforward method. The in-
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troduction of 1,3-diynes in macrocyclic peptides can provide new reactive
sites for post-cyclisation derivatization of the obtained macrocycles. This
is of importance to reach libraries of conformationally distinct peptide or-
ganizations, starting from one parent macrocycle. A thorough optimiza-
tion study of the Glaser-Hay coupling (> 50 conditions) using alkynylated
amino acid derivatives revealed that O-propargylserines and analogues un-
dergo much faster oxidative coupling as compared to propargylglycine
derivatives. A series of tetrapeptides, synthesised via SPPS and a solution
phase strategy, were cyclized under the optimised Glaser-Hay conditions
using Cu(OAc)2.H2O and NiCl2 as catalysts in EtOH or DMF at 60°C in
the presence of pyridine and triethylamine (14 examples; between 50 and
>99% conversion).[1] Moreover, the cyclic peptides were used as parent
molecules to obtain a variety of peptidic macrocycles containing a modi-
fied 1,3-diyne linker. Thiophenes and furans were introduced after reaction
of the diyne moiety with NaHS and H2O respectively under mild condi-
tions. New macrocycles were obtained after reaction with three different
1,2-bisnucleophiles (hydrazine, hydroxylamine and N-methylhydrazine).
In all cases, a mixture of regioisomers was obtained. In contrast, the re-
action of 1,2-bisnucleophiles with a macrocyclic non-symmetric 1-aryl-
4-alkyl-1,3-diyne resulted in only one regioisomer.[2] Recently, we have
shown that the 1,3-diyne linker can be used as a rigid “staple” for stabi-
lizing an α-helical peptide containing 12 amino acids. The figure below
shows one example where the linker stabilizes the helical fragment within
the macrocycle (i,i+7). Because the seemingly straightforward alkyne
alkyne coupling failed upon attempts to cyclize the O-propargylserine con-
taining peptide sequence, the 1,3-diyne unit is introduced as a dipeptidic
SPPS-compatible building block and the peptide is cyclised through head-
to-tail lactamisation. Furthermore, the influence of the configuration of the
O-propargylserines and the transformation of the 1,3-diyne towards hete-
rocycles on the secondary structure is studied.
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Gaining and losing the activity of antimicrobial [KL]n
peptides
Fabian Schweigardt1, Parvesh Wadhwani2, Erik
Strandberg2, Jochen Bürck2, Johannes Reichert2, Anne
Ulrich2
1KIT, IOC, Germany
2KIT, IBG-2, Germany
In the last decade, the development of peptides as drugs has experienced
a renaissance due to finding more and more applications to treat various
diseases. Further, they are generally expected to behave more predictably
in vivo and be less toxic than synthetic small molecule drugs. However,
their chemical and physical stability is susceptible to external factors, such
as pH, temperature and surface interactions which can lead to degradation
or aggregation/fibrillation and makes application and storage of peptidic
drugs challenging.
To study the influence of surface interactions on the activity of antimicro-
bial peptides, amphiphilic β -strands can be designed in different fashions.
In this study, the chosen design consists only of alternating lysine and
leucine residues, resulting in perfect segregation of charged K residues and
hydrophobic L residues and are thus excellent candidates to form β -pleated
amyloid fibrils. These so called KLn peptides ([KL]n/2-NH2) show high
antimicrobial activity against various bacterial strains which can be modi-
fied by variation of peptide length. Additionally the antimicrobial activity
of KLn peptides can be turned on by diminishing contact time to free phos-
phate ions. From these properties guidelines towards the mode of action
for these kind of peptides can be derived.
P136
Conformation and Domain Movement Analysis of
Human Matrix Metalloprotease-2: the role of
associated Zn2+ and Ca2+ ions
Leah Voit-Ostricki1, Sándor Lovas2, Charles Watts1
1Mayo Clinic Health System, United States
2Creighton University, United States
Matrix Metaloprotease-2 (MMP-2) is a 550 amino acid residue extracel-
lular Zn2+ protease that recognizes and degrades type I and IV collagens.
Its Expression is associated with several inflammatory, degenerative, and
malignant diseases. MMP-2 has three domains (fibronectin, catalytic, and
hemopexin) and five crystallographically assigned divalent cations (2 Zn2+
and 3 Ca2+). In this study, we compared the conformational properties
and domain movements of MMP-2 with attention to interactions between
the protein and its associated metal ions using 1.2 µs NPT (at 310 K and
101.325 kPa) MD simulations using the CHARMM36m force field and
metal ion parameters of Li et al.[1]. Dihedral principle component analysis
revealed 10 families of conformations with the greatest degree of variabil-
ity occurring in the loop connecting the catalytic and hemopexin domains.
Cross correlation analysis indicated a domain movement corresponding to
opening and closing of the hemopexin domain in relation to the fibronectin
and catalytic domains. The root mean square fluctuations of the metal ions
compared to the average conformation were as follows: Zn2+ ion 1: 0.59
nm, Zn2+ ion 2: 0.88 nm, Ca2 ion 1: 0.57 nm, Ca2+ ion 2: 2.91 nm,
and Ca2+ ion 3: 1.06 nm. The catalytic Zn2+ ion 1 is closely associ-
ated (0.21±0.01 nm) with the Nε atoms of His403, His407 and His413.
The non-catalytic Zn2+ ion 2 is closely associated (0.18±0.01 nm) with
the Oδ atoms of Asp180. Interaction energies were calculated using the
MMPBSA-interaction entropy analysis method [2,3] and are as follows:
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Zn2+ ion 1: -1113.51 ± 27.12 kJ mol-1, Zn2+ ion 2: -598.09 ± 29.09 kJ
mol-1, Ca2+ ion 1: -1153.69 ± 56.65 kJ mol-1, Ca2+ ion 2: -298.07 ±
27.33 kJ mol-1, and Ca2+ ion 33: -1147.73± 30.78 kJ mol-1. Present MD
simulations demonstrated significant stability in the interaction between
the protein and the catalytic Zn2+ ion. The second Zn2+ ion plays a mi-
nor role in conformational stability of the catalytic domain while the Ca2+
ions do not contribute significantly any of the structural properties.
References:
1. Li, P. et al. Theory Comput. 2013, 9, 2733-2748. 2. Sun, Z. et al. J.
Chem. Phys. 2017, 146, 124124. 3. Duan, L. et al. J. Am. Chem. Soc.
2016, 138, 5722-5728.
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Inhibitors of the Neuropilin-1 and Vascular
Endothelial Growth Factor 165 Interaction
Bartlomiej Fedorczyk1, Dagmara Tymecka1, Karolina
Grabowska1, Anna Puszko1, Piotr Lipinski2, Gerard Y.
Perret3, Aleksandra Misicka1
1Faculty of Chemistry, University of Warsaw, Poland
2Mossakowski Medical Research Center, PAS, Poland
3Université Paris 13, Sorbonne Paris Cité, France
Neuropilin-1 (NRP-1) has been found to be overexpressed in several kinds
of malignant tumors, and it is postulated that in pathological angiogenesis,
its interaction with the vascular endothelial growth factor 165 (VEGF165)
leads to progression of tumor vascularization and growth. Moreover this
signaling complex is also involved in suppression of immune response
against tumor cells. It has been previously shown, that heptapeptide
ATWLPPR (A7R) binds to NRP-1 and selectively inhibits VEGF-165 bind-
ing to NRP-1. Additionally in vivo treatment with A7R resulted in decreas-
ing breast cancer (MDA-MB-231) angiogenesis and growth. In the frame
of our work we synthetized peptidomimetics based on the C-terminal site
of A7R and proposed two types of very potent analogues: linear and cyclic.
In this poster we present structure-activity relationship studies which had
led us to obtain strong inhibitors of VEGF-165/NRP-1 interaction, which
might serve as prospective antitumor drugs.
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Use of Trifluoromethylated Pseudoprolines for the
Design of Collagen Triple Helix containing Unusual
C(5)-Substituted Proline Surrogates
Keyvan Rahgoshay1, Anaïs Terrien2, Nathalie Lensen1,
Thierry Brigaud1, Emeric Miclet2, Grégory Chaume1
1Université de Cergy-Pontoise, France
2Sorbonne Université, France
Collagen is the most abundant structural protein of mammals represent-
ing the major component of the extracellular matrix and is therefore
widespread all over the body. Its tertiary structure consists in three individ-
ual left-handed polyproline II helices (PPII, Φ ≈ -60°, ψ ≈ 150°) folded
into a right-handed triple helix which is stabilized by inter-strand hydro-
gen bonds and that has a single-residue offset.[1] Each strand comprises
the repeat of the (Xaa-Yaa-Gly) primary sequence where the (2S)-proline
(Pro,P) and the (2S,4R)-4-hydroxyproline (Hyp,O) are the most prevalent
at Xaa and Yaa positions, respectively.[2] Crystal structures of short-length
Collagen Model Peptides (CMPs) show that Pro and Hyp residues exhibit
preferentially C(4)-endo and C(4)-exo ring pucker, respectively.[3] As a
paradigm, this alternation has been proposed to be a prerequisite for the
formation of the triple helix since it preorganizes the individual strands in
suitable conformation, thereby decreasing the entropic cost.[4] Since both
Pro and Hyp residues exhibit the expected puckering, their prevalence im-
parts an excellent thermal stability to the collagen triple helix. Following
these rational design principles, numerous CMPs have been engineered
using (4S) and (4R)-substituted proline derivatives without a significant
destabilization of the collagen triple helix, provided that they have con-
formational properties similar to those of Pro and Hyp residues and do
not interfere with the interstrand H-bonds. Our group has developed the
synthesis of the CF3-pseudoprolines (CF3-ψPro) and their incorporation
into peptides.[5] We previously demonstrated that these proline analogues
allow to locally tune the peptide bond geometry, the puckering of the 5-
membered ring as well as the Φ and Ψ dihedral angles.[6] It was found
that the diastereoisomers TfmψP and tfmψP are acting as analogues of
the Pro and Hyp residues, respectively, by adopting the prerequisite puck-
ering necessary for the formation and stabilization of the triple helix. Here,
we will present the synthesis of fluorinated host-guest CMPs incorporating
in the middle of the sequence one or two CF3-ψPro. 1H and 19F NMR
structural analysis of the CMPs along with the CD and NMR studies of the
formation of the collagen triple helix and its stability will be also shown.
References [1] (a) Shoulders, M. D. et al. Annu. Rev. Biochem. 2009, 78,
929; (b) Bella, J. Biochem. J. 2016, 473, 1001. [2] Ramshaw, J. A. M. et
al. J. Struct. Biol. 1998, 122, 86. [3] Shoulders, M. D. et al. Proc. Natl.
Acad. Sci. U.S.A. 2010, 107, 559. [4] Okuyama, K. et al. Biopolymers
2012, 97, 607. [5] (a) Chaume, G. et al. J. Org. Chem. 2010, 75, 4135; (b)
Chaume, G. et al. J. Org. Chem. 2013, 78, 10144; (c) Chaume, G. et al. J.
Org. Chem. 2017, 82, 13602. [6] Feytens, D. et al. J. Phys Chem B. 2012,
116, 4069.
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Molecular dynamics simulations studies of
Gonadotropin Releasing Hormone (GnRH) and GnRH
Receptor
Haralambos Tzoupis1, Agathi Nteli1, Maria-Eleni
Androutsou2, Theodore Tselios1
1University of Patras, Greece
2Vianex S.A., Greece
Sexual maturation of human cells in ovaries and prostate is closely linked
to the secretion of Gonadotropin Releasing Hormone (GnRH). The hor-
mone binds to receptors (GnRH receptors) in the surface of the cells and
instigates an extensive biochemical cascade that leads to production and
release of luteinizing hormone (LH) and the follicle-stimulating hormone
(FSH). Sequence analysis data classify GnRH receptors (GnRHR) as part
of the G protein-coupled receptors (GPCRs). Structural data from GPCRs
show the presence of a seven trans-membrane helical bundle. The lack
of any structural data about GnRHR, impedes the rational design of ago-
nist or antagonist GnRH peptides or non-peptide mimetics for use in the
treatment of infertility and hormone dependent cancer. In this study, we
employ these common structural and sequence characteristics for the con-
struction of the homology model of GnRH receptor. Structural information
from the human B2-adrenergic receptor as well as rhodopsin has been used
in order to create a theoretical model of GnRHR. Furthermore, molecular
dynamics (MD) simulations have been used to refine the proposed model
and investigate the impact of the bilayer membrane in GnRHR conforma-
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tion. Additionally, MD simulations were implemented for the analysis of
the conformations of GnRH in aqueous solution. The results support the
proposed model in the literature regarding the bent conformation of the
hormone. The presence of a β -turn in the conformation of the peptide has
been shown to be paramount in the binding of GnRH to the receptor and
its subsequent activation.
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Structural Studies of Maximin-3
Silvia Benetti1, Patrick Timmons2, Chandralal Hewage2
1Department of Chemical Sciences, University of Padova, Italy and
Conway Institute of Biomolecular and Biomedical Research, School of
Biomolecular and Biomedical Science, Centre for Synthesis and
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2Conway Institute of Biomolecular and Biomedical Research, School of
Biomolecular and Biomedical Science, Centre for Synthesis and
Chemical Biology, University College Dublin, Ireland
Maximin-3 (GIGGKILSGLKTALKGAAKELASTYLH) is a 27-residue
long cationic antimicrobial peptide found in the skin secretion and brain
of the Chinese red belly toad Bombina maxima. The peptide is interesting
as it possesses anti-HIV activity, not found in the other maximin peptides,
in addition to its antimicrobial, antitumor, and spermicidal activities. Its
conformation was investigated in a 50/50% 2,2,2-trifluoroethanol (TFE-
d3)/water mixture using two-dimensional NMR spectroscopy. Maximin-3
was found to adopt an α-helical structure from residue Ile2 to Ala22, with
a break around Lys15 and Gly16, and a coiled structure extending from
Ser23 to the C-terminus. The peptide has a well-defined separation be-
tween polar and hydrophobic residues, therefore it is amphipathic. The
interactions with sodium dodecyl sulfate (SDS) micelles, a widely-used
bacterial membrane-mimicking environment, are then modelled employ-
ing molecular dynamics simulations. The peptide maintains an α-helical
conformation, occasionally displaying a flexibility around the Gly9/Leu10
and Gly16/Ala17 regions. It is found to preferentially adopt a position
parallel to the micellar surface, with the C-terminal segment from Ser23-
His27 protruding into the aqueous solvent. The hydrophobic face of the
amphipathic helix is in direct contact with the micelle core, while the polar
residues face the aqueous solvent and form electrostatic interactions with
the detergent’s polar sulphate headgroups.
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Amino acid sequence requirements of laminin α2
chain peptide A2G80 (VQLRNGFPYFSY) for
α-dystroglycan binding
Fumihiko Katagiri, Yuka Fukasawa, Jun Kumai, Kentaro
Hozumi, Yamato Kikkawa, Motoyoshi Nomizu, Yasuhiko
Yamada
Tokyo University of Pharmacy and Life Sciences, Japan
Dystroglycan (DG) is a component of the dystrophin-glycoprotein com-
plex (DGC) in skeletal muscle. DGC is a molecular complex composed of
dystrophin and membrane glycoprotein group and forms a structure link-
ing the basement membrane and the actin skeleton. The association of
basement membrane-cytoskeleton mediated by DGC is thought to be im-
portant for maintaining the strength of the muscle cell membrane which
can withstand mechanical stress such as elongation and contraction of the
muscle. DG binds with dystrophin directly under the cell membrane, it is
bound extracellularly to basement membrane molecules such as laminin
and play a role as a molecular axis linking the cytoskeleton and basement
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membrane. DG consists of two subunits α and β , αDG, which is an extra-
cellular subunit, binds ligands. βDG is a transmembrane subunit, which
binds αDG to the cell surface extracellularly, and binds dystrophin within
the cell. Laminin is known as a ligand molecule of αDG. Laminins are
major components of basement membrane, consists of three different sub-
units, α , β , and γ chains, and so far, five α , three β , and three γ chains have
been identified. We have constructed the synthetic peptide library derived
from the laminin sequences, and identified functional peptides. We have
reported that A2G78 (GLLFYMARINHA, mouse laminin α2 chain, 2796-
2807) and A2G80 (VQLRNGFPYFSY, mouse laminin α2 chain, 2812-
2823) peptides bind αDG [1]. In this study, we investigated the structure-
activity relationship of A2G80 to identify the specific residues for bind-
ing to αDG. The αDG was rough purified from mouse muscle myoblast
cell line C2C12. The A2G80 and its derivative peptides substituted each
amino acid residue to alanine were synthesized by Fmoc-solid phase meth-
ods, furthermore, the biotinylated peptides of A2G80 and its Ala substi-
tuted peptides were prepared. The circular dichroism (CD) spectra of the
peptides were measured for identification of secondary structure. The pep-
tides substituted Asn5, Phe7, Pro8, Tyr9, Phe10, and Ser11 for Ala were
different spectra to A2G80 peptide. The binding activity was evaluated
by enzyme immunoassay using biotinylated peptides and crude αDG. The
A2G80 peptide bound crude αDG with dose-dependent manner. The pep-
tides substituted Val1, Gln2, Arg4, Gly6, Phe8, Tyr9, and Tyr12 to Ala
lost the αDG-binding activity. From the result of X-ray crystallographic
analysis, it is reported that the Gln2, Arg4, Asn5, Phe7, Tyr9, and Ser11
residue is exposed on the protein surface. We concluded that the Gln2 and
Arg4 were critical residue for binding to αDG.
[1] Suzuki N, Hozumi K, Urushibata S, Yoshimura T, Kikkawa Y, Gumer-
son JD, Michele DE, Hoffman MP, Yamada Y, Nomizu M. Identification of
alpha-dystroglycan binding sequences in the laminin alpha2 chain LG4-5
module. Matrix Biol. 2010; 29: 143-151.
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Expanding the chemical and genetic diversity of the
cyanobactin family of natural products
David Fewer
University of Helsinki, Finland
Natural products are low molecular weight metabolites with diverse chem-
ical structures and potent biological activities. Cyanobactins are a class
of natural products produced through the post-translational modification
of short precursor peptides. Here we demonstrate that the capacity to pro-
duce cyanobactins is spread throughout the bacterial domain and many
cyanobactin gene clusters encode potent antimicrobial peptides. We report
novel cyanobactin post-translational modifications including prenylation,
phosphorylation and disulfide bridge formation. Our results demonstrate
that cyanobactin biosynthetic pathways encode rapidly evolving enzymes
that catalyze the regiospecific and stereospecific modification of amino
acids in macrocyclic and linear peptides. These findings broaden the struc-
tural diversity of the cyanobactin family to include highly modified linear
and macrocyclic peptides with rare post-translational modifications.
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Isolation of phytochemicals from Camellia sinensis
leaf with insulin releasing and glucose lowering effects
for treatment of type-2 diabetes
Prawej Ansari, Peter Flatt, Patrick Harriott, Yasser H.A.
Abdel Wahab
Diabetes Research Group, School of Biomedical Sciences, Ulster
University, Coleraine, N. Ireland, BT52 1SA, United Kingdom
Background: Camellia sinensis, referred to as black tea, has been tradition-
ally used as an antihyperglycemic agent. The present study of hot water
extracts of C. sinensis leaf were investigated for insulin release and glu-
cose homeostasis both in vitro and in vivo and possible mechanism/s of
action. Materials and Methods: Effects of hot water extracts of C. sinen-
sis on insulin release, membrane potential, and intracellular calcium were
tested using rat clonal β -cells (BRIN-BD11 cells). Moreover, insulin se-
cretory activity was observed using collagenase isolated mouse pancreatic
islets. Effects on starch digestion, DPP-IV enzyme activity, and protein
glycation were examined using in vitro model systems. High-fat fed rats
treated for 9 consecutive days with extracts (250mg/5ml/kg) were used to
evaluate the therapeutic impacts on glucose homeostasis. Result: The hot
water extracts of C. sinensis, substantially (P<0.05–P<0.001) increased in-
sulin release 1.3-4.3 fold (compared to 5.6mM/16.7mM glucose) in a linear
manner between concentration 1.6 to 5000µg/ml from BRIN-BD11 cells.
Comparable insulin secretory responses to 200-25 µg/ml C. sinensis ex-
tracts were observed using isolated mouse islets with stimulatory effects
equivalent in magnitude to 1µM GLP-1. However, insulinotropic effects
of C. sinensis at its non-toxic concentration (200µg/ml) on BRIN-BD11
cells were prominently reduced by verapamil (42%), diazoxide (40%) and
calcium-free conditions (43%), while the secretion was further potentiated
by the use of IBMX (200µM, 2.4-fold, P<0.001) tolbutamide (200µM, 2.2-
fold, P<0.05) and KCl (30mM, 2.6-fold, P<0.001). C. sinensis (200µg/ml)
depolarized membrane (6.2 fold) with an increase in intracellular Ca2+ by
4.5 fold suggesting the importance of ion channel and Ca2+ in the mech-
anism of action. Moreover, in vitro study resulted significant inhibition
of starch digestion by 10-40% (125 -1000µg/ml, P< 0.05-P<0.001), DPP-
IV enzyme activity by 5-60% (200-5000µg/ml, P<0.05-P<0.001), and re-
duced protein glycation by 17-53% (50-200µg/ml, P<0.01-P<0.001). Hot
water extract (250mg/5ml/kg) exhibited a significant decrease in blood glu-
cose and fluid intake by 13% and 18.5% in high-fat-fed rats over 9 days’
treatment, correlating to this plasma insulin (P<0.05) increased. The sig-
nificant decrease in energy intake was associated with decreased in body
weight. Significant improvement has been observed in impaired oral glu-
cose tolerance in fat-fed obese rats after 9 days’ treatment with hot wa-
ter extracts. High-fat diet significantly increased plasma DPP-IV activity
in rats that were substantially inhibited by C. sinensis (P<0.05-P<0.01).
Conclusion: These data suggest that hot water extracts of C. sinensis leaf
possess insulin releasing and antidiabetic properties both in vitro and in
vivo. This warrant further evaluation of the plant as a new therapy for the
treatment of type 2 diabetes.
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On-bead Analysis of Substrate Specificity of Caspases
using Peptide Modified by Qauternary Ammonium
Group as Ionization Enhancers
Remigiusz Ba˛chor1, Aneta Paluch1, Wioletta Rut2, Marcin
Dra˛g2, Zbigniew Szewczuk1
1Faculty of Chemistry, Wrocław University, Poland
2Department of Bioorganic Chemistry, Faculty of Chemistry, Wroclaw
University of Technology, Poland
Caspases are proteolytic enzymes at the heart of networks that govern
apoptosis and inflammation. Therefore the investigation of new substrates
for monitoring of their activity is of great importance. The one-bead-one-
compound (OBOC) peptide libraries are widely used in the investigation
of new biologically active compounds and mass spectrometry (MS) is cur-
rently the method of choice for the identification of compounds on sin-
gle beads. However, up to now, the analysis of on-bead enzyme activity
and the determination of on-bead cleavage site have not been investigated
by MS due to the necessity of analysis of trace amount of compound ob-
tained from a single resin bead (femtomole level) which may be insuffi-
cient for reliable sequence analysis. Previously we invented the applica-
tion of quaternary ammonium ionization tags for ultrasensitive sequencing
of peptides by tandem mass spectrometry [1, 2]. Here we present a new,
rapid and straightforward method of the on-bead caspase activity analysis
by LC-ESI-MS/MS method. A series of model peptides derivatized by bi-
cyclic quaternary ammonium groups at the N-terminus were synthesized
and used in the investigation of substrate specificity and enzyme activity
of caspases. The hydrolysis of peptide bond on the resin, occurring even
with low efficiency, release the peptide fragment bearing fixed charge tag
allowing sensitive detection and identification of fragments in supernatant
obtained after enzymatic digestion performed even on single resin bead.
The obtained results suggests the applicability of the proposed methodol-
ogy in the analysis of on-bead enzyme activity. This work was supported
by a grant No. UMO-2015/17/D/ST5/01329 from the National Science
Centre, Poland.
1. Ba˛chor R., Cydzik M., Rudowska M., Kluczyk A., Stefanowicz P.,
Szewczuk Z. Mol. Divers., 2012, 16, 613. 2. Ba˛chor R., Kluczyk A.,
Stefanowicz P., Szewczuk Z. Mol. Divers., 2013, 17, 605.
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Inhibition of angiotensin converting enzyme by
hydrolysates and peptides from wheat germ
Zohreh Karami1, Seyed Hadi Peighambardoust1, Javad
Hesari1, Behrouz Akbari-Adergani2, David Andreu3
1University of Tabriz, Iran
2Food and Drug Laboratory Research Center, Food and Drug
Organization, Ministry of Health and Medical Education, Tehran, Iran
3Pompeu Fabra University, Spain
Wheat germ flour has been used to generate protein hydrolysates (WGPH)
and peptides with anti-hypertensive activity upon proteinase K diges-
tion. The ACE-inhibitory activity of the hydrolysates increased in a
concentration-dependent manner in the 100-1000µg/mL interval. The
IC50 of 0.65 mg/mL determined suggests WGPH as an attractive source
of ACE-inhibitory peptides. To further characterize the active compo-
nents, WGPH was analyzed by reversed-phase semi-preparative HPLC
into twelve fractions that were examined for anti-hypertensive activity.
Fractions testing positive for ACE inhibition were then submitted to
nano LC-ESI-QTOF-MS (liquid chromatography-electrospray ionization-
quadrupole time of flight- mass spectrometry) sequencing. Five se-
quences from the most active peaks were selected to be synthetically
replicated. The corresponding synthetic versions (IGGIGTVPVGR,
SGGSYADELVSTAK, MDATALHYENQK, VDSLLTAAK and VALT-
GDNGHSDHVVHF) showed substantial IC50 values (125.7, 128.2, 303.6,
159.7 and 189.3 µg/mL, respectively) and may have potential as functional
food additives, or nutraceuticals to improve human health.
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The novel lasso peptide pseudomycoidin can be
matured in vivo by only one processing enzyme
Tatiana Zyubko
Skolkovo Institute of Science and Technology, Russia
Ribosomally synthesized and posttranslationally modified peptides
(RiPPs) are a major class of natural products with a high degree of struc-
tural diversity and a wide range of bioactivities. One intriguing family of
RiPPs are the Lasso peptides, the small molecules having unusual topol-
ogy resembling a lasso. The structure is insured by the single posttrans-
lationally installed isopeptide bond between the N-terminal amino group
and the side-chain carboxyl group of aspartate or glutamate at the position
from 7 to 9, forming an N-terminal macrocycle ring. The biosynthesis of
mature lasso-peptides occurs in two steps catalyzed by the processing en-
zymes – leader peptidase and macrolactam synthetase. All but few known
lasso peptides exhibit the “lassoed” form in which the C-terminal tail is
trapped through the ring. This knot-like fold provides high compactness,
extraordinary stability and diverse bioactivities, such as antimicrobial, an-
tiviral, receptor antagonistic or enzyme inhibitory activities. Via bioinfor-
matic analysis of genomic DNA of Bacillus sp. in particular, we found
the lasso-clusters in B. pseudomycoides DSM 12442, belonging to the re-
cently discovered family featuring a novel cluster architecture, similar to
the recently described lasso peptide paeninodin cluster found in genome
Paenibacillus dendritiformis C454. The observed cluster consists of the
biosynthetic genes coding the 43 residues precursor peptide, RiPP recogni-
tion element (RRE), leader peptidase and a lasso cyclase as well as the gene
of ABC- transporter. The heterologous expression of five mentioned genes
under individual T7 promoter each in E. coli resulted in the production of
predicted lasso peptide, called pseudomycoidin, with mass-spectrometry
detected average m/z = 2618. Quite unexpectedly, the cluster possessing
only one processing enzyme gene coding macrolactam synthetase under
heterologous expression in E. coli was still sufficient for the synthesizing
unphosphorylated lasso. The identity of these compounds was confirmed
by several biochemical methods and by MS-MS & NMR analysis. It is
particularly interesting because all lasso peptides described to date require
at least two essential specific enzymes for the lasso formation. Also, the
biochemical and structural investigations showed the pseudomycoidin hav-
ing a branched cycle rather than a threaded “lassoed” topology typical for
characterized homologs. But either way, we consider the macrolactam
synthetase from B. pseudomycoides as a promising candidate for the de-
velopment of a universal tool for large-scale in vivo synthesis of various
pseudomycoidin derivatives and, possibly, other lasso-compounds.
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Modulation of CYP3A4 by the RGD- and Neurotensin
(8-13)-analogues
Kaloyan Georgiev1, Maya Radeva1, Anelia Balacheva2,
Sylvia Michaylova1, Tamara Pajpanova2
1Medical University of Varna, Bulgaria
2Bulgarian Academy of Sciences, Bulgaria
RGD- and Neurotensin(8-13)-based drug design is a hopeful perspective
for drug development. There is a great deal of data of the observed thera-
peutic effects of both sequences (e.g. anticancer, analgesic etc.), but little
is known about the pharmacokinetic of these peptides and possible drug
interactions in which they can be involved. Because of that, we decided to
check whether these sequences can affect the activity of the most common
cytochrome P450 enzyme CYP3A4, responsible for the most drug inter-
actions. We used two RGD-analogues modified in the first position with
nonproteinogenic amino acids - Agb (1) and Agp (2), Neurotensin (8-13)
(3) and modified at position eight and nine with Lys-Cav (4). We used the
fourth peptides at concentrations of 25 to 100 µM. Both RGD-analogues (1
and 2) showed minor modification in the activity of CYP3A4 and the most
pronounced was in the largest used concentrations. Neurotensin (8-13) (3)
and its analogue (4) did not show activity on CYP3A4. The results have
shown that the use of the RGD-analogues (1 and 2) should be monitored
for possible drug interactions, while using Nuerotensin(8-13)-sequences
does not endanger drug interactions at the cytochrome P450 3A4 level.
Acknowledgements: The study was supported by National Science Fund,
Ministry of Education and Science, Bulgaria; Project: DN19/17 and by
Fund Science, at the Medical University of Varna/Bulgaria; Project: 16021
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Synthesis, characterization and nociceptive activity of
new Hemorphin-5 analogues
Petia Peneva1, Petar Todorov1, Daniela Pechlivanova2,
Stela Georgieva-Kiskinova1, Radka Hadjiolova3, Elena
Dzhambazova4
1University of Chemical Technology and Metallurgy, Department of
Organic Chemistry, 1756 Sofia, Bulgaria
2Institute of Neurobiology – BAS, 1113 Sofia, Bulgaria
3Medical University of Sofia, Medical Faculty, 1431 Sofia, Bulgaria
4Sofia University, Medical Faculty, 1407 Sofia, Bulgaria
Hemorphin-5, also known as Valorphin (Val-Val-Tyr-Pro-Trp-Thr-Gln),
is a naturally occurring, endogenous opioid peptide of the Hemorphin
family with affinity for opioid receptors and morphinomimetic properties.
Hemorphin-5 is short-chain peptide initially obtained from a particular re-
gion of the β -chain of hemoglobin. The Hemorphin peptides are increas-
ingly being used in the treatment of various diseases such as hypertension,
epilepsy, diabetes, chronic pain, cancer, and etc. In order to block the en-
zymes involving conversion of angiotensin peptides is required searching
of non-toxic substances with more efficient anti-inflammatory and anal-
gesic activity. This report refers to the investigation of nociceptive ac-
tivity of newly synthesized hemorphin-5 analogues containing unnatural
amino acids injected intracerebroventriculary in mice. The novel blood
peptide derivatives have been prepared by replacement of Gln at position
7 with unnatural amino acids (Val-Val-Tyr-Pro-Trp-Thr-X) using SPPS,
Fmoc-strategy. In order to inquiry of the influence of amino acid residues
have been incorporated of Ile/Aib at position 1 (X-Val-Val-Tyr-Pro-Trp-
Thr-Gln). The crude neuropeptides were purified on an RP-HPLC and the
molecular weights were determined, using ES-MS, and also determining
of the specific angles of optical rotation. The nociception was studied us-
ing acetic acid-induced writhing test. The mice were observed for typical
movements (writhes) for 30 minutes after the injection of the irritant. Some
of the newly-synthesized Valorphin-5 analogues showed significant time-
and dose-dependent antinociceptive effect compared to both the saline-
injected controls (p<0.001) and the reference compound at the same doses.
Acknowledgements: Financial support from BG05M20P001-2.009-0015
“Support for the development of capacity of doctoral students and young
researcher in the field of engineering, natural and mathematical sciences”
funded by the operational programme “Science and Education for Smart
Growth” 2014–2020 the co-financed by the European Union through the
European Social Fund is gratefully acknowledged.
P149
Synergy of short antimicrobial peptides with β -lactam
antibiotics against MRSA resides in the degradation of
peptidoglycan barrier
Ondrˇej Nešuta, Jakub Kyznar, Andrea Volejníková,
Václav Cˇerˇovský
Institute of Organic Chemistry and Biochemistry of the Czech Academy
of Sciences, Czechia
The mode of action of cationic antimicrobial peptides (AMPs) involves in-
teraction with the negatively charged phospholipid bilayer of bacterial cell
membrane causing its disruption via pore formation or detergent-like dis-
integration, thereby leading to cell death. In Gram-positive bacteria AMPs
have to pass through the cell wall that consists prevalently of a peptidogly-
can layer, before reaching the cytoplasmic membrane. Here we focused on
mechanism of the action of short cationic α-helical AMPs in the combina-
tion with common antibiotics against methicillin-resistant Staphylococcus
aureus (MRSA). We found that the studied peptides showed synergy only
with β -lactam antibiotics but not with vancomycin or gentamicin. To ex-
plain this phenomenon we prepared protoplasts of MRSA – the cells that
lack a cell wall. For this purpose we used lysostaphin which digested pep-
tidoglycan layer. Since β -lactams are known to inhibit cell wall synthesis,
the protoplasts became resistant to them. On the other hand the protoplasts
were more susceptible to all studied peptides. Assuming that the peptide
would have to pass through peptidoglycan barrier before reaching the cyto-
plasmic membrane we studied its interaction with peptidoglycan isolated
from Staphylococcus aureus. The study based on RP-HPLC methodology
showed that up to 25% of 10 µM peptide was trapped into peptidoglycan.
This occurred practically immediately after mixing of these two compo-
nents. Under the same conditions, approximately the same amount of pep-
tide was absorbed also into MRSA cells without killing them immediately,
but the cells were killed during next two hours. Our results indicate that
binding of AMP to peptidoglycan (and thus bacterial cell wall) causes con-
siderable interference during AMP-mediated killing the bacteria due to a
significant decrease of AMP concentration that is required for the disrup-
tion of cytoplasmic membrane. Based on presented results, we hypothesize
that in the course of the combination treatment, β -lactams cause degrada-
tion of peptidoglycan layer, resulting in a weakening of the cell wall, thus
allowing AMP easier approach to the cytoplasmic membrane and its subse-
quent disruption. Consequently, lower concentration of both antibiotic and
AMP is needed to kill the bacteria that finally results to synergistic effect.
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Development of bioinspired antimicrobials: the new
edge of pharmacological design
Octávio Franco
UCDB, Brazil
Peptide rational design was here used to guide the creation of novel com-
pounds that could help on resistant bacteria control. Firstly, two novel
short beta-lactamase inhibitors with five amino acid residues length were
generated. Molecular modeling associated to peptide synthesis improved
bactericidal efficacy in addition to amoxicillin, ampicillin and cefotaxime.
Docked structures were consistent with calorimetric analyses against bac-
terial beta-lactamases. These two compounds were further tested in mice.
Whereas commercial antibiotics alone failed to cure mice infected with
Staphylococcus aureus and Escherichia coli expressing β -lactamases, in-
fection was cleared when treated with antibiotics in combination with pep-
tides, clearly suggesting that peptides were able to neutralize bacterial re-
sistance. Moreover, host-defense peptides derived from mastoparan and
clavanin families were redesigned in order to improve antimicrobial activi-
ties and decrease mammalian cell toxicity. Both peptides were evaluated in
sepsis and wound model infections showing the ability to control the infec-
tion caused by Gram-positive and -negative pathogenic bacteria. Moreover
in all cases, immune response was also evaluated. In summary, the unusual
peptides here described provide leads to overcome beta-lactamase-based
resistance, a remarkable clinical challenge.
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Chemometric/cheminformatic - assisted approach in
the analysis of bitter peptides originating from food
proteins
Anna Iwaniak, Monika Hrynkiewicz, Justyna Bucholska,
Małgorzata Darewicz, Piotr Minkiewicz
Warmia & Mazury University, Faculty of Food Science, Chair of Food
Biochemistry, Pl. Cieszynski 1, Olsztyn, Poland
It is well-known that peptides derived from food protein sources show va-
riety of bioactivities like e.g.: cardioprotective, antioxidant, antibacterial,
immunomodulating etc. Additionally, biopeptides released during hydrol-
ysis of proteins may affect the taste of hydrolysates. Usually it is an off-
flavor bitter taste which is considered by as the one of limitations when pro-
ducing biologically, chemically, and functionally active foods. Unwanted
bitterness of food hydrolysates may be the obstacle in their practical use
in food and nutrition industries. During the recent years, the popularity
and continuous development of information technologies contributed to
the increase of data repositories (databases) as well as programs helpful for
prediction of some phenomena in the molecules like e.g. peptides and/or
proteins. The aim of the study was the application of information provided
in biological and chemical databases as well as multivariate analysis tech-
niques to create bitter di- and tripeptide datasets and finally to find the rela-
tionships between the structure (sequence) and bitterness of sequences an-
alyzed. The following in silico tools were used: BIOPEP-UWM database
of sensory peptides and amino acids, AAindex database, ProtScale, Bio-
logical Magnetic Resonance Data Bank, Statistica13.1®. PCA and MLR
carried out for bitter di- and tripeptide data matrices led to observe the im-
pact of the following attributes on the peptides’ taste: molecular weight,
bulkiness, number of carbon and hydrogen atoms, polarity and hydropho-
bicity (N- and C-terminal amino acids in a dipeptide chain). In case of
tripeptides there were: molecular weight, bulkiness (C-terminal and mid-
dle amino acid) and molecular weight, bulkiness and propensity to be ex-
posed to solvent (N-terminal residue). The approach applied confirmed
the results of other authors aiming the studies on structure-bitterness of
peptides. However, our data matrices are universal and can also be applied
to analyze structure-function of peptides with other activities. *** This
work was financed by Warmia and Mazury University in Olsztyn (project
number: 17.610.014-300)
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Peptides are ubiquitous in biological systems and present a class of
biomolecules involved in controlling and modulating various processes in
living organisms. Their chemical properties originate from the primary se-
quence and the related conformation. Knowledge of favorable structures
such as α-helices or β -sheets can be harnessed to design monomers ca-
pable of self-assembling in a defined way into large supramolecular struc-
tures. Decorating the surface of this nano-sized objects with immunogenic
molecular patterns results in a pathogen-mimicking particle thus potential
vaccine candidate. To induce an immune reaction against tumor-associated
thus endogenous structures, self-tolerance mechanisms must be overcome.
Therefore, simultaneous presentation of different epitopes and immunos-
timulating agents is beneficial. Each supramolecular monomer can be
specifically modified prior to self-assembly. Copolymerisation of these
building blocks in water yields polymers equipped with epitopes in a mul-
tivalent manner. We describe the synthesis of a modular peptidic platform
for antitumor vaccine development as well as their immunological evalu-
ation. The three-armed star shape of the structural monomer (SM) origi-
nates from the 1,3,5-triazine core which bears three amphiphilic ethylene
glycol (EG) modified tri-L-phenylalanine (F3) on the 2,4,6 positions. Im-
munogenic structures are conjugated via CuAAC to functional monomers
(FM), which feature one alkyne terminated F3 sequence, instead of EG in
SM. Three different cargos were loaded onto FM namely an immunostim-
ulating agent (TLR7/8 agonist, imidazoquinoline), a T cell epitope (p30,
tetanus toxin947-967) and a fully synthetic B cell epitope derived from
the tandem-repeat sequence of the MUC1 glycopeptide. Furthermore, the
latter incorporates the tumor-associated carbohydrate antigens Tn on thre-
onine 11 and 2,3-sialyl T on threonine 18. C57B/L mice were immunized
and the generated antisera exhibited high titers especially of the IgG2c iso-
type as determined from ELISA. FACS analysis revealed efficient binding
of the generated antibodies to T47D tumor cells with high affinity. These
results demonstrate the capabilities of supramolecular polymers to serve
as a vaccine platform and highly encourage further investigations.
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Trans-Blood brain barrier peptides to enhace delivery
of therapeutic molecules to treat Alzheimer’s disease
Vera Neves1, Frederico Aires-Da-Silva2, Lurdes Gano3,
Sofia Corte-Real4, João D. G Correia3, Miguel Castanho1
1Instituto de Medicina Molecular, Faculdade de Medicina da
Universidade de Lisboa, Portugal
2CIISA - Faculdade de Medicina Veterinária, Universidade de Lisboa,
Portugal
3Centro de Ciências e Tecnologias Nucleares, Instituto Superior técnico,
Universidade de Lisboa, Portugal
4TechnoPhage, SA, Portugal
The delivery of therapeutic molecules to the central nervous system is
hampered by poor delivery across the blood-brain barrier (BBB). Several
strategies have been proposed to enhance transport into the brain, includ-
ing invasive techniques and receptor-mediated transport (RMT) 1. Both
approaches have several drawbacks, such as BBB disruption, receptor sat-
uration and off-target effects, raising safety issues. In the quest to find
new peptides that can be used as trans-BBB peptide vectors we studied
natural viral proteins, because virus are molecular machines specialized
in cell penetration. Some domains in these proteins have characteris-
tics commonly found in cell penetrating peptides (CPP), such as being
cationic and lipophilic. We tested the four helical domains of Dengue
Virus type 2 capsid protein (DEN2C). Their mechanism of translocation
is receptor-independent and consistent with adsorptive-mediated transport
(AMT). One peptide in particular, PepH3, reaches equilibrium distribution
concentrations across the BBB in less than 24 hours in a cellular in vitro
assay. In addition, biophysical studies with pepH3 showed that this pep-
tide interacts with anionic membranes, similarly to what is found in brain
endothelial cells 2. Importantly, in vivo biodistribution data with radiola-
beled peptide derivatives shows high brain penetration. To demonstrate the
brain-shuttle capacity, the peptide was conjugated to a single domain an-
tibody (VL) targeted to Alzheimer’s disease (AD) 3. VL-PepH3 presents
fast clearance from brain and high levels of excretion, showing PepH3
competence as drug delivery system to take a cargo in and out the brain.
The activity of VL is retained in the several efficacy tests: antigen-ligand
kinetics (VL-Aβ1-42 binding kinetics), inhibition of Aβ aggregation and
recognition of senile plates in humans.
References 1. Neves, V. et al. Trends in biotechnology, 2016, 34 (1), 36-
48. 2. Neves, V., et al. ACS Chem. Biol., 2017, 12 (5), pp 1257–1268. 3.
Côrte-Real, S., Neves et al. WIPO PCT/IB2016/050467, January 29, 2016
Acknowledgements FCT I.P. (grants SFRH/BPD/94466/2013;
PTDC/BBBNAN/1578/2014); Marie Skłodowska-Curie Research and
Innovation Staff Exchange, call 20-MSCA-RISE-2014 (grant agreement
H20 644167 – INPACT).
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Probing N-terminal modification of ALM F50/5 with
triazolo – dipeptide on its conformation and bioactivity
Sanjit Das, Khoubain Ben Haj Salah, Nicolas Inguimbert
University of Perpignan, France
As anti-bacterial chemotherapy is facing tremendous challenges, antimi-
crobial peptides are showing a ray of hope to be used as an effective alterna-
tive to the traditional drugs [1, 2]. Although the mechanism of interaction
of this kind of peptide with membrane is not fully understood [3]. Here we
particularly focus on a strategy of enhancing bioactivity through structural
modification without altering its sequence. A bioactive peptaibol [4] like
alamethicin was used in this study as a template for structural modification
and investigating its influence on conservation of conformation and in turn,
bio-activity. The study was conducted for two main reasons. First, the in-
sertion of ‘so called’ peptidomimetic scaffold, ‘triazole’ at the N-terminal
end of alamethicin replacing amide bond to observe whether or not the
structure is perfectly poised and restore its conformation [5, 6,]. Secondly,
how the insertion of fluorinated aromatic moieties impart hydrophobicity
to the structure that lead to a better interaction. For the dipeptide synthe-
sis, principle of ‘Click chemistry’ [7, 8] was exploited as it is a highly
selective and reliable reaction to generate triazole moiety using copper as
catalyst. These dipeptide fragments were subsequently used for generation
of alamethicin analogues using Fmoc-based SPPS. Our main aim was to
find a way to rationalize the interaction of alamethicin with lipid membrane
through structural modification at the N-terminal end so as to augment the
biological activity of the peptaibol.
References: 1. M. F. Chellat, L. Raguz, R. Riedl, Angew. Chem. Int.
Ed., 2016, 55, 6600-6626 2. A. T. Y. Yeung, S. L. Gellatly, R. E. W. Han-
cock; Cell. Mol. Life Sci., 2011, 68, 2161 3. W. C. Wimley; ACS Chem.
Biol.; 2010, 5, 905-917 4. H. BrJckner, J. Maisch, C. Reinecke, A. Ki-
monyo, Amino Acids 1991, 1, 251. 5. Sanjit Das, Khoubaib Ben Haj
Salah, Emmanuel Wenger, Jean Martinez, Jules Kotarba, Vanessa Andreu,
Nicolas Ruiz, Filippo Savini, Lorenzo Stella, Claude Didierjean, Baptiste
Legrand, and Nicolas Inguimbert, Chem. Eur. J. 2017, 23, 17964 – 17972
6. Khoubaib Ben Haj Salah, Sanjit Das, Nicolas Ruiz, Vanessa Andreu,
Jean Martinez, Emmanuel Wenger, Muriel Amblard, Claude Didierjean,
Baptiste Legrand, and Nicolas inguimbert ; Org. Biomol. Chem, 2018,
(accepted) 7. Kolb, H.C.; Finn, M.G.; Sharpless, K.B. Click chemistry:
Diverse chemical function from a few good reactions. Angew. Chem. Int.
Ed. Engl. 2001, 40, 2004–2021. 8. Tornoe, C.W.; Christensen, C.; Meldal,
M. Peptidotriazoles on solid phase: [1, 2, 3]-Triazoles by regiospecific cop-
per (I)-catalyzed 1, 3-dipolar cycloadditions of terminal alkynes to azides.
J. Org. Chem. 2002, 67, 3057–3064.
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Antibody Epitope of human α-Galactosidase A
revealed by affinity-mass spectrometry
Hendrik Rusche1, Zdenek Kukacka2, Loredana Lupu2,
Lorenzo Altamore3, Fabio Borri3, Stefan Maeser2, Julia
Hennermann4, Michael Przybylski2, Anna Maria Papini3
1Peptlab@UCP and Laboratoire de Chimie Biologique, Universitè de
Cergy Pontoise, France
2Steinbeis Centre for Biopolymer Analysis and Biomedical Mass
Spectrometry, Rüsselsheim am Main, Germany
3Interdepartmental Laboratory of Peptide & Protein Chemistry &
Biology, Università degli Studi Firenze, Italy
4Department of Pediatrics/ Villa Metabolica, Universitätsmedizin Mainz,
55130 – Mainz, German, Germany
Alpha-galactosidase (αGal) is a lysosomal enzyme that hydrolyses the
alpha-galactosyl moiety from glycosphingo-lipids. Mutations in the αGal
genes lead to defect enzymes resulting in substrate accumulation and
pathophysiology. The deficiency of αGal, called Fabry’s Disease (FD),
belongs to the lysosomal storage diseases. Effective treatment of FD has
been developed by enzyme replacement therapy (ERT) by infusion of re-
combinant enzyme to increase enzyme levels and reduce accumulated sub-
strate. Immuno-reactivity and IgG antibody formation are major, therapy-
limiting complications of ERT. Here we report the antibody epitope iden-
tification of human αGal, αGal(309-332), using a combination of prote-
olytic excision of the immobilized immune complex. The epitope peptide,
αGal(309-332) was synthesized by solid-phase peptide synthesis; its affin-
ity was determined by SPR (KD, 39 x 10-9 M) nearly identical to that
of the full length enzyme (KD, 16 x 10-9 M). Proteolytic excision- mass
spectrometry is shown to be an efficient tool for epitope identification of
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immunogenic lysosomal enzymes. Since the full length enzyme and the an-
tibody epitope showed comparable binding affinities, this provides a basis
for reversing immunogenicity.
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The effects of glutathione analogues on Na,K-ATPase
activity in the kidneys of the wildtype and the Wfs1
gene mutated mice in vitro and in vivo
Ceslava Kairane, Riina Mahlapuu, Rando Porosk, Mihkel
Zilmer, Ursel Soomets
University of Tartu, Estonia
Protein S-glutathionylation, the reversible formation of mixed disulfides
between glutathione and cysteinyl residues of proteins, is a potential mech-
anism for dynamic, post-translational regulation of a variety of regula-
tory, structural, and metabolic proteins in cells. Na,K-ATPase is a cru-
cial plasma membrane enzyme in kidneys composed of α subunit, β
subunits and a regulatory subunit belonging to the FXYD protein fam-
ily, which all contain free cysteine residues. An α subunit have 23
free cysteine residues, the β have only one and FXYD protein two of
them. The WFS1 gene encodes wolframin, an endoplasmic reticulum
membrane glycoprotein, which regulates another protein folding and se-
cretion, cellular transport and calcium homeostasis. Mutations in WFS1
gene lead to changes in Na,K-ATPase activity and in the expression of
the α and β subunits. The aim of this study was to investigate the ef-
fect of glutathione (GSH) and its analogues UPF1 (o-methyl-L-tyrosinyl-
g-L-glutamyl-L-cysteinyl-glycine) and UPF17 (o-methyl-L-tyrosinyl-L-
glutamyl-L-cysteinyl-glycine) on Na,K-ATPase activity in two months old
wildtype and WFS1 knockout mice kidney in vitro and in vivo. In our
lab a small library of glutathione analogues (UPF peptides) was designed
and synthesized. The activity of the Na,K-ATPase was determined as the
ability to hydrolize ATP and expressed as µmol Pi/mg min. In vitro the
samples were pre-incubated with GSH and UPF peptides for 10 and 45
minutes at room temperature. In vivo glutathione analoques were admin-
istrated i.p. 1 mg/kg for 5 days. The experimental results of the study
showed that glutathione and UPF17 in concentrations 10-3 M inhibit the
activity of Na,K-ATPase in wildtype and WFS1 knockout mice kidney in a
time dependent manner. UPF1 in concentrations 10-3 M at pre-incubation
time 10 min inhibits the activity of Na,K-ATPase in wildtype, but acti-
vates in WFS1 knockout mice kidney. Same concentration of UPF1 at
pre-incubation time 45 min did not have any effect in both genotypes in
vitro. Intraperitoneal administration of UPF1 and UPF17 inhibit the activ-
ity of Na,K-ATPase in wildtype mice kidney, but did not have any effect
in WFS1 knockout mice in vivo. The various effects of glutathionylation
on the activity of Na,K-ATPase may be caused both by structural differ-
ences between the GSH and UPF peptides and by conformational changes
in the enzyme of WFS1 knockout mice. The present study was supported
by Institutional Research Funding No IUT20-42.
References: 1. Kairane C, Mahlapuu R, Ehrlich K, Zilmer M, Soomets U.
Curr Alzheimer Res. 2014. 2. Kairane C, Mahlapuu R, Porosk R, Zilmer
M, Soomets U. EFMC International Symposium on Medicinal Chemistry
2016. 3. Kairane C, Mahlapuu R, Ehrlich K, Kilk K, Zilmer M, Soomets
U. International Journal of Peptides, Volume 2012.
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New Tricks with Tridecaptins – Improving Peptidase
Stability, Cost-Efficiency and Identifying Novel
Mechanisms of Action
Stephen Cochrane, Ross Ballantine, Conor McCallion
Queen’s University Belfast, United Kingdom
The rapid emergence of multidrug resistant bacteria is a major global con-
cern. A recent UK report predicts that by 2050, antibiotic resistance will
cause 300 million premature deaths and kill more people than cancer.[1]
Therefore, there is a pertinent need for new antimicrobial compounds and
targets. In recent years antimicrobial peptides (AMPs) have become the
vanguard of new antibiotic candidates. The tridecaptins are a family of non-
ribosomally synthesized AMPs that show strong activity against Gram-
negative bacteria, including multidrug resistant strains of Klebsiella pneu-
moniae and Acinetobacter baumannii.[2] These tridecapeptides operate by
a currently unique mechanism of action – they bind specifically to lipid II
on the inner membrane of Gram-negative bacteria and disrupt the proton-
motive force.[3] The tridecaptins are inactive against Gram-positive bac-
teria and show low levels of cytotoxicity and hemolytic activity. They are
short, linear peptides and therefore easily accessible by solid-phase peptide
synthesis. Furthermore, the combination of L- and D-amino acids in their
structure provides excellent stability to normally encountered peptidases.
However, it was recently reported that the D-stereoselective peptidase TriF
hydrolyzes the tridecaptins, abolishing antimicrobial activity.[4] Through
analysis of the solution NMR structure of tridecaptin A1 bound to lipid
II, we have rationally designed and synthesized new cyclic tridecaptin ana-
logues that retain antimicrobial activity and are resistant to TriF. This was
achieved by replacement of a key hydrophobic interaction with a covalent
linkage. Another limitation of the tridecaptins is their cost of synthesis,
owing to the presence of several non-proteinogenic amino acids. We have
synthesized a library of new linear tridecaptin analogues that retain full
antimicrobial activity and can be synthesized at a fraction of the price. We
have also identified that the tridecaptins bind to a key enzyme involved in
bacterial lipoprotein synthesis and are investigating the molecular basis of
the inhibition mechanism.
References:
[1] O’Neil (2014) The Review on Antimicrobial Resistance, London, UK.
[2] Cochrane et al. J. Med. Chem. 2014, 57, 1127. [3] Cochrane et al.
Proc. Natl Acad. Sci. USA. 2016, 113, 11561. [4] Li et al. Nat. Chem.
Biol. 2018, 14, 381.
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Serpin A1 Derivatives as Collagen Turnover
Modulators for Cosmeceut cal Uses
Fosca Errante1, Simona Pascarella2, Caterina Cipriani2,
Lisa Giovannelli2, Anna Maria Papini2, Paolo Rovero2
1University of Florence and Espikem srl, Prato, Italy
2University of Florence, Italy
One of the main enzymes responsible for the degradation of collagen is
elastase, a protein secreted by neutrophils, which digests the components
of the extracellular matrix, giving rise to inflammatory phenomena. The
main physiological inhibitor of this enzyme is represented by serpin A1, a
component of the serpins family, which are proteins endowed with anti-
protease activity. Following to a preliminary report on the activity of
the C-terminal portion of this protein [1], we showed that the decapep-
tide SA1-III is able to modulate collagen type I turnover in cultured hu-
man fibroblasts [2]. With the purpose of investigating the mechanism of
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action of SA1-III, we synthesized four partially overlapping tetrapeptide
fragments of this peptide, using the solid-phase strategy, followed by chro-
matographic purification and analytical characterization by HPLC-MS. All
the peptides were used for in vitro studies on cell cultures derived from
neonatal dermal human fibroblasts (NHDFs) in order to determine the con-
centrations of collagen type I produced in the presence of each tetrapep-
tide, in comparison with the basal concentration of collagen, measured in
untreated fibroblasts. We performed Western blot test on culture medium
derived from fibroblasts treated with the peptides, as well as in cell lysates.
We chose to analyze specific protein bands, i.e. those related to the pro-
collagen forms, which is the precursor of collagen type I, and collagen
degraded by proteases released by fibroblasts in culture media. This analy-
sis showed that the mechanism of action leading to increased concentration
of collagen type I in cell treated with both SA1-III and its derivatives is an
anti-protease action rather than a stimulation of de novo collagen synthe-
sis. We excluded also a potential mitogenic effect of the tested peptides,
which could explain the observed increase in collagen concentration, but
which would determine toxicity in vivo. In particular, we assessed a signifi-
cant (p <0.05) activity of peptides SA1-III and AAT11, one of the tetrapep-
tides. Since the activity of collagen turnover modulators displayed by these
short peptides appears very promising from a cosmeceutical viewpoint, we
started a technology transfer activity, based on the new company Apotech
srl, aiming to formulate, test, and commercialize anti-age cosmeceutical
products based on the new peptides.
[1] Congote et al., ”Comparison of the effects of serpin A1, a recombinant
serpin A1-IGF chimera and serpin A1 C-terminal peptide on wound heal-
ing,” Peptides, vol. 29, no. 1, pp. 39-46, 2008. [2] Pascarella et al., ”Ser-
pin A1 C-Terminal Peptides as Collagen Turnover Modulator,” ChemMed-
Chem, vol. 11, no. 16, pp. 1850-1855, 2016.
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Nature-derived peptides as molecular tools to study
GPCR signaling
Edin Muratspahic, Christian W. Gruber
Center for Physiology and Pharmacology, Medical University of Vienna,
Austria
Peptides are important bioactive molecules found in all organisms from
bacteria to plants to mammals. They can function as hormones, neurotrans-
mitters or defense molecules against host-pathogens. Bearing large diver-
sity, naturally-occurring peptides represent novel ligands for a plethora of
molecular targets and thus constitute attractive lead structures for drug de-
velopment. An important group of such biological targets are G-protein
coupled receptors (GPCRs), which are involved in a variety of physio-
logical signaling processes and are therefore considered one of the most
promising drug target classes; approximately 30% of all approved drugs
are thought to act through modulation of these receptors. In this study we
aim to investigate the modulation of GPCR signaling by nature-derived
peptides. For this purpose, we will isolate and characterize peptides from
plants and insects using reversed-phase liquid chromatography and mass
spectrometry. These nature-derived peptides will be utilized as templates
to design novel chemically-modified peptide analogs by applying solid-
phase peptide synthesis. A focus of our research are oxytocin/vasopressin
and opioid receptors as representative members of the GPCR family; phar-
macological characterization of functionality and affinity of these receptors
will be conducted using second messenger quantification as well as radioli-
gand binding assays. To gain more insights into biased signaling properties
of our nature-derived peptides we will be measuring selective activation of
β -arrestin recruitment and receptor internalization by bioluminescence res-
onance energy transfer studies. The use of nature-derived peptide libraries
will enable us to identify novel peptide ligands capable of modulating se-
lective pathways of GPCR cellular signaling. These molecular tools may
in the future be used for in vitro and in vivo efficacy studies to develop lead
compounds for therapeutic indications such as multiple sclerosis, pain or
autism.
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How to control Pseudomonas aeruginosa-induced
pneumonia and keratitis? A lesson from the amphibian
skin-derived peptide Esculentin(1-21) and its
diastereomer
Maria Luisa Mangoni1, Floriana Cappiello1, Bruno
Casciaro1, Chen Chen2, Debarun Dutta3, Alison
McDermott4, Mark Dp. Willcox3, Peter Di2
1Sapienza University of Rome, Italy
2Pittsburgh University, United States
3UNSW, Sydney, Australia
4Northumbria University Newcastle upon Tyne, United Kingdom
The Gram-negative bacterium Pseudomonas aeruginosa is among micro-
bial pathogens for which new anti-infective agents are urgently needed.
It causes a large variety of infections including pneumonia especially in
cystic fibrosis sufferers and keratitis in contact lens wearers. Naturally oc-
curring antimicrobial peptides (AMPs) hold promise as novel therapeutics
(1). Amphibian skin secretions are one of the richest sources for AMPs.
We discovered that the frog skin-derived cationic AMP Esc(1-21) has (i)
rapid killing kinetics against both free-living and biofilm forms of P. aerug-
inosa, with membrane-perturbing activity as a plausible mode of action
which limits the emergence of resistance (2); (ii) the capability to preserve
the barrier integrity of airway epithelial cells better than the human AMP
LL-37; (iii) the ability to protect host from pulmonary Pseudomonas in-
fection after a single intra-tracheal instillation at a very low dosage (0.1
mg/kg) without provoking an inflammatory response (3,4); (iii) the ability
to stimulate migration of bronchial epithelial cells and, as a result, pre-
sumably to accelerate the recovery of an injured bronchial epithelium (5).
Furthermore, a diastereomer of Esc(1-21), containing two D-amino acids
was found to be less cytotoxic; more stable and with better in vivo effi-
cacy. Importantly, one of the drawbacks in developing AMPs as new thera-
peutics is their inefficient delivery to the target site. We discovered that
polymeric nanoparticles made of poly(lactic-co-glycolic) acid represent
a promising tool for pulmonary delivery of peptides and their sustained
release. We also demonstrated that the diastereomer is more efficient in
treating Pseudomonas-associated keratitis in murine models, as well as in
preventing bacterial attachment to soft contact lenses upon covalent conju-
gation to them. Overall, these peptides represent attractive alternatives to
control Pseudomonas-associated pneumonia and keratitis.
This work was supported by grants from Sapienza University of Rome;
the Italian Cystic Fibrosis Research Foundation (Project FFC#11/2014;
FFC#15/2017); NIH (R01 HL-125128 and AI-133361), NHMRC devel-
opment grant (APP107620) and an ARC discovery grant (DP160101664)
from the Australian Government
1. Zasloff M. Nature (2002) 415: 389–395. 2. Luca V et al. Cell Mol Life
Sci. (2013) 70:2773-2786 3. Kolar SS et al. Cell Mol Life Sci. (2015);
72: 617-627 4. Chen C et al. Sci Rep. (2017):8548 5. Cappiello F et al.
Antimicrob Agents Chemother.(2016) 60:7252-7262
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Development of an IgG/IgY sandwich-ELISA for the
bioactive polypeptide Prothymosin alpha
Chrysoula-Evangelia Karachaliou1, Persefoni Klimetzou1,
Maria Paravatou-Petsotas1, Ourania Tsitsilonis2, Wolfgang
Voelter3, Hubert Kalbacher3, Christos Zikos1, Evangelia
Livaniou1
1National Centre for Scientific Research ”Demokritos”, INRASTES,
Greece
2Department of Biology, University of Athens, Greece
3Interfaculty Institute of Biochemistry, University of Tuebingen, Germany
Prothymosin alpha (ProTα) is a highly acidic polypeptide (109 amino
acids in humans) expressed in all mammalian cells and acting both intracel-
lularly and extracellularly as an anti-apoptotic and proliferation-enhancing
factor or as an immunostimulating mediator, respectively [1]. Under cer-
tain cellular conditions ProTα may be enzymatically cleaved resulting
in biologically active peptidyl fragments, such as the N-terminal frag-
ment ProTα[1-28] (also known as thymosin alpha 1, Tα1) and the C-
terminal decapeptide ProTα[100-109] [2,3]. Immunoassays distinguish-
ing between intact parental ProTα and the active fragments thereof are
considered valuable laboratory tools for elucidating the precise mecha-
nism(s) of action of the polypeptide, thus facilitating its suggested clini-
cal exploitation. In this work, we have employed rabbit IgG- and chicken
IgY- antibodies -previously raised by our teams- to develop a sandwich-
ELISA which is highly specific for intact ProTα and shows no cross-
reactivity with ProTα[1-28] or ProTα[100-109]. More specifically, rab-
bit IgG-antibodies raised against a conjugate of synthetic ProTα[100-109]
with keyhole limpet hemocyanin (KLH) have been indirectly immobilized
on the ELISA microwells; standard solutions prepared by dissolving com-
mercially available ProTα in various cell culture media, and chicken IgY-
antibodies raised against a ProTα/KLH conjugate which show high speci-
ficity for the intact polypeptide [4,5] have been subsequently added to the
microwells. Commercially available enzyme-labelled secondary antibod-
ies have been used for signal development. The sandwich-ELISA shows
very good reproducibility (intra- and inter- assay CVs < 8%) and a de-
tection limit of < 2 ng/mL, while its high specificity for intact ProTα
has been verified by cross-reactivity studies with synthetic ProTα[1-28]
and ProTα[100-109] as well as synthetic peptides of the beta-thymosin
family. The sandwich-ELISA is currently being applied to the super-
natants of human cells cultured in the presence of various necrotic factors,
which may release intact ProTα as a damage-associated molecular pattern
(DAMP)/alarmin mediating responses of the innate immune system [1].
Acknowledgments: Dr. Karachaliou acknowledges IKY Scholarship Foun-
dation for a post-doctoral-fellowship (“Reinforcement of Postdoctoral Re-
searchers” MIS: 5001552, NSRF 2014-2020).
[1] Samara P, Karachaliou CE, Ioannou K et al., Curr Med Chem.
2017;24:1747-60 [2] Sarandeses CS et al., J Biol Chem. 2003;278:13286-
93 [3] Evstafieva AG et al., FEBS Lett. 2000;467:150-4 [4] Kliment-
zou P et al., Peptides. 2006;27:183-93 [5] Karachaliou CE et al., Euro-
biotech2018 (April 26-28, 2018, Athens, Greece); abstract pending publi-
cation in European Journal of Biotechnology
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Pore-forming antimicrobial peptides: design rules for
amphipathic α-helices
Erik Strandberg1, David Benz1, Ariadna Grau-Campistany2,
Parvesh Wadhwani1, Francesc Rabanal2, Anne Ulrich1
1Karlsruhe Institute of Technology, Germany
2University of Barcelona, Spain
Antimicrobial peptides (AMPs), also known as host defense peptides, can
kill microorganisms and constitutes a potential new class of antibiotics. It
has been proposed that some AMPs form pores in bacterial membranes,
thereby destroying the cell integrity. KIA peptides are cationic amphi-
pathic α-helical AMPs based on the sequence KIAGKIA, with varying
lengths from 14 to 28 amino acids. From antibacterial assays it was found
that a minimum length of KIA peptides was needed to kill bacteria, which
depends on the type of bacteria [1,2]. From vesicle leakage assays this
length was identified as the membrane hydrophobic thickness; peptides
must be long enough to span the membrane to induce leakage [1,2]. Using
solid-state 15N-NMR, the orientation of the peptides in a membrane could
be determined, and stable pores, formed with peptides in a transmembrane
orientation, was observed in lyso-lipid containing membranes [3]. It was
further found that the activity depends on the distribution of charges along
the peptide sequence. For the KIA peptides, activity is highest when there
are one or more positive charges at the N-terminus and the C-terminus is
strongly hydrophobic. The distribution of charged and hydrophobic amino
acids can be quantified by calculations of a 3D-hydrophobic moment (3D-
HM) [4], and we show that a 3D-HM vector pointing along the helix axis
of the peptides correlates with high activity. Based on this information we
present a model of how the peptides insert into the membrane and form
pores.
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References: [1] A Grau-Campistany et al. (2015) Sci Rep 5, 9388. [2]
A Grau-Campistany, E Strandberg, P Wadhwani, F Rabanal, AS Ulrich
(2016) J Phys Chem Lett 7, 1116-1120. [3] MC Gagnon et al. (2017) Bio-
chemistry, 56, 1680−1695. [4] S Reißer, E Strandberg, T Steinbrecher, AS
Ulrich (2014) Biophys J 106, 2385-2394.
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Synthetic peptides derived from Palmaria palmata
show promising antidiabetic actions in cultured cells,
as well as in acute in vivo studies in mice
Chris McLaughlin1, Vadivel Parthsarathy1, Padraigin
Harnedy2, Philip Allsopp3, Dick Fitzgerald2, Finbarr
O’Harte1
1Diabetes Research Group, Ulster University, Coleraine, Northern Ireland,
United Kingdom
2Department of Biological Sciences, University of Limerick, Limerick,
Ireland
3Nutrition Innovation Centre for Food and Health, School of Biomedical
Sciences, Ulster University, Coleraine, United Kingdom
Background and Aims: Secretion of the incretin hormone, glucagon-like
peptide-1(7-36)amide (GLP-1) from the intestinal enteroendocrine L-cells
plays a key role in improving glycaemic control following a meal, but this
peptide is rapidly inactivated by dipeptidylpeptidase-4 (DPP-4). Several
component peptides identified from protein hydrolysates of the edible red
seaweed Palmaria palmata, have been shown to possess DPP-4 inhibitory
actions. Here we examined the efficacy of three of these short synthetic
peptides to stabilise and improve the actions of GLP-1.
Materials and Methods: Peptides, Leu-Leu-Ala-Pro (LLAP), Met-Ala-
Gly-Val-Asp-His-Ile (MAGVDHI) and Ile-Leu-Ala-Pro (ILAP) at preserv-
ing the stability of the incretin hormone GLP-1 was examined using a
HPLC assay. GLP-1 stability was assessed over 24 h in the presence of
porcine DPP-4 (5 mU) at 37ºC in triethanolamine buffer (50 mM, pH 7.8)
with each peptide (10-6 M). In addition, peptides (10-12 to 10-6 M) were
tested for their ability to promote acute insulin secretion from cultured
pancreatic BRIN-BD11 cells at 5.6 mM glucose. The efficacy of peptides
on stimulation of GLP-1 and GIP release from GLUTag and STC-1 cells
respectively, was also assessed. Finally, peptides were administered by in-
traperitoneal (i.p.) injection individually (25 nmol/kg), or in combination
with GLP-1 (25 nmol/kg) along with glucose (18 mmol, ipGGT) to healthy
male NIH Swiss mice (aged 8-12 weeks) and tail blood samples collected
at regular intervals between 0-120 min.
Results: All three peptides LLAP, MAGVDHI and ILAP demonstrated
efficacy in inhibiting DPP-4 activity as assessed using an in vitro HPLC
assay. GLP-1 control exposed to DPP-4 alone had a half-life of 1.5 h, but
the above synthetic peptides extended the in vitro half-life of GLP-1 to 8,
10 and 13 h, respectively. LLAP and ILAP produced a dose-dependent
(10-11 and 10-6 M) increase in insulin secretion (1.4- to 2.0-fold) from
cultured BRIN-BD11 cells compared to 5.6 mM glucose controls (P<0.01
to P<0.001). During acute co-incubation using murine intestinal GLU-
Tag cells cultured at 2 mM glucose, no secretion of GLP-1 above baseline
was noted. However, co-incubation of ILAP and LLAP in STC-1 cells,
caused significant secretion of GIP (by 1.8- and 1.5-fold; P<0.05, P<0.01)
whereas in contrast MAGVDHI reduced GIP secretion by 40% (P<0.05).
When tested in vivo in mice, LLAP and ILAP produced a 43-52% reduc-
tion (P<0.05) in the blood glucose area under the curve (AUC0-120 min).
When co-injected with GLP-1, these peptides resulted in a further 13%
(LLAP) and 16% (ILAP) reduction in blood glucose AUC0-120 min ver-
sus GLP-1 injection alone.
Conclusion: Synthetic peptides derived from P. palmata have displayed
promising anti-diabetic actions helping to stabilise GLP-1 against DPP-4
degradation in vitro. Furthermore, LLAP and ILAP stimulated acute in-
sulin secretion in cultured pancreatic cells, as well as providing additive
therapeutic benefits when co-administered with GLP-1.
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Screening strategy to develop anticancer interfering
peptides by SPOT synthesis
Eric Vives1, Sébastien Deshayes2, Bérengère Chavey3,
Prisca Boisguerin2, Gudrun Aldrian3
1University of Montpellier, France
2Centre de Recherche en Biologie cellulaire de Montpellier, France
3Sys2Diag-CNRS, France
Cyclin-dependent kinases (CDK) are heterodimeric kinases whose sequen-
tial activation regulates cell cycle progression. Overexpression or exacer-
bated CDK-cyclin activity has been documented in several cancers (e.g.:
CDK4 and CDK6 are overexpressed in glioblastoma). Therefore CDK-
cyclin complexes are attractive pharmacological targets for the develop-
ment of anticancer drugs. To develop new interfering peptides targeting
these complexes, we analyzed the interaction of CDK4 with Cyclin D1, D2,
D3 and its inhibitor p16(INK4a). For this purpose, we used the following
screening strategy using peptide libraries synthesized by SPOT synthesis:
1) Determination of the different Cyclin D and p16(INK4a) epitopes using
a “PepScan” library; 2) Evaluation of the optimal epitope length using a
“LengthAna” library and 3) Dissection of the key residues important for
CDK4 interaction using a “SubAna” library. This strait forward screening
strategy led to new interfering peptides targeting CDK4/cyclin complex.
The best sequences have been synthesized as soluble peptides by SPPS
(solid phase peptide synthesis) and tagged with a Tamra-dye for affinity
measurements.
First results of these screenings will be presented. The next goal will be to
covalently link the inhibitory peptides to a cell penetrating peptide in order
to confirm their anti-proliferating activity in U87 cells.
Furthermore optimization of vectorization will be carried out with the aim
for therapeutic application in terms of tissue targeting and plasma stabil-
ity, to increase bioavailability of the therapeutic molecule at the site of the
tumor and to reduce non-specific side effects.
P165
A novel frog derived peptide with promising anti-
tuberculosis activity
Parvin Abraham1, Leny Jose2, Santhosh Kumar K3
1MIMS Research Foundation, India
2IUPUI, United States
3Rajiv Gandhi Centre For biotechnology, India
The rapid emergence and spread of multidrug-resistant tuberculosis (MDR-
TB) to currently available drugs highlights the importance of screening for
novel anti-TB agents. Cationic antibacterial peptides from amphibian skin
could be a potential alternative therapeutic agent against Mycobacterium
tuberculosis because of their unique mode of action. In our study, a peptide
that belongs to brevinin family, isolated from the skin secretion of an In-
dian frog showed potent in vitro mycobactericidal activity and inhibited M.
tuberculosis H37Rv strain. This peptide is non-toxic to macrophages but
eliminated intracellular mycobacteria in a concentration dependent man-
ner. It showed potent membranolytic activity and induced morphological
changes on the bacterial cell wall. This amphibian peptide could be de-
veloped into a potential alternative therapeutic agent for the treatment of
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tuberculosis. This is the first study demonstrating an amphibian derived
peptide with anti tuberculosis activity.
P166
Synthesis and in vitro biological activity of new
analogs of BIM-23052 containing unnatural amino
acids
Emilia Naydenova1, Diana Wesselinova2, Svetlana
Staykova3, Tatyana Dzimbova4
1University of Chemical Technology and Metallurgy, Bulgaria
2Institute of Experimental Morphology, Pathology and Anthropology
with Museum, Bulgarian Academy of Sciences, Bulgaria
3Institute of Molecular Biology “Acad. Roumen Tsanev”, Bulgarian
Academy of Sciences, Bulgaria
4South-West University “Neofit Rilski”, Blagoevgrad, Bulgaria
Somatostatin is an endogeneous cyclic tetradecapeptide hormone that ex-
erts multiple biological activities via a family of five receptors. The dual
actions of natural somatostatins (inhibition of hormone release and cell
growth) make them logical candidates as anticancer drugs, as well as for
the treatment of neuroendocrine disorders. Some peptide analogues of this
enzyme are widely used in clinical practice. However, their clinical effi-
cacy is limited because of some disadvantages. In this respect, the search
for new drugs of this type is an important task. BIM-23052 (DC-23-99)
D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH2 is a linear SST analog with
established in vitro GH-inhibitory activity in nM concentrations. It is char-
acterized by high affinity to str5, sstr3 and sstr2, as sstr5 and sstr2 are
present in high level in the cell membranes of a large number of tumor cells.
This gave us the reason to synthesize modified analogues of BIM 23052,
which are expected to possess anti-tumor activity. To study the relationship
structure-biological activity a series of new analogs of BIM-23052 have
been synthesized, where Thr, at position 6 was replaced with conforma-
tionally hindered Tle, Aib, Ac5c and Ac6c. The peptides were synthesized
by standard solid phase peptide chemistry methods Fmoc-strategy.The cy-
totoxic effects of the compounds were tested in vitro against a panel of
tumor cell lines: HT-29, MDA-MB-23, Hep-G2, HeLa and normal human
diploid cell line Lep-3. All five somatostatin receptor types were modeled
and docking was performed in order to determine the binding affinity of the
analogues. The new peptides exhibited different concentration-dependent
antiproliferative effect against the tumor cell lines after 24 h of treatment.
The compound 3B ( Aib6) demonstrated the most pronounced antiprolif-
erative effects on HepG-2 cells with the IC50 = 0.01349 nM. This effects
were proved with docking as the compound forms more stable complexes
with somatostatin receptors within all new peptides tested.
Acknowledgments: We gratefully acknowledge the financial support by
National Scientific Fund, grant 19/17.
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Structure-guided design and synthesis of peptides
targeting protein synthesis in bacteria
Christophe Andre1, Natacha Pérébaskine2, A. Carolin
Seefeldt2, Stéphanie Antunes1, Fabian Nguyen3, Céline
Douat1, Daniel N Wilson3, C. Axel Innis2, Gilles Guichard1
1CBMN, CNRS UMR5248, University of Bordeaux, France
2ARNA Laboratory, Inserm U1212, CNRS UMR 5320, University of
Bordeaux, France
3Institute for Biochemistry and Molecular Biology, University of
Hamburg, Germany
The rapid increase in drug-resistant infections poses a serious challenge
for common antimicrobial therapies. There is thus an urgent need to com-
bat this threat and to develop potent pharmaceutical agents that are effec-
tive against multi-drug resistant pathogens. Among antibacterial targets
developed in our laboratory, we will illustrate how high resolution struc-
tural studies lead to an improved structure-based design strategy and opti-
mized peptides that specifically bind and inactivate complex molecular ma-
chine. Our work focuses on proline-rich antimicrobial peptides (PrAMPs)
a particular class of Antimicrobial Peptides (AMPs), whose mechanism
of action involves specific inhibition of protein biosynthesis. AMPs are
an abundant and diverse group of natural molecules that are produced by
many tissues and cell types from prokaryotes to humans. Their unique
antibiotic spectrum is generally determined by amino acid sequences and
conformational properties. In contrast to many AMPs whose mechanism
of action often involves disruption of the bacterial cell membrane, PrAMPs
are actively transported inside the bacterial cell where they bind and inac-
tivate specific targets. It was found that a number of these peptides inhibit
protein synthesis by binding to the bacterial ribosome in the peptide exit
tunnel. The recently solved crystal structure of the complex between the
bacterial ribosome and Onc112, a representative member of the PrAMP
family has been used as a starting point to further optimize these peptides
and gain additional insight into the molecular determinants of this interac-
tion.
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Fighting melanoma - human lactoferricin derived
peptides kill cancer cells by inducing severe stress and
apoptosis
Sabrina Riedl1, Beate Rinner2, Helmut Schaider3,
Bernadette Liegl-Atzwanger4, Christina Wodlej5, Sarah
Grissenberger6, Julia Preishuber-Pflügl7, Karl Lohner1,
Dagmar Zweytick1
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Treatment of melanoma still remains a challenge. Poor cancer toxicity
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and side effects are often caused by lack of specificity for cancer cells.
Furthermore drug resistance and relapse of disease, due to weak treata-
bility of metastases, are major problems. We demonstrated that the neg-
atively charged lipid phosphatidylserine (PS) is specifically exposed by
cancer cells and metastases, thus representing a novel target for cancer
therapy and the basis for the design of cationic antitumor peptides de-
rived from human Lactoferricin (hLFcin) [1]. The hLFcin derivatives show
highly increased activity and specificity against malignant melanoma and
melanoma metastases compared to the parent peptide hLFcin. We im-
proved the peptide specificity towards cancer cells by variations of peptide
length, net positive charge and hydrophobicity, consequently affecting the
secondary structure and the killing mechanism. Our studies reveal charac-
teristic features of hLFcin derivatives facilitating specific killing of cancer
cells. 2D and 3D in vitro studies show that highly active but nonselective
peptides act through a direct membranolytic mechanism whereas selective
peptides trigger apoptosis, which is also membrane-mediated by primary
interactions with PS and subsequent interactions with intracellular targets
like the Golgi apparatus. Besides PS plasma membrane cholesterol is cru-
cial for the specificity of peptide-membrane interactions. Model systems
mimicking cancer and non-cancer cells with different ratios of PS, phos-
phatidylcholine and cholesterol reveal different mode of actions for the
peptides. The peptides alter the lipid distribution and fluidity of cancer cell
membranes, which may lead to changes of the permeability of the plasma
membrane and to secondary effects like the loss of function of membrane
proteins or the release of stress signals like ROS (reactive oxygen species)
and ATP. The specific cytotoxic effect of the designed peptides on cancer
cells was demonstrated in in vivo studies in mouse melanoma xenografts
showing tumor regression and suggesting them as potential candidates for
further (pre)clinical development. Acknowledgment: Austrian Science
Fund (FWF; grant no. P24608-B23) and Austrian Research Promotion
Agency (FFG; grant no. 855671) [1] Riedl et al. BBA 1808(11): 2638-
2645, 2011
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Lipopeptides derived from BP100 containing a
D-amino acid or a His residue
Àngel Oliveras, Esther Badosa, Emilio Montesinos, Lidia
Feliu, Marta Planas
University of Girona, Spain
Plant diseases caused by bacteria and fungi are currently one of the major
problems in agriculture, producing important economic losses. The solu-
tion to this problem relies on the use of copper derivatives, antibiotics or
fungicides. These compounds are efficient; however, they are regarded as
serious environmental contaminants. Moreover, antibiotics are not allowed
in many countries and their use is hampered by the appearance of resistant
strains [1].
Antimicrobial peptides have emerged as a good alternative to traditional
pesticides. They display a broad spectrum of activity and do not easily
facilitate the development of microbial resistance. In this context, the
LIPPSO research group, in collaboration with the Laboratory of Plant
Pathology, has identified the peptide H-Lys-Lys-Leu-Phe-Lys-Lys-Ile-Leu-
Lys-Tyr-Leu-NH2 (BP100), which displays high antibacterial activity in
vitro and is low hemolytic [2].
The acylation of antimicrobial peptides is a strategy to increase their bi-
ological activity and their stability to protease degradation. In fact, the
incorporation of an acyl chain into linear or cyclic peptides has rendered
lipopeptides with interesting biological activity, being the length of the hy-
drophobic chain crucial for the antibacterial activity [3]. Based on these
considerations, a collection of lipopeptides derived from BP100, incorpo-
rating an acyl chain at the N-terminus or at the side-chain of each residue of
the sequence, was synthesized. Lipopeptides with an interesting biological
activity profile were identified.
Herein, with the aim of improving the hemolysis and the stability in front
of protease degradation of the above sequences, 21 new lipopeptides con-
taining D-amino acids or a histidine residue were designed and synthesized.
Their antimicrobial activity, hemolysis, phytotoxicity and proteolytic sta-
bility will be presented and discussed.
References 1 G. N. Agrios, Plant Pathology, Academic Press, San Diego,
California, 5th ed., 2005. 2 E. Badosa, R. Ferre, M. Planas, L. Feliu, E. Be-
salú, J. Cabrefiga, E. Bardají and E. Montesinos, Peptides, 2007, 28, 2276.
3 S. Vilà, E. Badosa, E. Montesinos, M. Planas and L. Feliu, PLoS One,
2016, 11, e0151639.
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Discovery of Dermaseptin-PC from frog skin secretion
and rational design of broad-spectrum truncated
analogues against both planktonic and sessile bacteria
Yuan Ying, Chengbang Ma, Lei Wang, Mei Zhou,
Xinping Xi, Tianbao Chen
Queen’s University Belfast, United Kingdom
Background: Antimicrobial peptides (AMPs) derived from the amphib-
ian skin secretions are promising drug prototypes against ESKAPE strains.
However, their clinical trials to date have shown efficacy only as top-
ical agents, partly due to potential cytotoxicity. Material & Methods:
Dermaseptin-PC (DM-PC) was discovered by the combination of ‘shot-
gun’ cloning and MS/MS fragmentation sequencing. Peptide design was
carried out based on bioinformatics to enhance bio-efficacy and therapeu-
tic index. The parent peptide and its analogues were synthesized using
Tribute® synthesizer (Protein Technologies). The secondary structures of
natural peptide and the analogues were validated by circular dichroism,
and their antimicrobial efficacies were tested both on planktonic and ses-
sile bacterial cells. Results: DM-PC possesses potent and broad-spectrum
antimicrobial activity, but induce considerable haemolytic property that
precludes it for further development. Here, truncated mimetics DMPC-19
and DMPC-10 were designed to improved selectivity against microorgan-
isms. DMPC-19 maintained the activity and produced moderate haemoly-
sis, while DMPC-10 shows significant decreases on both antimicrobial and
haemolytic activities. Additionally, DMPC-10A, which contains Cha sub-
stituted at the C-terminus of DMPC-10, exhibits potent biological activity
and higher therapeutic index. Moreover, DM-PC, DMPC-19 and DMPC-
10A effectively inhibited the S.aureus and P. aeruginosa biofilms. Con-
clusion: With the optimisation of length of peptide chain and hydropho-
bicity, the therapeutic index can be improved. Additionally, the study of
dermaseptin peptide also provides new insight on lead antibiotic drug dis-
covery especially against Gram-negative bacteria and resistant strains.
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Synthesis and antimicrobial activity of the bacteriocin
pediocin PA-1 and analogs thereof
François Bédard1, Hammami Riadh2, Séverine Zirah3,
Sylvie Rebuffat3, Ismail Fliss2, Eric Biron1
1Faculty of Pharmacy and Institute of Nutrition and Functional Foods,
Université Laval, Canada
2STELA Dairy Research Centre, Institute of Nutrition and Functional
Foods, Université Laval, Canada
3Muséum national d’Histoire Naturelle, Sorbonne Universités, France
Bacteriocins are a family of ribosomally-synthesized antimicrobial pep-
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tides produced by a wide variety of bacteria. With their attractive proper-
ties and activities, these peptides are promising alternatives to conventional
antibiotics in the food and animal production industry as well as veterinary
and human medicine. Among class IIa bacteriocins, we were particularly
interested in pediocin PA-1, a peptide of 44 amino acids containing two
disulfide bonds produced by Pedioccocus acidilactici able to inhibit the
growth of several clinically relevant pathogens such as Listeria spp. De-
spite its great potential as an antimicrobial agent, the problems associated
with its production continue to limit its applicability and delay regulatory
approval. Using a combination of solid- and solution-phase strategies, we
were able to overcome difficulties due to instability and undesired reactions
and produce synthetic pediocin PA-1 in good yields. Pediocin PA-1 thus
synthesized was a potent inhibitor of Listeria monocytogenes (MIC = 6.8
nM), similar to the bacteriocin produced naturally by Pediococcus acidi-
lactici. Pediocin-derived peptides were also prepared to perform structure-
activity studies and structural analysis by NMR. Of particular interest is
that linear analogs lacking both of the disulfide bonds characterizing pe-
diocin PA-1 were as potent. One linear analog was also a strong inhibitor of
Clostridium perfringens (MIC = 37.8 nM), another important food-borne
pathogen. The total synthesis, characterization and antimicrobial activities
of pediocin PA-1 and analogs thereof will be presented and discussed in
light of conformational analyses and structure-activity relationship studies.
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Identification and characterization of cyclotides from
Brazilian Psychotria species
Meri Emili Pinto, Mariana Rosa, Vanderlan Bolzani,
Eduardo Cilli
Sao Paulo State University, Brazil
Psychotria genus below to tribe Psychotrieae (Rubiaceae) and comprises
approximately 2,000 species; some of them are reported as cyclotide-
containing plant species. Cyclotides are characterized by a head-to-tail
cyclized backbone usually composed of 28-37 amino acids, and a unique
knotted disulfide topology involving six conserved cysteine residues
termed the cyclic cystine-knot (CCK) motif. The CCK motif is respon-
sible for their exceptional resistance to chemical, enzymatic and thermal
degradation. This topology confers them remarkable stability and wide
range of biological and/or therapeutic applications, between them, anti-
HIV, insecticidal, antimicrobial, uterotonic, cytotoxic, hemolytic, trypsin
inhibitory, and immunosuppressive activities. This work deals with the
identification and characterization of cyclotides accumulated in the Brazil-
ian plant species: Psychotria vellosiana (stems and leaves) and Psycho-
tria leiocarpa (aerial parts). The dried plants were ground prior to solvent
extraction with a mixture of MeOH:CH2Cl2 (1:1; v/v) for 24 hours (4
times). The crudes extracts were dissolved in ACN:H2O (1:9; v/v) and
immediately used for solid phase extraction (SPE). C18 SPE cartridges
(Strata-Phenomenex C18 55um, 70Å, 500 mg) were activated with MeOH
and subsequently equilibrated with of aqueous 1 % FA. After application
of the extract, the cartridges were washed with ACN:H2O (2:8; v/v) and
ACN:H2O (8:2; v/v). To determine whether these fractions contained pep-
tides with disulfide bonds, they were treated with the reducing agent 10
mM dithiothreitol and alkylation agent 100 mM iodoacetomide, and the
mass increase of 348 Da was observed, suggesting that three disulfide
bonds had been reduced. The three extracts showed the presence of pep-
tides with masses in the range of 2900-3700 Da as analyzed by MALDI-
TOF mass spectrometry (MS). HPLC chromatography allowed to isolate
the novel möbius cyclotides, with m/z 2889 and 2905 from P. vellosiana
and to identify some cyclotides in P. leiocarpa. The cyclotides sequencing
were performed by reduction, alkylation and enzymatic digest with endo-
proteinases Glu-C, trypsin, chymotrypsin and followed by MS/MS analy-
sis. The spectra were carefully examined and the sequences were proposed,
based on the presence of both b- and y-series of ions (N- and C-terminal
fragments).
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Discovery of A Novel Membrane-Disruption Peptide
against Multi-Drug Resistant Gram-Positive Strains
Isolated from Cystic Fibrosis Patients
Yipeng Yuan, Xinping Xi, Mei Zhou, Lei Wang,
Chengbang Ma, Tianbao Chen
Queen’s University Belfast, United Kingdom
The prevalence of the infection by multi-drug resistant gram-positive
strains, especially methicillin-resistant Staphylococcus aureus (MRSA), is
increasing in the airways of cystic fibrosis (CF) patients. The survival of
CF patients with the presence of the associated infections was even worse.
Although antibiotic therapies have been employed to treat the infections,
the environment of CF respiratory tract increases the biofilm-forming abil-
ity, which makes bacteria intrinsically resistant to be eradicated. Antimi-
crobial peptide (AMP) is a promising candidate against drug-resistant bac-
teria as well as the biofilm. In this study, we reported a novel antimicro-
bial peptide identified from the skin secretion of Limnonectes fujianen-
sis by the combination of cDNA cloning and MS/MS sequencing, namely
Japonicin-2LF. The peptide possesses an α-helical segment and a typical
heptapeptide loop, rana box, at the C-terminus. The solid peptide synthesis
was performed using Tribute® synthesizer (Protein Technologies), and the
synthetic replicates exhibit potent antimicrobial activity against both wide-
typed and CF clinic-isolated gram-positive strains. The fluorescent stain-
ing reveals that Japonicin-2LF efficiently permeabilise the cell membrane
of bacteria, leading to cell death. In addition, Japonicin-2LF can inhibit
the formation of MRSA biofilm and eradicate it in vitro. To further investi-
gate the antimicrobial effect of Japonicin-2LF in vivo, the acute infection
module induced by CF isolated MRSA was employed, using larva of the
wax moth, Galleria mellonella. The results demonstrated that 25 mg/kg of
Japonicin-2LF increase the survival rate of MRSA infected larva signifi-
cantly, without producing any toxicity. The study suggests that Japonicin-
2LF is such potential molecule that can be developed as a new antibiotic
agent for treatment of MRSA associated chronic infection in CF respira-
tory tract.
P174
New 4-Aminopyridine derivatives containing peptide
fragment designed for the treatment of Alzheimer
disease and multiple sclerosis
Lyubomir Vezenkov, Borislav Anchev, Kristian Fidanov,
Daniela S. Tsekova
University of Chemical Technology and Metallurgy, Bulgaria
New 4-Aminopyridine derivatives containing peptide fragment designed
for the treatment of Alzheimer disease and multiple sclerosis L. Vezenkov,
B. Anchev, K. Fidanov, D. S. Tsekova Alzheimer’s disease (AD) and Mul-
tiple sclerosis (MS) are neurodegenerative diseases. The AD process is as-
sociated with plaques and tangles in the brain. MS is a disease that causes
inability of the CNS cells to comunnicate each to other. Neurodegeneration
leeds to problems with cognitive function (dementias) and / or movement.
According the literature data, no cure for AD and MS, but the treatments
can help for the changing of the diseases progresion. Among the most ef-
fective medicals used for both diseases treatment are 4-aminopyridine (4-
AP) and galanthamin. Based on the literature, we proposed an approach
to produce new hybrid molecules between 4-aminopyridine and different
peptide fragments, thus we expect to combine important pharmacological
effects to influence AD and MS:- Inhibition of β -secretase due to pep-
tide fragments; - Blocking of potassium channels leads to an increase in
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the level of acetylcholine in the brain as well as an anti-inflammatory ac-
tion due to 4-aminopyridine; - Easier passage through BBB, that due to
4-AP. 4-AP is of very high toxicity, limiting its use in the treatment of
neurodegenerative diseases. By introducing non-toxic peptide fragments
into the molecules of these compounds, we expect a significant reduction
in toxicity, which is reflected in an increase in LD50 values. Here we re-
port the synthesis of nine new hybride compounds containing 4-AP and
different peptide fragments. The syntheses were performed in solution
by sequentially joining the protected amino acids. The condensation was
carried out by TBTU method, with the reagents being dissolved in a min-
imal amount of DMF. The resulting crude products were recrystallized to
chromatographically pure products. The compounds were characterized
by m.p. thin layer chromatography and NMR. Performing tests for cito-
toxicity, LD50 was found as IC50>100µM (micromoles), which is much
higher compared to 4-AP. Cell toxicity screening was performed towards
the following three types cell cultures and cultivation 1. Human hepatocel-
lular cancer HEP-G2; 2. Mice neuroblastoma cell Neuro 2a; 3. Human
chronic myeloid leukemia - BV-173. In order to determine whether the
new 4-aminopyridine (4-AP) derivatives have a protective effect against
AD and MS a variotions of studies are still in progress, which results will
be reported in the Symposium presentation. This includes: - Tests for
learning and memory; - Tests for antiinflamatory activity – in-vitro and
in-vivo; - Tests for β -secretase inhibition activity, which due to the pep-
tide segment of the molecule. Acknowledgement: This study is supported
by the Scientific Research Fund of Bulgaria through the project DH 03/8,
“Galanthamine’s and 4-aminopyridine’s derivatives containing peptide mo-
tif with expected effect on the Alzheimer’s disease and multiple sclerosis”.
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GLP-1 and GIP receptors co-agonists
Elise S.C. Bernard, Jacky Metcalfe, Isabelle Sermadiras,
Andie Collinson, Jacqueline Naylor, David Hornigold,
Maria A. Bednarek
MedImmune Ltd, United Kingdom
It is predicted that in 2030, more than 15% of the United States popu-
lation will be diabetic and consequently, in time, suffer from additional
complications: kidney failure, vision loss, nerve damage, leg amputation
and others. Incretin-based therapies for the treatment of type 2 diabetes
exploit insulinotropic actions of two gastrointestinal hormones: glucagon-
like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP) - both hor-
mones increase insulin secretion from pancreatic beta-cell following food
ingestion. Previously, several classes of dual agonists at GLP-1 R and GIP
R have been shown to possess better antihyperglycemic and insulinotropic
efficacy than mono agonist peptides.
Here we report new, dual incretin co-agonists with balanced activity at
the human GLP-1 R and GIP R; potential candidates for the development
of the treatment for type 2 diabetes, obesity, and associated comorbidi-
ties. Structural similarities between GLP-1 and GIP sequences guided our
rational design of GLP-1 derived peptides and consequently yielded com-
pounds of high, balanced agonism at both receptors. Selective changes to
the GLP-1 sequence also allowed us to improve compounds’ resistance to
proteolytic enzymes. Further enhancement of pharmacokinetic profile of
those peptides was achieved by lipidation; which subsequently resulted in
candidates which required less frequent dosing.
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Identification of an Arg-Leu-Arg motif that contributes
to the binding interface between the cytokine MIF and
the chemokine receptor CXCR4
Christos Kontos1, Markus Brandhofer2, Michael Lacy2,
Kathleen Hille1, Dzmitry Sinitski2, Christine Krammer2,
Jürgen Bernhagen2, Aphrodite Kapurniotu1
1Division of Peptide Biochemistry, TUM School of Life Sciences,
Technische Universität München (TUM), Germany
2Department of Vascular Biology, Institute for Stroke and Dementia
Research, Ludwig-Maximilians-University of Munich, Germany
Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine
that is involved in the pathogenesis of inflammatory and cardiovascular dis-
orders. MIF triggers atherogenic leukocyte recruitment by interacting with
the classical CXC chemokine receptors CXCR2 and CXCR4 (Bernhagen
et al., Nat. Med. (2007)) and has been defined as an atypical chemokine
(ACK). While the residues and motifs contributing to the MIF/CXCR2
interface have been identified (summarized in Tillmann et al., Front Im-
munol 2013)), the molecular determinants governing the interaction be-
tween MIF and CXCR4 are incompletely understood. We recently showed
that the conserved proline-2 residue of MIF, its N-like loop that also sup-
ports MIF/CXCR2 binding, and the extracellular loops (ECL) 1 and 2
of CXCR4 contribute to MIF/CXCR4 binding (Rajasekaran et al., J Biol
Chem (2016)), but a complete understanding of the MIF/CXCR4 interface
including differences to classical CXCL12/CXCR4 binding events is lack-
ing. Here, we identified the Arg-Leu-Arg (RLR) region at position 87-89
of MIF as a novel hotspot of the MIF/CXCR4 interface. ‘RLR’ repre-
sents an apparent 3D extension of N-like loop of MIF and thus might con-
tribute to Site 1 interaction with CXCR4. This notion was experimentally
validated by peptide spot-array technology, structure-activity relationships
and molecular docking experiments. Importantly, a triple alanine mutant
of MIF (R87A-L88A-R89A-MIF) in which the ‘RLR’ motif was substi-
tuted by Ala residues was expressed in E. coli BL21/DE3, purified and
biophysically characterized. Although the mutated MIF shares a similar
secondary structure with the WT-MIF, it could not bind to the N-terminal
of CXCR4. Furthermore, we analyzed the activity of the triple alanine
mutated MIF with a focus on MIF/CXCR4-driven (patho)physiologic ef-
fects. R87A-L88A-R89A-MIF failed to activate CXCR4 in a cell system
of genetically modified Saccharomyces cerevisiae that measures CXCR4-
mediated cell signaling responses. Moreover, we tested the effect of the
triple alanine mutation on CXCR4-mediated chemotactic activity of MIF
using the human B cell line JVM-3. Wildtype MIF but not R87A-L88A-
R89A-MIF elicited the chemotactic migration of these B cells, confirming
that the ‘RLR’ sequence is an indispensable region of the MIF/CXCR4 in-
terface (Lacy*, Kontos* et al., Sci Reports 2018). Our results offer novel
information on MIF/CXCR4-specific inhibition strategies in inflammatory
and cardiovascular diseases.
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Chemical synthesis and investigation of the native
form and an improved gamma-core analogue of
Neosartorya fischeri antifungal protein 2 (NFAP2)
Györgyi Váradi1, Liliána Tóth2, Ákos Vendrinszky1, László
Galgóczy2, Gyula Batta3, Attila Borics4, Zoltán Kele1,
Gábor K. Tóth1
1Department of Medical Chemistry, University of Szeged, Hungary
2Department of Microbiology, Faculty of Science and Informatics,
University of Szeged, Hungary
3Department of Organic Chemistry, University of Debrecen, Hungary
4Institute of Biochemistry, Biological Research Centre, Hungarian
Academy of Sciences, Hungary
NFAP2 is a novel cysteine-rich antifungal protein from Neosartorya fis-
cheri NRRR 1811. The Minimum Inhibitory Concentration (MIC) val-
ues on clinically relevant Candida species vary between 0.391 and 1.563
µg/mL. Beside isolation from natural source and preparation by recom-
binant technology, NFAP2 was synthesized by chemical method. Native
chemical ligation of thioester of the N-terminal 22-mer and the C-terminal
30-mer provided the reduced form of the protein containing six free cys-
teine thiols2,3. Glutathione redox buffer at pH 7.5 has been applied for the
formation of natural disulfide bond pattern (abcabc). For functional map-
ping, fragments of NFAP2 were synthesized and tested. Antifungal sus-
ceptibility test revealed that not the highly-conserved gamma-core motif,
but the mid-N-terminal part had impact on antifungal activity. Our inves-
tigations proved the importance of physico-chemical properties, such as
net charge, on the antifungal effect. Based on these findings, an improved
gamma-core peptide was designed and synthesized. The lower MIC val-
ues of this peptide could be explained by its greater net positive charge.
An NFAP2 analogue containing the improved gamma-core in place of the
original one was synthesized. Preparation was performed by native chem-
ical ligation of two fragments of the protein. Different oxidation condi-
tions were tried for the formation of disulfide bridges: oxygen of air and
glutathione redox buffer. Both methods led to the same disulfide bond pat-
tern. Despite of the fact that the improved gamma-core protein exhibits
greater net positive charge than the native form, it proved to be less effec-
tive against Candida albicans.
1. Tóth, L., Kele, Z., Borics, A., Nagy, G. L., Váradi, G., Virágh, M., Takó,
M., Vágvölgyi, C., Galgóczy, L., AMB Express, 2016, 6:75 2. Dawson, P.
E., Muir, T. W., Clarklewis, I., Kent, S. B. H., Science, 1994, 266, 776-779
3. Váradi, G., Tóth, G. K., Kele, Z., Galgóczy, L., Fizil, Á., Batta, G.,
Chemistry – A European Journal, 2013, 19, 12684-12692
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Novel peptide-based control measures against the rice
fungal pathogen Pyricularia oryzae
Marta De Zotti1, Luca Sella1, A. Quarantin1, Carla
Castiglioni1, Angela Bolzonello1, Francesco Favaron1, A.M.
Picco2, R. Govind1, Silvio Tundo1, Silvana Odorizzi1, Le T.
Do3, Vu V. Van4, Nguyen M. Hung3
1University of Padova, Italy
2University of Pavia, Italy
3Duy Tan University, Viet Nam
4Nguyen Tat Thanh University, Viet Nam
The filamentous fungus Pyricularia oryzae is the main causal agent of the
rice blast disease, which accounts for 10-30% yield losses per year glob-
ally. New antimicrobial peptides, analogs of the natural peptaibol trichogin
GA IV, have been synthesized and tested in vitro against several P. oryzae
strains from different geographic origin. Trichogin GA IV is the main
component of the mixture of peptide congeners produced by Trichoderma
longibrachiatum as part of its defence mechanism against other microor-
ganisms. Its primary sequence is as follows: Oct-Aib-Gly-Leu-Aib-Gly-
Gly-Leu-Aib-Gly-Ile-Lol (where Aib is alpha-aminoisobutyric acid, Oct
is the n-octanoyl group and Lol is the 1,2-aminoalcohol leucinol). All
analogs were synthesized by SPPS using a cost-effective strategy. In this
presentation, the synthesis and conformational analysis of the peptides are
presented, together with the results obtained with our in vitro screening,
that has allowed the identification of several peptide sequences very effec-
tive in inhibiting spore germination and fungal growth. Those sequences
are currently being tested in vivo to confirm their efficacy in protecting
rice from the blast disease. This work is part of the Scientific and Tech-
nological Cooperation Agreement between the Italian Ministry of Foreign
Affairs and International Cooperation and the Department of International
Cooperation of the Ministry of Science and Technology of Vietnam.
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Novel Oligopeptides with angiotensin I-converting
enzyme inhibitory activity found in an elastase-treated
hydrolysate of porcine aortic elastin
Toshiya Hatakenaka1, Tamaki Kato1, Kouji Okamoto2
1Graduate School of Life Science and Systems Engineering, Kyushu
Institute of Technology, Japan
2Vital Resources Applied Laboratory, Inc., Japan
[Objective] Hypertension is one of the main risk factors causing cerebro-
and cardiovascular diseases. Angiotensin I-converting enzyme (ACE) cat-
alyzes the production of a vasoconstrictive peptide, angiotensin II from
angiotensin I. Therefore, the inhibition of ACE activity is an essential tar-
get for antihypertension. Elastin is an important macromolecular protein
which exists widely in elastic tissues such as arteris, ligaments, lung, skin,
etc. and exerts its elasticity to such elastic tissues. It was recently shown
that elastin is the protein with ACE inhibitory activity. The peptides with
ACE inhibitory activity were found in a thermolysin-treated hydrolysate of
bovine ligamentum nuchae elastin[1] and an elastase-treated hydrolysate
of porcine aortic elastin[2]. We are particularly interested in novel ACE in-
hibitory peptides derived from porcine aortic elastin. Here, we investigated
to isolate the ACE inhibitory peptides from a pancreatic elastase-treated
hydrolysate of porcine aortic elastin. [Methods] Porcine aortic elastin was
treated with pancreatic elastase and the hydrolysate was separated by the
use of HPLC. The ACE inhibitory activity of fractions obtained was ana-
lyzed by ACE inhibition assay using hippuryl-L-His-L-Leu as a substrate
(ACE inhibition assay). The peptides in ACE inhibitory fractions were
separated and their sequences were identified by means of LC/MS/MS and
chemically synthesized by solid-phase method. ACE inhibitory activity of
synthetic peptides was examined by ACE inhibition assay. [Results] The
novel ACE inhibitory peptides derived from pancreatic elastase-treated hy-
drolysate of porcine aortic elastin were oligo peptides in the crosslinked
regions. [Conclusion] The resulting ACE inhibitory peptides may be bene-
ficial as ingradients of functional foods for preventing hypertension.
[1]Y.Sato,et al., Biosci. Biotechnol. Biochem., 76 (7), 1329–1333(2012).
[2]I.Maeda,et al., Current Enzyme Inhibitation, 14(1), 67-74(2018).
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Cell-penetrating peptides restricting oligomerization of
G protein-coupled receptors: the CB1R-5HT2AR
dimer
Maria Gallo1, Estefania Moreno2, Juan Antonio Ortega3,
Vicent Casadò2, Patricia Robledo3, Rafael Maldonado1,
Leonardo Pardo4, David Andreu1
1Department of Experimental and Health Sciences, Universitat Pompeu
Fabra (UPF), Barcelona, Spain
2Department of Biochemistry and Molecular Biology, Faculty of Biology,
University of Barcelona, Barcelona, Spain
3Integrative Pharmacology and Systems Neuroscience, IMIM-Hospital
del Mar Medical Research Institute, Barcelona, Spain
4Laboratori de Medicina Computacional, Unitat de Bioestadística,
Facultat de Medicina, Universitat Autònoma de Barcelona, Spain
G protein-coupled receptors (GPCRs) have been classically described as
monomeric transmembrane (TM) receptors that form a ternary complex
between a ligand, the GPCR and its associated G protein. However, it
is now well accepted that many GPCRs form, in addition to functional
monomeric structures, higher-order oligomeric complexes constituted by
a number of equal (homo) or different (hetero) monomers (Figure 1A).
GPCR heteromers are defined as novel signaling units with functional prop-
erties different from homomers and represent a completely new field of
study. For instance, when coexpressed in specific brain regions, CB1R and
5HT2AR form heteromeric structures (Figure 1B) that have been related to
(tetrahydrocannabinol-linked) effects such as memory impairment, anxiety
and dependence.1 In the present study, in order to identify the functional
properties of the CB1R-5HT2AR heterodimer, we used synthetic peptides
with the amino acid sequence of the TM domains of CB1R, fused to a
cell-penetrating sequence derived from HIV TAT, to disrupt the formation
of the heteromer. These peptides were tested in bimolecular fluorescence
complementation assays in cells expressing receptors fused to two com-
plementary halves of YFP, and by their ability to modify cAMP and p-
ERK1/2 signaling when both receptors are co-activated with ligands. In
addition, we used molecular dynamics simulations of the CB1R-5HT2AR
heterodimer to identify hot-spots on the dimer interface. This has led to a
series of designed peptides fused to a CPP vector that effectively interfere
with this predicted CB1R-5HT2AR interface.
References 1. X.Vinals, E. Moreno, L. Lanfumey, A. Cordomi, A. Pastor,
R. de La Torre, P. Gasperini, G. Navarro, L. A. Howell, L. Pardo, C. Lluis,
E. I. Canela, P. J. McCormick, R. Maldonado, and P. Robledo PLoS Biol.
(2015) 13.
P181
The synthesis, oxidation and characterization of GLP-1
peptide receptor fragments
János Szolomájer1, Zoltán Kele1, Gábor K. Tóth1, Pál
Stráner2, András Perczel2
1University of Szeged, Department of Medical Chemistry, Hungary
2Eötvös Loránd University, MTA-ELTE Protein Model. Res. Group and
Laboratory of Structural Chemistry and Biology, Hungary
Glucagon is a 29-amino acid peptide hormone that is produced by the post-
translational cleavage of proglucagon, which is a 160-amino acid precursor
polypeptide expressed in pancreatic α-cells, intestinal L cells and brain
cells. In the intestine and the brain, proglucagon cleavage is catalysed
by the PC1/3 enzyme, leading to the formation of glucagon-like peptide-
1 (GLP-1), glucagonlike peptide-2 (GLP-2), glicentin and oxintomodulin.
GLP-1 is a 31-amino acid peptide hormone that has approximately 50%
amino acid sequence homology with glucagon, which is secreted mainly
by the intestinal L-cells in response to nutrient ingestion. Despite this high
degree of sequence homology, glucagon and GLP-1 perform opposing ac-
tions in glucose homeostasis. The main physiological role of glucagon
is to protect the organism against the damaging effects of hypoglycaemia.
[1] The mechanisms of action of GLP-1 go beyond just the augmentation
of glucose-induced insulin secretion and include increasing insulin expres-
sion, inhibiting beta-cell apoptosis and promoting beta-cell neogenesis re-
ducing glucagon secretion delaying gastric emptying, promoting satiety
and increasing peripheral glucose disposal. It is clear from these varied
actions that GLP-1 plays a central role in controlling postprandial blood
sugar levels. These multiple effects have generated a great deal of interest
in the discovery of long-lasting agonists of the GLP-1 receptor (GLP-1R)
in order to treat type 2 diabetes. The receptors of GLP-1 (GLP-1R) formed
a new branch of the GPCR superfamily, named ‘Family B’ which to date
includes 15 members. Family B GPCRs bind their peptide ligands via a
common mechanism known as the ‘two-domain model’ in which the NTD
first binds to the C-terminal helical region of the ligand, thereby enabling
a second interaction between the N-terminal region of the ligand and the
core domain of the receptor. The latter interaction is essential for enabling
agonist-induced receptor activation. [2] Our aims were the chemical syn-
thesis, oxidation and characterization of GLP-1 peptide receptor fragments
and the investigation of the peptide-ligand (GLP-1, liraglutide, exendin) in-
teraction using NMR spectroscopy. Due to the difficulty and the length of
the sequence we have decided to synthesize the 108 amino acid contain-
ing GLP-1 peptide receptor by native chemical ligation procedure. The
designed fragments compatible with native chemical ligation was synthe-
sized using solid phase peptide synthesis applying Fmoc/tBu strategy and
the synthesis was carried out using a CEM® microwave assisted fully au-
tomated peptide synthesizer. The oxidation of the synthesized GLP-1 pep-
tide receptor and the investigation of the peptide-ligand interaction is still
in progress.
1. Insuela, D.B.R. and V.F. Carvalho, Glucagon and glucagon-like peptide-
1 as novel anti-inflammatory and immunomodulatory compounds. Euro-
pean Journal of Pharmacology, 2017. 812: p. 64-72. 2. Donnelly, D.,
The structure and function of the glucagon-like peptide-1 receptor and its
ligands. British Journal of Pharmacology, 2012. 166(1): p. 27-41.
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Influence of Arginine Mimetics on the Biological
Effects of NT(8-13) Analogues
Silvia Michailova1, Maya Georgieva2, Tatyana Dzimbova2,
Thomas Bruckdorfer3, Tamara Pajpanova2
1Medical University of Varna Prof. Dr. Paraskev Stoyanov, Faculty of
Pharmacy, Bulgaria
2Roumen Tsanev Institute of Molecular Biology Bulgarian Academy of
Sciences, Bulgaria
3Iris Biotech GmbH, Germany
Neurotensin (NT, pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-
Leu) is a neuropeptide found in the periphery and in the central nervous
system. The physiological and biochemical actions of NT are mediated
through binding to NT receptors (NTRs). It is well-known that the ac-
tive fragment of neurotensin is 8-13 (RRPYIL). The main drawback in
the use of NT or any other endogenous peptide as a drug is extremely
short half-life as a result of their rapid degradation by the action of pepti-
dases. To overcome this problem, various neurotensin analogues were syn-
thesized, which include linear peptides, cyclic peptides and non-peptide
molecules. Additionally, incorporation of unnatural, guanidino containing
and hydrophobic amino acids in bioactive peptides, and as we already re-
ported, in the NT[8-13], increases both biological activity and resistance
toward enzyme degradation. These observations prompted us to develop
new analogues containing shorter homologues of Arg (having a chain of
5 carbons, α-amino-4-guanidino-butyric acid (Agb), and 4 carbon chain,
α-amino-3-guanidino-propionic acid (Agp) at the N-terminal end of the
NT[8-13]. In the present study, we thus investigated the effects of Agp/Agb
residue incorporation at the positions 8 and 9 of the NT[8-13] fragment on
biological activity (cytoxicity and central nervous activity).
Acknowledgements: The study was supported by National Science
Fund, Ministry of Education and Science, Bulgaria, Project: DN19/17,
20.12.2017 and by BAS, Project: DFNP-17-181.
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Antistaphylococcal activity of the KR-12 alanine scan
Maciej Jas´kiewicz1, Marta Bauer1, Kinga Sadowska2,
Wioletta Baran´ska-Rybak1, Elz˙bieta Kamysz2, Wojciech
Kamysz1
1Medical University of Gdan´sk, Poland
2University of Gdan´sk, Poland
Staphylococcus aureus bacteria are still the most frequently isolated
pathogens, responsible for mild as well as life threatening infections. De-
spite the constant progress in pharmaceutical sciences, the therapy of
staphylococcal infections is sometimes ineffective, mainly because of an
increasing resistance to antibiotics. Skin infections caused by staphylo-
cocci are associated with many interplaying factors, including genotypic
background, immunological abnormalities, and skin barrier defects. As
a matter of fact, patients with those diseases are characterized by an ex-
ceptional predisposition to be colonized, mostly by S. aureus. This can
be also due to synthesis dysregulation of endogenous antimicrobial pep-
tides (AMPs) such as LL-37. For this reason, the use of endogenous
AMPs or their analogues in therapy may be the solution for treatment of
staphylococcal skin infections. KR-12 (KRIVQRIKDFLR) is a 12-meric
α-helical antimicrobial peptide derived from human cathelicidin LL-37. It
exhibits anti-inflammatory and antimicrobial activity against broad spec-
trum of pathogens, including S. aureus. However, some staphylococcal
enzymes such as metalloproteinase which disactivates the activity of LL-
37 may also affect the peptide. The aim of this study was to learn whether
or not the alanine scan of KR-12 could lead the compounds with improved
activity of S. aureus and/or resistant to proteolytic activity. The biologi-
cal studies included determination of the minimum inhibitory concentra-
tion and activity against biofilm for reference as well as clinical isolates
of S. aureus. Moreover, to evaluate the cytotoxicity, the hemolytic activity
against human RBCs was determined. The results confirmed the validity of
the hypothesis. Some compounds exhibited the improved to KR12activity.
The hemolysis rate was referred to individual amino acid substitution. Ac-
knowledgments This study was supported by a grant from the Polish Na-
tional Science Centre (Project No. 2016/23/B/NZ7/02919)
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Synthesis and in vitro Assessment of the Cytotoxic
Effects of Novel RGD Analogues and Conjugates
Anelia Balacheva1, Momchil Lambev2, Roumyana
Detcheva1, Thomas Bruckdorfer3, Tamara Paypanova4
1Roumen Tsanev Institute of Molecular Biology, Bulgarian Academy of
Sciences, Bulgaria
2Medical University of Varna Prof. Dr. Paraskev Stoyanov, Faculty of
Pharmacy, Bulgaria
3Iris Biotech GmbH, Germany
4Institute of Molecular Biology ”Roumen Tsanev”, Bulgarian Academy
of Sciences, Bulgaria
Delivering peptides with antitumour action directly into cancer cells is one
of the most important strategies in recent decades. The amino acid se-
quence L-arginyl-glycyl-L-aspartic acid (RGD) plays role in interaction of
many adhesion protens by connecting with αvβ3 and αvβ5 integrin recep-
tors that are overexpressed on various cancer and angiogenic endothelial
cells. Synthetic RGD peptides may affect adhesion, and tumour metastais,
or directly induce apoptosis by activating caspases. Drug design based on
the RGD structure may provide opportunity for targeted drug delivery and
imaging, as well as a new chemotherapeutic treatment for cancer. We syn-
thesized a series of short RGD mimetics and RGD conjugates and exam-
ined their cytotoxic activity against three cancer cell lines. RGD-modified
peptides by shorter homologues of Arg (having a chain of 5 carbons, α-
amino-4-guanidino-butyric acid (Agb), and 4 carbon chain, α-amino-3-
guanidino-propionic acid (Agp), show an increase in the cytotoxic effect
compared to the parent RGD peptide.
Acknowledgements: The study was supported by National Science
Fund, Ministry of Education and Science, Bulgaria; Project: DN19/17,
20.12.2018.
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Computational Approaches to Peptide Permeability
Sookhee Ha, Jerome Hochman, Shiying Chen
Merck, United States
Resurgence of peptide drug discovery has taken place over recent years
because the peptides can target the large interface of protein-protein in-
teraction. However, there are some challenges - such as low membrane
permeability that cause low oral bioavailability and difficult access to the
intracellular targets. In this poster, we will discuss on the following com-
putational tools established at Merck to assess the passive permeability of
a peptide and a process of designing a peptide library guided by the de-
sign principles that led to identification of the permeable peptides. • Free
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energy of Transfer (DG) • QSAR models of permeability assays • Rule of
physicochemical parameters for passive permeability
P186
Novel hybrid reversed-phase packing material for high
productivity of insulin purification
Hiroki Kanezaki, Chiaki Iwata, Moemi Miyashita, Hiroyuki
Tanaka, Takashi Sato, Noriko Shoji, Naohiro Kuriyama
YMC Co., Ltd., Japan
Reversed-phase chromatography has an important role in purification of
high value–added insulin pharmaceutical. It’s very important to improve
productivity in insulin industrial purification and packing materials which
have long life time and high separation performance are strongly required.
In order to meet such demands, we have developed novel reversed phase
material based on hybrid silica, “Triart-SIL”. It’s commonly known that
the choice of appropriate pore size and hydrophobicity is important for pu-
rification of peptides and proteins, and the packing materials bonded C8
ligand with 200 Å pore size increase efficiency for insulin purification. To
enhance separation performance and stability for high productivity of in-
sulin, we have optimized the pore size distribution, the density of C8 func-
tional group and chemical bonding method. In this poster, we will show
characteristics and improvements of these novel hybrid based packing ma-
terial, and the chromatographic performance and advantages of them for
use in purification of insulin.
P187
Improving uptake and metabolic stability of the
therapeutic iCAL peptide in the context of cystic
fibrosis.
Quentin Seisel1, Dean R Madden2, Prisca Boisguerin1
1CRBM, CNRS UMR5237, UM, France
2Dartmouth College, United States
Cystic fibrosis (CF) is the most common lethal genetic disorder in popu-
lations of European descent. CF is due to loss-of-function mutations in
CFTR (cystic fibrosis transmembrane conductance regulator) (1), an ep-
ithelial ion channel strongly involved in cell homeostasis and airway mu-
cociliary clearance. Thus, CF patients suffer from airway obstruction and
chronic infection. One of the three known functional defects associated
with the most prevalent mutation, p.Phe508del-CFTR, addresses its stabil-
ity at the apical membrane of endothelial cells. In 2010, our group re-
ported the development of inhibiting peptides (iCAL) which are able to
decouple the deleterious interaction between the CFTR-associated protein
(CAL) and the C-terminal region of the p.Phe508del-CFTR, thereby rescu-
ing CFTR activity at the apical membrane (11% increase in chloride efflux)
(2-3). To further improve this therapeutic effect, we decided to optimize
the ADME properties of the iCAL peptides, especially their intracellular
delivery and their stability to the proteases encountered in CF lungs. In
a first part, we will show that iCAL internalization can be dramatically
improved by covalent coupling to cationic cell-penetrating peptides (CPP)
(4). Internalization efficiency, subcellular localization and internalization
mechanism on Caco-2 cells will be depicted and presented. In a second
part, we report the optimization of the iCAL peptide sequence in terms
of affinity and stability using the PIPEPLUS method (5), a variant of the
SPOT synthesis (6) allowing the screening of peptide libraries. In this con-
text, we will show that the introduction of non-natural amino acids within
iCAL sequences could increase affinity or selectivity of the peptides for
the CAL protein as well as their stability. Altogether, the presented results
will push forward the development of more efficient and specific iCAL
inhibitors as new therapeutics to treat the symptoms of CF patients.
References: (1) Kerem et al., Science, 245, 1073 (1989). (2) Vouilleme et
al., Angew Chem Int Ed Engl, 49, 9912 (2010). (3) Cushing et al., Angew
Chem Int Ed Engl, 49, 9907 (2010). (4) Heitz et al., Br J Pharmacol, 157,
195 (2009). (5) Seisel et al., Bioorg Med Chem Lett. 27(14), (2017). (6)
Frank, J Immunol Methods, 267, 13 (2002).
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Cytoplasmic delivery of a peptide modified with a
sonosensitizer by using ultrasound
Mizuki Kitamatsu1, Takashi Ohtsuki2
1Kindai University, Japan
2Okayama University, Japan
In this study, we developed an ultrasound (US)-sensitive molecule for cy-
toplasmic delivery. As the molecule, we designed a peptide consisting
of a functional peptide, a cell-penetrating peptide (CPP) and a sonosen-
sitizer. We chose Bim peptide (apoptosis inducing peptide; the BH3
domain derived from Bim apoptosis-inducing protein) as the functional
peptide. We also used Tat peptide derived from the HIV-1 transacti-
vator of transcription protein as the CPP. CPPs have been widely used
for intracellular delivery of various cargos. The conjugate of Bim pep-
tide with Tat, TatBim was synthesized by conventional Fmoc-based solid-
phase peptide synthesis. The TatBim was contained Cys residue at the C-
terminus for connecting with rose bengal (RB)-maleimide as the sonosen-
sitizer. The sequence of obtained US-sensitive molecule, TatBim-RB was
RKKRRQRRR-EIWAQELRRIGDEFNAYYARG-C(RB). To confirm cel-
lular delivery of TatBim-RB, Chinese hamster ovary (CHO) cells were in-
cubated with TatBim-RB and we observed the intracellular internalization
of TatBim-RB using fluorescence microscopy. TatBim-RB was detected in
the cells with a dotted localization pattern, indicating that the TatBim-RB
was entrapped in endocytotic compartments. CPP-fused molecules tend
to become entrapped in endosomes. TatBim-RB needs to escape from the
endosomes because a target of the Bim peptide exists in cytoplasm. To
promote escape of the entrapped Tat-Bim-RB molecules, the CHO cells
were irradiated with US. After US irradiation, stronger and diffuse fluores-
cence of TatBim-RB was observed in the cells, indicating that TatBim-RB
molecules had escaped from the endocytotic compartments and diffused
into the cytoplasm. To confirm apoptosis inducing by Bim peptide in the
US-sensitive molecule, the CHO cells were stained using apoptosis detect-
ing kit and the apoptotic cells stained were visualized using fluorescence
microscopy. We successfully detected apoptosis inducing by the molecule
irradiated with US. In the case of irradiation without US and treatment of
TatBim without RB, apoptosis inducing was not detected. These results in-
dicate that TatBim-RB induced apoptosis US-dependently. A fundamental
question related to this study is the means by which US induces the endo-
somal escape of TatBim-RB. A minimal answer may be that US induces
reactive oxygen species (ROS) generation in the presence of TatBim-RB
and the endosomal membrane might be disrupted by the attack of ROS gen-
erated from the endosomally entrapped TatBim-RB. We confirmed the US-
dependent generation of ROS in the presence of rose bengal using 2’,7’-
dichlorodihydrofluoresein, fluorescent ROS indicator. Our results suggest
that this peptide-sonosensitizer conjugate strategy may facilitate numerous
kinds of medicinal chemistry studies, and furthermore, this specific conju-
gate may exhibit potential as a novel therapeutic agent for the promotion
of apoptosis.
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Development of murine model of Fungal Keratitis to
test the antifungal efficacy of CPP conjugated
Natamycin
Harsha Rohira1, Sujithra Shankar1, Sushmita G Shah2,
Shikha Yadav3, Aastha Jain4, Archana Chugh1
1Indian Institute of Technology Delhi, India
2Dr CM Shah Charitable Trust-Netra Mandir, Mumbai, India
3National Institute of Biologicals, Noida, India
4Karlsruhe Institute of Technology, Germany
Corneal diseases including microbial keratitis are among the major causes
of visual impairment and blindness worldwide. About 50% of the total
microbial keratitis is caused by various fungal species. Fusarium and
Aspergillus species are found to be the most common isolates in India.
Natamycin is the only FDA approved drug which is used as a first line
of treatment for fungal keratitis. Drawbacks associated with the use of
natamycin is poor intraocular penetration and poor water solubility. Cell
penetrating peptides (CPPs) are positively charged short peptides that can
translocate across the cell membrane without damaging the cell. In our
study, one of the CPP i.e. TAT is used as a nanocarrier to deliver an
antifungal compound, Natamycin inside the corneal cells. Recently, we
have successfully shown the increased uptake of TAT dimer conjugated
natamycin by corneal cells in vitro. Also, conjugated natamycin showed
increased water solubility as well as antifungal activity in comparison to
natamycin alone. To further investigate the antifungal activity of CPP con-
jugated natamycin (TAT2-Natamycin) in vivo, we have developed a murine
model of Fusarium keratitis. Immunocompromised female BALB/c mice
were inoculated with different concentrations of Fusarium sp. spores and
were clinically graded (0 to 4 based on the severity of the disease) after
three days of infection. Based on clinical grading and microbiological
examination, 105 spores/5µl was found to be the optimum concentration
for the establishment of fungal keratitis. We are currently testing TAT2-
Natamycin on this animal model for its antifungal activity and the results
will be compared with the marketed formulation of natamycin (Natamycin
5% suspension).
P190
Design of amphiphilic helical inhibitor peptides for the
membrane interaction of pathological TDP-43
Vanessa Reusche, Franziska Thomas
Institute of Organic and Biomolecular Chemistry /
Georg-August-University Göttingen, Germany
The TAR DNA-binding protein 43 kDa (TDP-43) is an aggregation prone
protein with a high association propensity towards membrane surfaces.
Mutations in TDP-43 result in formation of insoluble aggregates, which
are suspected of causing dysregulation of RNA processing, mislocaliza-
tion of TDP-43 and formation of proteinaceous inclusions, whereby mem-
brane association plays a crucial role.[1] Pathological TDP-43 is found
in many neurodegenerative diseases, for instance Alzheimer’s disease,
frontotemporal dementia (FTD), Parkinson’s disease and amyotrophic lat-
eral sclerosis (ALS), with hosting most of the mutations in the prion-like
domain.[2,3] The membrane association of TDP-43 is mostly mediated
by the membrane-interacting subdomain of the prion-like domain (MIS),
which consists of two structural parts; a membrane-adhering α-helix and
a membrane-inserting Ω-loop. The membrane interaction of MIS is dis-
cussed as a potential drug target to slow down the progression of these
diseases.[1] We work on the design of synthetic inhibitor peptides target-
ing this interaction. The general concept involves a two-component system
with an amphiphilic α-helical peptide (AHP), to interact with the helical
part of MIS, and an aromatic N-terminal head group (aHG), to disturb
the loop conformation. As proof-of-concept initial studies with de novo
designed AHPs were performed, which revealed the potential of our de-
sign as an interference with the MIS-membrane interaction was detected
by circular dichroism (CD) spectroscopy, Förster resonance energy trans-
fer (FRET)-measurements and reflectometric interference spectroscopy
(RIfS). Currently, we are synthesizing a library of AHPs with different
aHGs to increase the efficiency of the inhibition of the MIS-membrane
interaction.
[1] L. Lim, Y. Wei, Y. Lu, J. Song, PLOS Biology 2016, 14, 1, e1002338.
[2] M. C. Kiernan, S. Vucic, B. C. Cheah, M. R. Turner, A. Eisen, O.
Hardiman, J. R. Burrell, M. C. Zoing, The Lancet 2011, 377, 942. [3]
X.-L. Chang, M.-S. Tan, L. Tan, J.-T. Yu, Mol. Neurobiol. 2016, 53, 3349.
P191
Apelin peptide analogues as novel cardioprotective
drugs
Conrad Fischer
University of Alberta, Canada
Cardiovascular diseases including heart attack, stroke and ischemic reper-
fusion injury are the top killers worldwide accounting for almost 30% of
global deaths.(1) Apelin is the natural peptide-substrate for the apeliner-
gic system (APJ receptor) – an endogenous peptide hormone system that
mediates a cascade of other cardio-metabolic processes ultimately fine-
regulating the cardiovascular output. Apelin gets rapidly degraded in
plasma owing to the activity of various proteases including Angiotensin
converting enzyme 2 (ACE-2) and Neprilysin (NEP), limiting its half-life
to under 2 minutes.(2,3) Apelin analogues including N-terminal extended
isoforms and peptide isosteres reflect a promising alternative to minimize
proteolytic degradation. The presentation will focus on the synthesis,
metabolic stability and physiological activity of such Apelin analogues.
These ACE2- and NEP-resistant drug candidates show potent blood pres-
sure lowering and ischemic reperfusion recovery effects. They have con-
siderable potential for their development as new agents for treatment of
cardiovascular diseases.(4)
(1) World Health Organization (WHO) Silent Killer, Global Public Health
Crisis. WHO; Geneva, USA: 2013. (accessed on 11 February 2017). A
global brief on hypertension; p. 40. (2) Wang, W., McKinnie, S.M.K.;
Farhan, M.; Paul, M.; McDonald, T.; McLean C.; Llorens-Cortes, C;
Hazra, S.; Murray, A.G.; Vederas, J.C.; Oudit, G.Y. Hypertension 2016,
68, 365-377. (3) McKinnie, S.M.K.; Fischer, C.; Tran, K.M.H.; Wang, W.;
Mosquera, F.; Oudit, G.Y.; Vederas, J.C. ChemBioChem 2016, 17, 1495-
1498. (4) McKinnie, S.M.K.; Wang, W., Fischer, C., McDonald, T.; Kalin,
K.R.; Iturrioz, X.; Lllorens-Cortes, C.; Oudit, G.Y.; Vederas, J.C. J. Med.
Chem. 2017, 60, 6408-6427.
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PI3King Apart a Protein-Protein Interaction: A
Peptide Approach
Danielle Paterson1, Paul Harris2, Daniel Furkert3, Peter
Shepherd4, Jack Flanagan4, Margaret Brimble3
1School of Medical Sciences, The University of Auckland, New Zealand
2School of Biological Sciences, The University of Auckland, New
Zealand
3School of Chemical Sciences, The University of Auckland, New Zealand
4Auckland Cancer Society Research Centre, University of Auckland,
New Zealand
The phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) enzymes func-
tion at the plasma membrane, transducing cell surface receptor activation
into internal cell signalling pathways. The PI3K/AKT/mTOR pathway is
a central regulator of cell growth and migration, both of which are hall-
marks of cancer. The PI3Kβ and PI3Kγ isoforms are activated by mul-
tiple mechanisms, one of which is a protein-protein interaction with G
protein βγ subunits released upon G protein coupled receptor (GPCR) ac-
tivation. The PI3Kβ isoform, expressed in all cells and tissues, and the
PI3Kγ isoform, expressed in immune cells, are targets for anti-cancer ther-
apeutic development. Currently the function of these GPCR-linked PI3K
enzymes is studied using small molecules that block ATP substrate bind-
ing and enzyme activity, or genetic methods that prevent the formation of
the G protein-PI3K enzyme complex. The many roles of the PI3Kβ and
PI3Kγ isoforms are not fully understood and evaluation of the up-stream
activators using current tools remains challenging. This project aims to
develop a chemical tool to target the protein-protein interaction between
Gβγ and the PI3Kβ and PI3Kγ enzymes as an opportunity for isoform se-
lective PI3K inhibition. This tool, comprising a peptide scaffold, will allow
the chemical dissection of the G-protein related signalling pathways that
activate the PI3K lipid kinase pathway. Protein-protein interactions are
typically difficult to target with small molecules because of the extended
interaction surfaces, although recently, peptides and peptidomimetic com-
pounds have been developed to target these. Previous investigations of
the binding interaction between PI3Kγ and Gβγ identified a crucial bind-
ing motif on one face of PI3Kγ . Small (10-24 residue) peptides derived
from this PI3Kγ binding region have been synthesised and evaluated in a
biochemical assay to assess their inhibitory activity at the protein-protein
interface. Computational analysis of the hotspot on Gβγ has been aided
by a previously discovered 15 residue peptide bound to Gβγ , guiding the
design of inhibitors.
Acknowledgments and Funding Sources: The University of Auckland and
the Maurice Wilkins Centre for Molecular Biodiscovery.
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Treatment with fatty acid modified analogues of
apelin-13 improves glycaemic control and lipid
profiles in diet induced obese diabetic mice
Finbarr O’Harte, Vadivel Parthsarathy, Christopher Hogg,
Peter Flatt
Ulster University, United Kingdom
Background: Apelin-13 is an adipokine which has promising metabolic
effects but is rapidly degraded in plasma. We have shown that mod-
ified apelin analogues exhibited enzyme resistance in plasma and im-
proved circulating half-life compared to apelin-13. The antidiabetic ef-
fects of chronic administration (28 days) of stable long acting fatty acid
modified apelin analogues, namely, (Lys8GluPAL)apelin-13 amide and
pGlu(Lys8GluPAL)apelin-13 amide, were investigated in diet induced
obese-diabetic mice. Methods: Male adult (8 week old) NIH Swiss
mice (groups n=8) were maintained either on a high-fat diet (45% fat)
for 20 weeks, or control mice were fed a normal rodent chow diet (10%
fat). When diet induced obesity-diabetes was established after high-fat
feeding, mice were injected i.p. once daily with apelin analogues, li-
raglutide (25 nmol/kg) or saline (controls). Results: Administration of
(Lys8GluPAL)apelin-13 amide and pGlu(Lys8GluPAL)apelin-13 amide
for 28 days significantly reduced food intake and decreased body weight.
Non-fasting glucose was reduced (p<0.01 to p<0.001) and circulating in-
sulin concentrations elevated (p<0.01 to p<0.001). This was accompanied
by enhanced insulin responses (p<0.01 to p<0.001) and significant reduc-
tions in glucose excursion after both oral (p<0.01) or i.p. (p<0.01) glu-
cose challenges and feeding. Apelin analogues also significantly improved
HbA1c (p<0.01), enhanced insulin sensitivity (p<0.01), reduced triglyc-
erides (p<0.001), increased HDL-cholesterol (p<0.01) and decreased LDL-
cholesterol (p<0.01), compared to saline treated diet induced obese mice.
Cholesterol levels were decreased (p<0.01) by pGlu(Lys8GluPAL)apelin-
13 amide and apelin treated mice showed improved bone mineral content,
reduced fat deposits and increased plasma GLP-1 concentrations. Daily
treatment with liraglutide mirrored many of these changes but not on
bone or adipose tissue. Consumption of O2, production of CO2, respira-
tory exchange ratio and energy expenditure were improved by apelin ana-
logues. These data show that long-term treatment with acylated analogues
(Lys8GluPAL)apelin-13 amide and particularly pGlu(Lys8GluPAL)apelin-
13 amide resulted in similar or enhanced therapeutic responses compared
to liraglutide in high-fat fed diet induced obese mice. Conclusion: Stable
fatty acid modified apelin-13 analogues represent a new and exciting thera-
peutic development which can ameliorate the effect of diet induced obesity
diabetes.
P194
A non-stereogenic imidazolidinyl proline as a
pH-sensitive and functionalizable probe to tune the
collagen triple helix stability
Matthew Aronoff, Jasmine Egli, Helma Wennemers
ETH Zurich, Switzerland
Numerous compounds have been developed to study the conformational
properties of proline-containing peptides and proteins as well as for pep-
tide functionalization [1]. Most proline derivatives possess substituents at
the C4-position, similar to the naturally occurring hydroxy group of pro-
line [2,3]. Notably, 4S/4R aminoprolines produce a number of different
conformational effects, but also provide sites for functionalization and pH
response of peptides [4-7]. We recently developed a minimal 4-azaproline
analogue based on a non-stereogenic pseudoproline-scaffold which can be
prepared in a single synthetic step, named Imp. The conformational prop-
erties of this proline analogue were investigated through NMR spectro-
scopic studies of model compounds and DFT calculations, and confirm
that both Imp and functionalized Imp effectively mimic proline and other
proline-based residues. Incorporation of Imp into a collagen model pep-
tide (CMP) produces pH responsive CMPs and CMPs that can be function-
alized through the Imp side-chain with sterically bulky groups. Thermal
denaturation studies of the CMPs corroborate computational insight and
suggest that Imp possesses a dynamic nature in the context of a peptide
where the lack of a stereogenic center at the 4-position of the ring can
alleviate steric constraints of bulky substituents that would otherwise be
created by a mismatched 4S/4R proline stereoisomer. We envision that
Imp will provide a useful alternative for the synthesis of functionalized
peptides, particularly in examples where a dynamic residue can benefit the
overall stability.
[1] Mauger, A. B.; Witkop, B., Chem. Rev. 1966, 66, 47-86. [2] Remuzon,
P., Tetrahedron 1996, 52, 13803-13835. [3] Dobitz, S.; Aronoff, M. R.;
Wennemers, H., Acc. Chem. Res. 2017, 50, 2420-2428. [4] Erdmann, R.
S.; Wennemers, H., Angew. Chem. Int. Ed 2011, 50, 6835-6838. [5] Erd-
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mann, R. S.; Wennemers, H., J. Am. Chem. Soc. 2012, 134, 17117-17124.
[6] Siebler, C.; Erdmann, R. S.; Wennemers, H., Angew. Chem. Int. Ed.
2014, 53, 10340-10344. [7] Egli, J.; Siebler, C.; Maryasin, B.; Erdmann,
R. S.; Bergande, C.; Ochsenfeld, C.; Wennemers, H., Chem. Eur. J. 2017,
23, 7938-7944.
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Fluorocarbon-peptide conjugates (FPC): new concept
to increase the metabolic stability of peptides for
therapeutic applications
Lucie Esteoulle1, Adrien Flahault2, Cendrine Seguin3,
Sylvie Fournel1, Benoît Frisch1, Xavier Iturrioz2, Catherine
Llorens-Cortes2, Dominique Bonnet3
1University of Strasbourg, France
2INSERM - Collège de France, France
3CNRS - University of Strasbourg, France
Over the past decade, peptides have shown an increasing interest for
therapeutic applications as they are selective and efficacious signaling
molecules [1]. However, they are often not directly suitable for use as
convenient therapeutics because they have intrinsic weaknesses, including
poor chemical and physical stability, and a short in vivo half-life due to
rapid enzymatic degradation [2]. To address peptide instability issue for
therapeutic applications, we propose a strategy based on the grafting of
fluorocarbon chains (F-chains) onto peptides. Thereby, the hypothesis was
to induce the self-organization of fluoropeptides in aqueous solution, re-
sulting in the protection of the native peptide from enzymatic degradation.
To demonstrate the efficacy of our approach, apelin peptide that presents a
short plasma half-life has been selected as model [3, 4]. Apelin is a neuro-
vasoactive peptide with potential interesting therapeutic applications for
the treatment of cardiovascular diseases. However, its therapeutic devel-
opment has been hampered by its low plasma stability. Different F-chains
were then grafted onto apelin following a solid-phase approach. The most
stable fluoroapelin (LIT01-196) was then evaluated in rat model demon-
strating the positive impact of F-chain to greatly improve the in vivo ef-
ficacy of native apelin [5]. In this communication, we will present also
the mechanism leading to the increase of human plasma stability of fluo-
roapelin using original fluorescent tools recently developed in our group
[6]. Altogether, these promising results should open the route to a conve-
nient, safe and general approach to greatly increase the metabolic stability
of numerous peptides for their in vivo use as pharmacological tools and/or
therapeutic agents.
References: 1) Fosgerau, K.; Hoffmann. T. Drug Discovery Today 2015,
20, 122-128. 2) Hallberg, M. Med Res Rev 2015, 35, 464-519. 3) Tate-
moto, K. et al. Biochem. Biophys. Res. Commun. 1998, 251, 471-476.
4) O’Carroll, A. M.; Lolait, S. J.; Harris, L. E.; Pope, G. R. J. Endocrinol.
2013, 219, 13-35. 5) Gerbier, R et al. FASEB J. 2017, 31, 687-700. 6)
Karpenko, I.A. et al. J. Am. Chem. Soc. 2015, 137, 405-412.
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PaMAP 1.9 and PaMAP 2: efficient multi-resistant
antimicrobial peptides show evidence of anticancer
activity
Mário R. Felício1, Octávio Franco2, Nuno C. Santos1,
Sónia Gonçalves1
1Instituto de Medicina Molecular, Faculdade de Medicina, Universidade
de Lisboa, Lisbon, Portugal
2Centro de Anláises Proteômicas e Bioquimicas, Universidade Católica
de Brasília, Brasília, DF, Brazil
The current healthcare scenario is bringing new challenges to the medical
field, due to the new threats that are becoming responsible for high mor-
tality ratios. Multi-resistant pathogens are one of them, with reports of
increased numbers of severe infections on patients that current available
drugs cannot attend. The World Health Organization has already pointed
out the urgency in finding new molecules against different pathogens,
named the ESKAPE group (Enterococcus faecium, Staphylococcus aureus,
Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa
and Enterobacter species). Furthermore, the number of drug resistance
cases in cancer patients has also increased in recent years, associated with
the occurrence of hospital infections that debilitate patients’ health. An-
timicrobial peptides (AMPs) are pointed out as a future alternative to con-
ventional drugs in these contexts. AMPs are usually small, highly hy-
drophobic and with a global positive charge, which promotes the inter-
action with the pathogens or cancer cells membranes (with negative sur-
face charges). Their mechanism of action is independent of intermediators,
transporters or protein channels, being active mostly by peptide-membrane
interaction, against bacteria, viruses or cancer cells (anticancer peptides,
ACPs). Even so, these mechanisms are not yet fully understood. In our
work, we focused in two AMPs (PaMAP 1.9 and 2), synthetically designed
using a natural AMP as template. After initial promising results against
bacteria, complemented by biocomputational studies, peptide-membrane
interactions were extensively studied, using lipid vesicles and bacterial
cells (including clinical multi-resistant strains). Different biophysical tech-
niques, including fluorescence spectroscopy and microscopy, flow cytome-
try, dynamic light scattering, zeta-potential, circular dichroism and atomic
force microscopy allowed to infer about the mechanism and efficiency in
promoting bacteria cell death. Data obtained were confirmed and further
extend by in vivo studies. Recently, we hypothesized if any of these AMPs
could be good candidates for cancer therapies. Using the same approach,
we demonstrated that PaMAP 1.9 has anticancer activity, but not PaMAP
2.
P197
Electric Field Assisted Inhibition of Aggregation in
Amyloidogenic Proteins.
Gaurav Pandey, Vibin Ramakrishnan
Indian Institute of Technology Guwahati, Assam, India
Impeding the toxic aggregation of tau protein, a central pathological agent
involved in Alzheimer’s disease (AD), can serve as a straightforward ther-
apeutic strategy. This present study presents a hybrid approach employing
physical (electric/magnetic fields) as well as molecular (structure based de-
signed peptides) perturbants for retarding the aggregation kinetics of core
peptide segments of tau protein (VQIVYK and VQIINK). Herein, we use
Thioflavin t staining, tyrosine fluorescence assay, dynamic and static light
scattering, infrared spectroscopy, electron microscopy, as well as toxic-
ity tests, to verify the effect of proposed self-assembly modulators on the
aggregation kinetics, morphology, conformational state and cellular toxi-
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city of the chosen model peptide systems. Our observations reveal that
these physical as well as molecular perturbants not only significantly ar-
rest the self-assembly of VQIVYK and VQIINK fibrils but also reduce
the neurotoxicity instigated by them in human neuroblastoma SH-SY5Y
cells. Our results utilizing field as aggregation inhibitor are in good agree-
ment with theoretical (References 1,2) (based on molecular dynamics) and
experimental (References 3-6) studies reported earlier on amyloid form-
ing molecular systems. Our work demonstrates that efficacy of hybrid
approach to inhibit aggregation of tau aggregation and can be further de-
veloped to serve as a useful therapeutic option, for treating Alzheimer’s
disease.
References
1) Ojeda-May, Pedro, and Martin E. Garcia. ”Electric field-driven disrup-
tion of a native β -sheet protein conformation and generation of a helix-
structure.” Biophysical journal 99, no. 2 (2010): 595-599. 2) Baumketner,
Andrij. ”Electric field as a disaggregating agent for amyloid fibrils.” The
Journal of Physical Chemistry B 118, no. 50 (2014): 14578-14589. 3)
Pandey, Gaurav, Jahnu Saikia, Sajitha Sasidharan, Deep C. Joshi, Subhash
Thota, Harshal B. Nemade, Nitin Chaudhary, and Vibin Ramakrishnan.
”Modulation of Peptide Based Nano-Assemblies with Electric and Mag-
netic Fields.” Scientific Reports 7, no. 1 (2017): 2726. 4) Pandey, Nitin
K., Subhadeep Mitra, Monojit Chakraborty, Sudeshna Ghosh, Shubhatam
Sen, Swagata Dasgupta, and Sunando DasGupta. ”Disruption of human
serum albumin fibrils by a static electric field.” Journal of Physics D: Ap-
plied Physics 47, no. 30 (2014): 305401. 5) Sen, Shubhatam, Monojit
Chakraborty, Snigdha Goley, Swagata Dasgupta, and Sunando DasGupta.
”Fibrillar disruption by AC electric field induced oscillation: A case study
with human serum albumin.” Biophysical chemistry 226 (2017): 23-33. 6)
Vibin Ramakrishnan, Gaurav Pandey, Harshal B. Nemade, Jahnu Saikia,
Sajitha S, and Nitin Chaudhary. Indian Patent Application no. TEMP/E-
1/25296/2017-KOL. Controller of Patents, Kolkata, India, 13 July 2017.
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RGD Bicycles: High-Affinity Ligands for Rapid
Integrin-Mediated Cell Adhesion
Dominik Bernhagen1, Nestor Gisbert Quilis2, Vanessa
Jungbluth2, Jakub Dostalek2, Filippo Cipriani3, Kees
Jalink4, Peter Timmerman1
1Pepscan Therapeutics, Netherlands
2AIT Austrian Institute of Technology GmbH, Austria
3Technical Proteins Nanobiotechnology, Spain
4Netherlands Cancer Institute, Netherlands
Integrins mediate cell-cell and cell-extracellular matrix interactions via in-
teraction with proteins such as fibronectin and vitronectin. Ligands that
mimic the function of these proteins can improve the cell adhesion and pro-
liferation properties of biomaterials. Bicyclic peptides recently attracted
interest as a powerful platform for novel therapeutics because of their high
binding affinities and proteolytic stability. We therefore screened hun-
dreds of different bicyclic peptides for binding to integrins αvβ3, αvβ5
and α5β1, and gradually improved the affinities and selectivities. The
best IC50 values were, for example, 30 nM for αvβ3 (GRGDS: 5 µM,
knottin-RGD: 38 nM), and 90 nM for α5β1 (GRGDS: >10 µM, knottin-
RGD: 114 nM). We also studied integrin-binding on cells via confocal
microscopy with Cy5-functionalized bicycles. Finally, cell behavior stud-
ies with peptide-functionalized soft 3D hydrogels and elastin-like recom-
binamers (ELRs) revealed superior cell adhesion and proliferation of the
bicycles compared with conventional RGD-peptides.
P199
Design and evaluation of dual GLP-1 and PYY
receptor agonists
Hannah L. Bolt, Elise S.C. Bernard, Kevin Minton, Andie
Collinson, Maria A. Bednarek
MedImmune, United Kingdom
Diabetes and obesity represent a severe global health epidemic with asso-
ciated metabolic problems resulting in significant mortality and increased
risk of cardiovascular disease, stroke or other complications. In the
last decade, dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-
1 (GLP-1) receptor agonists have drastically enhanced the management of
diabetes, providing greater benefits than glucose control alone, such as im-
provements in blood pressure, beta-cell function and positive effects on
body weight. Other naturally occurring gut hormones have the potential
to enhance the action of GLP-1 agonists in the clinic and focus within the
pharmaceutical industry is now directed towards the delivery of such gut
peptide hormone combinations for treatment of type 2 diabetes mellitus
and obesity.
One naturally occurring peptide that has the potential to enhance the ac-
tion of GLP-1 agonists is the anorectic peptide YY (PYY3-36); its actions,
in tandem with GLP-1, result in superior reductions of food intake and
body weight when compared to GLP-1 alone. Thus, the aim of this study
was to secure dual pharmacology peptides which could simultaneously de-
liver glucose-lowering effects of GLP-1 and appetite-suppressing effects
of PYY(3-36.)
The PYY(3-36) and GLP-1 peptides represent different families of peptide
hormones, with unrelated peptide sequences and vastly different secondary
structures. The N-terminal part of GLP-1 is known to be important for
activity, whereas in PYY(3-36), the C terminal part is a crucial pharma-
cophore. This provides the opportunity for peptide engineering to produce
a dual GLP-1/PYY(3-36) receptor agonist by combining these two key
fragments.
Herein, a library is presented of >100 peptides with dual agonistic proper-
ties at both the hGLP-1 and hY2R (PYY) receptors; the library includes
lipidated compounds and those modified to increase resistance to proteol-
ysis. New peptides were tested in vitro in cAMP based assays using cell
lines expressing human GLP-1 or Y2R (PYY) receptors and EC50 values
were determined. Individual peptides displayed a broad range of agonistic
potency and receptor selectivity. A selection of compounds that showed
potent activity at both the GLP-1 and PYY receptors is discussed. To our
knowledge, these GLP-1 based compounds are the first lipidated chimeric
peptides that display dual agonism at Y2R and GLP-1R.
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P200
Triple-negative breast cancer: new potential
therapeutics derived from SOCS3 protein
Sara La Manna, Daniela Marasco, Giancarlo Morelli
University of Naples Federico II, Italy
Suppressor of cytokine signaling (SOCS) proteins are a family of nega-
tive feedback regulators of cytokine signaling mediated by the JAK-STAT
pathway (Carow, et al. 2014). Only two members of this family, SOCS1
and SOCS3, contain a kinase inhibitory region (KIR) crucial for the in-
activation of JAKs, leading to suppression of inflammatory cytokines
(Yoshimura, et al. 2012). It has been suggested that SOCS proteins can
play pivotal roles in development and progression of cancers. Further, in
triple negative breast cancer (TNBC) subtype the proteolytic degradation
of SOCS3 protein causes the activation of inflammatory cytokines and, as
a whole, recombinant SOCS3 demonstrated able to prevent TNBC tumour
growth and metastasis by suppressing inflammatory cytokines (Kim, et
al. 2015). In this study we designed several SOCS3’mimetics derived
from the N-terminal region of SOCS3 encompasses KIR and ESS domain
that interface the complex with JAK2. These peptides were characterized
by Circular Dichroism and Surface Plasmon Resonance spectroscopies.
Moreover, the activity of one sequence, named KIRESS, which contained
crucial residues for the complex SOCS3/JAK2 was investigated in vivo
in mouse xenografts of MDA-MB-231-luci tumours as model of human
TNBC subtype. KIRESS peptide demonstrated capable to eliminate pul-
monary metastasis and showed a significant reduction of primary tumour
growth. KIRESS peptide can be considered as a starting point to create,
through structural and chemical modifications, compounds with high affin-
ity and stability as potential therapeutics in TNBC (La Manna, et al. 2018).
P201
Unraveling the Mechanism of Action of the Analgesic
Peptdie DD04107. Synaptotagmin-1 as a Putative
Target
Daniel Butrón1, Héctor Carrera-Zamora2, Isabel Devesa3,
Miguel A. Treviño2, M. Angeles Bonache1, Adrián
Velázquez-Campoy4, Antonio Ferrer-Montiel3, M. Angeles
Jiménez2, Rosario González-Muñiz1
1Instituto de Química Médica (IQM-CSIC), Spain
2Instituto de Química Física Rocasolano (IQFR-CSIC), Spain
3IBMC, Universidad Miguel Hernández, Spain
4Institute of Biocomputation and Physics of Complex Systems (BIFI),
IQFR-CSIC-BIFI, Spain
DD04107 (Palmitoyl-EEMQRR-NH2) is a peptide derived from the N-
terminal sequence of SNAP25, a protein component of the SNARE com-
plex. It blocks the inflammatory recruitment of TRPV1 ion channels to
the plasma membrane of nociceptors and inhibits the release of calcitonin
gene-related peptide (CGRP) from primary sensory neurons.1,2 DD04107
produces dose-dependent, long-lasting in vivo antihyperalgesic and antial-
lodynic activities in chronic models of inflammatory and neuropathic pain,
but to date its specific target(s) is(are) not known.3 In order to get insight
in the importance of the different side-chains for the inhibition of CGRP
release, we first performed an Ala scan, which indicated that E1, M3, Q4
and R6 are essential residues. Curiously, they resemble the residues of
SNAP25 involved in the SNARE/synaptotagmin-1 (Syt-1) complex, 4,5
namely E37, K40 residues from one copy of SNAP25 and the spatially
close N159, M163 and D166 residues of the second SNAP25 copy, within
the SNARE complex. This led us to hypothesize that DD04107 could ex-
ert its action through the direct interaction with Syt-1, probably competing
with the SNARE complex formation. To prove this hypothesis we stud-
ied the possible interaction of Syt-1 protein to DD04107 and linear and
cyclic analogues using ITC techniques, while molecular modeling stud-
ies allowed the proposal of a plausible mode of interaction. Additionally,
the conformational behavior of these peptides in solution (NMR) could be
considered as an approach to the bioactive conformation. In this commu-
nication we will describe the main results of all these studies.
This work was supported by the Spanish Ministerio de Economía y Com-
petitividad (SAF2015-66275-02R, CTQ2014-52633-P, CTQ2017-84371-
P). The NMR experiments were performed in the ”Manuel Rico” NMR
laboratory (LMR) of the Spanish National Research Council (CSIC).
References 1. Blanes-Mira C, et al. (2004) Small peptides patterned after
the N-terminus domain of SNAP25 inhibit SNARE complex assembly and
regulated exocytosis. J Neurochem 88:124 –135. 2. Camprubí-Robles M,
Planells-Cases R, and Ferrer-Montiel A (2009) Differential contribution of
SNARE-dependent exocytosis to inflammatory potentiation of TRPV1 in
nociceptors. FASEB J 23:3722–3733. 3. Ponsati, B. et al. (2012) An In-
hibitor of Neuronal Exocytosis (DD04107) Displays LongLasting In Vivo
Activity against Chronic Inflammatory and Neuropathic Pain. J. Pharma-
col. Exp. Ther. 341: 634–645. 4. Zhou, Q. et al. (2015). Architecture
of the synaptotagmin–SNARE machinery for neuronal Exocytosis. Na-
ture, 525, 62-67. 5. Brewer et al., (2015). Dynamic binding mode of a
Synaptotagmin-1-SNARE complex in solution. Nat Struct Mol Biol. 22,
555-564.
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Antimicrobial activity and action mechanism of
chemokine CXCL14-derived antimicrobial peptide,
CXCL14-C17 and its analogs
Shin Song Yub, Ganesan Rajasekaran
Chosun University, South Korea
CXCL14 is a CXC chemokine family that exhibits antimicrobial activ-
ity and contains an amphipathic cationic alpha-helical region in the C-
terminus, a characteristic structure of antimicrobial peptides (AMPs). In
this study, we designed three analogs of CXCL14(59-75)(named CXCL14-
C17) corresponding to the C-terminal alpha-helix of CXCL14, which dis-
played potential antimicrobial activity against a wide variety of gram-
negative and gram-positive bacteria with minimum inhibitory concentra-
tions (MICs) of 4-16 microM without mammalian cell toxicity. Fur-
thermore, two CXCL14-C17 analogs (CXCL14-C17-a1 and CXCL14-
C17-a3) with improved cell selectivity were engineered by introducing
Lys, Arg, or Trp in CXCL14-C17. Additionally, CXCL14-C17 analogs
showed much greater synergistic effect (fractional inhibitory concentra-
tion index [FICI]: 0.3125–0.375) with chloramphenicol and ciprofloxacin
against multidrug-resistant Pseudomonas aeruginosa (MDRPA) than LL-
37 did (FICI: 0.75–1.125). CXCL14-C17 analogs were more active against
antibiotic-resistant bacteria including methicillin-resistant Staphylococcus
aureus (MRSA), MDRPA, and vancomycin-resistant Enterococcus fae-
cium (VREF) than LL-37 and melittin. In particular, CXCL14-C17-a2
and CXCL14-C17-a3 completely inhibited the biofilm formation at sub-
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MIC. Membrane depolarization, sytox green uptake, ONPG hydrolysis,
flow cytometry, and confocal microscopy revealed the possible target of
the native peptide (CXCL14-C17) to likely be intracellular, and the am-
phipathic designed analogs targeted the bacterial membrane. CXCL14-
C17 also showed DNA binding characteristic activity similar to buforin-2.
Interestingly, CXCL14-C17-a2 and CXCL14-C17-a3 effectively inhibited
the production and expression of nitric oxide (NO), tumor necrosis fac-
tor (TNF)-alpha, interleukin (IL)-6, and monocyte chemoattractant protein
(MCP)-1 from lipopolysaccharide (LPS)-stimulated RAW264.7 cells, sug-
gesting that these peptides could be promising anti-inflammatory and an-
timicrobial agents.
P203
Combinatorially Screeened Peptide as Targeted
Covalent Binder
Shuta Uematsu1, Yudai Tabuchi1, Yuji Ito2, Masumi Taki1
1The University of Electro-Communications, Japan
2Graduate School of Science and Engineering, Kagoshima University,
Japan
Finding targeted covalent binders (also known as covalent drugs) is one of
the cutting-edge disciplines such as biomedical sciences / chemical biology
/ pharmaceuticals fields. As shown in the figure, we present here a novel
concept for finding a peptide covalent binder from fluoroprobe-modified
peptide library [1] on T7 bacteriophage constructed via the 10BASEd-T
[2], followed by a structure alteration into a reactive warhead [3]. Site- and
position-specific conjugation toward the target protein and target selectiv-
ity were confirmed. This is the first demonstration for finding peptide-type
targeted covalent binder by a combinatorial screening, instead of a ratio-
nal designing. We believe the discovery technology would be generally
applied to the discovery of novel covalent drugs for clinically-important
proteins (e.g., cancer-related cell-surface proteins). [1] Taki et al., Anal.
Chem. 2016, 88, 1096; Uematsu et al., AIP Conf. Proc. 2017, 1807,
020028. [2] Fukunaga et al., Chem. Commun. 2014, 50, 3921; inside
cover article. [3] Uematsu and Tabuchi et al., Bioconj. Chem. 2018, in
press.
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Factor XIIIA-Inhibitor Tridegin: On the role of
disulfide bonds for folding, stability and function
Thomas Schmitz1, Charlotte A. Bäuml1, Ajay A. Paul
George1, Monica Sudarsanam1, Kornelia Hardes2, Torsten
Steinmetzer2, Johannes Oldenburg3, Arijit Biswas3, Diana
Imhof1
1University of Bonn, Germany
2University of Marburg, Germany
3University Hospital of Bonn, Germany
Tridegin is a 66mer peptide isolated from the salivary gland of the giant
leech Haementeria ghilianii in 1997.[1] So far, it is the only known peptide
inhibitor with remarkable potency and specificity against the blood coag-
ulation factor XIIIa.[1,2] Tridegin inhibits the catalytic activity of FXIIIa
by impairing the cross-linking of fibrin in the final step of the blood co-
agulation cascade.[3] Consequently, tridegin represents an interesting tool
for thrombolytic therapy in future medical applications. However, tridegin
is a cysteine-rich peptide containing six cysteines linked by three disul-
fide bonds. This renders the selective synthesis of tridegin a challenging
process.[4,2] Hence, a simplification of tridegin’s structural complexity is
highly desirable. Former studies have shown that the truncation of tridegin
and the removal of all disulfide bonds leads to a significant loss of activity.
Additionally, only three of fifteen possible disulfide-bridged isomers were
identified as a result of an oxidative self-folding approach.[2] Interestingly,
these three isomers share a common disulfide bond between cysteine 19
and 25. This raises the question on the role of this specific disulfide bond
in the folding, stability and function of tridegin. We have thus selectively
synthesized analogs of the three isomers lacking the disulfide bond Cys19-
Cys25. The results are presented in three different parts resulting in a
comprehensive analysis of 2-disulfide bonded tridegin analogs: 1) Syn-
thesis and disulfide-bond analysis, 2) bioactivity studies, and 3) insights
into structure-function relationships using molecular dynamics and dock-
ing studies. The peptides were synthesized by solid-phase peptide synthe-
sis and a directed protecting group strategy with Acm-, and Trt-protected
cysteines. Subsequently, the disulfide connectivity was elucidated by enzy-
matic digestion and subsequent MS/MS analysis. The inhibitory potential
of these analogs on FXIIIa was tested in an in vitro activity assay and
compared with bioactive synthetic and recombinant tridegin from former
studies.[2] The molecular dynamics studies of the three different tride-
gin isomers were performed to elucidate the impact of the disulfide bond
Cys19-Cys25 on the structure and the analogs conformational stability. In
addition, molecular docking studies with the 2-disulfide-bonded analogs
docked on FXIIIa added insights into the binding modes of the individ-
ual peptides. Our studies present three novel tridegin analogs retaining
inhibitory activity while alleviating the synthesis effort. In conclusion, this
work opens interesting new directions for the scientific community in the
quest toward the development of novel FXIIIa inhibitors.
REFERENCES [1] Finney, S. et al., Biochem. J., 324, 797-805 (1997).
[2] Böhm, M. et al., J. Med. Chem., 57, 10355-10365 (2014). [3] Reed, G.
L. et al., Circulation, 99, 299-304 (1999). [4] Böhm, M. et al., ChemMed-
Chem, 7, 326-333 (2012).
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Deciphering specificity determinants for
FR900359-derived Gαq inhibitors based on
computational and structure-activity studies
Raphael Reher1, Toni Kühl1, Britta Nubbemeyer1, Suvi
Annala1, Tobias Benkel1, Desiree Kaufmann2, Stefan
Kehraus1, Max Crüsemann1, Evi Kostenis1, Daniel Tietze2,
Gabriele M. König1, Diana Imhof1
1University of Bonn, Germany
2University of Darmstadt, Germany
Heterotrimeric G proteins represent interesting targets in pharmacological
studies and for developing novel therapeutic approaches due to their impor-
tance in signal transduction mediated by G protein-coupled receptors. Nev-
ertheless, direct targeting of intracellular Gα subunits by chemical tools is
still challenging and only few compounds are known for this purpose. One
of these modulators is the Gq-inhibiting depsipeptide FR900359 (FR). The
high potency of FR and the structurally related compound YM-254890
(YM) brought these substances in the focus of several research groups.
These compounds represent small to medium-sized depsipeptides with a
high degree of chemical complexity, specific three-dimensional conforma-
tions, and consequently precise orientation of backbone and side chain
atoms through intrinsic rigidity. In a comprehensive structure-activity re-
lationship study novel FR-based analogs from natural sources, synthetic
cyclic peptides as well as all so-far known Gq inhibitors were analyzed.
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We grouped 14 new FR- and YM-derived compounds as well as all 23
published analogs according to their potency to identify tolerated, partially
tolerated, non-tolerated minor, and non-tolerated major modifications in
the original sequence(s).[1–6] Concomitant application of 2D NMR spec-
troscopy and molecular docking allowed us to identify unique features in
the macrocyclic structures important for binding to the target protein corre-
lating with inhibitory activity.[1] Ultimately, a strategy is presented for the
elucidation of characteristics that determine interaction with and inhibition
of Gq in the specific FR/YM binding pocket.[1] It is revealed how changes
in three distinct categories affect inhibitory potency compared to the lead
compounds, namely I) backbone conformation, II) backbone conforma-
tion influencing the intramolecular hydrogen bond network, and III) side
chain constitution and orientation.[1] Unfortunately, none of the analogs
surpassed the biological activity of FR on Gq nor did they show an effect
on Gi or Gs.[1] As a consequence the question remains whether depsipep-
tides such as FR already represent valuable tools for specific inhibition of
Gq and if they are suitable natural lead structures for the development of
novel compounds to target other Gα subunits.
REFERENCES [1] Reher, R. et al., ChemMedChem, doi:
10.1002/cmdc.201800304. [2] Zhang, H. et al., ChemMedChem, 12,
830-834 (2017). [3] Xiong, X. F. et al., Nat. Chem., 8, 1035-1041 (2016).
[4] Taniguchi, M. et al., Bioorg. Med. Chem., 12, 3125-3133 (2004). [5]
Crüsemann, M. et al., Angew. Chem. Int. Ed., 57, 836-840 (2018). [6]
Rensing, D. T. et al., Org. Lett., 17, 2270-2273 (2015).
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Impact of cysteine pairing on disulfide-bond
assignment and structure elucidation in different
conformational isomers of the µ-conotoxin PIIIA
Pascal Heimer1, Charlotte A. Bäuml1, Thomas Schmitz1,
Anja Resemann2, Franz Josef Mayer2, Detlev Suckau2,
Alesia Tietze3, Oliver Ohlenschläger4, Daniel Tietze3,
Diana Imhof1
1University of Bonn, Germany
2Bruker Daltonics Bremen, Germany
3TU Darmstadt, Germany
4Fritz Lipman Institute Jena, Germany
The elucidation of structural and functional properties of oligopeptides
containing more than four cysteine residues is a main topic in peptide
research.[1] In order to get fundamental insights into the structure of a
cysteine-rich peptide the determination of its disulfide connectivity is crit-
ical. Due to conformational restrictions, disulfide bonds confer stabil-
ity and support formation of a defined 3D structure which is crucial for
the bioactivity of such peptides. Depending on their disulfide connectiv-
ities, cysteine-rich peptides and proteins can adopt various 3D structures.
The unambiguous identification of such conformational isomers harbor-
ing more than two disulfide bonds is particularly challenging and exper-
imental approaches for unequivocal structural analysis are largely lack-
ing. Cysteine-rich peptides isolated from the venom duct of different cone
snails are known to have therapeutic potential in e.g. pain therapy and
are therefore interesting research targets.[2] Previously, our group synthe-
sized the 22mer conopeptide µ-PIIIA in an oxidative self-folding approach
from which we identified three different conformational isomers.[3] As a
direct consequence of these results, we now synthesized all 15 possible
disulfide isomers of µ-PIIIA by means of a protecting-group strategy.[4]
Subsequently, 2D NMR spectroscopy and MS/MS were applied in order
to elucidate the structure of the individual disulfide isomers. This study
allows for crucial insights in how disulfide connectivity alters the global
fold of a toxin. In addition, HPLC coelution experiments were carried
out with the intention of investigating the chromatographic separation per-
formance on different disulfide isomers of the same peptide. In total, this
study revealed the complexity of targeted synthesis and chemical character-
ization of a cysteine-rich conotoxin. The comprehensive analysis of the 15
different isomers using NMR and MS/MS techniques provided evidence
that the unambiguous assignment of disulfides in cysteine-rich peptides
and proteins requires extensive analysis procedures combining the meth-
ods mentioned. In addition, we conclude that standard compounds are of
eminent importance for elucidating disulfide bonds and 3D structures of
cysteine-rich peptides and proteins.
REFERENCES: [1] Góngora-Benítez, M. et al., Chem. Rev., 114, 901-926
(2013). [2] Prashanth, J.R. et al., Future Med. Chem., 6, 1659-75 (2014).
[3] Tietze, A.A., et al. Angew. Chem. Int. Ed., 51, 4058-4061 (2012). [4]
Heimer, P., et al. Anal. Chem., 90(5), 3321-3327 (2018).
P207
Metabolic effects of Adrenomedullin in combination
with glucagon-like peptide-1 in lean NMRI mice
Karin Mannerstedt, Katrine Fabricius, Kristoffer
Voldum-Clausen, Kristoffer Rigbolt, Søren L. Pedersen,
Jacob Jelsing
Gubra ApS, Denmark
Adrenomedullin (ADM) is a vasoactive peptide expressed in several pe-
ripheral organs and known primarily for its beneficial vasoactive effects.
However, ADM is also known to inhibit insulin secretion, and central ad-
ministration of ADM has been shown to elicit anorexigenic effects. Here,
we investigated if peripheral co-administration of ADM and glucagon-like
peptide 1 (GLP-1) could subdue the hypoglycaemic effects of ADM while
enhancing its anorectic properties. The effects of mono- and combination
therapy of ADM and GLP-1 on appetite regulation and glucose homeosta-
sis were assessed acutely in male NMRI mice for 18 hrs, while effects on
glucose homeostasis were assessed by oral glucose tolerance tests (OGTT).
While the monotherapy with GLP-1 and ADM resulted in modest anorex-
igenic effects, co-administration of the two peptides led to a marked syn-
ergistic reduction in food intake. Moreover, while post-prandial blood glu-
cose excursions were significantly increased by ADM monotherapy, co-
administration of ADM with a lower dose of GLP-1 normalized glucose
excursions. In conclusion, we demonstrate, for the first time an anorectic
synergy between ADM and the pharmaceutically relevant incretin GLP-1.
Additionally, we show that a low dose of GLP-1 can reverse ADM-induced
impairment of the glucose tolerance. Consequentially, ADM could be in-
teresting as a potential target for the treatment of obesity if combined with
GLP-1.
P208
Small Synthetic, Multivalent Bicyclic Peptides That
Activate T Cell Costimulatory Protein CD137
Katerine van Rietschoten1, Peter Park2, Julia Kristensson1,
Rachid Lani1, Gemma Mudd1, W. Frank An2, Liuhong
Chen1, Gavin Bennett1, Kevin McDonnell2, Nicholas
Keen2
1Bicycle Therapeutics, United Kingdom
2Bicycle Therapeutics, United States
CD137 agonism is a promising immunotherapeutic approach and there are
currently two agonistic antibodies in clinical trials. CD137 receptors on im-
mune cells form trimeric complexes in the activated state. Peptides binding
to human CD137 ligand-binding site were identified by phage screening
using proprietary Bicycle technology. Further chemical optimisation al-
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lowed systematic generation of a matrix of dimeric, trimeric and tetrameric
CD137 synthetic agonists with a broad range of cell-activity properties.
CD137 synthetic multimers were shown to be stable in plasma and to have
in vivo half-life of approximately 30 minutes. A trimer and tetramer us-
ing the Lysine 3 attachment point were efficacious in preventing syngeneic
tumour growth in the hCD137 mouse model.
P209
Gold Nanoparticles Coated with Antimicrobial
Peptides for Biological Activity Enhancement against
Multidrug Resistant Bacteria
Eduardo Festozo Vicente1, Sunil Claire2, Siobhan King2,
Edson Crusca Jr3, Reinaldo Marchetto4, Norival Alves
Santos-Filho5, Eduardo Cilli4, Jessica Blair6, Zoe
Pikramenou2
1School of Science and Engineering - Sao Paulo State University (Unesp),
Brazil
2School of Chemistry, University of Birmingham, United Kingdom
3Sao Carlos Institute of Physics, University of Sao Paulo, Brazil
4Institute of Chemistry, Sao Paulo State University (Unesp), Brazil
5Registro Experimental Campus, Sao Paulo State University (Unesp),
Brazil
6Institute of Microbiology and Infection, University of Birmingham,
United Kingdom
Nowadays, the growing of multidrug resistant bacteria has brought severe
problems to public health over the world. Thus, there is an urgency need
for the development of new strategies or discoveries to tackle this alarming
situation. Gold nanoparticles (AuNPs) have been widely applied in many
areas of Medicine and Biotechnology, such as biosensors, diagnostics, im-
munoassays, imaging, and therapeutics. Considering gold’s inertness, it
is known to be a safe and biocompatible to the organism. On this way,
the integration of the promising antimicrobial peptides (AMPs) with the
AuNPs seems to be very interesting and relevant for the improvement to
fight against multidrug resistant bacteria. In this study, the objective is to
functionalize AuNPs (13 nm) with two AMPs: Ctx(Ile21)-Ha and Pantinin-
1, both isolated from the skin secretion of an arboreal South American frog,
Hypsiboas albopunctatus and the scorpion venon Pandinus imperator, also
with a Europium probe for able diagnostical essays via fluorescence stud-
ies. The primary sequences were modified, adding a cysteine residue in
the amidated C-terminus to facilitate the peptides’ attachment. Firstly, the
AuNPs were precoated with PEG-SH and sonicated for 10 min to avoid ag-
gregation. AuNP-PEG-SH were centrifuged at 11.8 rpm and 13.3 g for 30
min. This proceeding yielded approximately 10 mL of AuNP in a concen-
tration of 20 nM. The pH was raised to 9 with NaOH. After, the solution
was added in glass flasks of 1 mL 500 uL of water and 500 uL AuNPs
at 20 nM and add the peptides until 12 uL, in increments of 3 uL. Then,
were added the Eu probe (stock solution of 0.2 mM) in a volume of 15
uL (increments of 3 uL for each addition). Finally, add 1:5 of 1 M NaCl
solution, stirring with a magnet bar, which stabilize the final conjugated
yielded (red coloured). After that, the peptides and the conjugated were
tested in multidrug bacteria strains: Pseudomonas aeruginosa (regular and
PA02 – clinical resistant), Acinetobacter baumannii, Klebsiella pneumo-
niae and Staphylococcus aureus. In conclusions, after several attempts, we
synthesized the gold nanoparticles tethered with the suggested peptides,
also containing an europium fluorescence probe. Although, it could see
biological activity against the multidrug resistant bacteria strains for the
pure peptides, in the results were not observed any biological activity for
the AuNP/AMP/Eu conjugated. More experiments need to be done in or-
der to improve the quality, characterization and the biological activity of
these news compounds.
P210
Site-specific chemical modification of IgG antibody
using Z34C affinity peptide
Satoka Mori, Arisa Himeno, Naoto Ishikawa, Yuji Ito
Kagoshima University, Japan
We have developed a conjugation method of human IgG through
an affinity peptide composed of 17 amino acids (IgG-BP: GPD-
CAYHKGELVWCTFH, whose two cysteines formed the disulfide bond)1.
We call this chemical conjugation method CCAP (Chemical Conjugation
by Affinity Peptide). This method enables to label Lys248 (or Lys 246)
residue on IgG-Fc with a cross-linker reagent like DSG (disuccinimidyl
glutarate), which is attached to the amino groups of the side chain of Lys8
on the peptide. This CCAP can generate ADC (antibody-drug conjugate)
and IgG diagnostic drug for PET imaging, by using IgG-BP which was
attached to drug or metal chelator like DOTA. As this IgG-BP can bind to
human IgG1, 2, 4 and rabbit IgG, CCAP method using this peptide can
be applied for labeling for these antibodies, but not for rodent antibodies,
because of its lack of the binding abilities toward them. To overcome this
limitation, we developed a new CCAP method using Z43C peptide, which
is well known as a Fc-binding peptide originated from Protein A, with
broad specificities toward rodent antibodies as well as human antibodies2.
We designed the labeling reagent of Z34C whose N-terminal region was
designed for cross-linking. The Fc of murine and rat IgG as well as hu-
man (IgG1, 2 and 4) and rabbit IgG antibodies was efficiently and site-
specifically labeled with this peptide though a cross-linker. The CCAP
method with broad specificities using Z34C peptide can be applied for la-
beling/conjugation of murine and rat antibodies, which are widely used as
diagnostic and research reagents.
1. ITO, Y. Specific modification of antibody by IgG-binding peptide.
PCT/JP2016/065061 (2016). 2. Starovasnik, M. A., Braisted, A. C., Wells,
J. A. & Wolynes, P. G. Structural mimicry of a native protein by a mini-
mized binding domain. Biochemistry 94, 10080–10085 (1997).
P211
Hybrid peptidomimetics for the use in neuropathic
pain
Ewa Witkowska1, Jowita Osiejuk1, Magda Godlewska1,
Sandra Gatarz1, Beata Wilenska1, Joanna Starnowska2,
Anna Piotrowska-Murzyn2, Joanna Mika2, Barbara
Przewlocka2, Aleksandra Misicka1
1University of Warsaw, Poland
2Institute of Pharmacology, Krakow, Poland
Neuropathic pain is defined as a type of chronic pain that occurs when
nerves in the central nervous system become injured or damaged. It is es-
timated that approximately 7.7% of people in European countries suffer
from neuropathic pain. This kind of pain is difficult to treat because it re-
sponds poorly to standard treatments, including those used to treat acute
pain. The pain sensation associated with neuropathic pain significantly af-
fects the quality of life of a patient. A new approach to the neuropathic
pain treatment and the search for new, effective drugs and their combina-
tions are needed. In this work we present the synthesis and in vivo assay
results of novel hybrid peptidomimetics for the use in neuropathic pain,
comprising two ligands: an opioid receptors agonist (OP) and an MC4
receptor antagonist. Ligands were connected by spacers (linkers) of dif-
ferent lengths and rigidities. Some of the hybrid compounds showed high
activity in preclinical studies in a mouse and rat model of neuropathic pain
(ED50 0.004-0.0002 nM). Acknowledgment This work was supported by
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National Science Centre grant No. 2012/06/A/NZ4/0002 (to B.P.)
P212
Design, synthesis and evaluation of new
peptidotriazole peptidomimetics as specific modulators
of the Aβ42 peptide oligomerization process
Loreen Hericks1, Nicolo Tonali1, Oliver Kracker1,
Radoslaw Krzemieniecki1, Veronica Dodero1, Julia Kaffy2,
Carmela Michalek1, Anke Nieß1, Sandrine Ongero2,
Norbert Sewald1
1Bielefeld University, Germany
2Université Paris Saclay, France
The misfolding and aggregation of the Amyloid-β 1-42 (Aβ42) peptide
plays a central role in the pathogenesis of Alzheimer’s disease (AD. [1]
Targeting the highly cytotoxic oligomeric species that form during its ag-
gregation process represents a promising therapeutic strategy to reduce the
toxicity associated with Aβ42.[2] Exploiting our knowledge in Aβ42 pep-
tide oligomerization, we developed a new and easy real time BODIPY fluo-
rescence assay for screening inhibitors of the early Aβ42 oligomerization.
This new BODIPY-binding assay could be routinely used for screening
larger compound libraries, demonstrating reproducibility and statistical ro-
bustness of the results. We synthesized new peptidotriazoles as specific in-
hibitors of Aβ42 oligomerization. These peptidomimetics were designed
on basis of the two hot-spot sequences of Aβ42: the hydrophobic nucle-
ation site KLVFF and the C-terminal part (GVVIA). The structure-activity
relationship study demonstrated the importance of the triazole ring posi-
tion in the sequence and the possibility to obtain new peptidomimetics
that are able to reduce the toxicity of Aβ42, by specifically targeting the
oligomerization process instead of the fibrillization process.
Reference [1] a) D. B. Teplow, Alzheimer’s Res Ther, 2013, 5, 39-50; b)
D. B. Teplow, N. D. Lazo, Acc Chem Res, 2006, 395(9), 635-645; c) P.
Prangkio, E. C. Yusko, PLoS One, 2012, 7, e47261; d) P. Cizas, R. Bud-
vytytec, Arch. Biochem. Biophys, 2010, 496, 84-92; e) I. Benilova, E.
Karran, Nat. Neurosci., 2012, 15, 349-357. [2] E. McDade, R. J. Bateman,
Nature, 2017, 457, 153-155.
P213
A Bifunctional Biased Mu Opioid Agonist -
Neuropeptide FF Receptor Antagonist as Analgesic
with Improved Acute and Chronic Side Effects
Armand Drieu la Rochelle1, Karel Guillemyn2, Maria
Dumitrascuta3, Simon Gonzalez2, Charlotte Martin2,
Valérie Utard1, Raphaëlle Quillet1, Séverine Schneider4,
François Daubeuf4, Tom Willemse2, Pieter Mampuys5, Bert
Maes5, Nelly Frossard4, Frédéric Bihel4, Mariana Spetea6,
Frédéric Simonin1, Steven Ballet2
1Biotechnologie et Signalisation Cellulaire, UMR 7242 CNRS, Université
de Strasbourg, Illkirch, France
2Research Group of Organic Chemistry, Vrije Universiteit Brussel,
Brussels, Belgium
3Opioid Research Group, Department of Pharmaceutical Chemistry,
CMBI, University of Innsbruck, Innsbruck, Austria, Austria
4Laboratoire Innovation Thérapeutique, UMR 7200 CNRS, Université de
Strasbourg, Illkirch, France
5Organic Synthesis, Department of Chemistry, University of Antwerp,
Antwerp, Belgium
6Opioid Research Group, Department of Pharmaceutical Chemistry,
CMBI, University of Innsbruck, Innsbruck, Austria
Opioid analgesics, such as morphine, oxycodone and fentanyl are estab-
lished standard treatments for moderate to severe pain. However, upon
chronic administration, their use leads to several side effects such as anal-
gesic tolerance, dependence liability, respiratory depression or constipa-
tion.[1],[2] In order to achieve safer treatment of pain, two main strategies
have recently emerged: the development of G protein-biased mu opioid
receptor (MOPr) agonists, and the production of designed multiple ligands
(DMLs), combining opioid and non-opioid activities.[3],[4]
We designed multitarget peptidomimetics combining high affinity bind-
ing to MOPr and neuropeptide receptors (NPFF1R and NPFF2R). Indeed,
neuropeptide FF and its receptors have been identified as a pronocicep-
tive system involved in opioid-induced hyperalgesia and analgesic toler-
ance.[5],[6] In vitro characterization of our peptidomimetics allowed us
to identify two lead sequences KGFF03 and KGFF09 as G protein-biased
MOPr agonists with full agonist or antagonist activity at the NPFFRs, re-
spectively.[7] In vivo experiments with mice confirmed the benefit of G
protein-biased MOPr agonist activity, since KGFF03/09 showed reduced
respiratory depression compared to the unbiased parent opioid agonist
KGOP01. Interestingly, only the opioid agonist - NPFFRs antagonist,
KGFF09, exhibits a favorable profile upon chronic administration. It gave
way to reduction of hyperalgesia and analgesic tolerance after chronic sub-
cutaneous administration in mice. In addition, KGFF09 displays reduced
withdrawal syndrome compared to KGOP01 and KGFF03, indicating that
it induced less physical dependence.
Altogether, our data establish that combining, within a single molecule,
G protein-biased MOPr agonism and NPFFR antagonism, has beneficial
effects on both acute and chronic side effects of conventional opioid anal-
gesics.
References: [1] Chou R. et al., Annals of internal medicine, 2015, 162(4),
276-286. [2] Pasternak G.W. et al., Pharmacological reviews, 2013, 65(4),
1257-1317. [3] Gunther T. et al., British journal of pharmacology, in press.
[4] Kleczkowska P. et al., Current pharmaceutical design, 2013, 19(42),
7435-7450. [5] Ayachi S. et al., Frontiers in endocrinology, 2014, 5, 158.
[6] Simonin F. et al., Drugs Future, 2006, 31(7), 603-609. [7] la Rochelle
D. et al., Pain, 2018, DOI: 10.1097/j.pain.0000000000001262
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Peptide-Oligonucleotide Conjugates as Nanoscale
Building Blocks
Josephine Boesen1, Kasper Sørensen1, Chenguang Lou2,
Jesper Wengel2, Knud J. Jensen1
1University of Copenhagen, Denmark
2Southern University of Denmark, Denmark
Directed self-assembly, using two bioorthogonal principles, offers the
prospect of creating nanoscale building blocks and synthetic peptides. De-
livery of therapeutics is often the most challenging part of drug develop-
ment. Designed peptide-oligonucleotide conjugates (POCs) could attain
a vital role in the delivery of drugs, as vehicles for drug transport. Here
we synthesized an 8.9 kDa peptide-oligonucleotide conjugate, where the
oligonucleotide forms an antiparallel duplex and the peptide has a high
propensity to form an antiparallel dimer. It can thus form large nano-
assemblies. Dynamic light scattering and circular dichroism were used
to investigate one such peptide-oligonucleotide conjugate. Both methods
indicated the formation of nanoscale assemblies, many times larger than
the starting materials, through the formation of peptide coiled coils and
hybridized oligonucleotide duplexes.
P215
Design, synthesis and biological evaluation of stapled
helical peptides targeting the myddosome
Victor Terrier1, Jonas Verhoeven2, Charlotte Martin2,
Karlijn Hollanders2, Nicolas Triballeau3, Patrick Mollat3,
Steven Van Der Plas3, Gert De Wilde3, Steven Ballet2
1Aelin Therapeutics, France
2Vrije Universiteit Brussel, Belgium
3Galapagos NV, Belgium
Protein-protein interactions (PPI) are involved in the regulation of a large
variety of biological processes and their malfunctioning may lead to the
development of diseases. These targets, considered as largely undruggable
less than a decade ago, are receiving an increased interest in the discovery
of novel therapeutic agents.1 An important challenge originates from the
extended contact surfaces of interaction, to be targeted by small molecule
modulators. Peptides, as small protein segments, can cover larger surface
areas while three-dimensional stability can be preserved via chemical mod-
ifications, such as peptide macrocyclization or helical constraints.2,3
The target of this study is the intracellular adapter protein MyD88, which
is involved in the signaling pathways of the Toll-like receptor (TLRs) and
Interleukin-1 receptor (IL-1), both playing a crucial role in the innate im-
mune and inflammatory response. The MyD88 protein consists of two
domains: a TIR domain that interacts with TLRs and IL-1R, and a death
domain which multimerizes with Interleukin-1 receptor-associated kinases
(IRAKs) to form the myddosome.4 An X-ray structure of this challeng-
ing PPI target shows a left-handed helical oligomer that consists of sev-
eral MyD88 proteins, IRAK4 and IRAK2 death domains, resulting in
highly complex interactions.5 Three types of interfaces (type I-III) are
revealed when the multimeric protein is unfolded along the helical axis.
The type I interface, composed by a seven amino acid long helical epi-
tope from MyD88, is particularly interesting as it shows several interaction
points with IRAK4. Moreover, a non-occupied hydrophobic pocket on the
IRAK4 side is found close to key side chains in MyD88.
Supported by molecular modeling, rationally designed stapled peptides
were synthesized as helix mimetics of the type I epitope, to be evaluated
as potential inhibitors of this PPI. Therefore, macrocyclizations were per-
formed via lactamisation, ring-closing metathesis and copper-catalyzed
azide-alkyne click chemistry (CuAAC). Currently, ten stapled peptides
were identified to bind the IRAK4 domain in a surface plasmon resonance
(SPR) assay. Circular dichroism (CD) spectroscopy confirmed that macro-
cyclization successfully induces helicity in several of the short sequence
peptides. The optimized synthetic pathways, as well as structural peptide
information and binding data will be discussed.
(1) Modell, A. E., Blosser, S. L., Arora, P. S., Trends Pharmacol. Sci.,
2016, 37, 702. (2) Petta, I., Lievens, S., Libert, C., Tavernier, J., De Boss-
cher, K., Mol. Ther. 2016, 24, 707. (3) Nevola, L., Giralt, E., Chem.
Commun., 2015, 51, 3302. (4) Vyncke, L., Bovijn, C., Pauwels, E., Van
Acker, T., Ruyssinck, E., Burg, E., Tavernier, J., Peelman, F., Structure,
2016, 24, 437. (5) Lin, S. C., Lo, Y. C., Wu, H., Nature, 2010, 465, 885.
P216
Sequence-activity relationship analysis for peptide
optimization using Machine Learning techniques
Hugo Villar1, Jane Razumovskaya2, Jason Hodges2, Mark
Hansen2
1University of California San Diego, United States
2Altoris, United States
Optimization of therapeutic biologics has traditionally followed a series
of steps in which activity is maximized, followed by target selectivity,
and then subsequently multiple other pharmacokinetic and toxicological
properties. A significant degree of efficiency could be achieved if multi-
ple properties could be optimized simultaneously. Machine learning tech-
niques could be used to generate sequence-biological activity relationships
to be optimized. The first step is to develop methods to facilitate the anal-
ysis of structure activity relationships for peptides. We present several
approaches to facilitate the identification of such trends and their analysis.
The next challenge resides in that the most appropriate methods for each
property can be different and require some expertise in their use. We have
created a computer system that automatically examines the utility of differ-
ent machine learning techniques for a dataset and selects the most predic-
tive methods for different properties of clinical interest for peptides. The
combination of these best in class algorithms provides an avenue to solve
the multifactorial problem of biologics optimization. We illustrate that a
wide range of machine learning techniques are needed to make accurate
prediction for the full range of preclinical properties of interest. To that
end we analyzed large datasets that revealed that while properties such as
half-life or affinity towards a target can be modeled using Bayesian regres-
sion techniques, in other cases techniques such as support vector machines
are needed to predict amyloid aggregation, when using positional physic-
ochemical descriptors. The models can be used to predict peptides most
likely to have the desired activity from within the combinatorial expansion
of amino acids, natural, unnatural including modified peptides. Our ulti-
mate goal is to develop a decision support system that guides the optimiza-
tion of peptides towards the definition of a clinical candidate minimizing
the number of peptides that need to be evaluated that can be used by non-
experts
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Development of the Stapled Peptide Targeting the
NCOA1/STAT6 Protein-Protein Interaction
Yeongju Lee1, Jeayoung Song2, Hyun-Suk Lim1
1Pohang University of Science and Technology (POSTECH), South Korea
2New Drug Development Center, Daegu Gyeongbuk Medical Innovation
Foundation, South Korea
Aberrantly activated STAT6 transcriptional activity is implicated in various
human diseases, and thus inhibition of STAT6 signaling has been proposed
as a promising therapeutic strategy. Here we report the identification of a
cell-permeable, proteolytically stable, stabilized α-helical peptide directly
targeting NCOA1, a coactivator required for STAT6 transcriptional activ-
ity. This stapled peptide disrupted the NCOA1/STAT6 interaction, thereby
inhibiting STAT6-mediated signaling. Furthermore, we solved the first
crystal structure of a stapled peptide in complex with NCOA1. Impor-
tantly, this stapled peptide is able to specifically inhibit the NCOA1/STAT6
interaction, while current STAT6 inhibitors and biological methods (e.g.,
siRNA knockdown) suppress the entire functions of STAT6. The stapled
peptide there-fore represents a highly useful chemical probe for dissecting
the precise role of the NCOA1/STAT6 interaction and an excellent starting
point for the development of a novel class of therapeutic agents.
P218
Designed macrocyclic peptides as a novel class of
nanomolar inhibitors of amyloid self-assembly
Anna Spanopoulou1, Luzia Heidrich1, Hong-Ru Chen2,
Christina Frost3, Dean Hrle4, Jürgen Bernhagen2, Martin
Zacharias3, Gerhard Rammes4, Aphrodite Kapurniotu1
1Division of Peptide Biochemistry, TUM School of Life Sciences,
Technische Universität München (TUM), Germany
2Chair of Vascular Biology, Institute for Stroke and Dementia Research,
Ludwig-Maximilians-University (LMU), Germany
3Chair of Biomolecular Dynamics, Department of Physics, Technische
Universität München, Germany
4Department of Anesthesiology, Technische Universität München /
Klinikum Rechts der Isar, Germany
Amyloid self-assembly is linked to more than 25 devastating cell-
degenerative diseases including Alzheimer’s disease (AD) and type 2 di-
abetes (T2D). The design of inhibitors of amyloid self-assembly is, how-
ever, a difficult task; major reasons are the conformational flexibility of
many amyloidogenic polypeptides, the high affinity of self-assembly me-
diating interactions and the dynamic nature and large size of involved sur-
faces. The key components of the amyloid plaques in AD and T2D are
the intrinsically disordered polypeptides β -amyloid peptide (Aβ ) and islet
amyloid polypeptide (IAPP). Notably, increasing amounts of evidence sug-
gest a link between the pathogenesis of the two diseases. A large num-
ber of peptide-based inhibitors of Aβ or IAPP amyloidogenesis has been
derived from the sequences of their targets. However, full-length IAPP
analogs have been also shown to inhibit amyloid self-assembly of Aβ as
well (Yan et al., Angew. Chem. Int. Ed. (2007) & (2013)). More re-
cently, we have designed linear peptides derived from the partial IAPP
sequence IAPP(8-28) as mimics of IAPP self-/cross-interaction surfaces
(Andreetto et al., Angew. Chem. Int. Ed. (2015)). These peptides
were termed interaction surface mimics (ISMs) and have been shown to
be highly potent inhibitors of amyloid self-assembly and related cell tox-
icity of Aβ , IAPP or both polypeptides. Here we will present designed
macrocyclic peptides as a novel class of nanomolar inhibitors of amy-
loid self-assembly of both Aβ and IAPP or of Aβ alone. These pep-
tides were termed macrocyclic inhibitory peptides (MCIPs) and were de-
signed using minimal IAPP-derived recognition elements (Spanopoulou et
al., Angew. Chem. Int. Ed. (2018)). Most importantly, sequence optimiza-
tion yielded an Aβ -selective MCIP exhibiting high proteolytic stability in
human plasma and human blood-brain-barrier (BBB) crossing ability in a
cell model. Based on their favourable properties, MCIPs are promising
leads for anti-amyloid drugs and useful templates for the design of small
molecules as modulators of pathogenic protein aggregation in AD or in
both AD and T2D.
P219
Synthesis of Novel Amino Acids Incorporating
Zinc-Binding Groups as Inhibitors of HDAC1:MTA1
Co-repressor Complex
Amit Mahindra1, Peter Watson2, Chris Millard2, John
Schwabe2, Andrew Jamieson1
1University of Glasgow, United Kingdom
2University of Leicester, United Kingdom
Epigenetic regulation of the human genome is vital for understanding both
the etiology and fundamental mechanisms of diseases. Molecular regu-
lation of gene expression is controlled in part by two distinct classes of
lysine-modifying enzymes, the histone deacetylases (HDACs) and the hi-
stone acetyltransferases (HATs). HDACs have attracted considerable at-
tention as therapeutic targets, especially due to their ability to modify the
landscape of post-translational modifications (PTMs) on histone proteins
in chromatin. Modifications in HDAC function have been linked to neu-
rological disorders, muscular dystrophy, cardiac hypertrophy, cancer, HIV
infection, and many other diseases. Class I, II and IV HDACs are zinc de-
pendent enzymes. These isozymes are inhibited by molecules having zinc
binding groups (ZBGs) such as SAHA (Figure). Here, we describe the syn-
thesis of novel amino acids containing ZBGs and their incorporation into
H3K27 histone tail. The foremost advantage of these amino acids (AAs)
is they can be incorporated at any position in the peptide sequence without
modification of standard Fmoc SPPS protocols. This synthetic strategy is
facilitating the rapid generation of peptide inhibitors. Initial data demon-
strates that these peptides are potent inhibitors of the HDAC1:MTA1 co-
repressor complex and provide critical structure information for the devel-
opment of next generation of HDAC inhibitors.
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Potent inhibition of CYP3A4 by the endomorphin-2
analogues
Kaloyan Georgiev1, Maya Radeva1, Tamara Pajpanova2
1Medical University of Varna, Bulgaria
2Bulgarian Academy of Sciences, Bulgaria
Endomorphins (endomorphin-1, EM-1, Tyr-Pro-Trp-Phe-NH2,
endomorphin-2, EM-2, Tyr-Pro-Phe-Phe-NH2) are endogenous peptides,
which are very potent and highly selective µ-opioid receptor agonists.
Moreover, they possess a potent analgesic activity comparable to that
of morphine but are devoided of its undesirable effects. However, their
use as therapeutic agents is limited due to their pharmacokinetic features,
such as stability and permeability via blood-brain barrier (BBB). In our
previous developments, modifications in the structure of endomorphine-
2 have shown an improvement in stability and permeability through the
membranes. In the current study, the goal was to investigate another phar-
macokinetic feature, namely the risk of drug interactions at the level of
cytochrome enzymes. CYP3A4 is the most important drug metabolizing
enzyme in humans. It is highly expressed in liver and gastrointestinal
mucosa and is involved in the metabolism of more than 50% of the used
drugs. Therefore, the risk of drug interactions is greatest in drugs modify-
ing the activity of CYP3A4. We used four endomorphin-2 analogues, two
of them were modified at the third position - Phe(pF) (1) and conjugated
at forth position with 1,2-ethylenediamine (2). The other two, were con-
jugated at first position with deoxycholic acid and modified at the third
position - Phe(pF) (3) and Phe (pCl) (4). The four endomorphin-2 analogs
used in concentrations of 25 to 100 µM showed potent and concentration-
dependent inhibition of CYP3A4. On two of them (1 and 2), their effect
was close to that of the classical inhibitor of CYP3A4 - ketoconazole.
The results have shown some possible drug interactions of endomorphin-2
analogues which should be considered if they are used in clinical practice.
Acknowledgments: This work was supported by Project 16021” Study of
drug interactions at biotransformation level”, Fund Science, at the Medical
University of Varna/Bulgaria.
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Injectable Peptide Hydrogels for Controlled Drug
Release
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Belgium
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Austria
3Department of Pharmaceutical Chemistry and Drug Analysis, Vrije
Universiteit Brussel, Belgium
4In Vivo Cellular and Molecular Imaging, Vrije Universiteit Brussel,
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5Organic and Biomimetic Chemistry Research Group, Ghent University,
Krijgslaan, 281, 9000 Ghent, Belgium
6Supramolecular Chemistry Group, Ghent University, Krijgslaan 281,
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Currently, most drugs are given to patients, via oral or parenteral routes. In
order to get the desired therapeutic effect, high doses are often required due
to substantial clearance and biodegradation of the drug prior to interaction
with the biological target, which may lead to adverse effects. To overcome
this problem, hydrogels have been reported as suitable controlled drug-
delivery systems. More specifically, peptide hydrogels loaded with active
ingredients can liquefy during injection, followed by a quick hydrogel ref-
ormation once injected. These systems present several advantages includ-
ing drug protection from enzymatic degradation through encapsulation in
the hydrogel network, while maintaining the therapeutic plasma drug con-
centration over a long period of time. Consequently, lower dosage and
frequency of administration are possible, resulting in improved drug effi-
cacy while lowering the risk of side effects. Due to their biocompatibility,
low toxicity and physically crosslinked network structure, peptide-based
hydrogels represent an important class of injectable hydrogels suited to be
matrices for controlled and slow drug release. In this work, a new family of
hydrogel-forming peptides was designed starting from a short, tunable and
amphipathic hexapeptide hydrogelator. After characterization, and aiming
for the evaluation of their therapeutic potential, new hydrogels have been
used for entrapment and sustained release of opioid drugs. The peptide-
based hydrogelators were co-formulated with morphine, the gold-standard
opioid analgesic.[1,2] Due to the well-known deleterious effects produced
by morphine and other commonly used opioid analgesics, the development
of alternative therapeutics is of utmost importance. Peptidomimetics of
endogenous opioid peptides, especially ligands binding at the µ-opioid re-
ceptor, were designed and subsequently co-formulated with hydrogelators,
and assessed in a mouse model of acute thermal nociception. We have
demonstrated an extended antinociceptive effect up to 96 h after subcuta-
neous injection in mice. These promising results open an avenue for new
therapies to treat chronic pain.
References [1] Martin et al. Med. Chem. Commun. 2016, 7, 542. [2]
Martin et al. Mater. Today Chemistry 2017, 3, 49.
S159
Po
st
e
rs
P222
Peptide carriers for retinal drug delivery
Marta De Zotti1, Ivan Guryanov2, Tatiana Tennikova2,
Madhushree Bhattacharya3, Arto Urtti3
1University of Padova, Italy
2St. Petersburg State University, Russia
3University of Helsinki, Finland
In ophthalmology retinal drug therapy is one of the major challenges, as
it is hampered by ineffective and/or short-acting drug delivery to the tar-
gets, often located in intracellular compartments. Thus, there is a need
for drug delivery systems able to transfer pharmaceutical cargo into reti-
nal cells. Many retinal therapeutics are based on proteins and oligonu-
cleotides with poor cell permeability. The development of cell-penetrating
carriers can noticeably enhance their therapeutic effect. From this point of
view membrane-active trichogin analogs are very promising candidates as
carriers in retinal drug-delivery systems. In order to increase water solu-
bility, we introduced lysine residues into the trichogin native sequence at
different positions. The secondary structure of the corresponding peptides
was studied by CD spectroscopy and 2D-NMR. Cell viability experiments
showed low cytotoxicity up to 0.8 µM concentration. At the same time the
peptides were efficiently internalized into retinal pigment epithelium cells.
Thus, water-soluble trichogin analogs described herein can be very effec-
tive membrane-permeating molecules that can be used for drug delivery in
the treatment of various diseases of the eye. This work has been performed
in the framework of the project Megagrant 14.W03.31.0025.
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Targeting the coiled-coil domain of BCR-ABL1 kinase
with new weapons
Yen-Hua Huang1, Toby Passioura2, Hayden Peacock2,
Sónia Troeira Henriques1, Conan Wang1, Quentin Kaas1,
Hiroaki Suga2, David Craik1
1The University of Queensland, Australia
2The University of Tokyo, Japan
The Philadelphia chromosome (Ph) encoded oncogenic tyrosine kinase
BCR-ABL1 is the underlying cause of around 95% of chronic myeloid
leukemia (CML) and 25% of adult acute lymphoblastic leukemia (Ph+
ALL). Current treatments for CML patients rely on ATP-competitive ty-
rosine kinase inhibitors. Nevertheless, 20−30% of patients manifest drug
resistance associated with point mutations within the drug-binding site of
BCR-ABL1. To overcome the drug resistance, discovery of inhibitors tar-
geting the coiled-coil region involved in the activation of BCR-ABL1 ki-
nase could be an alternative approach to generate drug leads with durable
therapeutic response and to prevent or delay the emergence of resistance.
In the current study, the coiled-coil domain BCR1-72 was synthesised
chemically and screened against a thioether-macrocyclic peptide library
generated using a cutting-edge technique named RaPID (Random nonstan-
dard Peptides Integrated Discovery). Fourteen lead molecules discovered
by the RaPID system showed significant binding affinities to the BCR1-72
in surface plasmon resonance and three of them further displayed growth
inhibitory effects on K562 cells in the low micromolar range but did not
show toxicity against human peripheral blood mononuclear cells. Taken
together, the macrocyclic peptides discovered using RaPID system exhib-
ited inhibitory activity towards the CML blast crisis cell line but not to the
non-malignant human cells, indicating that they are promising candidates
for therapeutic agent development.
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Entanglement: self-assembling peptide nanofibers that
entrap and kill bacteria
Jennifer Payne, Mark Del Borgo, Ketav Kulkarni, Thierry
Izore, Alex Fulcher, Mibel Aguilar, Max Cryle
Monash University, Australia
We are facing an era where the antibiotic cornerstone of modern medicine
is under threat due to bacterial resistance. Deadly superbugs are not only
resistant to current treatments, but can also evade the body’s own defense
strategy – our immune system. Adding to this crisis is that no new an-
tibiotics have reached the pharmacy shelves in over 20 years. Antibiotics’
standard tactic is straightforward: annihilation. But the strategy we are de-
veloping does this and more: by self-assembling into nanofibers this treat-
ment entraps and kills bacteria. This mimics the body’s own defense tactic
of neutrophil extracellular traps (NETs), an important part of the innate
immune system arsenal. Just like NETs, these nanofibers are decorated
with peptides that kill bacteria, in this case the glycopeptide antibiotic van-
comycin.
These fibers form by use the propensity of lipidated tri-beta-peptides
self-assemble into nanofibers. To decorate these fibers with antibiotics
we directly linked a beta3-peptide to vancomycin. Mixing these two
beta3-peptides in different ratios resulted in vancomycin incorporated into
fibers with different structures that have been visualized using electron mi-
croscopy, atomic force microscopy and stimulated emission depletion mi-
croscopy. These distinct fibers have different antimicrobial activity against
the antibiotic resistant Staphylococcus aureus.
P225
Multicyclic Peptides via Templated Tandem
CLIPS/CuAAC Cyclizations
Gaston Richelle1, Marcel Schmidt2, Henk Hiemstra3, Timo
Nuijens2, Jan van Maarseveen3, Peter Timmerman1
1Pepscan, Netherlands
2Enzypep B.V., Netherlands
3University of Amsterdam, Netherlands
Multicyclic peptides provide a very attractive molecular format for the de-
sign of novel therapeutics,[1] Therefore, novel routes for synthesis and
HTS-screening of this fascinating class of compounds are desperately
needed. A decade ago, we launched a novel scaffold-assisted peptide-
cyclization technology platform, termed “CLIPS”, to generate in a one-
steps procedure a new class of mono- and bicyclic peptides able to act as
potent inhibitors of hitherto undruggable therapeutics targets.[2,3]
Following this, we now present a next-generation technology that com-
bines both CLIPS and CuAAC chemistry into a one-pot methodology
that enables the manufacturing of structurally complex peptide multicy-
cles (tri-,[5] tetra-, penta- and hexacyclic constructs) by using either lin-
ear or backbone-cyclized[4] peptides. We present the chemical synthesis
of two different types of CLIPS/CuAAC-scaffolds (T4 and T6) and show
how these scaffolds behave in the synthesis of highly complex peptide con-
structs.
[1] D. J. Craik, D. P. Fairlie, S. Liras, D. Price, Chem. Biol. Drug Des.
2013, 81, 136–147. [2] P. Timmerman, J. Beld, W. C. Puijk, R. H. Meloen,
ChemBioChem 2005, 6, 821–824. [3] C. Heinis, T. Rutherford, S. Freund,
G. Winter, Nat. Chem. Biol. 2009, 5, 502–507. [4] M. Schmidt, A. Toplak,
P. J. L. M. Quaedflieg, H. Ippel, G. J. J. Richelle, T. M. Hackeng, J. H. Van
Maarseveen, T. Nuijens, Adv. Synth. Catal. 2017, 359, 2050–2055. [5] G.
S160
Po
st
e
rs
J. J. Richelle, S. Ori, H. Hiemstra, J. H. van Maarseveen, P. Timmerman,
Angew. Chem. Int. Ed. 2018, 57, 501–505.
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Hyaluronan based scaffold for cardiomyocyte adhesion
Sergej Karel1, Jana Sogorkova1, Lucie Marholdova1,
Martin Flegel2, Vladimír Velebný1
1Contipro a.s., Czechia
2University of Chemistry and Technology Prague, Czechia
Hyaluronic acid (HA) is a biocompatible and biodegradable glycosamino-
glycan which has a potential to be used in tissue engineering as a scaffold
for cell or drug delivery. Since HA is highly soluble in aqueous solutions
and is biologically inert, it is worth to modify the surface of material by
functional groups or biologically active compounds which also stabilize
the structure [1]. The modification of HA scaffold can be achieved by
covalent bonding of peptides to primary hydroxyl group of N-acetyl-D-
glucosamine unit in terms of Solid Phase Peptide Synthesis (SPPS) [2].
Our approach made possible to use HA in the form of fiber or non-woven
textile as a carrier for direct preparation or binding of peptides. This con-
struct can be directly employed for the study of certain chemical and phys-
ical properties and basic biological effects without need of peptide detach-
ment. Different short peptides specifically enabling adhesion of cardiomy-
ocytes were chosen for this study. A linker between HA and peptide con-
taining two 6-aminohexanoyl units (Ahx-Ahx) was used to make adhesive
motif more available for cell surface receptors. One of the advantages of
this procedure is the water insolubility of the peptide-HA conjugate. More-
over, higher stability of this material is achieved in the presence of the Ahx-
Ahx linker. Hyaluronan non-woven textiles bearing these specific peptides
could be advantageously employed in various biomedicine applications,
for example, as a patch in cardiac tissue repair or for wound healing. Its
biodegradable composition is the main advantage because it eliminates the
need of removal after the treatment. Preliminary results of the biologi-
cal effects of prepared HA-peptide models confirmed the good direction
of our approach. [1] A.M. Abdel-Mohsen et al. Carbohydr. Polym. 92
(2013) 1177–1187. [2] S. Karel et al. J. Pep. Sci. 22 (2016) S64.
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Novel HIV-1 protease inhibitor prodrugs using a
degradation reaction of N-amidino-peptides
Yoshio Hamada, Kenji Usui
Konan University, Japan
The selective cleavage of an amide bond at room temperature or physiolog-
ical conditions will be a powerful tool for life science and medicinal chem-
istry. However, the cleavage of amide bonds requires considerable energy,
whereas ester bonds can be easily cleaved. The amide bond cleavage reac-
tions are known in nature; for example, a protein, intein, undergoes protein
splicing that involves an amide bond cleavage. To develop an amide bond
cleavage reaction, we investigated the decomposition reaction of arginine
methyl ester, which was reported by Photaki et al. In this reaction, the
guanidino group of an arginine methyl ester attacks the ester carbonyl car-
bon of another arginine methyl ester, forming an arginine dimer. Next, the
N-terminal amino group of the dimer attacks the guanidino-carbon within
the molecule, forming a heterocyclic compound and ornithine methyl es-
ter. We assumed that the driving force of this decomposition reaction is
the release of the heterocyclic compound that is stabilized because of a
conjugate structure. Previously, we reported a novel N-terminal degrada-
tion reaction of peptides via N-amidination. We designed and synthesized
a series of N-amidino-peptides. Surprisingly, these peptides released N-
degraded peptides at room temperature. Furthermore, we reported novel
prodrugs of sparingly-soluble drugs, such as phenytoin and sulfa drug, us-
ing this degradation reaction. In this study, we designed and synthesized
water-soluble prodrugs of HIV-1 protease inhibitor, ritonavir. The ritonavir
prodrugs were stable in water and acidic media such as gastric fluid, and
could release its parent drug rapidly and spontaneously under physiologi-
cal condition such as gastrointestinal fluids. The ritonavir prodrugs appear
to be suitable for an orally administered drug.
P228
Imaging Evaluation of an In-vivo Long-acting
Neuropeptide(NPY) Analogue for Multimodality
Breast Tumor Therapy
Ming-Hsin Li, Su-Jung Chen, Ming-Wei Chen, Chun-Fang
Feng, Yuan-Ruei Huang, Sheng-Nan Lo, Cheng-Hui
Chuang, Shih-Ying Lee, Chih-Hsien Chang
Institute of Nuclear Energy Research, Taiwan
Neuropeptide Y (NPY) is a 36-amino acid peptide and regulates in var-
ious physiological functions through its four receptors. Recently, NPY
receptor- Y1R has been found to be overexpressed in breast carcino-
mas. Although the truncated NPY analog has high affinity with Y1R, it
is rapidly metabolized, resulting in low tumor uptake. Circulation time
of NPY could be prolonged by conjugation with EB to enhance the tu-
mor uptake in the body. The aims of this study were to synthesize a
long-circulated NPY analog and evaluate tumor image of the 4T1 an-
imal model as a candidate for breast cancer therapy. We synthesized
DOTA-Boron-ENPY, which is a 16-amino acid NPY analog. Its struc-
ture consists of four parts-(1)tetraazacyclododecane-1, 4, 7, 10-tetraacetic
acid (DOTA), a chelate for radiolabeling(2)m-Carborane-1,7-dicarboxylic
acid(C4H12B10O4) for high-density boron source(3)truncated Evans Blue
as a good human serum albumin binder (4)truncated NPY analogue for
high affinity with breast cancer. In the radiolabeling procedure, the amount
of DOTA-Boron-ENPY was dissolved in sodium acetate buffer, followed
by addition of (3-6mCi) In-111 or Lu-177, and incubated for 15-30 min
at 95° C. The labeling efficiency was determined by Radio-TLC. The
Radio-HPLC are used for analyzing labeling purity. In animal study, tu-
mor xenografts were performed in 6-wk-old female BALB/c mice by sub-
cutaneous injection of2*106 4T1 cells, and nanoSPECT/CT imaging was
performed at 0.5 h to 48h after injecting of the111In- DOTA-Boron-ENPY.
We can get the high labeling efficiency (>95%) of 177Lu- DOTA-Boron-
ENPY after 30min labeling with Lu 177. However, the labeling efficiency
of 111In- DOTA-Boron-ENPY is greater than 90% after reacting 15min
with 111In. In vivo study, the nanoSPECT/CT image of the 4T1 animal
model revealed that 111In- DOTA-Boron-ENPY has high tumor uptake
value (ID%/g>10)and high tumor to muscle (T/M>9) ratio in 48 hours af-
ter tail vein injection. The result shows the DOTA-Boron-ENPY is easy to
radiolabel with Lu177 and In111. The two compounds are high labeling ef-
ficiency and high resolution of the image. From the in vivo study, we con-
sider the DOTA-Boron-ENPY as a long circulation radiopharmaceutical
candidate for companion diagnostics (CDx). It could be long-acting in 48
hours after tail vein injection and has high tumor uptake value (ID%/g>10)
and high tumor to muscle ratio (T/M>9). Furthermore, we apply such
DOTA-Boron-ENPY for the design of boron carriers. Peptide Receptor Ra-
dionuclide Therapy (PRRT) is a widely known molecular targeted therapy.
PRRT is performed by using a small peptide which is combined with ra-
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dionuclides. DOTA-Boron-ENPY is a small peptide combined with boron
and Evens Blue, and thus it can circulate longer in the animal model. It is
not only a good tracer for BNCT but also a therapeutic drug by labeling
with Lu177. The capabilities of DOTA-Boron-ENPY make it a potential
drug for multimodality breast tumor therapy.
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NGR-DAU Conjugates, a Favorable Tumor-Homing
Motif with Potential Dual-Targeting
Andrea Angelo Pierluigi Tripodi1, Szilard Toth2, Ivan
Randelovic3, Jozsef Tovari3, Gábor Mezó1
1MTA-ELTE Research Group of Peptide Chemistry, Hungary
2Institute of Enzimology, Research Center for Natural Sciences,
Hungarian Academy of Sciences, Hungary
3National Institute of Oncology, Dept. of Experimental Pharmacology,
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Cancer is currently one of the major health-related issues world-wide.
Strategies to target and defeat tumor are limited due to the access to tu-
mor, side effects and absence of selectivity to the tumor tissue. Peptides
containing the Asn-Gly-Arg (NGR) motif can act as tumor-homing com-
pounds that are recognized by Aminopeptidase N (APN/CD13) which is
receiving an accurate attention due to its role in tumor growth, metastasis
and immune regulation, generally expressed on the monolayer cell surface
of malignant cells [1]. As stated in the literature the Asn-Gly-Arg sequence
is inclined to Asn deamidation bearing the formation of a succinimide in-
termediate, generating isoDGR derivative which can bind to integrins [2].
This tendency of the NGR motif provides an ideal starting point for the
development of conjugates with a selective dual acting anti-tumor effect.
We recently described that the Dau=Aoa-GFLGK(c[KNGRE]-GG-)-NH2
conjugate has a significant anti-tumor activity against both CD13 positive
HT-1080 human fibrosarcoma and CD13 negative but integrin positive HT-
29 human colon adenocarcinoma cells [3]. However, it seems that the free
ε-amino group of Lys in the cycle is not necessary for the biological ac-
tivity. Therefore, we developed novel cyclic NGR peptide – daunomycin
conjugates in which Lys was replaced by different amino acids [4]. From
these investigations the Nle conjugate as the most efficient compound was
selected for additional studies. The cytotoxic effect of the novel cyclic
NGR peptide Dau conjugates were evaluated in vitro on HT-1080 (human
fibrosarcoma), HT-29 (human colon adenocarcinoma) and KS (Kaposi Sar-
coma) cell lines. The stability in cell culture medium and the lysosomal
degradation in presence of rat liver homogenate were determined by LC-
MS. As daunomycin present fluorescent properties, internalization of both
peptides was also detected by flow cytometry. The achieved results from
these studies confirm that the Lys - Nle replacement provides not only an
easier synthetic route but also enhance the anti-tumor activity of the conju-
gate.
This project had received fundings from the European Union’s Horizon
2020 research and Innovation program under the Marie Sklodowska-Curie
grant agreement No 642004, and from the National Research, Develop-
ment and Innovation Office (NKFIH K119552), Hungary. ____ [1] F. Cur-
nis, G. Arrigoni, A. Sacchi, L. Fischetti, W. Arap, R. Pasqualini, A. Corti,
Cancer Res 2002, 62, 867-74. [2] Y. C. Meinwald, E. R. Stimson, H. A.
Scheraga, Int J Pept Protein Res 1986, 28, 79-84. [3] K. N. Enyedi, S. Toth,
G. Szakacs, G. Mezo, PLoS One 2017, 12, e0178632. [4] A. A. P. Tripodi,
S. Toth, K. N. Enyedi, G. Schlosser, G. Szakacs, G. Mezo, Beilstein J. Org.
Chem. 2018, 14, 911-918.
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Small interfering RNAs (siRNAs) present a strong therapeutic potential
because of their ability to inhibit the expression of any desired protein.
However, siRNAs show a very weak propensity to cross the plasma mem-
brane on their own. We recently developed a series of new cell-penetrating
peptides able to form stable peptide-based nanoparticles (PBNs) once in-
cubated with a given ratio of siRNA.1 With regard to future in vivo appli-
cations, we also studied recently the influence of the polyethylene glycol
(PEG) grafting onto the PBNs on their in vitro and in vivo siRNA delivery
properties. 2 We also planed to address specifically PBNs to tumor sites
upon the incorporation of peptide targeting sequences on PBNs. Thanks to
strategies offered by peptide chemistry, we designed, prepared and studied
new PBNs made of several different peptides blocks (siRNA complexa-
tion, siRNA cellular transfer, targeting and prolonged blood-circulation)
in order to improve significantly the cell-specific delivery of siRNAs.
1 Vaissière A, Aldrian G, Konate K, Lindberg MF, Jourdan C, Telmar A,
Seisel Q, Fernandez F, Viguier V, Genevois C, Couillaud F, Boisguerin
P, Deshayes S. A retro-inverso cell-penetrating peptide for siRNA deliv-
ery. J Nanobiotechnology. 2017; 15 (1): 34-51. 2 Aldrian G, Vaissière A,
Konate K, Seisel Q, Vivès E, Fernandez F, Viguier V, Genevois C, Couil-
laud F, Démèné H, Aggad D, Covinhes A, Barrère-Lemaire S, Deshayes S,
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Boisguerin P. PEGylation rate influences peptide-based nanoparticles me-
diated siRNA delivery in vitro and in vivo. J. Control. Release. 2017; 256:
79-91.
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Peptides specifically target bacteriophage MS2, filled
with an apoptosis-inducing agent, to tumour
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Rybalkina3, Marina Melnikova1, Yulia Filatova1, Alexey
Chistov1, Igor Sivov4
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Bacteriophages, especially MS2, are often used recently as containers for
delivery (including the targeted one) of drugs, nucleic acids, etc. into
cells. We employed bacteriophages MS2 for the tar-geted delivery of an
apoptosis-inducing agent into tumour tissue. The targeted delivery was
provid-ed by peptides of iRGD type, that specifically bound integrins pre-
sumably located on the surface of endotheliocytes of a novel vasculature
formed in tumour tissues. Peptides were obtained by SPPS and cyclized
via formation of S-S bridge. The peptides contained a spacer, through
which they were conjugated to phage capsid proteins. Tl+ ions in the
form of TlNO3 were used as apoptosis-induced agents, since it was known
that multiple drug-resistant cancer cells could not eliminate Tl+. Tl+ was
shown to penetrate into phage particles and to bind tightly to phage RNA,
with the drop in Tl+ concentration in the media up to 30 times compared
to the initial one. Peptide-modified MS2 preparations filled with Tl+ were
tested on several solid tumour cell cultures. Filling of peptide-modified
MS2 with 3.5 mkg of TlNO3 resulted in 80-85% cell death, while no cell
death was observed in control experiments. When peptide-modified MS2
filled with Tl+ was in-jected to MCF7- and DA-MB-231-xenograft nude
mice, it resulted in tumour mass loss up to 2.5 times compared to control.
Overall concentration of TlNO3 in peptide-modified MS2 filled with Tl+
was 500000 times lower than TlNO3 LD50, and therapeutic index of the
phage-based preparation was about 15000. The results show the perspec-
tive of the use of bacteriophage MS2 filled with Tl+ and containing a tar-
get delivery system as a lead substance for solid tumour therapy. Peptides
repre-sent a convenient target delivery system for such preparations be-
cause of their easy and well-defined conjugation to phage capsid proteins.
The research was supported by the State contract with the Russian Min-
istry of Education and Sci-ence No. 14.N08.11.0188 (27.11.2017) (unique
project ID 171771053913577100100100030807219241). Peptides were
synthesized with the use of the equip-ment of “Human Proteome” Core
Facility of the Institute of Biomedical Chemstry (Moscow, Russia) sup-
ported by Ministry of Education and Science of the Russian Federation
(unique project ID RMEFI62117X0017).
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Bacterial colonization and establishment of antibiotic-resistant biofilms
represent a significant healthcare problem. Also, the quick decline in the
effectiveness of current antibiotics is boosting the search for new and effec-
tive strategies [1], among which antimicrobial peptides (AMP)-related ap-
proaches have been steadily gaining prominence; one example of a highly
promising field of research in this area is development of AMP-based ma-
terials [2]. In this connection, the main goal of our work was to evaluate
the effect of surface immobilization of Dhvar-5, an AMP with head-to-tail
amphipathicity, on its antibacterial activity. To this end, Cu(I)-catalyzed
azide-alkyne cycloaddition (CuAAC) “click” reactions were explored for
covalent immobilization of the peptide onto chitosan, a biopolymer with
intrinsic antibacterial and bioadhesive properties. Dhvar-5 grafting onto
chitosan by CuAAC was carried out either on (i) ground chitosan powder
next used to prepare thin films (type 1 coatings), or (ii) pre-formed chi-
tosan thin films (type 2 coatings). Also, peptide tethering was evaluated
in both possible orientations, i.e., the peptide was covalently immobilized
via either its N- or its C-terminus [3,4]. Antimicrobial activity assays were
conducted using a combination dye of the LIVE/DEAD® Bacterial Via-
bility Kit (Baclight™) for quantifying the viability of adherent bacteria.
Results demonstrated that the mode of action and antibacterial efficacy
of immobilized Dhvar-5 depended on both the strategy of immobilization
and peptide orientation. As such, type 1 coatings displayed bactericidal ef-
fects, whereas anti-adhesive properties were exhibited by type 2 coatings.
Moreover, higher antimicrobial activity was observed when Dhvar-5 was
immobilized through its cationic C-terminus, i.e., exposing its hydropho-
bic domain. Altogether, findings made thus far suggest that CuAAC “click”
chemistry is an attractive chemoselective approach to graft AMP onto chi-
tosan, yielding bulk materials that are suitable to produce tailored bioma-
terials with excellent prospects for application as antimicrobial coatings.
References [1] Sánchez et al. BMC Infect Dis 2013, 13:47. [2] Costa et
al. Acta Biomater 2011, 7:1431-40. [3] Costa et al. Biomaterials 2015,
52:531-8. [4] Barbosa et al. Carbohydr Polym 2017, 165:384-93.
Acknowledgments FCT: UID/QUI/50006/2013; SFRH/BD/108966/2015;
SFRH/BPD/79439/2011; (CCDR-N)/NORTE2020/ Portugal2020: DE-
SignBIOtechHealth (ref. Norte-01-0 145-FEDER-000024); Bioengi-
neered Therapies for Infectious Diseases and Tissue Regeneration (ref.
NORTE-01-0145-FEDER-000012).
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The treatment of chronic kidney diseases like ADPKD can benefit from
drugs that specifically target the kidney. This can potentially reduce side
effects and provide higher drug efficacy within renal tissue. In this context,
peptide sequences (KKEEE)nK were reported to target the renal cortex1.
In order to be able to assess the renal targeting ability of this family of
peptides by in vivo optical imaging, we synthesised peptides (KKEEE)nK
(n=2 and n=3) bearing the near IR Vivo-tag 680 XL dye at the N-terminus.
These syntheses can be challenging due to the high cost of the Vivo-tag 680
XL dye and the use of a large excess of reagent typical of SPPS. Instead,
an inverse approach was applied in which 0.3-0.5 eq of dye were used and
the corresponding tagged and untagged peptides were easily separated by
preparative HPLC. These peptides, when injected IV into normal mice, ac-
cumulated in the cortex of the kidney, specifically in the proximal tubules,
and uptake by other organs was not observed.
1 Wischnjow et al. Bioconjugate Chem, 2016, 27, 1050-57
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Due to their poor pharmacodynamic and pharmacokinetic properties, ex-
perimental and therapeutic delivery of neuropeptides or their synthetic ana-
logues to human brain has been hampered. Indeed, when administered sys-
temically, these compounds are rapidly degraded, do not readily pass the
blood-brain barrier (BBB), and often evoke potent hormone-like side ef-
fects when circulating in the blood. Thus, for their potential future clinical
applications, it is mandatory to find an alternative route of neuropeptide ad-
ministration to reach their parenchyma targets. Since more than a decade,
the intranasal (i.n.) route has received considerable attention because of
low proteolytic activity compared to the oral route, high vascularization
and large absorptive surface, resulting in improved absorption. In addition,
the intranasal route can offer a direct access to the brain to peculiar com-
pounds. The diazepam-binding inhibitor-derived peptide ODN acts as a
potent anorexigenic compound in rodents when injected intracerebroven-
tricularly (i.c.v.). However, intravenous injection of 200-fold the minimal
i.c.v. effective dose does not modify feeding behaviour suggesting that
ODN does not comply to systemic administration. Hence, we have evalu-
ated the ability of ODN, its isoactive C-terminal fragment OP and a potent
and constrained analogue cyclo(1-8)OP to induce anorexigenic effects in
mice via i.n. administration. Preliminary investigations revealed that i.n.
administration (1 µg/twice a day/7d) of OP induces a significant reduction
in body weight in mice, while ODN and cyclo(1-8)OP i.n. applications do
not modify body weight compared to the vehicle injected group. The effect
of OP was settled after 3 days of treatment and lasted until the end of treat-
ment. Neither rebound hyperphagia nor gaining weight was observed after
treatment cessation. Investigation performed using qPCR revealed that i.n.
administration of OP induces an increase in UCP1 transcript expression
in brown adipose tissue, suggesting that OP stimulates energy metabolism
via sympathetic activation. Additionally, our investigation also revealed
that i.n. administration of OP causes liver lipid metabolism modifications.
Indeed, OP increased mRNA levels of gene related to both lipid oxidation
(PPAR-γ , CPT-1α) and lipid uptake (FABP-1, FATP-1, CD-36), suggest-
ing that OP i.n. administration enhances fatty acid β -oxidation in the liver.
In conclusion, our data show that OP injected by intranasal route can reach
the central nervous system by skirting around the BBB and then activates
central anorexigenic pathways. Moreover, they provide evidence that the
physicochemical characteristics of the compound govern its brain delivery.
Supported by ANR EZICROM (ANR-16-CE14-0011).
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Many pathogenic bacteria and fungi strains have become resistant to the
most of commercially available antibiotics as the result of their common
and excessive use in medical practice. One of the most promising strat-
egy for searching for new compounds with antimicrobial activity is bio-
conjugation, covalent or non-covalent connection, of at least two chemical
molecules of compounds with different activity that in the end display a dif-
ferent mechanism of action than the parent compounds. The main aim of
our work was to obtain a new class of compounds with antimicrobial activ-
ity. These compounds are peptidic hybrids composed of two peptides with
antimicrobial activity. First peptide is a modified 15-29 fragment of human
neutrophil peptide 1 (HNP-1), a member of α-defensins [1]. This peptide
displays antimicrobial activity against a broad spectrum of pathogens, the
closest to that of full length HNP-1. Second peptide is bovine lactofer-
rampin (LFampB) which is the fragment 268-284 of bovine lactoferrin
[2]. This peptide also exhibits broad antimicrobial action against several
gram-positive and gram-negative bacteriaas well as candidacidal activity
[3,4]. In the present study, we synthesized series of compounds consisting
of two peptide chains conjugated by isopeptide bond and disulfide bridge.
All peptides were screened against the wide range of microorganisms, in-
cluding Gram-negative, Gram-positive bacteria and fungi from Candida
species. Broth microdilution method for MIC determination was used as
a standard procedure. As a result, we obtained three peptidic hybrids that
effectively inhibited the growth of selected bacterial strains, but none of
the chimeric peptides was able to inhibit fungi growth. Cytotoxicity as-
says on tumor and healthy cells show that tested chimera peptides induce a
relatively low cytotoxicity in reference to antimicrobial drugs widely used
in clinic. More interestingly, these compounds displayed a higher helical
content and more potent antibacterial activities than the constituent pep-
tides individually or their equimolar mixtures. These results indicate a
significant influence of the linker used in chimera peptides on their biolog-
ical activity and secondary structure of the studied compounds. We proved
that a covalent linkage of two antimicrobial peptides significantly improves
antibacterial activity, which makes such hybrids good lead structure for de-
signing antimicrobial drugs.
Acknowledgement:This work was supported by the National Science Cen-
tre (NCN) under grant No UMO-2016/21/B/ST5/00101.
References [1]Lundy F.T., Nelson J., Lockhart D., Greer B., Harriott P.,
Marley J. Mol Immunol 45, 190-193 (2008). [2]Brock J.H. Biochem Cell
Biol. 90, 245-251 (2012). [3]van der Kraan M.I.A., Groenink J., Nazmi
K., Veerman E.C.I., Bolscher J.G.M., NieuwAmerongen A.V. Peptides, 25,
77–183 (2004). [4]Haney E.J., Nazmi K., Lau F., Bolscher J.G.M., Vogel
H.J. Biochimie 91, 141-154 (2009).
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Despite the increasing need for antibiotics to fight infectious diseases,
fewer new antibiotics are available on the market. Unfortunately, devel-
oping a new class of antibiotics is associated with high commercial risk.
Therefore, modification or combination of existing antibiotics to improve
their efficacy is a promising strategy. In this broad field, peptide–drug con-
jugates linked by non-cleavable or intracellular cleavable structures have
evolved as highly promising agents. Here we report synthesis and biolog-
ical investigations a series of peptide conjugates composed of modified
bovine lactoferricin truncated analogues (LFcinB) and three antibiotics,
ciprofloxacin (CIP), levofloxacin (LVX) and fluconazole (FLC) commonly
used in medicinal practice. The first two belong to the class of fluoro-
quinolone displaying broad spectrum of antimicrobial activity against both
Gram-positive and Gram-negative bacteria. They inhibit DNA gyrase and
topoisomerases. FLC, similarly to other azole drugs, inhibits the lanosterol
14α-demethylase and decreases the level of ergosterol required for the in-
tegrity of cell membrane [1]. LFcinB displays a broad spectrum of antibac-
terial and antifungal activity and also cooperative effect with azole types
of antifungal agents [2]. Our intention was to design a new class of antimi-
crobial compounds. Series of 8 new peptide conjugates containing 3 above
mentioned antibiotics were obtained. Four different approaches were ap-
ply to couple a peptide and the antimicrobial agent. We developed an
optimized conditions for coupling of levofloxacin via its carboxylic group,
ciprofloxacin via its carboxylic and amino group to peptide chain using
solid phase peptide synthesis. Also intermolecular disulfide bridge was
used as a linker between peptide and CIP. In case of fluconazole-based con-
jugates, a “click chemistry” method was used to attach this antifungal agent
derivative to a peptidic component. All studied peptides exhibited antimi-
crobial activity showing preferences to Gram-positive. Similar to the con-
stituent peptides, synthesized conjugates exerted highest activity against
S. epidermidis. The most active ones were conjugates containing CIP at-
tached to the peptide by the redox-sensitive disulfide bridge. They dis-
played not only higher efficacy than constituent peptides, but also broader
activity, inhibiting other experimental strains. Microscopic observations
showed that such conjugate as well as its constituent peptide penetrate well
into S. epidermidis cells. The obtained results indicate an important role of
linker between antibiotic and peptide. Cytotoxicity assays on cancer and
non-cancer cell lines show that tested conjugates induce a relatively low
cytotoxic effect (especially to the later) in reference to antibiotics widely
used in clinic, thus they can be considered as good candidates for drug
development.
Acknowledgement: This work was supported by the National Science Cen-
tre (NCN) under grant No UMO-2016/21/B/ST5/00101.
References [1] Kabir M.A., Ahmad Z., ISRN Preventive Medicine,
http://dx.doi.org/10.5402/2013/763628 (2013). [2] Wakabayashi H., Abe
S., Teraguchi S., Hayasawa H., Yamaguchi H. Antimicrob Agents
Chemother, 42, 1587–1591 (1998).
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Conjugates, in which two molecules differing by chemical and physical
properties are connected, are a promising group of compounds. Conju-
gates consist of a cell penetrating peptide (CPP) and a molecule with ther-
apeutic properties are among most frequently studied compounds. CPPs
can deliver to eukaryotic and prokaryotic cells a vast range of different bi-
ologically active compounds, including chemotherapeutic agents (e.g. an-
tibiotics). Transportan (TP) reported by Langel group, is a chimeric pep-
tide composed of the first 12 amino acid residues of neuropeptide galanin
and 14 amino acid residues-long wasp venom peptide, mastoparan, con-
nected via a lysine residue. A short variant, named TP10, with deletion of
the N-terminal hexapeptide, retains the efficient cell penetration property
of the parent compound with significantly less potential side effects [1].
Taking into the consideration the above mentioned literature data, we de-
cided to design, synthesize and determine antimicrobial (antibacterial and
antifungal) activity of peptide conjugates composed of TP10 and antibi-
otics: levofloxacin, ciprofloxacin and fluconazole. Three different linkers
(methylene carbonyl, amide and disulfide bridge) were used to connect
both components. TP10 may not only help to transport antibiotic across
the microbial cell membranes, but having intrinsic antimicrobial activity,
it can potentiate and even change the molecular mechanism of conjugated
antibiotic. In order to determine the cellular uptake of TP10 and its con-
jugate with ciprofloxacin, their fluorescently-labeled analogues were also
synthesized (TP10-F and CIP-TP10-F). The synthesized conjugates, TP10,
levofloxacin and ciprofloxacin were tested for growth inhibitory activity
against several fungal stains. TP10, levofloxacin and ciprofloxacin did not
exhibit antifungal activity at concentrations up to 100 µg/mL; however,
two conjugates with ciprofloxacin were active against C. albicans, C. kru-
sei and S. cerevisiae. Antibacterial in vitro activity of studied compounds
was determined against four bacterial strains, S. aureus, S. epidermidis,
E.coli and P. aeruginosa. TP10 did not display antimicrobial activity at con-
centrations up to 200 µg/ mL, whereas its conjugates with ciprofloxacin
inhibited growth of all studied bacteria. To assess the cytotoxic effect
of TP10, ciprofloxacin and its two conjugates, we evaluated IC50 values
(using MTT assay) for two human cell lines: liver cancer cells (HepG2)
and cell line of embryonic kidney (HEK 293), as well as a cell line iso-
lated from kidney of male pig (LLC-PK1). In case of LLC-PK1 cells,
TP10 and two conjugates were 4 times less toxic than ciprofloxacin. Us-
ing carboxyfluorescein-labeled TP10 and its conjugate with ciprofloxacin,
we we shown that both compounds penetrate well into C. albicans SC
5314, and C. albicans ATCC 10231. Acknowledgement: This work was
supported by the National Science Centre (NCN) under grant No UMO-
2016/21/B/ST5/00101. References: 1. Soomets U., Lindgren M., Gallet
X., Hällbrink M., Elmquist A., Balaspiri L., Zorko M., Pooga M., Brasseur
R., Langel Ü., BBA, 1467 (2000) 165-176
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The Herpes simplex virus-1 (HSV-1) infects host cells via surface receptors
such as nectin1 or Herpes virus entry mediator (HVEM)2, the virus parti-
cle uses its envelope glycoproteins to effect the entry. Unlike with other
herpes viruses, in case of the HSV the gD glycoprotein has an important
role in the mechanism of entry. In this study regions of the HSV-1 gD were
chosen based on the known tertiary structure of the complex of the HSV-1
gD and the nectin-1 and HVEM receptors, respectively, for cellular inter-
nalisation studies. The peptides were prepared with Fmoc/tBu chemistry
by solid phase peptide synthesis, with or without 5(6)-carboxyfluorescein
attached to their N-termini. The RP-HPLC purified peptides were char-
acterised chemically by ESI-MS and their fluorescence spectra. Their in
vitro cytostatic properties were studied with tetrazolium test3, and then
their cellular uptake by SH-SY5Y4 (CRL-2266) neuroblastoma cell cul-
ture was investigated by flow cytometry in a peptide concentration range
of 0,4 – 50 µM. The secondary structure of selected peptides was stud-
ied by electronic circular dichroism. We have found a sequence in the
C-terminal region of the gD glycoprotein showing high efficiency in the
cellular entry, and further peptides showed low to moderate entry in a con-
centration dependent manner. Inhibition of internalisation revealed that the
entry is (partially) effected via receptor mediated endocytosis. ECD stud-
ies revealed that the peptides with internalising ability partially retained
their helix like secondary structure adopted within the protein even in ECD
circumstances when using the ordered structure promoting solvent TFE or
TFE-water mixture. The marked difference in the cellular entry of the pep-
tides demonstrates that the peptide sequences corresponding to the most
effectively internalising peptides are located in the nectin-1 binding region
of HSV-1 gD glycoprotein.
Our research has been supported by the Hungarian Research Fund
(K104385, 104275).
1. Di Giovine, P.; Settembre, E.C.; Bhargava, A.K.; Luftig, M.A.; Lou, H.;
Cohen, G.H.; Eisenberg, R.J.; Krummenacher, C.; Carfi, A. PLoS Pathog
2011, 7(9),e1002277. 2. Carfí, A.; Gong, H.; Lou, H.; Willis, S.H.; Cohen,
G.H.; Eisenberg, R.J.; Wiley, D.C. Acta Crystallogr D Biol Crystallogr
2002, 58,836. 3. Liu, Y.; Peterson, D.A.; Kimura, H.; Schubert, D. J Neu-
rochem. 1997, 69, 581. 4. Datki, Z.; Papp, R.; Zádori, D.; Soós, K., Fülöp,
L.; Juhász, A.; Laskay, G.; Hetényi, C.; Mihalik, E.; Zarándi, M.; Penke,
B. Neurobiol Dis. 2004, 17, 507.
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Cryptophycins are potent microtubule destabilizers that can not be used as
traditional chemotherapeutic due to their lack of tumor preference, which
causes neurotoxic side effects and lack of efficacy in vivo. However,
their high potency, which is 100- to 1000- fold greater than paclitaxel or
other tubulin binders, and the lack of drug resistance makes them a very
promising agent to be used in targeted therapy.[1,2] The parent compound
cryptophycin-52 lacks an addressable group that would allow the conjuga-
tion to a homing device. For this reason, the discovery of novel analogues
that maintain the cytotoxicity of the parental compound and presents a
functional group has received much attention.[3,4] Cryptophycin-55 glyci-
nate has emerged as potential payload to be used in tumor targeted ther-
apy. This synthetic analogue retains the cytotoxicity and includes a func-
tional group for conjugation to an antibody or small molecule. The con-
jugation of cryptophycin-55 glycinate to octreotide using different linkers
lead to small molecule-drug conjugates targeting the somatostatin recep-
tors (SSTRs). The binding affinity to the SSTRs, the cytotoxic effect on
different tumor cell lines and the plasma stability will be reported. More-
over, a conjugate bearing an infrared dye instead of the drug was used to
test the specificity of octreotide towards SSTRs and was evaluated in vitro
and in vivo.
[1] M. Srinivasarao, P. S. Low, Chem. Rev. 2017, 117, 12133–12164. [2]
C. Weiss, B. Sammet, N. Sewald, Nat. Prod. Rep. 2013, 30, 924–940.
[3] C. Weiss, E. Figueras, A. N. Borbely, N. Sewald, J. Pept. Sci. 2017,
23, 514–531. [4] E. Figueras, A. Borbély, M. Ismail, M. Frese, N. Sewald,
Beilstein J. Org. Chem. 2018, 14, 1281–1286.
This project has received funding from the European Union’s Horizon
2020 research and innovation program under the Marie Sklodowska-Curie
grant agreement No 642004.
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Based on statistical data, it is known that cancer is the second most com-
mon cause of death worldwide. Chemotherapy has a great importance in
the treatment of cancer patients. However, the vast majority of chemother-
apeutic drugs used today can cause serious side effects. Targeted tumour
therapy may offer an opportunity to overcome this problem by conjugating
chemotherapeutic drugs to tumour specific peptides. NGR (Asn-Gly-Arg)
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peptides received particular interest when phage display libraries were
used to identify non-RGD integrin binding motifs. Among the non-RGD
peptides the NGR motif was the most frequent that showed integrin bind-
ing properties [1]. However, peptides containing the NGR motif are not
integrin ligands, but specifically recognize specific CD13/aminopeptidase
N isoforms that are selectively overexpressed in tumour neovasculature
[2]. In addition, these sequences prone to spontaneous decomposition
through a succinimide-ring formation, forming isoAsp and Asp derivatives
which is strongly influenced by the structure. The resulting isoaspartyl
(isoDGR) derivatives are recognized by RGD-integrins that are essential
for tumour metastasis [3]. Hence NGR peptides are of high interest, due to
their simultaneous and selective targeting of CD13 and RGD-integrin re-
ceptors, therefore potential applications in dual drug targeting Based on
the literature and our earlier work, we have chosen seven small cyclic
NGR peptides as our targeting molecules: c[KNGRE]-NH2, c[NleNGRE]-
NH2, c[GNSarRGK], Ac-c[CNGRC]-NH2 and H-c[CNGRC]-NH2, and
also the thioether bond containing c[CH2-CO-KNGRC]-NH2 and c[CH2-
CO-NGRC]-NH2 [4,5,6]. Using these small cyclic NGR derivatives as a
homing moiety, we designed, synthesised and characterized novel cyclic
NGR peptide-drug conjugates with a well-known chemotherapeutic agent,
daunomycin (Dau). Since sequences of certain peptides allowed the con-
jugation of daunomycin in different positions, where possible, not only
the C-terminal elongated, but also branched variants were prepared. To
ensure selective drug release for targeted tumor therapy we have incorpo-
rated an extracellular MMP-2 enzyme labile spacer into the conjugates.
The cytotoxicity effect of the novel cyclic NGR peptide-Dau conjugates
were examined in vitro on CD13 positive HT1080 (human fibrosarcoma)
and KS (Kaposi’s sarcoma) and, as a CD13 negative control, on HT-29
(human adenocarcinoma) cell lines. The results were compared with the
data acquired from chemostability, and degradation measurements.
The research was founded by NKFIH K119552 and Horizon 2020 re-
search and innovation program under the Marie Sklodowska-Curie grant
(No 642004, Magicbullet).
[1] Pasqualini et al. Cancer Res. 2000; 60: 722-727. [2] Hildenbrand et al.
Int J Oncol. 2009; 34: 15-23. [3] Curnis et al. J Biol Chem. 2010; 285:
9114–9123. [4] Enyedi et al. J. Med. Chem. 2015; 58: 1806-1817. [5]
Tripodi et al. Beilstein J Org Chem. 2018; 14: 911–918. [6] Corti et al.
Adv Funct Mater. 2017; 27: 1701245.
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Photodynamic therapy (PDT) combines non-toxic components, a photo-
sensitizer, light and oxygen. The photosensitizer can be activated to its
excited states by irradiation with visible light, which produces reactive
oxygen species after crashing with molecular oxygen in the tissue. In most
cases a singlet oxygen is generated that has a short intracellular life time
(3 µs) and a very small intracellular diffusion distance that makes PDT
highly selective [1]. Conjugation of the photosensitizer to a carrier peptide
that itself has anti-tumor effect can increase the efficacy and selectivity of
the treatment. Gonadotropin-releasing hormone (GnRH) is a decapeptide
(<EHWSYGLRPG-NH2) that plays a central role in the vertebrate repro-
duction by regulating gonadal activity. Its receptor was found on several tu-
mor cells, which makes this peptide a proper targeting moiety for targeted
tumor therapy.[2] In this work GnRH-protoporphyrin IX conjugates were
synthesized. Various GnRH analogues were used, in most cases the 4Ser
in the sequence was replaced by a butyric acid modified lysine (Lys(Bu))
since this change increases the receptor binding affinity and the stability of
the molecule against enzymes [3]. In the sequences of GnRH-I and GnRH-
II analogues 6Gly was replaced by D-Lys to have a proper conjugation
site for the photosensitizer [4], while in case of the GnRH-III derivative
the Protoporphyrin IX (Pp) was attached to the side chain of the 8Lys. In
GnRH-III the side chain of 6Asp was blocked as methyl ester because
in this case the carboxyl group of Asp cannot react under the conditions
used for amide bond formation. Since the solubility of these conjugates
was limited, Pp was derivatized with PEG-NH2 and a PEG-Pp-GnRH-I
analogue was prepared, as well. The in vitro biological assays were per-
formed on Detroit-562 human pharynx carcinoma cells that highly express
GnRH receptors [5]. We found that all GnRH-Pp conjugates showed excel-
lent anti-tumour effect at low concentrations ( 1 µM) with short irradiation
time (10 min), and we also observed that the PEGylation highly increased
the solubility.
This project has received funding from the National Research, Develop-
ment and Innovation Office (NKFIH K119552, NVKP_16-1-2016-0036),
Hungary.
[1] N. Malatesti, I. Munitic, I. Jurak, Biophys Rev., 2017; 9, 149-168. [2]
G. Mezó, M Manea, Expert Opin. Ther. Patents, 2009; 19(12), 1771-1785.
[3] R. Hegedüs et al., Eur. J. Med. Chem., 2012; 56, 155-165. [4] S. Ba-
jusz et al., PNAS, 1989; 86(16), 6313-6317. [5] J. Murányi et al., J. Pept.
Sci., 2016; 22, 552-560.
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Breast cancer is one of the most leading causes of death worldwide. In
20% of all cases human epidermal growth factor receptor 2 (HER2/ErbB2)
is found on breast cancer tissues. The overexpression of HER2 leads to ag-
gressive course of disease. Recently, targeted tumor therapy is a promising
research area based on the increased selectivity of antitumor drug attached
to a targeting molecule, which binds to tumor specific antigens/receptors.
Since HER2 might be a good target to prevent tumor growth, current re-
searches are directed to discover HER2 targeting moieties for drug deliv-
ery. Kadcyla® as an antibody−drug conjugate (ADC) is on market now.
In spite of benefits of ADCs (long half-life in circulation and high selec-
tivity) there are some disadvantages of ADCs (low tissue penetration and
high costs). Therefore, small molecule−drug conjugates (SMDCs) based
on peptides as targeting moieties might have advantages over ADCs. Ap-
propriate homing peptides can be selected by phage displays or molecular
dynamic simulations. In our research KCCYSL peptide selected by phage
display [1] as well as GYYNPT peptide that bind selectively to HER2
according to MD modelling [2] were chosen to study their in vitro cel-
lular uptake by HER2+ cancer cells. Furthermore, the cysteine residues
were replaced by alanine or serine in KCCYSL peptide to investigate the
role of cysteines. The two different peptide sequence were combined
(KAAYSLGYYNPT, KSCYSLGYYNPT) too, to increase the biological
activity. All compounds were labelled with 5(6)-carboxyfluorescein (CF)
on their N-terminus. The in vitro cellular uptake was measured by flow cy-
tometry on MDA-MB-453 HER2+ cancer cells. The results indicated that
CF-KCCYSL-NH2 and its modified analogs were taken up by cells with
low intensity while CF-GYYNPT-NH2 did not internalized. The amino
acid replacements in the KCCYSL sequence did not show significant in-
fluence on internalization. In contrast to the CF-labelled hexapeptides, the
recognition of the combined peptides by cells was high also at low con-
centrations. Interestingly, the localization of CF-labelled combined pep-
tides was detected rather on the cell membrane than intracellularly. The
extracellular localization was also indicated by trypsinization resulted in
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significantly lower fluorescence intensity. This observation suggested that
the combined peptide suitable for receptor binding with high affinity but
the internalization of receptor conjugate complex is low. Therefore, these
homing peptides may be applied for tumor diagnostic (PET) or selective
delivery of radiotracers with therapeutic activity. In addition, the applica-
tion of extracellular enzyme (elastase, MMPs) cleavable spacers between
the homing peptide and an antitumor agent might be a good choice for
the development of conjugates as drug delivery systems. This project was
founded by the National Research, Development and Innovation Office
(NKFIH K119552, NVKP_16-1-2016-0036), Hungary.
[1] Karasseva, N.G.,et al.; J. Prot. Chem., 21, 287-296 (2002) [2] Geng,
L., et al.; Theranostics, 6, 1261-1273 (2016)
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Cryptophycins are novel and compelling antimitotic payloads for tumor tar-
geting applications, owing to their high potency as tubulin polymerization
inhibitors and retention of activity against MDR cell lines [1]. Different
cryptophycin analogues have been designed and synthetized to elucidate
what moieties are essential for the biological activity. In addition, the func-
tionalization of the drug for conjugation to tumor targeting peptides or anti-
bodies has been attempted [2,3]. The synthetic cryptophycin-55-glycinate
that has been reported to be active in the low nM range, contains a func-
tional group providing the possibility of conjugation, as well as shows
increased stability of the macrocycle compared to the parent compound.
Therefore, it has the potential to be used as payload in the construction of
drug conjugates. In this study, cryptophycin-55-glycinate was conjugated
to monomeric or tetrameric cyclic[RGDfK] peptide ligands targeting inte-
grin αvβ3 [4]. The protease cleavable dipeptide Val-Cit and the PABC
self-immolative spacer were inserted between the drug and the tumor tar-
geting ligand [5]. The in vitro cytotoxicity of the conjugates was evaluated
on M21, M21-L human melanoma cells, showing increased antitumor ac-
tivity of the tetrameric conjugate against the antigen-positive M21 cell line.
The in vitro plasma metabolic stability of the monomeric conjugate and the
lysosomal drug release will be also reported.
(1) Weiss, C. et al., J. Pept. Sci. 2017, 23 (7–8), 514–531. (2) Weiss, C.
et al., Nat. Prod. Rep. 2013, 30 (7), 924–940. (3) Figueras, E. et al.,
Beilstein J. Org. Chem. 2018, 14 (1), 1281–1286. (4) Garanger, E. et al.,
Org. Biomol. Chem. 2006, 4 (10), 1958–1965. (5) Dubowchik, G. M. et
al., Bioconjug. Chem. 2002, 13 (4), 855–869.
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Cell-penetrating peptide sequences for high precision
targeting, imaging and sensing in live cells
Aisling Byrne, Christopher Burke, Tia Keyes, Aaron Martin
Dublin City University, Ireland
The recent development of fluorescent probes has allowed biologists to vi-
sualize subcellular components in vivo, both structurally and functionally.
The observation of many biological processes relies on the ability to iden-
tify and locate subcellular environments. There have been many reports
of Ru(II) metal complexes as imaging and sensing probes, but require the
use of detergents as well as requiring high concentrations in order to get
them to cross the cell membrane. Once in the cell, there is no control as to
where the probes will localize. We have demonstrated that the use of cell-
penetrating peptide (CPP) sequences can overcome these drawbacks and
achieve high precision targeting of our probes, selectively to specific or-
ganelles in the cell. CPPs are short, positively charged peptide sequences,
and function to promote and facilitate cellular uptake of molecules at low
concentrations. To date, however, there have been few reports on the use
of CPPs to direct metal complexes into live cells. Here we present the
CPP sequences we have successfully exploited for cell imaging and sens-
ing. We have examined simple oligoarginine sequences, as well as more
complicated signal peptide sequences. In particular, we have exploited
the mitochondrial penetrating peptide (MPP) sequence FrFKFrFK to se-
lectively target the mitochondria and direct [Ru(bpy)2(phen)-MPP]7+, an
O2 sensing probe, exclusively to the mitochondria. Here we were able
to measure O2 and ROS in vivo based on the luminescent lifetime of the
probe using Fluorescence Lifetime Imaging Microscopy (FLIM). We have
also conjugated a nuclear-localizing signal peptide, from the transcription
factor NFkB, and an endoplasmic reticulum (ER) peptide sequence, to di-
rect [Ru(dppz)(bpy)2-NLS]6+ and [Ru(bpy)2(phen)-ER]9+ to the nucleus
and ER of live cells. This allowed us to carry out super-resolution STED
imaging of chromosomal DNA at the stages of mitosis, as well as achieve
high-resolution images of the ER. Using this NLS peptide, we reported
the first example of [Ru(tap)2(bpy)-NLS]6+ to the nucleus of live cells for
photo-induced DNA damage. In all cases, without the CPP present, the
parent complexes did not enter the cells. This, along with their targeting
capabilities, demonstrates the value of using CPPs for imaging and sensing
probes.
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Development of a New Tetrafunctional Hybrid to
Target Cancer Cells
Maya Georgieva1, Androniki Kostagianni2, Eirinaios
Vrettos2, Maria Chatziathanasiadou2, Andreas Tzakos2,
Tamara Pajpanova1
1Institute of Molecular Biology Roumen Tsanev, Bulgarian Academy of
Sciences, Bulgaria
2University of Ioannina, Department of Chemistry, Section of Organic
Chemistry and Biochemistry, Greece
Dysregulation of apoptotic pathways that enable apoptosis escape is a main
feature of cancer cells that is an overwhelming problem for conventional
cancer therapy. Another problem is still unselective activity of drugs over
both cancer and normal cells. Herein we designed a hybrid containing
Smac peptide fragment along with RGD targeting unit, a unit for conju-
gation of drugs/dyes and Canavanine in order to lower down the apop-
totic thresholds and trigger apoptosis in cancer cells. AVPI (Ala-Val-Pro-
Ile) sequence is the functionally essential tetrapeptide sequence of the N-
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terminus of pro-apoptotic regulator Smac (Second mitochondria derived
activator of caspases). Smac is shown to help proceeding of extrinsic and
intrinsic apoptotic pathways by inhibiting IAP proteins (Inhibitor of Apop-
tosis Proteins). Furthermore it is reported an inverse correlation between
Smac and IAP protein levels in a wide range of cancer cells, defining these
regulators interesting for targeted drug design. We combined a modified
AVPI sequence with RGD (Arg-Gly-Asp), known to bind molecules over-
expressed on cancer cell membrane. Cell permeability predictions led us
to the attachment of a canavanine-tail of three canavanines. Canavanine
is a non-proteinogenic arginine analogue. The peptide was synthesized
by SPPS (solid phase protein synthesis) stepwise method. The purity of
peptide was defined by HPLC, and Mass-spectrometry. The cytotoxic po-
tential of the peptide was tested over A549 lung cancer cell line by MTT
assay.
Acknowledgements: The study was supported by National Science
Fund, Ministry of Education and Science, Bulgaria; Project: DN19/17,
20.12.2017; EPS Mobility Fellowship 2018.
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VirD2 Derived Cell Penetrating Peptide Exhibits
Efficient Cellular Translocation and Cargo Delivery in
Plants
Vivek Kumar, Aastha Jain, Mudit Mishra, Archana Chugh
IIT Delhi, India
Cell penetrating peptides (CPP) are relatively short peptides, with the in-
herent ability to traverse impermeable biological membrane. They are ex-
tensively studied as efficient tool in field of drug delivery. Amino acid
sequences of VirD2 of three different Agrobacterium strains revealed that
these sequences are well conserved. VirD2 protein of Agrobacterium tume-
faceins play significant role in nuclear localization and integration of T-
DNA in plant genome. In present study, the membrane translocability of
VirD2 derived peptides namely Vir, Vir1, Vir2 and Vir3 has been investi-
gated. Vir peptide directs the β -galactosidase to the nuclei of wheat cell
and tissues. Interestingly Vir2 formed by substitution of arginine with
alanine from N terminus enhances the β -galactosidase delivery ability.
Thus, our results show the importance of Cterminus arginine in macro-
molecule delivery. Additionally, circular dichroism was performed where
the increase in α-helical percentage of Vir2 - β -galactosidase complex in
the presence of membrane mimicking environment was clearly observed.
Slight unfolding with change in conformation of β -galactosidase was ob-
served which enable the complex to translocate across the cell membrane
with the help of CPPs. For the first time we have conclusively demon-
strated that cargo protein is transported by CPP in its relaxed/ unfolded
state.
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Development of Helix-Stabilized Amphipathic
Cell-Penetrating Peptides for siRNA Delivery
Takashi Misawa1, Nobumichi Ohoka1, Makoto Oba2,
Masakazu Tanaka2, Mikihiko Misawanaito1, Yosuke
Demizu1
1National Institute of Health Sciences, Japan
2Nagasaki University, Japan
Cell-penetrating peptides (CPPs) are receiving much attention as an intra-
cellular delivery tool for hydrophilic cargo molecules such as drugs, pro-
teins, and nucleic acids. It has been reported that CPPs contain a high rel-
ative abundance of positively charged amino acids such as arginine (Arg),
and the interaction between cationic side chains of arginines and acidic
groups existing on the cell surface is essential for cell membrane perme-
ability. On the other hand, the relationship between secondary structures
of CPPs and their cell membrane permeability still remains unclear. Previ-
ously we reported that amphipathic Arg rich helical peptides whose helical
structures were stabilized with hydrophobic 2-aminoisobutyric acid (Aib)
residues, penetrated cells more effectively than non-helical Arg-rich pep-
tides. However, these helical peptides showed lower cell permeability than
nonaarginine (R9) because replacement of cationic Arg with hydrophobic
Aib reduced in the number of arginine and/or change distribution of argi-
nine in peptide. We also reported that (Leu-Leu-Aib)n-peptides (1) are
capable of acting as a useful helical promoter. Based on this knowledge,
we hypothesized that conjugation of helical peptide 1 with R9 could stabi-
lize the helical structure and enhance cell membrane permeability. Herein,
we designed and synthesized a helix-stabilized R9-based peptide [Block3:
FAM-bAla-(Leu-Leu-Aib)3-(Gly)3-(Arg)9]. At first, we performed pre-
ferred secondary structural analysis using CD spectra. As a result, Block3
showed negative maxima around 208 and 222nm indicating Block3 formed
a stable helical structure whereas R9 did random structures. Furthermore,
we evaluated effects of the peptides on delivery of the plasmid DNA or
siRNA into cells. MCF-7 cells were treated with the complex of peptide
and pDNA or siRNA, and the target gene expression were evaluated by re-
porter gene luciferase assay and western blotting analysis, respectively. As
a result, Block3 efficiently deliver the pDNA and siRNA into cells. These
results suggest that conjugation of helical promoter peptide 1 with R9 en-
hanced cell-penetrating ability and the Block3 could be a candidate for a
novel intracellular delivery tool.
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PPMO’s as Therapeutic Modulators for Myotonic
Dystrophy Type 1
Ashling Holland, Miguel Varela, Arnaud F. Klein, Richard
Raz, Andrey Arzumanov, Michael J. Gait, Matthew J.A.
Wood
University of Oxford, United Kingdom
Myotonic dystrophy type 1 (DM1) is the most common form of muscu-
lar dystrophy in adults. DM1 is caused by the pathological microsatel-
lite (CTG) repeat expansion in the 3’untranslated region of the DMPK
gene. Mutant RNAs containing the repeat CUG expansions are retained
in the nucleus as foci and sequester proteins required for the regulation of
mRNA splicing and translation. These perturbations result in a multisys-
temic disorder characterised by myotonia, progressive muscle weakness,
cardiac arrhythmias, cataracts and impaired endocrine and nervous system
function. To date there is no cure for DM1. Antisense oligonucleotides
(ASOs) are a promising genetic therapy for RNA gain-of function diseases
like DM1. A leading strategy for an enhanced delivery system is modula-
tion of ASO chemistry though peptide conjugation. This allows for tissue-
specific delivery while directly targeting CUG repeat expansions that can
interfere with abnormal sequestration and binding of RNA-binding pro-
teins like MBNL1. This study investigates the therapeutic ability of an
arginine-rich cell-penetrating peptide, pip6a, conjugated to an ASO tar-
geting the CUG repeat in DM1 patient cells and in the HSALR mouse
model of DM1. Pip6a-PMO treatment in vitro can correct molecular abnor-
malities by liberating MBNL1 and normalising splicing profiles in patient
cells. Single intravenous administration of pip6a-PMO can partially cor-
rect mis-splicing events in gastrocnemius muscle. Repeat administration
of PPMO successfully normalises mis-splicing events in skeletal muscle,
has reduced foci, illustrates redistribution of MBNL1 and fully corrects
myotonia phenotype. This treatment also has positive long lasting effects,
up to 6 months, in HSALR mouse skeletal muscle. This work provides
insights into the application of arginine-rich cell-penetrating peptide cou-
pled to PMOs for treatment of myotonic dystrophy type 1. Pip6a-PMO
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demonstrates an encouraging therapeutic potential for DM1 patients.
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Homology Modelling and Evaluation of the
Cannabinoid Receptor Type 2
Fatima Sapundzhi, Tatyana Dzimbova, Nevena Pencheva,
Peter Milanov
South-West University ”Neofit Rilski”, Bulgaria
The human cannabinoid receptor type 2 (CB2) is linked to a variety of
immune functional events which are found primarily in brain and tissues
of immune and hematopoietic systems like spleen, tonsil, and thymus. In
the absence of crystal structure of CB2 receptor, 3D homology patterns
with different templates are built. The aims of the present study are: (1)
to choose within the recently published crystallographic structures tem-
plates for homology modelling of the CB2 receptor; (2) to evaluate the
models with different computational tools; and (3) to precise the most reli-
able model basing on the correlation between data from molecular docking
and the values of the biological activity of the cannabinoid ligands. A new
model of the CB2 was generated and evaluated by different approaches.
The scoring function correlates (Pearson r = -0.945, p-value = 0.0013) with
the biological activity of a series of cannabinoid ligands known from lit-
erature. Therefore, the current investigation allows suggesting a reliable
model of CB2. The model of CB2 receptor obtained by homology mod-
elling could be used further for in silico experiments, structure-activity re-
lationship evaluations and it will give possibility for the design of selective
and effective ligands for the CB2 receptor.
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Software-aided workflow for predicting sites of
cleavage using molecular descriptors of the natural and
synthetic amino acids in peptide-based drug discovery
Tatiana Radchenko1, Ismael Zamora2, Fabien Fontaine3,
Luca Morettoni4
1UPF; Lead Molecular Desing S.L., Spain
2Lead Molecular Desing S.L.; Molecular Discovery, Spain
3Lead Molecular Desing S.L., Spain
4Molecular Discovery, United Kingdom
Predicting possible sites of cleavage for individual proteases is an impor-
tant task to be completed during drug-design process of peptide therapeu-
tics to improve their stability and availability as a promising drug. In this
study we presented a new approach in WebMetabase that helps to predict
cleavage sites for the specific peptide family or for specific experimen-
tal condition (i.e. individual protease). One of the main advantages of
this approach is that it generates a searchable database for the information
coming from LC-MS based experimental data or from external sources
such as MEROPS database. In this database each amino acid is described
as a vector of physicochemical properties, Volsurf molecular descriptors,
and/or pharmacophoric properties, SHOP descriptors. This way to store
the data can be utilized to perform frequency analysis to discover the most
frequent scissile bonds within the generated database. These results can
be used to train predictive models for individual proteases or complex ma-
trices. This database enables the user to combine the external and internal
sources of information. We used database that contained data extracted
from MEROPS and experimental data to train several models using dif-
ferent classifier learning approaches for eighteen proteases from four pro-
tease families: serine, cysteine, aspartic and matrix metalloproteases. In
the training dataset each sequence pattern around the potential cleavage
site and actual site of cleavage was represented as a combination of Vol-
surf descriptors that characterized the physicochemical properties of the
residues in the sequence of the site of cleavage. In this case there would
be no limitations related to the amino acids used for the training. We com-
pared the predictive performance of the models trained with different learn-
ing approaches applying 5-fold cross validation test and more importantly
prediction results on an external dataset. Moreover, we examined the in-
fluence of the local window sequence size around the site of cleavage by
comparing the models trained for P1-P1’ and P4-P4’ range. We revealed
that the logistic regression and random forest classification models trained
using window P4-P4’ outperformed other machine learning methods or
the models trained using the P1-P1’ window. We demonstrated that predic-
tive performance of the models trained with different learning approaches
was comparable to the other publicly available tools (PROSPERous and
SitePredicting). In contrary to the state-of-the art tool, developed tool en-
ables the user to build the private models for internal use. This knowledge
can be applied during the design-make-test drug discovery cycle.
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